AMINO-SUBSTITUTED ISOTHIAZOLES

Abstract

The present invention relates to amino-substituted isothiazoles of general formula (I): in which A, R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

##STR00001##

Claims

1. A compound of formula (I) ##STR00571## in which: A represents a heteroaryl group selected from: ##STR00572## wherein one of X.sup.1, X.sup.2 and X.sup.3 represents an N, O or S as ring atom and the others of X.sup.1, X.sup.2 and X.sup.3 represent carbon as ring atoms, and wherein X.sup.4, X.sup.5, X.sup.6 and X.sup.7 represent carbon as ring atoms or one of X.sup.4, X.sup.5, X.sup.6 and X.sup.7 represents an N atom, and the others of X.sup.4, X.sup.5, X.sup.6 and X.sup.7 represent carbon as ring atoms, and wherein X.sup.1 and X.sup.2 or X.sup.2 and X.sup.3 or X.sup.4 and X.sup.5 or X.sup.5 and X.sup.6 or X.sup.6 and X.sup.7 optionally form part of an additional 5-membered or 6-membered ring, which optionally contains one further heteroatom selected from the group consisting of O, N and S, and which ring is unsaturated or partially saturated, and wherein * indicates the point of attachment of said groups with the rest of the molecule, said heteroaryl group, which is monocyclic or bicyclic, being optionally substituted, one or two times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, 5-membered heteroaryl, —(═O)OR.sup.3, —(═O)(NR.sup.4)R.sup.5, —N(R.sup.4)R.sup.5, said phenyl and 5-membered heteroaryl being optionally substituted, one or two times, identically or differently, with a substituent selected from: a halogen atom, or a C.sub.1-C.sub.3-alkyl-, or a C.sub.1-C.sub.3-alkoxy-group, R.sup.1 represents a C.sub.1-C.sub.3-alkyl-group, R.sup.2 represents a group selected from: phenyl or pyridinyl, said phenyl and pyridinyl being substituted, one or two times, identically or differently, with a group selected from: HO—(C.sub.1-C.sub.6-alkyl)-, HO—(C.sub.2-C.sub.6-alkoxy)-, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, (C.sub.1-C.sub.3-alkoxy)-(C.sub.2-C.sub.6-alkoxy)-, (C.sub.1-C.sub.3-haloalkoxy)-(C.sub.1-C.sub.6-alkyl)-, cyano, R.sup.7(R.sup.8)N—(C.sub.1-C.sub.6-alkyl)-, R.sup.6O(C═O)—(C.sub.1-C.sub.6-alkyl)-, cyano-(C.sub.1-C.sub.6-alkyl)-, R.sup.6O(C═O)—(C.sub.1-C.sub.6-alkoxy)-, R.sup.7(R.sup.8)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.7(R.sup.8)N—(C.sub.2-C.sub.6-alkoxy)-, R.sup.7(R.sup.8)NC(═O)—(C.sub.1-C.sub.6-alkoxy)-, —(═O)OR.sup.6, —N(R.sup.7)R.sup.8, —N(R.sup.9)C(═O)R.sup.10, —N(R.sup.9)C(═O)OR.sup.13, —(═O)N(R.sup.7)R.sup.8, R.sup.13OC(═O)N(R.sup.9)—(C.sub.1-C.sub.6-alkyl)-, R.sup.13OC(═O)N(R.sup.9)—(C.sub.2-C.sub.6-alkoxy)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.1-C.sub.6-alkyl)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.2-C.sub.6-alkoxy)-, R.sup.14S—, R.sup.14S(═O)—, R.sup.14S(═O).sub.2—, R.sup.14S(═NR.sup.15)(═O)—, R.sup.14S—(C.sub.1-C.sub.6-alkyl)-, R.sup.14S(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.14S(═O).sub.2—(C.sub.1-C.sub.6-alkyl)-, R.sup.14S(═NR.sup.15)(═O)—(C.sub.1-C.sub.6-alkyl)-, —S(═O).sub.2N(R.sup.11)R.sup.12, heterocycloalkyl having 5- to 7-members, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkyl)-, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkoxy)-, (heterocycloalkyl having 5- to 7-members)-O—, phenyl, phenoxy, heteroaryl, heteroaryl-O, (C.sub.1-C.sub.6-alkyl)-S(═O).sub.2N(H)—, aryl-S(═O).sub.2N(H)—, an azetidinyl-S(═O).sub.2N(H)— group, or a (heterocycloalkyl having 5- to 7-members)-S(═O).sub.2N(H)— group, said phenyl and phenoxy group being substituted, one or two times, identically or differently, with a substituent selected from: a C.sub.1-C.sub.3-haloalkyl-, (C.sub.1-C.sub.3-haloalkyl)-S—, or a C.sub.1-C.sub.3-haloalkoxy-group, or with two substituents which are in ortho-position to one another and form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, or butane-1,4-diyl, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, and being optionally substituted, one or two times, identically or differently, with a substituent selected from: a halogen atom, a C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.3-haloalkyl, a C.sub.1-C.sub.3-alkoxy, or a C.sub.1-C.sub.3-haloalkoxy-group, said azetidinyl group being optionally substituted with a substituent selected from: a C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, —(═O)OR.sup.6, —(═O)NR.sup.11R.sup.12, HC(═O)—, or (C.sub.1-C.sub.6-alkyl)C(═O)— group, or a halogen atom, said heterocycloalkyl having 5- to 7-members being optionally substituted, 1 to 3 times, identically or differently, with a substituent selected from: a C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.3-C.sub.6-cycloalkyl, cyano, —(═O)OR.sup.6, —(═O)NR.sup.11R.sup.12, HC(═O)—, or (C.sub.1-C.sub.6-alkyl)C(═O)— group, or a halogen atom, and, said phenyl and pyridinyl optionally being additionally substituted, one or two times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, or a halogen atom, R.sup.3 represents: a hydrogen atom, or a group selected from C.sub.1-C.sub.6-alkyl, R.sup.4 represents: a hydrogen atom, or a group selected from C.sub.1-C.sub.6-alkyl, R.sup.5 represents: a hydrogen atom, or a group selected from C.sub.1-C.sub.6-alkyl, or, R.sup.4 and R.sup.5 together with the nitrogen to which they are attached represent: a 5- to 6-membered heterocycloalkyl which optionally contains one further heteroatom selected from the group consisting of O, N and S, R.sup.6 represents: a hydrogen atom, a C.sub.1-C.sub.6-alkyl-group, or a phenyl-(C.sub.1-C.sub.6-alkyl)— group, R.sup.7 and R.sup.8 are independently of each other selected from a group selected from: hydrogen, C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.3-C.sub.6-alkenyl, C.sub.3-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, HO—(C.sub.2-C.sub.6-alkyl)-, (C.sub.1-C.sub.3-alkoxy)-(C.sub.2-C.sub.6-alkyl)-, (C.sub.1-C.sub.3-halolkoxy)-(C.sub.2-C.sub.6-alkyl)-, R.sup.6OC(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.2-C.sub.6-alkyl)-, R.sup.13OC(═O)(R.sup.9)N—(C.sub.2-C.sub.6-alkyl)-, R.sup.14S—(C.sub.2-C.sub.6-alkyl)-, R.sup.14S(═O)—(C.sub.2-C.sub.6-alkyl)-, R.sup.14S(═O).sub.2—(C.sub.2-C.sub.6-alkyl)-, R.sup.14S(═NR.sup.15)(═O)—(C.sub.2-C.sub.6-alkyl)-, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.6-alkyl)-, heteroaryl-(C.sub.1-C.sub.6-alkyl)-, an azetidine-group, heterocycloalkyl having 5- to 7-members, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkyl)-, or R.sup.17, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, cyano, —N(R.sup.11)R.sup.12, or —NR.sup.9C(═O)R.sup.10, whereby two substituents of said phenyl group, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, or butane-1,4-diyl, said azetidine group being optionally substituted with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)-phenyl-(═O)—, heteroaryl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, —(═O)OR.sup.6, or with two halogen atoms, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, said heterocycloalkyl having 5- to 7-members being optionally substituted, one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O), -phenyl-(═O)—, heteroaryl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, or —(═O)OR.sup.6, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, or, R.sup.7 and R.sup.8 together with the nitrogen to which they are attached represent: a azetidine group, said azetidine group optionally being substituted with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-(═O)—, heteroaryl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, —(═O)OR.sup.6, or with two halogen atoms, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, a halogen atom, or cyano, or, R.sup.7 and R.sup.8 together with the nitrogen to which they are attached represent: a heterocycloalkyl having 5- to 7-members, said heterocycloalkyl having 5- to 7-members being optionally substituted, one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom,cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-(═O)—, heteroaryl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, or —(═O)OR.sup.6, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, R.sup.9 represents: a hydrogen atom, or a C.sub.1-C.sub.6-alkyl group, R.sup.10 represents: a hydrogen atom, a C.sub.1-C.sub.6-haloalkyl, or a C.sub.1-C.sub.6-alkyl group, R.sup.11 and R.sup.12 are independently of each other selected from: a hydrogen atom, a C.sub.1-C.sub.6-alkyl or a C.sub.1-C.sub.6-haloalkyl group, or R.sup.11 and R.sup.12 together with the nitrogen to which they are attached represent: an azetidine group or a heterocycloalkyl having 5- to 7-members, said azetidine group being optionally substituted with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-(═O)—, heteroaryl-(═O)—, —(═O)OR.sup.6, or with two halogen atoms, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, said heterocycloalkyl having 5- to 7-members being optionally substituted, 1 to 3 times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-(═O)—, heteroaryl-(═O)—, or —(═O)OR.sup.6, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, R.sup.13 represents a: C.sub.1-C.sub.6-alkyl group, or a phenyl-(C.sub.1-C.sub.6-alkyl)— group, R.sup.14 represents a group selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.3-haloalkyl, or a C.sub.3-C.sub.6-cycloalkyl group, R.sup.15 represents a group selected from: a hydrogen atom, cyano, or —(═O)R.sup.16, R.sup.16 represents a group selected from: C.sub.1-C.sub.6-alkyl, or C.sub.1-C.sub.6-haloalkyl, R.sup.17 represents a C.sub.1-C.sub.6-alkyl group, which is substituted two times, identically or differently, with a substituent selected from: hydroxy, (C.sub.1-C.sub.4-alkoxy), —(═O)OR.sup.6, or —(═O)N(R.sup.18)R.sup.19, R.sup.18 and R.sup.19 are independently of each other selected from: a hydrogen atom, or a C.sub.1-C.sub.3-alkyl group, or R.sup.18 and R.sup.19 together with the nitrogen to which they are attached represent: a 5- to 6-membered heterocycloalkyl which optionally contains one further heteroatom selected from the group consisting of O, N and S, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

2. The compound according to claim 1, wherein: A represents a heteroaryl group selected from: ##STR00573## wherein one of X.sup.1, X.sup.2 and X.sup.3 represents an N, O or S as ring atom and the others of X.sup.1, X.sup.2 and X.sup.3 represent carbon as ring atoms, and wherein X.sup.4, X.sup.5, X.sup.6 and X.sup.7 represent carbon as ring atoms or one of X.sup.4, X.sup.5, X.sup.6 and X.sup.7 represents an N atom, and the others of X.sup.4, X.sup.5, X.sup.6 and X.sup.7 represent carbon as ring atoms, and wherein X.sup.1 and X.sup.2 or X.sup.2 and X.sup.3 or X.sup.4 and X.sup.5 or X.sup.5 and X.sup.6 or X.sup.6 and X.sup.7 optionally form part of an additional 5-membered or 6-membered ring, which optionally contains one further heteroatom selected from the group consisting of O, N and S, and which ring is unsaturated or partially saturated, and wherein * indicates the point of attachment of said groups with the rest of the molecule, said heteroaryl group, which is monocyclic or bicyclic, being optionally substituted, one or two times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, 5-membered heteroaryl, —(═O)OR.sup.3, —(═O)(NR.sup.4)R.sup.5, —N(R.sup.4)R.sup.5, said phenyl and 5-membered heteroaryl being optionally substituted, one or two times, identically or differently, with a substituent selected from: a halogen atom, or a C.sub.1-C.sub.3-alkyl-, or a C.sub.1-C.sub.3-alkoxy-group, R.sup.1 represents a methyl-group, R.sup.2 represents a group selected from: phenyl or pyridinyl, said phenyl and pyridinyl being substituted, one or two times, identically or differently, with a group selected from: HO—(C.sub.1-C.sub.6-alkyl)-, HO—(C.sub.2-C.sub.6-alkoxy)-, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, (C.sub.1-C.sub.3-alkoxy)-(C.sub.2-C.sub.6-alkoxy)-, (C.sub.1-C.sub.3-haloalkoxy)-(C.sub.1-C.sub.6-alkyl)-, cyano, R.sup.7(R.sup.8)N—(C.sub.1-C.sub.6-alkyl)-, R.sup.6O(C═O)—(C.sub.1-C.sub.6-alkyl)-, cyano-(C.sub.1-C.sub.6-alkyl)-, R.sup.6O(C═O)—(C.sub.1-C.sub.6-alkoxy)-, R.sup.7(R.sup.8)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.7(R.sup.8)N—(C.sub.2-C.sub.6-alkoxy)-, R.sup.7(R.sup.8)NC(═O)—(C.sub.1-C.sub.6-alkoxy)-, —(═O)OR.sup.6, —N(R.sup.7)R.sup.8, —N(R.sup.9)C(═O)R.sup.10, —N(R.sup.9)C(═O)OR.sup.13, —(═O)N(R.sup.7)R.sup.8, R.sup.13OC(═O)N(R.sup.9)—(C.sub.1-C.sub.6-alkyl)-, R.sup.13OC(═O)N(R.sup.9)—(C.sub.2-C.sub.6-alkoxy)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.1-C.sub.6-alkyl)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.2-C.sub.6-alkoxy)-, R.sup.14S—, R.sup.14S(═O)—, R.sup.14S(═O).sub.2—, R.sup.14S(═NR.sup.15)(═O)—, R.sup.14S—(C.sub.1-C.sub.6-alkyl)-, R.sup.14S(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.14S(═O).sub.2—(C.sub.1-C.sub.6-alkyl)-, R.sup.14S(═NR.sup.15)(═O)—(C.sub.1-C.sub.6-alkyl)-, —S(═O).sub.2N(R.sup.11)R.sup.12, heterocycloalkyl having 5- to 7-members, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkyl)-, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkoxy)-, (heterocycloalkyl having 5- to 7-members)-O—, phenyl, phenyxy, heteroaryl, heteroaryl-O, (C.sub.1-C.sub.6-alkyl)-S(═O).sub.2N(H)—, aryl-S(═O).sub.2N(H)—, an azetidinyl-S(═O).sub.2N(H)— group, or a (heterocycloalkyl having 5- to 7-members)-S(═O).sub.2N(H)— group, said phenyl and phenoxy group being substituted, one or two times, identically or differently, with a substituent selected from: a C.sub.1-C.sub.3-haloalkyl-, (C.sub.1-C.sub.3-haloalkyl)-S—, or a C.sub.1-C.sub.3-haloalkoxy-group, or with two substituents which are in ortho-position to one another and form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, or butane-1,4-diyl, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, and being optionally substituted, one or two times, identically or differently, with a substituent selected from: a halogen atom, a C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.3-haloalkyl, a C.sub.1-C.sub.3-alkoxy, or a C.sub.1-C.sub.3-haloalkoxy-group, said azetidinyl group being optionally substituted with a substituent selected from: a C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.3-C.sub.6-cycloalkyl, cyano, —(═O)OR.sup.6, —(═O)NR.sup.11R.sup.12, HC(═O)—, or (C.sub.1-C.sub.6-alkyl)C(═O)— group, or a halogen atom, said heterocycloalkyl having 5- to 7-members being optionally substituted, 1 to 3 times, identically or differently, with a substituent selected from: a C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, —(═O)OR.sup.6, —(═O)NR.sup.11R.sup.12, HC(═O)—, or (C.sub.1-C.sub.6-alkyl)C(═O)— group, or a halogen atom, and, said phenyl and pyridinyl optionally being additionally substituted, one or two times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, or a halogen atom, R.sup.3 represents: a hydrogen atom, or a group selected from C.sub.1-C.sub.6-alkyl, R.sup.4 represents: a hydrogen atom, or a group selected from C.sub.1-C.sub.6-alkyl, R.sup.5 represents: a hydrogen atom, or a group selected from C.sub.1-C.sub.6-alkyl, or, R.sup.4 and R.sup.5 together with the nitrogen to which they are attached represent: a 5- to 6-membered heterocycloalkyl which optionally contains one further heteroatom selected from the group consisting of O, N and S, R.sup.6 represents: a hydrogen atom, a C.sub.1-C.sub.6-alkyl-group, or a phenyl-(C.sub.1-C.sub.6-alkyl)— group, R.sup.7 and R.sup.8 are independently of each other selected from a group selected from: hydrogen, C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.3-C.sub.6-alkenyl, C.sub.3-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, HO—(C.sub.2-C.sub.6-alkyl)-, (C.sub.1-C.sub.3-alkoxy)-(C.sub.2-C.sub.6-alkyl)-, (C.sub.1-C.sub.3-halolkoxy)-(C.sub.2-C.sub.6-alkyl)-, R.sup.6OC(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.2-C.sub.6-alkyl)-, R.sup.13OC(═O)(R.sup.9)N—(C.sub.2-C.sub.6-alkyl)-, R.sup.14S—(C.sub.2-C.sub.6-alkyl)-, R.sup.14S(═O)—(C.sub.2-C.sub.6-alkyl)-, R.sup.14S(═O).sub.2—(C.sub.2-C.sub.6-alkyl)-, R.sup.14S(═NR.sup.15)(═O)—(C.sub.2-C.sub.6-alkyl)-, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.6-alkyl)-, heteroaryl-(C.sub.1-C.sub.6-alkyl)-, an azetidine-group, heterocycloalkyl having 5- to 7-members, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkyl)-, or R.sup.17, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, cyano, —N(R.sup.11)R.sup.12, or —NR.sup.9C(═O)R.sup.10, whereby two substituents of said phenyl group, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, or butane-1,4-diyl, said azetidine group being optionally substituted with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)-phenyl-(═O)—, heteroaryl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, —(═O)OR.sup.6, or with two halogen atoms, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, said heterocycloalkyl having 5- to 7-members being optionally substituted, one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O), -phenyl-(═O)—, heteroaryl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, or —(═O)OR.sup.6, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, or, R.sup.7 and R.sup.8 together with the nitrogen to which they are attached represent: a azetidine group, said azetidine group optionally being substituted with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-(═O)—, heteroaryl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, —(═O)OR.sup.6, or with two halogen atoms, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, a halogen atom, or cyano, or, R.sup.7 and R.sup.8 together with the nitrogen to which they are attached represent: a heterocycloalkyl having 5- to 7-members, said heterocycloalkyl having 5- to 7-members being optionally substituted, one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom,cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-(═O)—, heteroaryl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, or —(═O)OR.sup.6, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, R.sup.9 represents: a hydrogen atom, or a C.sub.1-C.sub.6-alkyl group, R.sup.10 represents: a hydrogen atom, a C.sub.1-C.sub.6-haloalkyl, or a C.sub.1-C.sub.6-alkyl group, R.sup.11 and R.sup.12 are independently of each other selected from: a hydrogen atom, a C.sub.1-C.sub.6-alkyl or a C.sub.1-C.sub.6-haloalkyl group, or R.sup.11 and R.sup.12 together with the nitrogen to which they are attached represent: an azetidine group or a heterocycloalkyl having 5- to 7-members, said azetidine group being optionally substituted with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-(═O)—, heteroaryl-(═O)—, —(═O)OR.sup.6, or with two halogen atoms, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, said heterocycloalkyl having 5- to 7-members being optionally substituted, 1 to 3 times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-(═O)—, heteroaryl-(═O)—, or —(═O)OR.sup.6, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, R.sup.13 represents a: C.sub.1-C.sub.6-alkyl group, or a phenyl-(C.sub.1-C.sub.6-alkyl)— group, R.sup.14 represents a group selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.3-haloalkyl, or a C.sub.3-C.sub.6-cycloalkyl group, R.sup.15 represents a group selected from: a hydrogen atom, cyano, or —(═O)R.sup.16, R.sup.16 represents a group selected from: C.sub.1-C.sub.6-alkyl, or C.sub.1-C.sub.6-haloalkyl, R.sup.17 represents a C.sub.1-C.sub.6-alkyl group, which is substituted two times, identically or differently, with a substituent selected from: hydroxy, (C.sub.1-C.sub.4-alkoxy), —(═O)OR.sup.6, or —(═O)N(R.sup.18)R.sup.19, R.sup.18 and R.sup.19 are independently of each other selected from: a hydrogen atom, or a C.sub.1-C.sub.3-alkyl group, or R.sup.18 and R.sup.19 together with the nitrogen to which they are attached represent: a 5- to 6-membered heterocycloalkyl which optionally contains one further heteroatom selected from the group consisting of O, N and S, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

3. The compound according to claim 1 or 2, wherein: A represents a heteroaryl group selected from: ##STR00574## wherein X.sup.1 represents an S as ring atom and X.sup.2 and X.sup.3 represent carbon as ring atoms, and wherein X.sup.4, X.sup.5, X.sup.6 and X.sup.7 represent carbon as ring atoms or X.sup.5 represents an N atom, and X.sup.4, X.sup.6 and X.sup.7 represent carbon as ring atoms, and wherein X.sup.2 and X.sup.3 or X.sup.6 and X.sup.7 optionally form part of an additional 5-membered or 6-membered ring, which optionally contains one further heteroatom selected from the group consisting of O, N and S, and which ring is unsaturated or partially saturated, and wherein * indicates the point of attachment of said groups with the rest of the molecule , said heteroaryl group, which is monocyclic or bicyclic, being optionally substituted, one or two times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, a halogen atom, cyano, R.sup.1 represents a methyl-group, R.sup.2 represents a group selected from: phenyl or pyridinyl, said phenyl and pyridinyl being substituted, one or two times, identically or differently, with a group selected from: HO—(C.sub.1-C.sub.6-alkyl)-, HO—(C.sub.2-C.sub.6-alkoxy)-, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, (C.sub.1-C.sub.3-alkoxy)-(C.sub.2-C.sub.6-alkoxy)-, (C.sub.1-C.sub.3-haloalkoxy)-(C.sub.1-C.sub.6-alkyl)-, cyano, R.sup.7(R.sup.8)N—(C.sub.1-C.sub.6-alkyl)-, R.sup.6O(C═O)—(C.sub.1-C.sub.6-alkyl)-, cyano-(C.sub.1-C.sub.6-alkyl)-, R.sup.6O(C═O)—(C.sub.1-C.sub.6-alkoxy)-, R.sup.7(R.sup.8)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.7(R.sup.8)N—(C.sub.2-C.sub.6-alkoxy)-, R.sup.7(R.sup.8)NC(═O)—(C.sub.1-C.sub.6-alkoxy)-, —(═O)OR.sup.6, —N(R.sup.7)R.sup.8, —N(R.sup.9)C(═O)R.sup.10, —N(R.sup.9)C(═O)OR.sup.13, —(═O)N(R.sup.7)R.sup.8, R.sup.13OC(═O)N(R.sup.9)—(C.sub.1-C.sub.6-alkyl)-, R.sup.13OC(═O)N(R.sup.9)—(C.sub.2-C.sub.6-alkoxy)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.1-C.sub.6-alkyl)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.2-C.sub.6-alkoxy)-, R.sup.14S—, R.sup.14S(═O)—, R.sup.14S(═O).sub.2—, R.sup.14S(═NR.sup.15)(═O)—, R.sup.14S—(C.sub.1-C.sub.6-alkyl)-, R.sup.14S(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.14S(═O).sub.2—(C.sub.1-C.sub.6-alkyl)-, R.sup.14S(═NR.sup.15)(═O)—(C.sub.1-C.sub.6-alkyl)-, —S(═O).sub.2N(R.sup.11)R.sup.12, heterocycloalkyl having 5- to 7-members, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkyl)-, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkoxy)-, (heterocycloalkyl having 5- to 7-members)-O—, phenyl, phenoxy, heteroaryl, heteroaryl-O, (C.sub.1-C.sub.6-alkyl)-S(═O).sub.2N(H)—, aryl-S(═O).sub.2N(H)—, an azetidinyl-S(═O).sub.2N(H)— group, or a (heterocycloalkyl having 5- to 7-members)-S(═O).sub.2N(H)— group, said phenyl and phenoxy group being substituted, one or two times, identically or differently, with a substituent selected from: a C.sub.1-C.sub.3-haloalkyl-, (C.sub.1-C.sub.3-haloalkyl)-S—, or a C.sub.1-C.sub.3-haloalkoxy-group, or with two substituents which are in ortho-position to one another and form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, or butane-1,4-diyl, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, and being optionally substituted, one or two times, identically or differently, with a substituent selected from: a halogen atom, a C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.3-haloalkyl, a C.sub.1-C.sub.3-alkoxy, or a C.sub.1-C.sub.3-haloalkoxy-group, said azetidinyl group being optionally substituted with a substituent selected from: a C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, —(═O)OR.sup.6, —(═O)NR.sup.11R.sup.12, HC(═O)—, or (C.sub.1-C.sub.6-alkyl)C(═O)— group, or a halogen atom, said heterocycloalkyl having 5- to 7-members being optionally substituted, 1 to 3 times, identically or differently, with a substituent selected from: a C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.3-C.sub.6-cycloalkyl, cyano, —(═O)OR.sup.6, —(═O)NR.sup.11R.sup.12, HC(═O)—, or (C.sub.1-C.sub.6-alkyl)C(═O)— group, or a halogen atom, and, said phenyl and pyridinyl optionally being additionally substituted, one or two times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, or a halogen atom, R.sup.6 represents: a hydrogen atom, a C.sub.1-C.sub.6-alkyl-group, or a phenyl-(C.sub.1-C.sub.6-alkyl)— group, R.sup.7 and R.sup.8 are independently of each other selected from a group selected from: hydrogen, C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.3-C.sub.6-alkenyl, C.sub.3-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, HO—(C.sub.2-C.sub.6-alkyl)-, (C.sub.1-C.sub.3-alkoxy)-(C.sub.2-C.sub.6-alkyl)-, (C.sub.1-C.sub.3-halolkoxy)-(C.sub.2-C.sub.6-alkyl)-, R.sup.6OC(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.2-C.sub.6-alkyl)-, R.sup.13OC(═O)(R.sup.9)N—(C.sub.2-C.sub.6-alkyl)-, R.sup.14S—(C.sub.2-C.sub.6-alkyl)-, R.sup.14S(═O)—(C.sub.2-C.sub.6-alkyl)-, R.sup.14S(═O).sub.2—(C.sub.2-C.sub.6-alkyl)-, R.sup.14S(═NR.sup.15)(═O)—(C.sub.2-C.sub.6-alkyl)-, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.6-alkyl)-, heteroaryl-(C.sub.1-C.sub.6-alkyl)-, an azetidine-group, heterocycloalkyl having 5- to 7-members, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkyl)-, or R.sup.17, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, cyano, —N(R.sup.11)R.sup.12, or —NR.sup.9C(═O)R.sup.10, whereby two substituents of said phenyl group, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, or butane-1,4-diyl, said azetidine group being optionally substituted with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)-phenyl-(═O)—, heteroaryl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, —(═O)OR.sup.6, or with two halogen atoms, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, said heterocycloalkyl having 5- to 7-members being optionally substituted, one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O), -phenyl-(═O)—, heteroaryl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, or —(═O)OR.sup.6, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, or, R.sup.7 and R.sup.8 together with the nitrogen to which they are attached represent: a azetidine group, said azetidine group optionally being substituted with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-(═O)—, heteroaryl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, —(═O)OR.sup.6, or with two halogen atoms, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, a halogen atom, or cyano, or, R.sup.7 and R.sup.8 together with the nitrogen to which they are attached represent: a heterocycloalkyl having 5- to 7-members, said heterocycloalkyl having 5- to 7-members being optionally substituted, one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom,cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-(═O)—, heteroaryl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, or —(═O)OR.sup.6, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, R.sup.9 represents: a hydrogen atom, or a C.sub.1-C.sub.6-alkyl group, R.sup.10 represents: a hydrogen atom, a C.sub.1-C.sub.6-haloalkyl, or a C.sub.1-C.sub.6-alkyl group, R.sup.11 and R.sup.12 are independently of each other selected from: a hydrogen atom, a C.sub.1-C.sub.6-alkyl or a C.sub.1-C.sub.6-haloalkyl group, or R.sup.11 and R.sup.12 together with the nitrogen to which they are attached represent: an azetidine group or a heterocycloalkyl having 5- to 7-members, said azetidine group being optionally substituted with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, cyano, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-(═O)—, heteroaryl-(═O)—, —(═O)OR.sup.6, or with two halogen atoms, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, said heterocycloalkyl having 5- to 7-members being optionally substituted, 1 to 3 times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-haloalkoxy, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyloxy, hydroxy, a halogen atom, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, HC(═O)—, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-(═O)—, heteroaryl-(═O)—, or —(═O)OR.sup.6, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.1-C.sub.3-alkoxy, C.sub.3-C.sub.6-cycloalkyloxy, C.sub.1-C.sub.3-haloalkyl, C.sub.1-C.sub.3-haloalkoxy, halogen, or cyano, R.sup.13 represents a: C.sub.1-C.sub.6-alkyl group, or a phenyl-(C.sub.1-C.sub.6-alkyl)— group, R.sup.14 represents a group selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.3-haloalkyl, or a C.sub.3-C.sub.6-cycloalkyl group, R.sup.15 represents a group selected from: a hydrogen atom, cyano, or —(═O)R.sup.16, R.sup.16 represents a group selected from: C.sub.1-C.sub.6-alkyl, or C.sub.1-C.sub.6-haloalkyl, R.sup.17 represents a C.sub.1-C.sub.6-alkyl group, which is substituted two times, identically or differently, with a substituent selected from: hydroxy, (C.sub.1-C.sub.4-alkoxy), —(═O)OR.sup.6, or —(═O)N(R.sup.18)R.sup.19, R.sup.18 and R.sup.19 are independently of each other selected from: a hydrogen atom, or a C.sub.1-C.sub.3-alkyl group, or R.sup.18 and R.sup.19 together with the nitrogen to which they are attached represent: a 5- to 6-membered heterocycloalkyl which optionally contains one further heteroatom selected from the group consisting of O, N and S, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

4. The compound according to any one of claim 1, 2 or 3, wherein: A represents a heteroaryl group selected from: ##STR00575## wherein X.sup.1 represents an S as ring atom and X.sup.2 and X.sup.3 represent carbon as ring atoms, and wherein X.sup.4, X.sup.5, X.sup.6 and X.sup.7 represent carbon as ring atoms or X.sup.5 represents an N atom, and X.sup.4, X.sup.6 and X.sup.7 represent carbon as ring atoms, and wherein X.sup.2 and X.sup.3 or X.sup.6 and X.sup.7 optionally form part of an additional 5-membered or 6-membered ring, which optionally contains one further heteroatom selected from the group consisting of O, N and S, and which ring is unsaturated or partially saturated, and wherein * indicates the point of attachment of said groups with the rest of the molecule, said heteroaryl group, which is monocyclic or bicyclic, being optionally substituted, one or two times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, a halogen atom, cyano, R.sup.1 represents a methyl-group, R.sup.2 represents a group selected from: phenyl or pyridinyl, said phenyl and pyridinyl being substituted, one or two times, identically or differently, with a group selected from: HO—(C.sub.2-C.sub.6-alkoxy)-, (C.sub.1-C.sub.3-alkoxy)-(C.sub.2-C.sub.6-alkoxy)-, R.sup.6O(C═O)—(C.sub.1-C.sub.6-alkyl)-, cyano-(C.sub.1-C.sub.6-alkyl)-, R.sup.6O(C═O)—(C.sub.1-C.sub.6-alkoxy)-, R.sup.7(R.sup.8)N—(C.sub.2-C.sub.6-alkoxy)-, - C(═O)OR.sup.6, —N(R.sup.7)R.sup.8, —N(R.sup.9)C(═O)R.sup.10, —N(R.sup.9)C(═O)OR.sup.13, —(═O)N(R.sup.7)R.sup.8, R.sup.13OC(═O)N(R.sup.9)—(C.sub.2-C.sub.6-alkoxy)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.2-C.sub.6-alkoxy)-, R.sup.14S(═O).sub.2—, —S(═O).sub.2N(R.sup.11)R.sup.12, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkoxy)-, (heterocycloalkyl having 5- to 7-members)-O—, phenoxy, heteroaryl, heteroaryl-O, an azetidinyl-S(═O).sub.2N(H)— group, or a (heterocycloalkyl having 5- to 7-members)-S(═O).sub.2N(H)— group, said phenoxy group being substituted, one or two times, identically or differently, with a substituent selected from: a C.sub.1-C.sub.3-haloalkyl-, or a (C.sub.1-C.sub.3-haloalkyl)-S— group, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, and being optionally substituted, one or two times, identically or differently, with a substituent selected from: a C.sub.1-C.sub.6-alkyl-group, said azetidinyl group being optionally substituted with a substituent selected from: a C.sub.1-C.sub.6-haloalkyl-group, said heterocycloalkyl having 5- to 7-members being optionally substituted, 1 to 3 times, identically or differently, with a substituent selected from: a C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.3-C.sub.6-cycloalkyl, cyano, —(═O)OR.sup.6, —(═O)NR.sup.11R.sup.12, HC(═O)—, or (C.sub.1-C.sub.6-alkyl)C(═O)— group, or a halogen atom, and, said phenyl and pyridinyl optionally being additionally substituted, one or two times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkoxy, or a halogen atom, R.sup.6 represents: a hydrogen atom, a C.sub.1-C.sub.6-alkyl-group, or a phenyl-(C.sub.1-C.sub.6-alkyl)— group, R.sup.7 and R.sup.8 are independently of each other selected from a group selected from: hydrogen, C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, C.sub.3-C.sub.6-alkynyl, C.sub.3-C.sub.6-cycloalkyl, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, HO—(C.sub.2-C.sub.6-alkyl)-, (C.sub.1-C.sub.3-alkoxy)-(C.sub.2-C.sub.6-alkyl)-, R.sup.6OC(═O)—(C.sub.1-C.sub.6-alkyl)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.2-C.sub.6-alkyl)-, R.sup.13OC(═O)(R.sup.9)N—(C.sub.2-C.sub.6-alkyl)-, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.6-alkyl)-, heteroaryl-(C.sub.1-C.sub.6-alkyl)-, an azetidine-group, heterocycloalkyl having 5- to 7-members, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkyl)-, or R.sup.17, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkoxy, halogen, —N(R.sup.11)R.sup.12, or —NR.sup.9C(═O)R.sup.10, whereby two substituents of said phenyl group, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, said azetidine group being optionally substituted with a substituent selected from: C.sub.1-C.sub.6-haloalkyl, said heterocycloalkyl having 5- to 7-members being optionally substituted, one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-haloalkyl, a halogen atom, or —(═O)OR.sup.6, or, R.sup.7 and R.sup.8 together with the nitrogen to which they are attached represent: a heterocycloalkyl having 5- to 7-members, said heterocycloalkyl having 5- to 7-members being optionally substituted, one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-haloalkyl, (C.sub.1-C.sub.3-alkoxy)-(C.sub.1-C.sub.6-alkyl)-, phenyl, heteroaryl, phenyl-(C.sub.1-C.sub.3-alkyl)-, heteroaryl-(C.sub.1-C.sub.3-alkyl)-, (C.sub.1-C.sub.6-alkyl)-(═O)—, phenyl-C(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.6-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.6-alkyl)-, or —(═O)OR.sup.6, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: halogen, or cyano, R.sup.9 represents: a hydrogen atom, or a C.sub.1-C.sub.6-alkyl group, R.sup.10 represents: a C.sub.1-C.sub.6-haloalkyl, or a C.sub.1-C.sub.6-alkyl group, R.sup.11 and R.sup.12 are independently of each other selected from: a hydrogen atom, or a C.sub.1-C.sub.6-alkyl group, or R.sup.11 and R.sup.12 together with the nitrogen to which they are attached represent: a heterocycloalkyl having 5- to 7-members, said heterocycloalkyl having 5- to 7-members being optionally substituted, 1 to 3 times, identically or differently, with a substituent selected from: a halogen atom, or —(═O)OR.sup.6, R.sup.13 represents a: C.sub.1-C.sub.6-alkyl group, R.sup.14 represents a group selected from: C.sub.1-C.sub.6-alkyl, or a C.sub.1-C.sub.3-haloalkyl group, R.sup.17 represents a C.sub.1-C.sub.6-alkyl group, which is substituted two times, identically or differently, with a substituent selected from: hydroxy, (C.sub.1-C.sub.4-alkoxy), —(═O)OR.sup.6, or —(═O)N(R.sup.18)R.sup.19, R.sup.18 and R.sup.19 are independently of each other selected from: a hydrogen atom, or a C.sub.1-C.sub.3-alkyl group, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

5. The compound according to any one of claims 1 to 4, wherein: A represents a heteroaryl group selected from: ##STR00576## wherein X.sup.1 represents an S as ring atom and X.sup.2 and X.sup.3 represent carbon as ring atoms, and wherein X.sup.4, X.sup.5, X.sup.6 and X.sup.7 represent carbon as ring atoms or X.sup.5 represents an N atom, and X.sup.4, X.sup.6 and X.sup.7 represent carbon as ring atoms, and wherein X.sup.2 and X.sup.3 or X.sup.6 and X.sup.7 optionally form part of an additional 6- membered ring, which ring is unsaturated, and wherein * indicates the point of attachment of said groups with the rest of the molecule, said heteroaryl group, which is monocyclic or bicyclic, being optionally substituted, one or two times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, trifluoromethyl, cyano, R.sup.1 represents a methyl-group, R.sup.2 represents a group selected from: phenyl or pyridinyl, said phenyl and pyridinyl being substituted, one or two times, identically or differently, with a group selected from: HO—(C.sub.2-C.sub.3-alkoxy)-, (C.sub.1-C.sub.3-alkoxy)-(C.sub.2-C.sub.3-alkoxy)-, R.sup.6O(C═O)—(C.sub.1-C.sub.4-alkyl)-, cyanomethyl-, R.sup.6O(C═O)—(C.sub.1-C.sub.3-alkoxy)-, R.sup.7(R.sup.8)N—(C.sub.2-C.sub.3-alkoxy)-, —(═O)OR.sup.6, —N(R.sup.7)R.sup.8, —N(R.sup.9)C(═O)R.sup.10, —N(R.sup.9)C(═O)OR.sup.13, —(═O)N(R.sup.7)R.sup.8, R.sup.13OC(═O)N(R.sup.9)—(C.sub.2-C.sub.3-alkoxy)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.2-C.sub.3-alkoxy)-, R.sup.14S(═O).sub.2—, —S(═O).sub.2N(R.sup.11)R.sup.12, (heterocycloalkyl having 5- to 7-members)-(methoxy)-, (heterocycloalkyl having 5- to 7-members)-O—, phenoxy, heteroaryl, heteroaryl-O, an azetidinyl-S(═O).sub.2N(H)— group, or a (heterocycloalkyl having 5- to 7-members)-S(═O).sub.2N(H)— group, said phenoxy group being substituted, one or two times, identically or differently, with a substituent selected from: a trifluoromethyl-, or a (trifluoromethyl)-S— group, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, and being optionally substituted, one or two times, identically or differently, with a substituent selected from: a C.sub.1-C.sub.4-alkyl-group, said azetidinyl group being optionally substituted with a substituent selected from: a C.sub.1-C.sub.3-haloalkyl-group, said heterocycloalkyl having 5- to 7-members being optionally substituted, 1 to 3 times, identically or differently, with a substituent selected from: a C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.4-haloalkyl, —(═O)OR.sup.6, (C.sub.1-C.sub.3-alkyl)C(═O)— group, or a halogen atom, and, said phenyl and pyridinyl optionally being additionally substituted, one or two times, identically or differently, with a substituent selected from: methoxy, or a halogen atom, R.sup.6 represents: a hydrogen atom, a C.sub.1-C.sub.4-alkyl-group, or a benzyl-group, R.sup.7 and R.sup.8 are independently of each other selected from a group selected from: hydrogen, C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.2-haloalkyl, propargyl, cyclopropyl, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.3-alkyl)-, HO—(C.sub.2-C.sub.3-alkyl)-, methoxy-(C.sub.2-C.sub.3-alkyl)-, R.sup.6OC(═O)—(C.sub.1-C.sub.2-alkyl)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.2-C.sub.3-alkyl)-, R.sup.13OC(═O)(R.sup.9)N—(C.sub.2-C.sub.3-alkyl)-, phenyl, benzyl-, heteroaryl-(C.sub.1-C.sub.2-alkyl)-, an azetidine-group, heterocycloalkyl having 5- to 7-members, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.2-alkyl)-, or R.sup.17, wherein phenyl is optionally substituted one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkoxy, halogen, —N(R.sup.11)R.sup.12, or —NR.sup.9C(═O)R.sup.10, whereby two substituents of said phenyl group, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, said azetidine group being optionally substituted with a substituent selected from: C.sub.1-C.sub.3-haloalkyl, said heterocycloalkyl having 5- to 7-members being optionally substituted, one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-haloalkyl, a halogen atom, or —(═O)OR.sup.6, or, R.sup.7 and R.sup.8 together with the nitrogen to which they are attached represent: a heterocycloalkyl having 5- to 7-members, said heterocycloalkyl having 5- to 7-members being optionally substituted, one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-haloalkyl, methoxy-(C.sub.1-C.sub.2-alkyl)-, phenyl, heteroaryl, benzyl-, heteroaryl-(C.sub.1-C.sub.2-alkyl)-, acetyl, phenyl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.3-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.3-alkyl)-, or —(═O)OR.sup.6, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: halogen, or cyano, R.sup.9 represents: a hydrogen atom, or a methyl group, R.sup.10 represents: a C.sub.1-C.sub.3-haloalkyl, or a C.sub.1-C.sub.4-alkyl group, R.sup.11 and R.sup.12 are independently of each other selected from: a hydrogen atom, or a C.sub.1-C.sub.3-alkyl group, or R.sup.11 and R.sup.12 together with the nitrogen to which they are attached represent: a heterocycloalkyl having 5- to 7-members, said heterocycloalkyl having 5- to 7-members being optionally substituted, 1 to 3 times, identically or differently, with a substituent selected from: a halogen atom, or —(═O)OR.sup.6, R.sup.13 represents a: C.sub.1-C.sub.4-alkyl group, R.sup.14 represents a group selected from: C.sub.1-C.sub.4-alkyl, or a C.sub.1-C.sub.3-haloalkyl group, R.sup.17 represents a C.sub.1-C.sub.3-alkyl group, which is substituted two times, identically or differently, with a substituent selected from: hydroxy, (C.sub.1-C.sub.4-alkoxy), —(═O)OR.sup.6, or —(═O)N(R.sup.18)R.sup.19, R.sup.18 and R.sup.19 are independently of each other selected from: a hydrogen atom, or a methyl group, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

6. The compound according to any one of claim 1, 2 or 3, wherein: A represents a heteroaryl group selected from: ##STR00577## wherein X.sup.1 represents an S as ring atom and X.sup.2 and X.sup.3 represent carbon as ring atoms, and wherein X.sup.4, X.sup.5, X.sup.6 and X.sup.7 represent carbon as ring atoms or X.sup.5 represents an N atom, and X.sup.4, X.sup.6 and X.sup.7 represent carbon as ring atoms, and wherein X.sup.2 and X.sup.3 or X.sup.6 and X.sup.7 optionally form part of an additional 6- membered ring, which ring is unsaturated, and wherein * indicates the point of attachment of said groups with the rest of the molecule, said heteroaryl group, which is monocyclic or bicyclic, being optionally substituted, one or two times, identically or differently, with a substituent selected from: trifluoromethyl, cyano, R.sup.1 represents a methyl-group, R.sup.2 represents a group selected from: phenyl or pyridinyl, said phenyl and pyridinyl being substituted, one or two times, identically or differently, with a group selected from: HO—(C.sub.2-C.sub.3-alkoxy)-, (methoxy)-(C.sub.2-C.sub.3-alkoxy)-, R.sup.6O(C═O)—(C.sub.1-C.sub.4-alkyl)-, cyanomethyl-, R.sup.6O(C═O)—(C.sub.1-C.sub.3-alkoxy)-, R.sup.7(R.sup.8)N—(C.sub.2-C.sub.3-alkoxy)-, —(═O)OR.sup.6, —N(R.sup.7)R.sup.8, —N(R.sup.9)C(═O)R.sup.10, —N(R.sup.9)C(═O)OR.sup.13, —(═O)N(R.sup.7)R.sup.8, R.sup.13OC(═O)N(R.sup.9)—(C.sub.2-C.sub.3-alkoxy)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.2-C.sub.3-alkoxy)-, R.sup.14S(═O).sub.2—, —S(═O).sub.2N(R.sup.11)R.sup.12, heterocycloalkyl having 5- to 7-members, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkyl)-, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.2-alkoxy)-, (heterocycloalkyl having 5- to 7-members)-O—, phenoxy, heteroaryl, heteroaryl-O, an azetidinyl-S(═O).sub.2N(H)— group, or a (heterocycloalkyl having 5- to 7-members)-S(═O).sub.2N(H)— group, said phenoxy group being substituted, one or two times, identically or differently, with a substituent selected from: a trifluoromethyl-, or a (trifluoromethyl)-S— group, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, and being optionally substituted, one or two times, identically or differently, with a substituent selected from: a C.sub.1-C.sub.4-alkyl-group, said azetidinyl group being optionally substituted with a substituent selected from: a C.sub.2-C.sub.3-haloalkyl-group, said heterocycloalkyl having 5- to 7-members being optionally substituted, 1 to 3 times, identically or differently, with a substituent selected from: a C.sub.2-C.sub.4-alkyl, C.sub.2-C.sub.3-haloalkyl, —(═O)OR.sup.6, acetyl-group, or a fluorine atom, and, said phenyl and pyridinyl optionally being additionally substituted, one or two times, identically or differently, with a substituent selected from: methoxy, or a fluorine atom, R.sup.6 represents: a hydrogen atom, a C.sub.1-C.sub.4-alkyl-group, or a benzyl-group, R.sup.7 and R.sup.8 are independently of each other selected from a group selected from: hydrogen, C.sub.1-C.sub.4-alkyl, C.sub.2-C.sub.3-haloalkyl, propargyl, cyclopropyl, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.3-alkyl)-, HO—(C.sub.2-C.sub.3-alkyl)-, methoxy-(C.sub.2-C.sub.3-alkyl)-, R.sup.6OC(═O)—(C.sub.1-C.sub.2-alkyl)-, R.sup.10C(═O)(R.sup.9)N—(C.sub.2-C.sub.3-alkyl)-, R.sup.13OC(═O)(R.sup.9)N—(C.sub.2-C.sub.3-alkyl)-, phenyl, benzyl-, heteroaryl-(C.sub.1-C.sub.2-alkyl)-, an azetidine-group, heterocycloalkyl having 5- to 7-members, (heterocycloalkyl having 5- to 7-members)-(C.sub.1-C.sub.3-alkyl)-, or R.sup.17, wherein phenyl is optionally substituted one, two or three times, identically or differently, with a substituent selected from: methoxy, a fluorine atom, —N(R.sup.11)R.sup.12, or —NR.sup.9C(═O)R.sup.10, whereby two substituents of said phenyl group, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, said azetidine group being optionally substituted with a substituent selected from: C.sub.2-haloalkyl, said heterocycloalkyl having 5- to 7-members being optionally substituted, one, two or three times, identically or differently, with a substituent selected from: C.sub.2-haloalkyl, a fluorine atom, or —(═O)OR.sup.6, or, R.sup.7 and R.sup.8 together with the nitrogen to which they are attached represent: a heterocycloalkyl having 5- to 7-members, said heterocycloalkyl having 5- to 7-members being optionally substituted, one, two or three times, identically or differently, with a substituent selected from: C.sub.1-C.sub.3-alkyl, C.sub.2-C.sub.3-haloalkyl, 2-methoxy(ethyl)-, phenyl, heteroaryl, benzyl-, heteroaryl-(C.sub.1-C.sub.2-alkyl)-, acetyl, phenyl-(═O)—, —N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)N—(C.sub.2-C.sub.3-alkyl)-, —NR.sup.9C(═O)R.sup.10, —(═O)N(R.sup.11)R.sup.12, R.sup.11(R.sup.12)NC(═O)—(C.sub.1-C.sub.3-alkyl)-, or —(═O)OR.sup.6, said heteroaryl group being a heteroaryl containing 1 to 3 heterotatoms, wherein phenyl and heteroaryl groups are optionally substituted one, two or three times, identically or differently, with a substituent selected from: a fluorine atom, or cyano, R.sup.9 represents: a hydrogen atom, or a methyl group, R.sup.10 represents: a trifluoromethyl-, or a methyl-group, R.sup.11 and R.sup.12 are independently of each other selected from: a hydrogen atom, or a C.sub.1-C.sub.2-alkyl group, or R.sup.11 and R.sup.12 together with the nitrogen to which they are attached represent: a heterocycloalkyl having 5- to 7-members, R.sup.13 represents a: C.sub.1-C.sub.4-alkyl group, R.sup.14 represents a methyl group, R.sup.17 represents a C.sub.1-C.sub.3-alkyl group, which is substituted two times, identically or differently, with a substituent selected from: hydroxy, (C.sub.1-C.sub.4-alkoxy), —(═O)OR.sup.6, or —(═O)N(R.sup.18)R.sup.19, R.sup.18 and R.sup.19 are independently of each other selected from: a hydrogen atom, or a methyl group, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

7. The compound according to any one of claims 1 to 6, which is selected from the group consisting of: N-[3-Fluoro-4-(2-methoxyethoxy)phenyl]-3-methyl-5-{[4-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino}-1,2-thiazole-4-carboxamide; N-[6-(2-Hydroxyethoxy)pyridin-3-yl]-3-methyl-5-{[4-(trifluoromethyl)-1,3-benzo-thiazol-2-yl]amino}-1,2-thiazole-4-carboxamide; N-[6-(2-Methoxyethoxy)pyridin-3-yl]-3-methyl-5-{[4-(trifluoromethyl)-1,3-benzo-thiazol-2-yl]amino}-1,2-thiazole-4-carboxamide; N-[3-Fluoro-4-(2-hydroxyethoxy)phenyl]-3-methyl-5-{[4-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino}-1,2-thiazole-4-carboxamide; tert-Butyl 4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate; 3-Methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]-amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(2-Fluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoro-methyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(2,2-Difluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2yl]amino}-N-(6-{[1-(3,3,3-trifluoropropyl)-piperidin-4-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-{6-[(1-Acetylpiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-5-{[5-(trifluoromethyl)-pyrazin-2yl]amino}-1,2-thiazole-4-carboxamide; tert-Butyl 4-[(5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate; 3-Methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[6-(trifluoromethyl)pyrazin-2-yl]-amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(2-Fluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(2,2-Difluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-5-{[6-(trifluoromethyl)pyrazin-2yl]amino}-1,2-thiazole-4-carboxamide; N-{6-[(1-Acetylpiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-5-{[6-(trifluoromethyl)-pyrazin-2yl]amino}-1,2-thiazole-4-carboxamide; tert-Butyl 4-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)pyridin-2-yl]oxy}piperidine-1-carboxylate; 3-Methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(6-{[1-(2,2-difluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-Methyl-5-(quinoxalin-2-ylamino)-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}-pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-{6-[(1-acetylpiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; tert-Butyl 4-({5-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}- carbonyl)amino]pyridin-2-yl}oxy)piperidine-1-carboxylate; 5-[(4-Cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-1,2-thiazole-4-carboxamide; 5-[(4-Cyanopyridin-2-yl)amino]-3-methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; 5-[(4-Cyanopyridin-2-yl)amino]-N-{6-[(1-ethylpiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-1,2-thiazole-4-carboxamide; tert-Butyl 4-({5-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)piperidine-1-carboxylate; 5-[(5-Cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-1,2-thiazole-4-carboxamide; 5-[(5-Cyanopyridin-2-yl)amino]-N-(6-{[1-(2-fluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-1,2-thiazole-4-carboxamide; 5-[(5-Cyanopyridin-2-yl)amino]-3-methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; tert-Butyl 3-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)pyridin-2-yl]oxy}piperidine-1-carboxylate; 3-Methyl-N-[6-(piperidin-3-yloxy)pyridin-3-yl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(6-{[1-(2,2-Difluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; tert-Butyl 3-({5-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)piperidine-1-carboxylate; 5-[(4-Cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-3-yloxy)pyridin-3-yl]-1,2-thiazole-4-carboxamide; tert-Butyl 3-({5-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)piperidine-1-carboxylate; 5-[(5-Cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-3-yloxy)pyridin-3-yl]-1,2-thiazole-4-carboxamide; 5-[(5-Cyanopyridin-2-yl)amino]-N-(6-{[1-(2-fluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-3-methyl-1,2-thiazole-4-carboxamide; 5-[(5-Cyanopyridin-2-yl)amino]-N-(6-{[1-(2,2-difluoroethyl)piperidin-3-yl]oxy}-pyridin-3-yl)-3-methyl-1,2-thiazole-4-carboxamide; 5-[(5-Cyanopyridin-2-yl)amino]-3-methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; tert-Butyl 3-{[5-({[3-methyl-5-(pyrazin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-pyridin-2-yl]oxy}piperidine-1-carboxylate; tert-Butyl (3-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)pyridin-2-yl]oxy}propyl)carbamate; tert-Butyl [3-({5-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)propyl]carbamate; N-[6-(3-Aminopropoxy)pyridin-3-yl]-5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazole-4-carboxamide; 5-[(4-Cyanopyridin-2-yl)amino]-N-(6-{3-[(2,2-difluoroethyl)amino]propoxy}pyridin-3-yl)-3-methyl-1,2-thiazole-4-carboxamide; tert-Butyl [3-({5-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)propyl]carbamate; tert-Butyl (3-{[5-({[3-methyl-5-(pyrazin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)pyridin-2-yl]oxy}propyl)carbamate; N-[6-(3-Aminopropoxy)pyridin-3-yl]-3-methyl-5-(pyrazin-2-ylamino)-1,2-thiazole-4-carboxamide; tert-Butyl 3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoate; Methyl 3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoate; 3-({[3-Methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)benzoic acid, 3-Methyl-N-[3-(morpholin-4-ylcarbonyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-[3-(tert-Butylcarbamoyl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide.; tert-Butyl N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)benzoyl]glycinate; tert-Butyl 4-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)benzoyl]piperazine-1-carboxylate; tert-butyl N.sup.2-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)benzoyl]glutaminate; tert-Butyl O-tert-butyl-N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4 yl]-carbonyl}amino)benzoyl]threoninate; N-(3-{[2-(Dimethylamino)ethyl](methyl)carbamoyl}phenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-{3-[(2-hydroxyethyl)(methyl)carbamoyl]phenyl}-3-methyl-5-(quinoxalin-2-yl-amino)-1,2-thiazole-4-carboxamide; 3-Methyl-N-(3-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-[3-(1,4′-Bipiperidin-1′-ylcarbonyl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-Methyl-N-{3-[methyl(prop-2-yn-1-yl)carbamoyl]phenyl}-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-[3-(1,3-Benzodioxol-5-ylcarbamoyl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-Methyl-5-(quinoxalin -2-ylamino)-N-{3-[(2,2,2-trifluoroethyl)carbamoyl]phenyl}-1,2-thiazole-4-carboxamide; 3-Methyl-N-(3-{[4-(morpholin-4-yl)phenyl]carbamoyl}phenyl)-5-(quinoxalin-2-yl-amino)-1,2-thiazole-4-carboxamide; N-(3-{[2-(Acetylamino)ethyl]carbamoyl}phenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-{3-[Ethyl(methyl)carbamoyl]phenyl}-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(3-{[3-(Dimethylamino)propyl](methyl)carbamoyl}phenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-Methyl-5-(quinoxalin-2-ylamino)-N-{3-[(3,4,5-trimethoxybenzyl)carbamoyl]-phenyl}-1,2-thiazole-4-carboxamide; N-{3-[(4-Acetylpiperazin-1-yl)carbonyl]phenyl}-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-Methyl-N-(3-{[2-(morpholin-4-yl)ethyl]carbamoyl}phenyl)-5-(quinoxalin-2-yl-amino)-1,2-thiazole-4-carboxamide; 3-Methyl-N-(3-{[2-(pyrrolidin-1-yl)ethyl]carbamoyl}phenyl)-5-(quinoxalin-2-yl-amino)-1,2-thiazole-4-carboxamide3-Methyl-N-[3-(prop-2-yn-1-ylcarbamoyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; Methyl N-[3-({[3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoyl]-β-alaninate; N-(3-{[2-(dimethylamino)ethyl]carbamoyl}phenyl)-3-methyl-5-(quinoxalin-2-yl-amino)-1,2-thiazole-4-carboxamide; Methyl N-methyl-N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]-carbonyl}amino)benzoyl]glycinate; 3-Methyl-5-(quinoxalin-2-ylamino)-N-{3-[(3,4,5-trimethoxyphenyl)carbamoyl]-phenyl}-1,2-thiazole-4-carboxamide; N-(3-{[4-(2-Fluorophenyl)piperazin-1-yl]carbonyl}phenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-Methyl-N-(3-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}phenyl)-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(3-{[4-(2-Cyanophenyl)piperazin-1-yl]carbonyl}phenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-Methyl-N-(3-{methyl[2-(pyridin-4-yl)ethyl]carbamoyl}phenyl)-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(3-{[2-(Acetylamino)phenyl]carbamoyl}phenyl)-3-methyl-5-(quinoxalin-2-yl-amino)-1,2-thiazole-4-carboxamide; N-{3-[(3-Methoxypropyl)carbamoyl]phenyl}-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(3-{[(3S)-3-(acetylamino)pyrrolidin-1-yl]carbonyl}phenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(3-{[4-(3-Fluorophenyl)piperazin-1-yl]carbonyl}phenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-{3-[(4-Benzoylpiperazin-1-yl)carbonyl]phenyl}-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-[3-({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(3-{[4-(2-Methoxyethyl)piperazin-1-yl]carbonyl}phenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(3-{[4-(4-Fluorobenzyl)piperazin-1-yl]carbonyl}phenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-Methyl-N-[3- ({4-[2-(pyridin-2-yl)ethyl]piperazin-1-yl}carbonyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-Methyl-N-(3-{[3-(morpholin-4-yl)propyl]carbamoyl}phenyl)-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; tert-Butyl 4-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}benzoate; 4-{[(3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]-amino}benzoic acid; tert-Butyl 4-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}carbonyl)-amino]benzoate; N-[3-({[3-Methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)benzoyl]-glycine; Methyl N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoyl]glycinate; 3-Methyl-N-[3-(piperazin-1-ylcarbonyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-Methyl-N-{3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N.sup.2-[3-({[3-Methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoyl]glutamine; O-tert-Butyl-N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]-carbonyl}amino)benzoyl]threonine; N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoyl]threonine; 3-Methyl-N-[3-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-[3-(5-tert-Butyl-1,3,4-oxadiazol-2-yl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-[3-(3-tert-Butyl-1,2,4-oxadiazol-5-yl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; tert-Butyl 3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate; tert-Butyl 3-{[(5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate; 3-Methyl-N-[4-(methylsulfamoyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(6-{2-[Acetyl(methyl)amino]-ethoxy}pyridin-3-yl)-3-methyl-5-{[4-(trifluoro-methyl)-1,3-benzothiazol-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-N-[3-(pyrrolidin-1-ylcarbonyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 5-[(4-Cyanopyridin-2-yl)amino]-3-methyl-N-[3-(pyrrolidin-1-ylcarbonyl)phenyl]-1,2-thiazole-4-carboxamide; 3-Methyl-N-[4-(methylsulfonyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-[4-(Ethylsulfamoyl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-Methyl-5-(quinoxalin-2-ylamino)-N-{6-[3-(trifluoromethyl)phenoxy]pyridin-3-yl}-1,2-thiazole-4-carboxamide; 5-[(5-Cyanopyridin-2-yl)amino]-3-methyl-N-{6-[3-(trifluoromethyl)phenoxy]pyridin-3-yl}-1,2-thiazole-4-carboxamide; 5-[(4-Cyanopyridin-2-yl)amino]-3-methyl-N-[6-(pyridin-3-yloxy)pyridin-3-yl]-1,2-thiazole-4-carboxamide; 3-Methyl-N-[6-(pyrrolidin-3-ylmethoxy)pyridin-3-yl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoroacetic acid; N-(6-{[1-(2-fluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-N-(6-{[1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; tert-Butyl (3R)-3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate; 3-Methyl-N-{6-[(3R)-pyrrolidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with hydrochloric acid; N-(6-{[(3R)-1-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-N-(6-{[(3R)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3R)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; tert-Butyl (3S)-3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate; 3-Methyl-N-{6-[(3S)-pyrrolidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with hydrochloric acid; N-(6-{[(3S)-1-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-N-(6-{[(SR)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3S)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; tert-Butyl (3S,4R)-3-fluoro-4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate; N-(6-{[(3S,4R)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoroacetic acid; N-(6-{[(3S,4R)-1-(2,2-difluoroethyl)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3S,4R)-3-fluoro-1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3S,4R)-3-fluoro-1-(3,3,3-trifluoropropyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3S,4R)-3-fluoro-1-propylpiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3S,4R)-1-butyl-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; tert-Butyl (3R,4S)-3-fluoro-4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate; N-(6-{[(3R,4S)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoroacetic acid; N-(6-{[(3R,4S)-1-(2,2-difluoroethyl)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4S)-3-fluoro-1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4S)-3-fluoro-1-(3,3,3-trifluoropropyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4S)-3-fluoro-1-propylpiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4S)-1-butyl-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 5-[(6-fluoroquinoxalin-2-yl)amino]-3-methyl-N-(4-sulfamoylphenyl)-1,2-thiazole-4-carboxamide; 5-[(5-cyanopyridin-2-yl)amino]-3-methyl-N-[3-(methylsulfonyl)phenyl]-1,2-thiazole-4-carboxamide; N-(3-carbamoyl-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-acetamido-4-fluorophenyl)-5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazole-4-carboxamide; N-(4-{[2-(3,3-difluoropiperidin-1-yl)ethyl]carbamoyl}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-{[4-(2,2-difluoroethyl)piperazin-1-yl]carbonyl}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-{[2-(3-fluoropiperidin-1-yl)ethyl]carbamoyl}phenyl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-{[2-(3,3-difluoropiperidin-1-yl)ethyl]carbamoyl}phenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(4-{[4-(2,2-difluoroethyl)piperazin-1-yl]carbonyl}phenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; tert-butyl 3,3-difluoro-5-{[4-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)benzoyl]amino}piperidine-1-carboxylate; 3-methyl-5-(quinoxalin-2-ylamino)-N-(4-{[4-(2,2,2-trifluoroethyl)-1,4-diazepan-1-yl]carbonyl}phenyl)-1,2-thiazole-4-carboxamide; N-{6-[(1-isopropylpiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-fluoro-4-{[1-(2-fluoroethyl)piperidin-4-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-fluoro-4-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-{[1-(2,2-difluoroethyl)piperidin-4-yl]oxy}-3-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(4-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]carbamoyl}phenyl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; tert-butyl 3-{[(5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}piperidine-1-carboxylate; 3-methyl-N-(4-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]carbamoyl}phenyl)-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; tert-butyl 4-(2-fluoro-5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)piperidine-1-carboxylate; 3-methyl-N-[6-(morpholin-4-yl)pyridin-3-yl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; tert-butyl N-{5-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}carbonyl)amino]pyridin-2-yl}alaninate; tert-butyl 3-({5-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}carbonyl)amino]pyridin-2-yl}amino)piperidine-1-carboxylate; N-[6-(cyclopropylamino)pyridin-3-yl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 5-[(5-cyanopyridin-2-yl)amino]-N-[6-methoxy-2-(morpholin-4-yl)pyridin-3-yl]-3-methyl-1,2-thiazole-4-carboxamide; 5-[(4-cyanopyridin-2-yl)amino]-N-(3-{[2-(diethylamino)ethyl]carbamoyl}phenyl)-3-methyl-1,2-thiazole-4-carboxamide; 5-[(4-cyanopyridin-2-yl)amino]-N-[3-(cyclopropylcarbamoyl)phenyl]-3-methyl-1,2-thiazole-4-carboxamide; methyl 3-{3-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}carbonyl)amino]phenyl}propanoate; tert-butyl {4-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}carbonyl)amino]phenyl}carbamate; tert-butyl [3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)phenyl]carbamate; tert-butyl {3-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}carbonyl)amino]phenyl}carbamate; N-(3-aminophenyl)-5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazole-4-carboxamide; tert-butyl 4-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)benzoate; tert-butyl 4-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}carbonyl)amino]benzoate; 5-[(4-cyanopyridin-2-yl)amino]-N-{3-[(2,2-dimethylpropanoyl)amino]phenyl}-3-methyl-1,2-thiazole-4-carboxamide; tert-butyl 4-({[3-methyl-5-(pyrazin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)benzoate; N-{4-[(2,2-dimethylpropanoyl)amino]phenyl}-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-{3-[(2,2-dimethylpropanoyl)amino]phenyl}-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 4-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)benzoic acid, 3-methyl-N-[2-(methylsulfonyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; tert-butyl 3-[(5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate; tert-butyl {3-[(5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]propyl}carbamate; tert-butyl {2-[(5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]ethyl}carbamate; tert-butyl {2-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]ethyl}carbamate; tert-butyl tert-butyl 4-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}benzoate; 3-methyl-N-[3-(methylsulfonyl)phenyl]-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-[3-(methylsulfonyl)phenyl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-[6-(2-aminoethoxy)pyridin-3-yl]-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide N-[6-(2-aminoethoxy)pyridin-3-yl]-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; tert-butyl 3-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)pyridin-2-yl]oxy}propanoate; tert-butyl 3-({5-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}carbonyl)amino]pyridin-2-yl}oxy)propanoate; tert-butyl 3-({5-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}carbonyl)amino]pyridin-2-yl}oxy)propanoate; N-(4-carbamoyl-3-fluorophenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(3-carbamoyl-4-fluorophenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(3-carbamoyl-4-fluorophenyl)-5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazole-4-carboxamide; N-(3-carbamoyl-4-fluorophenyl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-acetamido-4-fluorophenyl)-3-methyl-5-(pyrazin-2-ylamino)-1,2-thiazole-4-carboxamide; N-(3-acetamido-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-[3-fluoro-4-(methylcarbamoyl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 5-[(5-cyanopyridin-2-yl)amino]-N-[3-fluoro-4-(methylcarbamoyl)phenyl]-3-methyl-1,2-thiazole-4-carboxamide; N-[6-(3-aminopropoxy)pyridin-3-yl]-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 5-[(4-cyanopyridin-2-yl)amino]-3-methyl-N-[4-(methylsulfamoyl)phenyl]-1,2-thiazole-4-carboxamide; 3-methyl-N-[4-(methylsulfamoyl)phenyl]-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-[4-(methylsulfamoyl)phenyl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide N-(4-{[2-(3-fluoropiperidin-1-yl)ethyl]carbamoyl}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-{[2-(3,3-difluoropiperidin-1-yl)ethyl]carbamoyl}phenyl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; tert-butyl [2-(2-fluoro-4-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)ethyl]carbamat; tert-butyl [2-(2-fluoro-4-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)ethyl]carbamate; tert-butyl 4-(2-fluoro-4-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)piperidine-1-carboxylate; N-{6-[(1-isopropylpiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-{6-[(1-methylpiperidin-4-yl)oxy]pyridin-3-yl}-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-{6-[(1-methylpiperidin-4-yl)oxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-N-[4-(2-aminoethoxy)-3-fluorophenyl]-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; tert-butyl 4-[(4-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}benzoyl)amino]piperidine-1-carboxylate; N-(3-fluoro-4-{[1-(2-fluoroethyl)piperidin-4-yl]oxy}phenyl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-{[1-(2,2-difluoroethyl)piperidin-4-yl]oxy}-3-fluorophenyl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N—N-(4-{[1-(2,2-difluoroethyl)piperidin-4-yl]carbarmoyl}phenyl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; tert-butyl 4-{[(5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}piperidine-1-carboxylate; tert-butyl 4-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}piperidine-1-carboxylate; tert-butyl 3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}piperidine-1-carboxylate; tert-butyl 4-(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)piperidine-1-carboxylate; 5-[(4-cyanopyridin-2-yl)amino]-3-methyl-N-{6-[3-(trifluoromethyl)phenoxy]pyridin-3-yl}-1,2-thiazole-4-carboxamide; 3-methyl-N-[6-(pyridin-3-yloxy)pyridin-3-yl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-methyl-5-(quinoxalin-2-ylamino)-N-(6-{4-[(trifluoromethyl)sulfanyl]phenoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; tert-butyl 4-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)pyridin-2-yl]amino}piperidine-1-carboxylate; N-[2-(cyanomethyl)-6-methoxypyridin-3-yl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; tert-butyl N-[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)pyridin-2-yl]-beta-alaninate; dimethyl 5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)isophthalate; tert-butyl 4-({[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)pyridin-2-yl]amino}methyl)piperidine-1-carboxylate; tert-butyl 3-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl]carbonyl)amino}benzoate; tert-butyl 3-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl]carbonyl)amino}benzoate; tert-butyl 3-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)pyridin-2-yl]amino}piperidine-1-carboxylate; 5-[(4-cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-3-ylamino)pyridin-3-yl]-1,2-thiazole-4-carboxamide; N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; tert-butyl (2-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)pyridin-2-yl]amino}ethyl)carbamate; N-{6-[(3,4-difluorophenyl)amino]pyridin-3-yl}-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 5-[(5-cyanopyridin-2-yl)amino]-3-methyl-N-[4-(methylsulfonyl)phenyl]-1,2-thiazole-4-carboxamide; N-(3-{[2-(diethylamino)ethyl]carbamoyl}phenyl)-3-methyl-5-(pyrazin-2-ylamino)-1,2-thiazole-4-carboxamide; tert-butyl 4-[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)pyridin-2-yl]piperazine-1-carboxylate; N-[3-(cyclopropylcarbamoyl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 5-[(5-cyanopyridin-2-yl)amino]-N-[3-(cyclopropylcarbamoyl)phenyl]-3-methyl-1,2-thiazole-4-carboxamide; N-[3-(ethylcarbamoyl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 5-[(5-cyanopyridin-2-yl)amino]-N-[3-(ethylcarbamoyl)phenyl]-3-methyl-1,2-thiazole-4-carboxamide; N-[3-(isopropylcarbamoyl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 5-[(4-cyanopyridin-2-yl)amino]-N-[3-(isopropylcarbamoyl)phenyl]-3-methyl-1,2-thiazole-4-carboxamide; 5-[(5-cyanopyridin-2-yl)amino]-N-[3-(isopropylcarbamoyl)phenyl]-3-methyl-1,2-thiazole-4-carboxamide; methyl 4-{4-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}carbonyl)amino]phenyl}butanoate; methyl 3-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)phenyl]propanoate; tert-butyl 4-{[4-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)phenyl]sulfamoyl}piperidine-1-carboxylate; N-(4-{[1-(2,2-difluoroethyl)piperidin-4-yl]carbamoyl}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(4-{[4-(2,2,2-trifluoroethyl)piperazin-1-yl]carbonyl}phenyl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-{4-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 5-[(4-cyanopyridin-2-yl)amino]-N-(6-{[1-(2,2-difluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[1-(2,2-difluoroethyl)piperidin-4-yl]oxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(2-fluoroethyl)piperidin-4-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}phenyl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[1-(2,2-difluoroethyl)piperidin-4-yl]oxy}-4-fluorophenyl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(2-fluoroethyl)piperidin-4-yl]oxy}phenyl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(4-{[1-(2,2,2-trifluoroethyl)azetidin-3-yl]carbamoyl}phenyl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-{[1-(2,2-difluoroethyl)azetidin-3-yl]carbamoyl}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(4-{[4-(2,2,2-trifluoroethyl)piperazin-1-yl]carbonyl}phenyl)-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-{[4-(2,2-difluoroethyl)piperazin-1-yl]carbonyl}phenyl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-{[4-(2-fluoroethyl)piperazin-1-yl]carbonyl}phenyl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-{4-[(4-ethylpiperazin-1-yl)carbonyl]phenyl}-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-[6-(2-hydroxyethoxy)pyridin-3-yl]-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-[6-(2-hydroxyethoxy)pyridin-3-yl]-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-[6-(3-hydroxypropoxy)pyridin-3-yl]-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-[6-(3-hydroxypropoxy)pyridin-3-yl]-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(4{[1-(2,2,2-trifluoroethyl)azetidin-3-yl]carbamyl}phenyl)-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-(quinoxalin-2-ylamino)-N-[3-({[1-(2,2,2-trifluoroethyl)piperidin-4-yl]sulfonyl}amino)phenyl]-1,2-thiazole-4-carboxamide; N-[3-({[1-(2,2-difluoroethyl)piperidin-4-yl]sulfonyl}amino)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-methyl-5-(quinoxalin-2-ylamino)-N-[3-({[1-(3,3,3-trifluoropropyl)piperidin-4-yl]sulfonyl}amino)phenyl]-1,2-thiazole-4-carboxamide; 3-tert-butyl (3-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenyl)carbamate; 3-methyl-5-(quinoxalin-2-ylamino)-N-[3-({[1-(2,2,2-trifluoroethyl)azetidin-3-yl]sulfonyl}amino)phenyl]-1,2-thiazole-4-carboxamide; N-[3-({[1-(2,2-difluoroethyl)azetidin-3-yl]sulfonyl}amino)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; N-[3-({[1-(2-fluoroethyl)azetidin-3-yl]sulfonyl}amino)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide; 3-methyl-5-(quinoxalin-2-ylamino)-N-[3-({[1-(3,3,3-trifluoropropyl)azetidin-3-yl]sulfonyl}amino)phenyl]-1,2-thiazole-4-carboxamide; 3-methyl-5-(quinoxalin-2-ylamino)-N-[3-({[1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]sulfonyl}amino)phenyl]-1,2-thiazole-4-carboxamide; tert-butyl 3-{[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)phenyl]sulfamoyl}pyrrolidine-1-carboxylate; benzyl 3-{[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)phenyl]sulfamoyl}piperidine-1-carboxylate; 3-methyl-N-(6-{3-[(2,2,2-trifluoroethyl)amino]propoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{3-[(2,2-difluoroethyl)amino]propoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{3-[(3,3,3-trifluoropropyl)amino]propoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-(6-{[1-(2-fluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(2,2-difluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{[1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-[4-(dimethylamino)-3-{3-[methyl(2,2,2-trifluoroethyl)amino]propoxy}phenyl]-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-[4-(dimethylamino)-3-{3-[methyl(3,3,3-trifluoropropyl)amino]propoxy}phenyl]-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{3-[(2,2-difluoroethyl)(methyl)amino]propoxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{3-[methyl(2,2,2-trifluoroethyl)amino]propoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{3-[methyl(3,3,3-trifluoropropyl)amino]propoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[1-(3,3,3-trifluoropropyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-(6-{2-[(2,2-difluoroethyl)amino]ethoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{3-[(2,2,2-trifluoroethyl)amino]propoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{3-[(3,3,3-trifluoropropyl)amino]propoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[1-(2,2-difluoroethyl)piperidin-4-yl]methoxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(2-fluoroethyl)piperidin-4-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(3,3,3-trifluoropropyl)piperidin-4-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[1-(1,3-difluoropropan-2-yl)piperidin-4-yl]methoxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(1,3-difluoropropan-2-yl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[1-(2,2-difluoroethyl)pyrrolidin-3-yl]oxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[1-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(2-fluoroethyl)pyrrolidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[1-(1,3-difluoropropan-2-yl)pyrrolidin-3-yl]methoxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{2-[(2-fluoroethyl)amino]ethoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{2-[(2,2,2-trifluoroethyl)amino]ethoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{2-[(3,3,3-trifluoropropyl)amino]ethoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-(6-{[1-(1,3-difluoropropan-2-yl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(2-fluoroethyl)piperidin-3-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-3-yl]methoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(2,2-difluoroethyl)piperidin-3-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[1-(3,3,3-trifluoropropyl)piperidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-(6-{[1-(2-fluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(2,2-difluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[1-(3,3,3-trifluoropropyl)piperidin-3-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-(6-{[1-(1,3-difluoropropan-2-yl)piperidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[1-(2,2-difluoroethyl)piperidin-3-yl]methoxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[1-(2,2-difluoroethyl)piperidin-3-yl]methoxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(2-fluoroethyl)piperidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(2,2,2-trifluoroethyl)piperidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(3,3,3-trifluoropropyl)piperidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[(3R)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[(3R)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[(3R)-1-(2,2-difluoroethyl)piperidin-3-yl]methoxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[(3R)-1-(2,2,2-trifluoroethyl)piperidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[1-(3,3,3-trifluoropropyl)piperidin-4-yl]oxy}phenyl)-3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(2-fluoroethyl)piperidin-4-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(2,2-difluoroethyl)piperidin-4-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]methoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[1-(3,3,3-trifluoropropyl)piperidin-4-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-(6-{2-[(2-fluoroethyl)(methyl)amino]ethoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{2-[(2,2-difluoroethyl)(methyl)amino]ethoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{2-[methyl(2,2,2-trifluoroethyl)amino]ethoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{2-[methyl(3,3,3-trifluoropropyl)amino]ethoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{3-[(2-fluoroethyl)(methyl)amino]propoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{3-[(2,2-difluoroethyl)(methyl)amino]propoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{3-[methyl(2,2,2-trifluoroethyl)amino]propoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{3-[methyl(3,3,3-trifluoropropyl)amino]propoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{2-[1-(2,2-difluoroethyl)piperidin-4-yl]ethyl}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-{6-[1-(2,2-difluoroethyl)piperidin-4-yl]pyridin-3-yl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-{6-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-{6-[4-(2,2-difluoroethyl)piperazin-1-yl]pyridin-3-yl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-{6-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-[6-{4-(3,3,3-trifluoropropyl)piperazin-1-yl]pyridin-3-yl}-1,2-thiazole-4-carboxamide; N-(6-{[(3S,4S)-1-(2,2-difluoroethyl)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3S,4S)-3-fluoro-1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3S,4S)-3-fluoro-1-(3,3,3-trifluoropropyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3S,4S)-1-ethyl-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4R)-1-(2,2-difluoroethyl)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4R)-3-fluoro-1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4R)-3-fluoro-1-(3,3,3-trifluoropropyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4R)-1-ethyl-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3S,4S)-3-fluoro-1-propylpiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4R)-3-fluoro-1-propylpiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-{5-[4-(2,2-difluoroethyl)piperazin-1-yl]pyridin-2-yl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-{5-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]pyridin-2-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-{5-[4-(3,3,3-trifluoropropyl)piperazin-1-yl]pyridin-2-yl}-1,2-thiazole-4-carboxamide; N-(6-{[(3R)-1-(2,2-difluoroethyl)piperidin-3-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{[(3R)-1-(2,2,2-trifluoroethyl)piperidin-3-yl]methoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3R)-1-(3,3,3-trifluoropropyl)piperidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3S)-1-(3,3,3-trifluoropropyl)piperidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-(6-{[(3R)-1-(2,2-difluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{[(3R)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3R)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-(6-{[(3S)-1-(2,2-difluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{[(3S)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3S)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-(6-{[(3R)-1-(2,2-difluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{[(3R)-1-(2,2,2-trifluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3R)-1-(3,3,3-trifluoropropyl)piperidin-3-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-(6-{[(3S)-1-(2,2-difluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-N-(6-{[(3S)-1-(2,2,2-trifluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3S)-1-(3,3,3-trifluoropropyl)piperidin-3-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-(6-{[3,3-difluoro-1-(2,2,2-trifluoroethyl)piperidin-4-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-{6-[(1-ethyl-3,3-difluoropiperidin-4-yl)methoxy]pyridin-3-yl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-{6-[(3,3-difluoro-1-propylpiperidin-4-yl)methoxy]pyridin-3-yl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[(3R)-1-(3,3,3-trifluoropropyl)piperidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-{6-[(1-butyl-3,3-difluoropiperidin-4-yl)methoxy]pyridin-3-yl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[(3S)-1-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[(3S)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-fluoro-3-{[(3S)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[(3S)-1-(2,2-difluoroethyl)piperidin-3-yl]methoxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[1-(2,2-difluoroethyl)-3,3-difluoropiperidin-4-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[3,3-difluoro-1-(3,3,3-trifluoropropyl)piperidin-4-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[(3R)-1-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-N-(6-{[(3S)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 5-[(5-Cyanopyridin-2-yl)amino]-3-methyl-N-(6-{[(3S)-1-(2,2,2-trifluoroethyl)-pyrrolidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-{6-[(1-Ethyl-3,3-difluoropiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-5-{[5-(trifluoro-methyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-{6-[2-(4,4-Difluoropiperidin-1-yl)ethoxy]pyridin-3-yl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4S)-4-Fluoro-1-propylpyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4S)-4-Fluoro-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4S)-4-Fluoro-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4S)-1-(2,2-Difluoroethyl)-4-fluoropyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[(3R)-1-(2,2-Difluoroethyl)pyrrolidin-3-yl]oxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-Fluoro-3-{[(3R)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-Fluoro-3-{[(3R)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-Fluoro-3-{[(3S)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-Fluoro-3-{[(3S)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(3-{[(3S)-1-(2,2-Difluoroethyl)pyrrolidin-3-yl]oxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; N-(4-Fluoro-3-{[(3S)-1-(3,3,3-trifluoropropyl)piperidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide N-(4-Fluoro-3-{[(3S)-1-(2,2,2-trifluoroethyl)piperidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{2-[1-(3,3,3-trifluoro-propyl)piperidin-4-yl]ethyl}pyridin-3-yl)-1,2-thiazole-4-carboxamide; 3-Methyl-N-(6-{[(3R)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3R)-1-(3,3,3-trifluoro-propyl)piperidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; 3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3R)-1-(3,3,3-trifluoro-propyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide; N-(6-{[(3R,4S)-1-Ethyl-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-N-(6-{2-[(trifluoroacetyl)amino]ethoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[1-(3,3,3-trifluoropropyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide, salt with hydrochloric acid; N-(4-Fluoro-3-{3-[(trifluoroacetyl)amino]propoxy}phenyl)-3-methyl-5-{[5-(trifluoro-methyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-N-(6-{3-[(trifluoroacetyl)amino]propoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; tert-Butyl methyl{2-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]ethyl}carbamate; tert-Butyl methyl{2-[(5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]ethyl}carbamate; N-[3-Fluoro-4-(piperidin-4-yloxy)phenyl]-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide; 3-Methyl-5-(quinoxalin-2-ylamino)-N-{3-[(trifluoroacetyl)amino]phenyl}-1,2-thiazole-4-carboxamide; 5-[(5-Cyanopyridin-2-yl)amino]-N-{6-[(3,4-difluorophenyl)amino]pyridin-3-yl}-3-methyl-1,2-thiazole-4-carboxamide; tert-Butyl methyl(2-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]-carbonyl}amino)pyridin-2-yl]amino}ethyl)carbamate; N-(6-Acetamidopyridin-3-yl)-5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazole-4-carboxamide; tert-Butyl (3S,4R)-3-fluoro-4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]-amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]pyrrolidine-1-carboxylate; N-(6-{[(3R,4S)-4- Fluoropyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with hydrochloric acid tert-Butyl (3R)-3-(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)pyrrolidine-1-carboxylate; N-{4-Fluoro-3-[(3R)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoro acetic acid; tert-Butyl (3R)-3-(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)pyrrolidine-1-carboxylate; N-{4-Fluoro-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoro acetic acid; tert-Butyl (3S)-3-[(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]-amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)methyl]piperidine-1-carboxylate; N-{4-Fluoro-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoro acetic acid; tert-Butyl 4-[2-(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)ethyl]piperidine-1-carboxylate; N-{4-Fluoro-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoro acetic acid; tert-Butyl (3R)-3-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]pyrrolidine-1-carboxylate; 3-Methyl-N-{6-[(3R)-pyrrolidin-3-yloxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with hydrochloric acid; tert-Butyl (3R)-3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}piperidine-1-carboxylate; 3-Methyl-N-{6-[(3R)-piperidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with hydrochloric acid; and N-(3-Aminophenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide.

8. A method of preparing a compound of general formula (I) according to any one of claims 1 to 7, said method comprising the step of allowing an intermediate compound of general formula (II): ##STR00578## in which R1 and R2 are as defined for the compound of general formula (I) according to any one of claims 1 to 7, to react with a compound of general formula (III):
A-X   (III), in which A is as defined for the compound of general formula (I) according to any one of claims 1 to 7,and X represents a halogen atom, for example a chlorine, bromine or iodine atom, or a perfluoroalkylsulfonate group, for example a trifluoromethylsulfonate group or a nonafluorobutylsulfonate group, or a boronic acid, thereby giving a compound of general formula (I): ##STR00579## in which A, R1 and R2 are as defined for the compound of general formula (I) according to any one of claims 1 to 7.

9. A compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 7, for use in the treatment or prophylaxis of a disease.

10. A pharmaceutical composition comprising a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 7, and a pharmaceutically acceptable diluent or carrier.

11. A pharmaceutical combination comprising: one or more first active ingredients selected from a compound of general formula (I) according to any of claims 1 to 7, and one or more second active ingredients selected from chemotherapeutic anti-cancer agents.

12. Use of a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 7, for the prophylaxis or treatment of a disease.

13. Use of a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, according to any one of claims 1 to 7, for the preparation of a medicament for the prophylaxis or treatment of a disease.

14. Use according to claim 9, 12 or 13, wherein said disease is a disease of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response, particularly in which the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is a haematological tumour, a solid tumour and/or metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

15. A compound of general formula (II): ##STR00580## in which R1 and R2 are as defined for the compound of general formula (I) according to any one of claims 1 to 7.

16. Use of a compound of general formula (II) according to claim 15 for the preparation of a compound of general formula (I) according to any one of claims 1 to 7.

Description

EXAMPLES

Example 1

[1576] N-[3-Fluoro-4-(2-methoxyethoxy)phenyl]-3-methyl-5-{[4-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino}-1,2-thiazole-4-carboxamide

##STR00121##

[1577] A mixture of 5-amino-N-[3-fluoro-4-(2-methoxyethoxy)phenyl]-3-methyl-1,2-thiazole-4-carboxamide [Intermediate 1] (75 mg, 0.23 mmol, 1.2 eq), 2-chloro-4-(trifluoromethyl)-1,3-benzothiazole [CAS-RN: 898784-15-7] (46 mg, 0.19 mmol, 1.0 eq) and cesium carbonate (144 mg, 0.44 mmol, 2.3 eq) in 2.0 mL dioxane/DMF (7/1) was placed in a microwave vial and flushed with argon. Then, palladium(II) acetate (4 mg, 0.02 mmol, 0.1 eq) and Xantphos (11 mg, 0.02 mmol, 0.1 eq) were added. The vial was capped and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was partitioned between dichloromethane and water. After filtration over Celite, the organic phase was separated and concentrated in vacuo. The crude product purified via preparative HPLC under acidic conditions (column: Chromatorex C.sub.18, eluent: acetonitrile/water (2/1).fwdarw.acetonitrile) to give 50 mg (40% yield of theory) of the title compound.

[1578] UPLC-MS (Method 1): Rt=1.47 min; MS (El.sub.neg): m/z=525 [M−H].sup.−.

[1579] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=2.53 (s, 3H), 3.31 (s, 3H), 3.66 (m, 2H), 4.15 (m, 2H), 7.18 (t, 1H), 7.32-7.45 (m, 2H), 7.71-7.81 (m, 2H), 8.23 (d, 1H), 10.41 (s br, 1H), 12.07 (s br, 1H).

Example 2

N-[6-(2-Hydroxyethoxy)pyridin-3-yl]-3-methyl-5-{[4-(trifluoromethyl)-1,3-benzo-thiazol-2-yl]amino}-1,2-thiazole-4-carboxamide

[1580] ##STR00122##

[1581] To a mixture of N-[6-(2-{[tert-butyl(dimethyl)silyl]oxy}ethoxy)pyridin-3-yl]-3-methyl-5-{[4-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino}-1,2-thiazole-4-carboxamide [Intermediate 5] (236 mg, 0.37 mmol, 1.0 eq) in 5.3 mL in THF was added tetra-N-butyl ammoniumfluoride hydrate (582 mg, 1.84 mmol, 5.0 eq). The reaction mixture was stirred at rt overnight. Then, the reaction mixture was partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate (3×) and the combined organic phases were washed with brine. The organic phase were passed through a Whatman filter and concentrated in vacuo. The crude material was crystallized by the use of ice-cooled methanol. The precipitate was isolated by filtration and washed with a small portion of ice-cooled methanol. The resulting solid was dried at the high-vacuum to deliver 80 mg (42% yield of theory) of the title compound.

[1582] UPLC-MS (Method 2): R.sub.t=0.85 min; MS (Elne.sub.g): m/z=494 [M−H].sup.−.

[1583] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=3.70 (t, 2H), 4.25 (t, 2H), 4.80 (s br, 1H), 6.86 (d, 1H), 7.39 (t, 1H), 7.74 (d, 1H), 8.04 (dd, 1H), 8.23 (d, 1H), 8.49 (s, 1H), 10.42 (s br, 1H), 12.09 (s br, 1H), 1×CH.sub.3 covered by solvent signal.

Example 3

N-[6-(2-Methoxyethoxy)pyridin-3-yl]-3-methyl-5-{[4-(trifluoromethyl)-1,3-benzo-thiazol-2-yl]amino}-1,2-thiazole-4-carboxamide

[1584] ##STR00123##

[1585] A mixture of 5-amino-N-[6-(2-methoxyethoxy)pyridin-3-yl]-3-methyl-1,2-thiazole-4-carboxamide [Intermediate 6] (393 mg, 1.02 mmol, 80% purity, 1.2 eq), 2-chloro-4-(trifluoromethyl)-1,3-benzothiazole [CAS-RN: 898784-15-7] (202 mg, 0.85 mmol, 1.0 eq) and cesium carbonate (638 mg, 1.96 mmol, 2.3 eq) in 8.8 mL dioxane/DMF (7/1) was placed in a microwave vial and flushed with argon. Then, palladium(II) acetate (19 mg, 0.09 mmol, 0.1 eq) and Xantphos (49 mg, 0.09 mmol, 0.1 eq) were added. The vial was capped and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the volatile components were removed in vacuo. The crude material was then subjected preparative HPLC (column: Chromatorex C.sub.18, eluent: acetonitrile/water (2/1).fwdarw.acetonitrile) to give 282 mg (54% yield of theory) of the title compound.

[1586] UPLC-MS (Method 2): R.sub.t=0.94 min; MS (El.sub.neg): m/z=508 [M−H].sup.−.

[1587] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=2.53 (s, 3H), 3.30 (s, 3H), 3.65 (m, 2H), 4.35 (m, 2H), 6.83 (d, 1H), 7.10 (t, 1H), 7.51 (d, 1H), 7.92 (d, 1H), 8.01 (dd, 1H), 8.40 (d, 1H), 12.71 (s, 1H), 1H not assigned.

Example 4

N-[3-Fluoro-4-(2-hydroxyethoxy)phenyl]-3-methyl-5-{[4-(trifluoromethyl)-1,3-benzothiazol-2-yl]amino}-1,2-thiazole-4-carboxamide

[1588] ##STR00124##

[1589] To a mixture of N-[4-(2-{[tert-butyl(dimethyl)silyl]oxy}ethoxy)-3-fluorophenyl]-3-methyl-5-{[4-(trifluoromethyl)-1, 3-benzothiazol-2-yl]amino}-1,2-thiazole-4-carboxamide [Intermediate 8] (178 mg, 0.28 mmol, 1.0 eq) in 4.1 mL in THF was added tetra-N-butyl ammoniumfluoride hydrate (448 mg, 1.84 mmol, 5.0 eq). The reaction mixture was stirred at rt overnight. Then, the reaction mixture was partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate (3×) and the combined organic phases were washed with brine. The organic phase were passed through a Whatman filter and concentrated in vacuo. The crude material was crystallized by the use of ice-cooled methanol. The precipitate was isolated by filtration and washed with a small portion of ice-cooled methanol. The resulting solid was dried at the high-vacuum to deliver 99 mg (67% yield of theory) of the title compound.

[1590] UPLC-MS (Method 2): R.sub.t=0.90 min; MS (El.sub.neg): m/z=511 [M−H].sup.−.

[1591] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=2.42 (s, 3H), 3.72 (t, 2H), 4.04 (t, 2H), 7.18 (t, 1H), 7.30-7.45 (m, 2H), 7.69-7.82 (m, 2H), 8.23 (d, 1H), 10.40 (s br, 1H), 12.07 (s br, 1H), 1H not assigned.

Example 5

tert-Butyl 4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate

[1592] ##STR00125##

[1593] A mixture of tert-butyl 4-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-pyridin-2-yl)oxy]piperidine-1-carboxylate [Intermediate 14] (199.5 mg, 0.46 mmol, 1.2 eq), 2-chloro-5-(trifluoromethyl)pyrazine (CAS-RN: 799557-87-2) (70 mg, 0.38 mmol, 1.0 eq) and cesium carbonate (287 mg, 0.88 mmol, 2.3 eq) in 3.9 mL dioxane/DMF (5.5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (8.6 mg, 0.038 mmol, 0.1 eq) and Xantphos (22 mg, 0.038 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 10 g SNAP cartridge: dicloromethane.fwdarw.dichloromethane/ethanol 91:9) to give 220 mg impure material of the title compound. Final purification of this impure material was done via preparative MPLC (Biotage Isolera; 11 g NH-cartridge: dicloromethane.fwdarw.dichloromethane/ethanol 50:50) to give 35 mg of the title compound which was suspended in methyl t-butyl ether. The supernatant was removed with a pipette.

[1594] The solid residue was dryed in vacuo to give 32 mg (13% yield of the theory) of the title compound.

[1595] UPLC-MS (Method 2): Rt=0.97 min; MS (El.sub.pos): m/z=580 [M+H].sup.+.

[1596] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.40 (s, 9 H), 1.44-1.64 (m, 2H), 1.86-2.04 (m, 2H), 3.09-3.20 (m, 2H), 3.55-3.79 (m, 2H), 5.09-5.18 (m, 1H), 6.84 (d, 1H), 8.06 (s br, 1H), 8.50 (s br, 1H), 8.81 (s br, 1H), 8.89 (s br, 1H), 10.30 (s br, 1H), 11.44 (s br, 1H), 1×CH.sub.3 obscured by solvent signal.

[1597] In a larger batch a mixture of tert-butyl 4-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate [Intermediate 14] (800 mg, 1.85 mmol, 1.2 eq), 2-chloro-5-(trifluoromethyl)pyrazine (CAS-RN: 799557-87-2) (281 mg, 1.54 mmol, 1.0 eq) and cesium carbonate (1152 mg, 3.54 mmol, 2.3 eq) in 15.6 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (34.5 mg, 0.15 mmol, 0.1 eq) and Xantphos (89 mg, 0.15 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. The final purification of this crude material was achieved via preparative MPLC (Biotage Isolera; 50 g SNAP cartridge: dicloromethane.fwdarw.dichloromethane/ethanol 9:1) to give 886 mg ( almost quantitative yield of theory) of the title compound.

Example 6

3-Methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1598] ##STR00126##

[1599] tert-Butyl 4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate [Example 5] (557 mg, 0.96 mmol, 1.0 eq) was suspended in 18.5 mL dichloromethane and trifluoro acetic acid (CAS-RN: 76-C.sub.5-1) (1.5 mL, 19.2 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. The crude reaction mixture was dissolved in a mixture of dichloromethane and methanol (1:1) mixed with toluene and the volatile components were removed in vacuo. The crude trifluoro acetate salt of the title compound was used for further derivatization without further purification. A Sample of the TFA salt was dissolved in a mixture of dichloromethane and methanol and triethylamine was added. The volatile components were removed in vacuo and the purification was conducted via preparative HPLC (Method B) to give the title compound as free base.

[1600] UPLC-MS (Method 2): R.sub.t=0.80 min; MS (El.sub.pos): m/z=480 [M+H].sup.+.

[1601] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.76-1.92 (m, 2H), 2.08-2.22 (m, 2H), 2.55 (s, 3H), 3.05-3.19 (m, 2H), 3.21-3.27 (m, 2H), 5.14-5.25 (m, 1H), 6.81 (d, 1H), 8.14-8.27 (m, 2H), 8.29-8.47 (m, 2H), 8.51-8.63 (m, 2H), 13.32 (s br, 1H).

Example 6-1

3-Methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with hydrochloric acid

[1602] ##STR00127##

[1603] tert-Butyl 4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate [Example 5] (300 mg, 0.52 mmol, 1.0 eq) was suspended in 13 mL dioxane and 2.6 mL hydrogen chloride solution (4.0 M) in dioxane (CAS-RN: 7647-01-0) (1.5 mL, 19.2 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. The precipitate of the crude hydrochloric acid salt of the title compound was isolated by filtration (350 mg) and used for further derivatization without further purification.

[1604] UPLC-MS (Method 2): R.sub.t=0.80 min; MS (El.sub.pos): m/z=480 [M+H].sup.+.

Example 7

[1605] N-(6-{[1-(2-Fluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

##STR00128##

[1606] A mixture of the crude TFA salt of 3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-[{5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide [Example 6] (134 mg, 50% purity, 0.14 mmol, 1.0 eq), 2-fluoroethyl 4-methylbenzenesulfonate (CAS-RN: 383-50-6) (46 mg, 0.21 mmol, 1.5 eq), potassium carbonate (97 mg, 0.67 mmol, 5.0 eq) and potassium iodide (2 mg, 0.01 mmol, 0.1 eq) in 6 mL acetonitrile was placed in a microwave vial that was flushed with argon.

[1607] Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. The Volume of the reaction mixture was reduced in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 47 mg (58% yield of theory) of the title compound.

[1608] UPLC-MS (Method 2): R.sub.t=0.82 min; MS (El.sub.pos): m/z=526 [M+H].sup.+.

[1609] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.64-1.85 (m, 2H), 1.93-2.09 (m, 2H), 2.55 (s, 3H), 2.70-3.12 (m, 4H), 4.50-4.58 (m, 1H), 4.60-4.71 (m, 1H), 4.93-5.11 (m, 1H), 6.78 (d, 1H), 8.10-8.25 (m, 1H), 8.45 (s br, 1H), 8.54 (d, 1H), 8.58 (s br, 1H), 2xNH not detected, 1×CH.sub.2 and 1×CH.sub.3 obscured by the solvent signal.

Example 8

N-(6-{[1-(2,2-Difluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1610] ##STR00129##

[1611] A mixture of the crude TFA salt of 3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide [Example 6] (121 mg, 54% purity, 0.14 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (43 mg, 0.20 mmol, 1.5 eq), potassium carbonate (94 mg, 0.68 mmol, 5.0 eq) and potassium iodide (2mg, 0.01 mmol, 0.1 eq) in 3.6 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. Afterwards another 1.5 eq 2,2-difluoroethyl trifluoromethanesulfonate (CAS 74427-22-8) (39 mg, 0.18 mmol) and another 2 eq potassium carbonate (34 mg, 0.24 mmol) in 5 mL acetonitrile were added and the vial was sealed and the reaction mixture was stirred again at an environmental temperature of 70° C. for another 18 h under argon atmosphere. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. The volume of the reaction mixture was reduced in vacuo and the purification of this crude material was achieved via preparative MPLC (Biotage Isolera; 25 g SNAP cartridge: dicloromethan.fwdarw.dichloromethane/ethanol 9:1). The volatile components of the collected fractions were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 30 mg (39% yield of theory) of the title compound.

[1612] UPLC-MS (Method 2): R.sub.t=0.87 min; MS (El.sub.pos): m/z=544 [M+H].sup.+.

[1613] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.58-1.76 (m, 2H), 1.91-2.03 (m, 2H), 2.70-2.95 (m, 4H), 4.91-5.05 (m, 1H), 6.00-6.30 (m, 1H), 6.82 (d, 1H), 8.00-8.13 (m, 1H), 8.49 (s br, 1H), 8.80 (s br, 1H), 8.88 (s br, 1H), 10.28 (s br, 1H), 11.44 (s br, 1H), 1×CH.sub.2 and 1×CH.sub.3 obscured by solvent signal.

Example 9

-Methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1614] ##STR00130##

[1615] A mixture of the crude TFA salt of 3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide [Example 6] (100 mg, 54% purity, 0.13 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (39 mg, 0.17 mmol, 1.5 eq) potassium carbonate (78 mg, 0.56 mmol, 5.0 eq) and potassium iodide (2 mg, 0.01 mmol, 0.1 eq) in 8 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. Final purification was conducted via preparative HPLC (Method B) to give 44 mg (65% yield of theory) of the title compound.

[1616] UPLC-MS (Method 2): R.sub.t=0.93 min; MS (El.sub.pos): m/z=562 [M+H].sup.+.

[1617] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.53-1.76 (m, 2H), 1.87-2.04 (m, 2H), 2.79-2.98 (m, 2H), 3.13-3.26 (m, 2H), 4.93-5.04 (m, 1H), 6.67-6.92 (m, 1 H), 8.10 (s br, 1H), 8.42-8.57 (m, 1H), 8.63-8.95 (m, 2H), 10.28 (s br, 1H), 11.49 (s br, 1H), 1×CH.sub.2and 1×CH.sub.3 obscured by solvent signal.

Example 10

3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[1-(3,3,3-trifluoro-propyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide

[1618] ##STR00131##

[1619] A mixture of the crude salt of 3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with hydrochloric acid [Example 6-1] (300 mg, 70% purity, 0.51 mmol, 1.0 eq), 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (206 mg, 0.77 mmol, 1.5 eq), potassium carbonate (353 mg, 2.56 mmol, 5.0 eq) and potassium iodide (8.5 mg, 0.05 mmol, 0.1 eq) was taken up in 13.5 mL acetonitrile. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h under a atmosphere of argon. Another 0.5 eq of 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS 2342-67-8) (70 mg, 0.26 mmol) were added and the reaction mixture was stirred for another 24 hours. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 189 mg (64% yield of theory) of the title compound.

[1620] UPLC-MS (Method 2): R.sub.t=0.93 min; MS (El.sub.pos): m/z=576 [M+H].sup.+.

[1621] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.56-1.80 (m, 2H), 1.93-2.10 (m, 2H), 2.30-2.45 (m, 2H), 2.54 (s, 3H), 2.60-2.75 (m, 2H), 2.77-2.94 (m, 2H), 4.94-5.07 (m, 1H), 6.79 (d, 1H), 8.07-8.19 (m, 1H), 8.49-8.54 (m, 1H), 8.54-8.64 (s br, 1H), 8.65-8.76 (s br, 1H), 11.28 (s br, 1H), 13.12 (s br, 1H).

Example 11

N-{6-[(1-Acetylpiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-5-{[5-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1622] ##STR00132##

[1623] A mixture of the crude TFA salt of 3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide [Example 6] (114 mg, 54% purity, 0.13 mmol, 1.0 eq), pyridine (CAS 110-86-1) (208 μL, 2.6 mmol, 20 eq) and acetic anhydride (CAS-RN: 108-24-7) (242 μL, 2.6 mmol, 20 eq) was placed in a microwave vial and the reaction mixture was stirred at room temperature overnight. The volatile components were removed in vacuo. Purification of this crude material was achieved via preparative MPLC (Biotage Isolera; 25 g SNAP cartridge: dicloromethane.fwdarw.dichloromethane/ethanol 9:1) to give 50 mg (75% yield of theory) of the title compound.

[1624] UPLC-MS (Method 2): R.sub.t=0.79 min; MS (El.sub.pos): m/z=522 [M+H].sup.+.

[1625] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.46-1.57 (m, 1H), 1.57-1.69 (m, 1H), 1.88-2.06 (m, 5 H), 3.12-3.26 (m, 1H), 3.34-3.42 (m, 1H), 3.59-3.77 (m, 1 H), 3.79-3.95 (m, 1H), 5.07-5.29 (m, 1H), 6.85 (d, 1H), 8.05 (d, 1H), 8.51 (s br, 1H), 8.83 (s, 1H), 8.91 (s, 1H), 10.30 (s, 1H), 11.44 (s, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 12

tert-Butyl 4-[(5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate

[1626] ##STR00133##

[1627] A mixture of tert-butyl 4-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-pyridin-2-yl)oxy]piperidine-1-carboxylate [Intermediate 14] (500 mg, 1.15 mmol, 1.2 eq), 2-iodo-6-(trifluoromethyl)pyrazine (CAS-RN: 141492-94-6) (263 mg, 0.96 mmol, 1.0 eq) and cesium carbonate (720 mg, 2.2 mmol, 2.3 eq) in 9.7 mL dioxane/DMF (6/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (21 mg, 0.09 mmol, 0.1 eq) and Xantphos (56 mg, 0.09 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). Purification of this crude material was achieved via preparative MPLC (Biotage Isolera; SNAP cartridge: dicloromethane.fwdarw.dichloromethane/ethanol 9:1) to give 25 mg (almost quantitative yield of theory) of the title compound.

[1628] UPLC-MS (Method 2): Rt=0.95 min; MS (El.sub.pos): m/z=580 [M−H].sup.+.

[1629] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.40 (s, 9 H), 1.49-1.59 (m, 2H), 1.87-1.99 (m, 2H), 3.11-3.24 (m, 2H), 3.58-3.75 (m, 2H), 5.05-5.24 (m, 1H), 6.77-6.92 (m, 1H), 7.95-8.13 (m, 1 H,) 8.45-8.55 (m, 1H), 8.61-8.69 (m, 1H), 8.99 (s, 1H), 10.21-10.33 (m, 1H), 11.34-11.47 (m, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 13

3-Methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[6-(trifluoromethyl)pyrazin-2-yl]-amino}-1,2-thiazole-4-carboxamide

[1630] ##STR00134##

[1631] tert-Butyl 4-[(5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate [Example 12] (557 mg, 0.96 mmol, 1.0 eq) was suspended in 18.5 mL dichloromethane and trifluoro acetic acid (CAS-RN: 76-C.sub.5-1) (1.5 mL, 19.2 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. The reaction mixture was dissolved in a mixture of methanol and toluol (1:1) and the volatile components were removed in vacuo. The crude trifluoro acetate salt of the title compound was used for further derivatization without further purification.

[1632] A Sample of the TFA salt was dissolved in a mixture of dichloromethane and methanol and triethylamine was added. The volatile components were removed in vacuo and the purification was conducted via preparative HPLC (Method B) to give the title compound as free base.

[1633] UPLC-MS (Method 2): R.sub.t=0.78 min; MS (El.sub.pos): m/z=480 [M+H].sup.+.

[1634] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.80-1.90 (m, 2H), 2.09-2.19 (m, 2H), 2.55 (s, 3H), 3.09-3.18 (m, 2H), 3.22-3.29 (m, 2H), 5.12-5.23 (m, 1H), 6.81 (d, 1H), 8.01 (s br, 1H), 8.15-8.22 (m, 1H), 8.31-8.42 (m, 2H), 8.57-8.62 (m, 2H), 13.38 (s, 1H).

Example 14

N-(6-{[1-(2-Fluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[6-(trifluoro-methyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1635] ##STR00135##

[1636] A mixture of the crude TFA salt of 3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide [Example 13] (128 mg, 50% purity, 0.13 mmol, 1.0 eq), 2-fluoroethyl 4-methylbenzenesulfonate (CAS-RN: 383-50-6) (44 mg, 0.2 mmol, 1.5 eq), potassium carbonate (92 mg, 0.67 mmol, 5.0 eq) and potassium iodide (2mg, 0.01 mmol, 0.1 eq) in 6 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 37 mg (48% yield of theory) of the title compound.

[1637] UPLC-MS (Method 2): R.sub.t=0.80 min; MS (El.sub.pos): m/z=526 [M+H].sup.+.

[1638] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.70-1.81 (m, 2H), 1.94-2.05 (m, 2H), 2.55 (s, 3H), 2.69-2.92 (m, 4H), 4.50 (t, 1H), 4.62 (t, 1H), 5.01 (tt, 1H), 6.68-6.80 (m, 1H), 8.01-8.11 (m, 1H), 8.24 (s br, 1H), 8.48 (d, 1H), 8.74 (s br, 1H), 2×NH not detected, 1×CH.sub.2and 1×CH.sub.3 obscured by solvent signal.

Example 15

N-(6-{[1-(2,2-Difluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1639] ##STR00136##

[1640] A mixture of the crude TFA salt of 3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide [Example 13] (117 mg, 50% purity, 0.12 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (39 mg, 0.18 mmol, 1.5 eq), potassium carbonate (84 mg, 0.61 mmol, 5.0 eq) and potassium iodide (2 mg, 0.01 mmol, 0.1 eq) in 3.2 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. Afterwards another 1.5 eq 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (39 mg, 0.18 mmol) and another 2 eq potassium carbonate (34 mg, 0.24 mmol) in 5 mL acetonitrile were added and the vial was sealed and the reaction mixture was stirred again at an environmental temperature of 70° C. for another 18 h under argon atmosphere. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was achieved via preparative MPLC (Biotage Isolera; SNAP cartridge: dicloromethane.fwdarw.dichloromethane/ethanol 9:1). The volatile components of the collected fractions were removed in vacuo. Final purification was conducted via preparative HPLC (Method A) to give 25 mg (36% yield of theory) of the title compound.

[1641] UPLC-MS (Method 2): R.sub.t=0.84 min; MS (El.sub.pos): m/z=544 [M+H].sup.+.

[1642] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.54-1.76 (m, 2H), 1.92-2.25 (m, 2H), 2.69-2.96 (m, 4H), 4.91-5.05 (m, 1H), 6.00-6.30 (m, 1H), 6.82 (d, 1H), 8.04 (s br, 1H), 8.49 (s br, 1H), 8.64 (s br, 1H), 8.98 (s br, 1H), 10.26 (s br, 1H), 11.39 (s br, 1H), 1×CH.sub.2 and 1×CH.sub.3 obscured by solvent signal.

Example 16

3-Methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1643] ##STR00137##

[1644] A mixture of the crude TFA salt of 3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide [Example 13] (100 mg, 50% purity, 0.14 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (36 mg, 0.16 mmol, 1.5 eq) potassium carbonate (72 mg, 0.52 mmol, 5.0 eq) and potassium iodide (2mg, 0.01 mmol, 0.1 eq) in 2.8 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. The precipitate observed was isolated by filtration. Final purification was conducted via preparative HPLC (Method B) to give 45 mg (71% yield of theory) of the title compound.

[1645] UPLC-MS (Method 2): R.sub.t=0.90 min; MS (El.sub.pos): m/z=562 [M+H].sup.+.

[1646] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.53-1.81 (m, 2H), 1.85-2.08 (m, 2H), 2.76-2.98 (m, 2H), 3.10-3.25 (m, 2H), 4.91-5.12 (m, 1H), 6.66-6.90 (m, 1H), 8.09 (s br, 1H), 8.35-8.63 (m, 2H), 8.91 (s br, 1H),10.27 (s br, 1H), 11.41 (s br, 1H) 1×CH.sub.2 and 1×CH.sub.3 obscured by solvent signal.

Example 17

N-{6-[(1-Acetylpiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-5-{[6-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1647] ##STR00138##

[1648] A mixture of the crude TFA salt of 3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide [Example 13] (100 mg, 0.11 mmol, 1.0 eq), pyridine (CAS-RN: 110-86-1) (179 μL, 2.2 mmol, 20 eq) and acetic anhydride (CAS-RN: 108-24-7) (209 μL, 2.2 mmol, 20 eq) was placed in a microwave vial and the reaction mixture was stirred at room temperature overnight. The volatile components were removed in vacuo. Purification of this crude material was achieved via preparative MPLC (Biotage Isolera; SNAP cartridge: dicloromethane.fwdarw.dichloromethane/ethanol 9:1). The volatile components of the collected fractions were removed in vacuo. Final purification was conducted via preparative HPLC (Method A) to give 29 mg (48% yield of theory) of the title compound.

[1649] UPLC-MS (Method 2): R.sub.t=0.76 min; MS (El.sub.pos): m/z=522 [M+H].sup.+.

[1650] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.46-1.57 (m, 1H), 1.57-1.69 (m, 1H), 1.89-1.95 (m, 1H), 1.96-2.01 (m, 1H), 2.02 (s, 3H), 3.16-3.25 (m, 1H), 3.32-3.38 (m, 1H), 3.65-3.73 (m, 1H), 3.80-3.95 (m, 1H), 5.14-5.21 (m, 1H), 6.85 (d, 1H), 8.05 (d, 1H), 8.51 (s br, 1H), 8.64 (s br, 1H), 8.99 (s, 1H), 10.27 (s br, 1H), 11.40 (s br, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 18

tert-Butyl 4-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)pyridin-2-yl]oxy}piperidine-1-carboxylate

[1651] ##STR00139##

[1652] A mixture of tert-butyl 4-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-pyridin-2-yl)oxy]piperidine-1-carboxylate [Intermediate 14] (200 mg, 0.46 mmol, 1.2 eq), 2-chloroquinoxaline (CAS-RN: 1448-87-9) (63 mg, 0.38 mmol, 1.0 eq) and cesium carbonate (288 mg, 0.9 mmol, 2.3 eq) in 3.8 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (9 mg, 0.04 mmol, 0.1 eq) and Xantphos (22 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 32 mg (14% yield of theory) of the title compound.

[1653] UPLC-MS (Method 2): Rt=0.96 min; MS (El.sub.pos): m/z=562 [M+H].sup.+.

[1654] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.40 (s, 9 H), 1.44-1.66 (m, 2H), 1.79-2.05 (m, 2H), 3.06-3.27 (m, 2H), 3.56-3.82 (m, 2H), 5.14 (dt, 1H), 6.84 (d, 1 H), 7.60 (s br, 1H), 7.76 (s br, 1H), 7.95 (s br, 2H), 8.08 (d, 1H), 8.53 (s br, 1H), 9.00 (s br, 1H), 10.30 (s br, 1H), 11.36 (s br, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 19

3-Methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[1655] ##STR00140##

[1656] tert-Butyl 4-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)pyridin-2-yl]oxy}piperidine-1-carboxylate [Example 18] (158 mg, 0.28 mmol, 1.0 eq) was suspended in 5.5 mL dichloromethane and trifluoro acetic acid (CAS-RN: 76-C.sub.5-1) (0.4 mL, 19.2 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. The volatile components were removed in vacuo and the purification was conducted via preparative HPLC (Method B) to give 107 mg (78% yield of theory) the title compound as free base.

[1657] UPLC-MS (Method 2): R.sub.t=0.78 min; MS (Elne.sub.g): m/z=460 [M−H].sup.−.

[1658] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.78-1.93 (m, 2H), 2.05-2.22 (m, 2H), 2.53 (s, 3H), 3.05-3.19 (m, 2H), 3.21-3.29 (m, 2H), 5.15-5.29 (m, 1H), 6.90 (d, 1H), 7.51-7.72 (m, 1H), 7.74-7.85 (m, 1H), 7.99 (d, 2H), 8.04-8.14 (m, 1H), 8.45-8.60 (m, 2H), 9.02 (s, 1H), 10.32 (s br, 1H), 11.33 (s br, 1H).

Example 20

N-(6-{[1-(2,2-difluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[1659] ##STR00141##

[1660] A mixture of 3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-(quinoxalin-2-yl-amino)-1,2-thiazole-4-carboxamide [Example 19] (210 mg, 50% purity, 0.23 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (73 mg, 0.34 mmol, 1.5 eq), potassium carbonate (158 mg, 1.1 mmol, 5.0 eq) and potassium iodide (4 mg, 0.02 mmol, 0.1 eq) in 6 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. Afterwards another 1.5 eq 2,2-difluoroethyl trifluoromethanesulfonate (CAS 74427-22-8) (73 mg, 0.34 mmol) and another 2 eq potassium carbonate (63 mg, 0.44 mmol) in 5 mL acetonitrile were added and the vial was sealed and the reaction mixture was stirred again at an environmental temperature of 70° C. for another 18 h under argon atmosphere. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). All volatile components were removed in vacuo. Purification of this crude material was achieved via preparative MPLC (Biotage Isolera; 25 g SNAP cartridge: dicloromethan.fwdarw.dichloromethane/ethanol 9:1). The volatile components of the collected fractions were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 52 mg (40% yield of theory) of the title compound.

[1661] UPLC-MS (Method 2): R.sub.t=0.84 min; MS (EI.sub.pos): m/z=526 [M+H].sup.+.

[1662] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.54-1.79 (m, 2H), 1.90-2.03 (m, 2H), 2.65-2.92 (m, 4H), 4.90-5.05 (m, 1H), 5.91-6.36 (m, 1H), 6.83 (d, 1H), 7.54-7.69 (m, 1H), 7.72-7.83 (m, 1H), 7.97 (d, 2H), 8.07 (d, 1H), 8.51 (s, 1H), 9.02 (s, 1H), 10.26 (s br, 1H), 11.32 (s br, 1H),1x CH.sub.2 and 1×CH.sub.3 obscured by solvent signal.

Example 21

3-Methyl-5-(quinoxalin-2-ylamino)-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}-pyridin-3-yl)-1,2-thiazole-4-carboxamide

[1663] ##STR00142##

[1664] A mixture of of 3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-(quinoxalin-2-yl-amino)-1,2-thiazole-4-carboxamide [Example 19] (36 mg, 0.08 mmol, 1.0 eq), 1,1,1-trifluoro-2-iodoethane (CAS-RN: 353-83-3) (33 mg, 0.16 mmol, 1.5 eq) and sodium carbonate (17 mg, 0.16 mmol, 2.0 eq) in 2 mL DMF was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 60° C. for three hours. Afterwards the mixture was stirred at 120° C. overnight. After adding of 1 eq 1,1,1-trifluoro-2-iodoethane (CAS-RN: 353-83-3) (22 mg, 0.1 mmol) and 2 eq sodium carbonate (17 mg, 0.16 mmol) the reaction mixture was stirred for another 24 hours. The volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method A) to give 6 mg (13% yield of theory) of the title compound.

[1665] UPLC-MS (Method 3): R.sub.t=1.38 min; MS (El.sub.pos): m/z=544 [M+H].sup.+.

[1666] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.54-1.78 (m, 2H), 1.90-2.04 (m, 2H), 2.55-2.65 (m, 2H), 2.80-2.94 (m, 2H), 3.11-3.27 (m, 2H), 4.93-5.04 (m, 1 H), 6.84 (d, 1H), 7.51-7.69 (m, 1H), 7.69-7.86 (m, 1H), 7.98 (d, 2H), 8.06 (d, 1H), 8.51 (s br, 1H), 9.03 (s, 1H), 10.28 (s br, 1H), 11.33 (s br, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 22

N-{6-[(1-acetylpiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[1667] ##STR00143##

[1668] A mixture of the trifluoroacetic acid salt of 3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide [Example 19] (164 mg, 50% purity, 0.18 mmol, 1.0 eq), pyridine (CAS-RN: 110-86-1) (288 μL, 3.6 mmol, 20 eq) and acetic anhydride (CAS-RN: 108-24-7) (336 μL, 3.2 mmol, 20 eq) was placed in a microwave vial and the reaction mixture was stirred at room temperature for 2.5 days. The volatile components were removed in vacuo. Purification of this crude material was achieved via preparative MPLC (Biotage Isolera; 25 g SNAP cartridge: dicloromethan.fwdarw.dichloromethane/ethanol 9:1) to give 53 mg (53% yield of theory) of the title compound.

[1669] UPLC-MS (Method 2): R.sub.t=0.75 min; MS (EI.sub.pos): m/z=504 [M+H].sup.+.

[1670] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.42-1.58 (m, 1H), 1.58-1.72 (m, 1H), 1.89-1.97 (m, 1H), 1.98-2.01 (m, 1H), 2.02 (s, 3H), 3.14-3.26 (m, 1H), 3.33-3.42 (m, 1H), 3.65-3.74 (m, 1H), 3.84-3.94 (m, 1H), 5.19 (tt, 1H), 6.86 (d, 1 H), 7.56-7.72 (m, 1H), 7.72-7.83 (m, 1H), 7.93-8.02 (m, 2H), 8.06 (d, 1H), 8.52 (s br, 1H), 9.03 (s, 1H), 10.27 (s, 1H), 11.31 (s, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 23

tert-Butyl 4-({5-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)piperidine-1-carboxylate

[1671] ##STR00144##

[1672] A mixture of tert-butyl 4-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-pyridin-2-yl)oxy]piperidine-1-carboxylate [Intermediate 14] (200 mg, 0.46 mmol, 1.2 eq), 2-chloroisonicotinonitrile (CAS-RN: 33252-30-1) (53 mg, 0.38 mmol, 1.0 eq) and cesium carbonate (288 mg, 0.9 mmol, 2.3 eq) in 3.8 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (9 mg, 0.04 mmol, 0.1 eq) and Xantphos (22 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 12 mg (6% yield of theory) of the title compound.

[1673] UPLC-MS (Method 1): Rt=1.40 min; MS (El.sub.pos): m/z=536 [M+H].sup.+.

[1674] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.40 (s, 9 H), 1.46-1.64 (m, 2H), 1.85-2.06 (m, 2H), 2.46 (s, 3H), 3.07-3.25 (m, 2H), 3.58-3.82 (m, 2H), 5.13 (dt, 1 H), 6.72-6.90 (m, 1H), 7.36 (d, 1H), 7.69-7.84 (m, 1H), 8.03 (d, 1H), 8.48 (s br, 1H), 8.60 (d, 1H), 10.18 (s br, 1H), 10.89 (s br, 1H).

Example 24

5-[(4-Cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-1,2-thiazole-4-carboxamide

[1675] ##STR00145##

[1676] tert-Butyl 4-({5-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)piperidine-1-carboxylate [Example 23] (152 mg, 0.28 mmol, 1.0 eq) was suspended in 5.5 mL dichloromethane and trifluoro acetic acid (CAS-RN: 76-C.sub.5-1) (0.4 mL, 0.57 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. The reaction mixture was dissolved in a mixture of dichloromethane and methanol (1:1) and the volatile components were removed in vacuo. The TFA salt was dissolved in a mixture of dichloromethane and methanol and triethylamine was added. The volatile components were removed in vacuo and the purification was conducted via preparative HPLC (Method B) to give the 46 mg (35% yield of theory) title compound as free base.

[1677] UPLC-MS (Method 3): R.sub.t=0.83 min; MS (El.sub.pos): m/z=436 [M+H].sup.+.

[1678] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.76-1.88 (m, 2H), 2.07-2.19 (m, 2H), 2.53 (s, 3H), 3.03-3.13 (m, 2H), 3.18-3.27 (m, 2H), 5.12-5.24 (m, 1H), 6.79 (d, 2H), 7.47 (s, 1H), 8.09-8.28 (m, 2H), 8.36-8.46 (d, 2H), 8.60 (d, 1H), 13.50 (s br, 1H).

Example 25

5-[(4-Cyanopyridin-2-yl)amino]-3-methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide

[1679] ##STR00146##

[1680] A mixture of the trifluoro acetate salt of 5-[(4-cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-1,2-thiazole-4-carboxamide [Example 24] (200 mg, 70% purity, 0.32 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (112 mg, 0.48 mmol, 1.5 eq), potassium carbonate (222 mg, 1.6 mmol, 5.0 eq) and potassium iodide (5 mg, 0.32 mmol, 0.1 eq) in 7.5 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. overnight. The volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method A) to give 76 mg (43% yield of theory) of the title compound.

[1681] UPLC-MS (Method 2): R.sub.t=0.97 min; MS (El.sub.pos): m/z=518 [M+H].sup.+.

[1682] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.56-1.74 (m, 2H), 1.87-2.03 (m, 2H), 2.44 (s, 3H), 2.52-2.61 (m, 2H), 2.81-2.96 (m, 2H), 3.11-3.24 (m, 2H), 4.97 (tt, 1H), 6.82 (d, 1H), 7.28-7.40 (m, 1H), 7.76 (s br, 1H), 7.94-8.12 (m, 1H), 8.47 (s br, 1H), 8.60 (dd, 1H), 10.14 (s br, 1H), 10.89 (s br, 1H)

Example 26

5-[(4-Cyanopyridin-2-yl)amino]-N-{6-[(1-ethylpiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-1,2-thiazole-4-carboxamide

[1683] ##STR00147##

[1684] A mixture of the trifluoro acetate salt of 5-[(4-cyanopyridin-2-yl)amino]-3-methyl-N -[6-(piperidin-4-yloxy)pyridin-3-yl]-1,2-thiazole-4-carboxamide [Example 24] (200 mg, 70% purity, 0.32 mmol, 1.0 eq), ethyl 4-methylbenzenesulfonate (CAS-RN: 80-40-0) (97 mg, 0.48 mmol, 1.5 eq), potassium carbonate (222 mg, 1.6 mmol, 5.0 eq) and potassium iodide (5 mg, 0.32 mmol, 0.1 eq) in 7.5 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. overnight. The volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method A) to give 25 mg (17% yield of theory) of the title compound.

[1685] UPLC-MS (Method 2): R.sub.t=0.84 min; MS (El.sub.pos): m/z=464 [M+H].sup.+.

[1686] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.04 (t, 3H), 1.60-1.80 (m, 2H), 1.96-2.11 (m, 2H), 2.24-2.42 (m, 2H), 2.80-2.96 (m, 2H), 4.97 (tt, 1H), 6.75 (d, 1H), 6.81 (d, 1H), 7.53 (s br, 1H), 8.10-8.28 (m, 1H), 8.40 (d, 1H), 8.54 (d, 1H), 13.53 (s br, 1H), 1x CH.sub.2 and 1×CH.sub.3 obscured by the solvent signal, 1xNH not detected.

Example 27

[1687] tert-Butyl 4-({5-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)piperidine-1-carboxylate

##STR00148##

[1688] A mixture of tert-butyl 4-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]-amino}pyridin-2-yl)oxy]piperidine-1-carboxylate [Intermediate 14] (200 mg, 0.46 mmol, 1.2 eq), 6-chloronicotinonitrile (CAS-RN: 33252-28-7) (53 mg, 0.38 mmol, 1.0 eq) and cesium carbonate (288 mg, 0.9 mmol, 2.3 eq) in 3.8 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (9 mg, 0.04 mmol, 0.1 eq) and Xantphos (22 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 18 mg (8% yield of theory) of the title compound.

[1689] UPLC-MS (Method 2): Rt=0.94 min; MS (El.sub.pos): m/z=536 [M+H].sup.+.

[1690] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.40 (s, 9 H), 1.46-1.64 (m, 2H), 1.82-2.06 (m, 2H), 2.45 (s br, 3H), 3.07-3.25 (m, 2H), 3.57-3.79 (m, 2H), 5.12 (dt, 1H), 6.82 (d, 1H), 7.43 (s br, 1H), 8.03 (d, 1H), 8.12 (s br, 1H), 8.48 (d, 1H), 8.86 (s br, 1H), 10.26 (s br, 1H), 11.08 (s br, 1H).

Example 28

5-[(5-Cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-4-yloxy)pyridin-3-yl]-1,2-thiazole-4-carboxannide

[1691] ##STR00149##

[1692] tert-Butyl 4-({5-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)piperidine-1-carboxylate [Example 27] (153 mg, 0.29 mmol, 1.0 eq) was suspended in 5.5 mL dichloromethane and trifluoro acetic acid (CAS-RN: 76-C.sub.5-1) (0.4 mL, 0.57 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. The reaction mixture was dissolved in a mixture of dichloromethane and methanol (1:1) and the volatile components were removed in vacuo. The TFA salt was dissolved in a mixture of dichloromethane and methanol and triethylamine was added. The volatile components were removed in vacuo and the purification was conducted via preparative HPLC (Method B) to give the 62 mg (49% yield of theory) title compound as free base.

[1693] UPLC-MS (Method 3): R.sub.t=0.81 min; MS (El.sub.pos): m/z=436 [M+H].sup.+.

[1694] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.75-1.91 (m, 2H), 2.06-2.20 (m, 2H), 2.52 (s, 3H), 3.03-3.16 (m, 2H), 3.18-3.27 (m, 2H), 5.18 (tt, 1H), 6.80 (d, 1H), 7.00 (d, 1H), 7.67 (dd, 1H), 8.06-8.16 (m, 1H), 8.29-8.52 (m, 1H), 8.54 (d, 1H), 8.60 (d, 1H), 13.49 (s br, 1H), 1xNH not detected.

Example 29

5-[(5-Cyanopyridin-2-yl)amino]-N-(6-{[1-(2-fluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-1,2-thiazole-4-carboxamide

[1695] ##STR00150##

[1696] A mixture of 5-[(5-cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-4-yloxy)-pyridin-3-yl]-1,2-thiazole-4-carboxamide [Example 28] (200 mg, 70% purity, 0.32 mmol, 1.0 eq), 2-fluoroethyl 4-methylbenzenesulfonate (CAS-RN: 383-50-6) (105 mg, 0.48 mmol, 1.5 eq), potassium carbonate (222 mg, 1.6 mmol, 5.0 eq) and potassium iodide (5 mg, 0.03 mmol, 0.1 eq) in 7.5 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. overnight. After cooling on rt all volatile components were removed in vacuo and final purification was conducted via preparative HPLC (Method B) to give 39 mg (23% yield of theory) of the title compound.

[1697] UPLC-MS (Method 2): R.sub.t=0.82 min; MS (El.sub.pos): m/z=482 [M+H].sup.+.

[1698] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.55-1.74 (m, 2H), 1.88-2.04 (m, 2H), 2.17-2.39 (m, 2H), 2.53 (s, 3H), 2.55-2.65 (m, 1H), 2.66-2.73 (m, 1H), 2.75-2.85 (m, 2H), 4.47 (t, 1H), 4.59 (t, 1H), 4.94 (tt, 1H), 6.74 (d, 1H), 6.78-6.88 (m, 1H), 7.52 (s br, 1H), 8.14-8.26 (m, 1H), 8.39 (d, 1H), 8.53 (d, 1H), 11.03 (s br, 1H), 13.54 (s br, 1H).

Example 30

5-[(5-Cyanopyridin-2-yl)amino]-3-methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide

[1699] ##STR00151##

[1700] A mixture of of 5-[(5-cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-4-yl-oxy)pyridin-3-yl]-1,2-thiazole-4-carboxamide [Example 28] (32 mg, 85% purity, 0.06 mmol, 1.0 eq), 1,1,1-trifluoro-2-iodoethane (CAS-RN: 353-83-3) (26 mg, 0.13 mmol, 2 eq) and sodium carbonate (13 mg, 0.13 mmol, 2.0 eq) in 1.5 mL DMF was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 60° C. for three hours. Afterwards the mixture was stirred at 120° C. overnight. After adding of 1 eq 1,1,1-trifluoro-2-iodoethane (CAS 353-83-3) (13 mg, 0.06 mmol) and 2 eq sodium carbonate (13 mg, 0.13 mmol) the reaction mixture was stirred for another 24 hours. The volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method A) to give 9 mg (26% yield of theory) of the title compound.

[1701] UPLC-MS (Method 3): R.sub.t=1.27 min; MS (El.sub.pos): m/z=518 [M+H].sup.+.

[1702] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.52-1.75 (m, 2H), 1.89-2.07 (m, 2H), 2.44 (s, 3H), 2.53-2.62 (m, 2H), 2.78-2.98 (m, 2H), 3.09-3.27 (m, 2H), 4.97 (tt, 1H), 6.82 (d, 1H), 7.43 (d, 1H), 8.03 (d, 1H), 8.12 (d, 1H), 8.47 (d, 1H), 8.86 (d, 1H), 10.25 (s br, 1H), 11.07 (s br, 1H)

Example 31

tert-Butyl 3-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)pyridin-2-yl]oxy}piperidine-1-carboxylate

[1703] ##STR00152##

[1704] A mixture of tert-butyl 3-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-pyridin-2-yl)oxy]piperidine-1-carboxylate [Intermediate 17] (200 mg, 0.46 mmol, 1.2 eq), 2-chloroquinoxaline (CAS-RN: 1448-87-9) (63 mg, 0.38 mmol, 1.0 eq) and cesium carbonate (288 mg, 0.9 mmol, 2.3 eq) in 3.8 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (9 mg, 0.04 mmol, 0.1 eq) and Xantphos (22 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification was conducted via preparative HPLC (Method A) to give 18 mg (8% yield of theory) of the title compound.

[1705] UPLC-MS (Method 1): Rt=1.46 min; MS (El.sub.pos): m/z=562 [M+H].sup.+.

[1706] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.36 (s, 9 H), 1.42-1.56 (m, 1H), 1.67-1.85 (m, 2H), 1.87-2.05 (m, 1H), 2.56 (s br, 3H), 3.28-3.48 (m, 2H), 3.46-3.58 (m, 1H), 3.61-3.70 (m, 1H), 4.89-5.04 (m, 1H), 6.79 (d, 1H), 7.29-7.51 (m, 1H), 7.52-7.68 (m, 1H), 7.77 (t, 1H), 7.92-8.02 (m, 2H), 8.07 (d, 1H), 8.51 (d, 1H), 9.01 (s, 1H).

Example 32

3-Methyl-N-[6-(piperidin-3-yloxy)pyridin-3-yl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxannide

[1707] ##STR00153##

[1708] tert-Butyl 3-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)pyridin-2-yl]oxy}piperidine-1-carboxylate [Example 31] (162 mg, 0.29 mmol, 1.0 eq) was suspended in 5.5 mL dichloromethane and trifluoro acetic acid (CAS-RN: 76-C.sub.5-1) (0.4 mL, 5.7 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. The volatile components were removed in vacuo and the purification was conducted via preparative HPLC (Method A) to give 127 mg (91% yield of theory) the title compound.

[1709] UPLC-MS (Method 2): R.sub.t=0.76 min; MS (El.sub.pos): m/z=462 [M+H].sup.+.

[1710] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.62-1.80 (m, 1H), 1.81-2.05 (m, 3H), 2.53 (s, 3H), 3.03-3.14 (m, 2H), 3.20-3.28 (m, 1H), 3.35-3.43 (m, 1H), 5.19-5.35 (m, 1H), 6.91 (d, 1H), 7.52-7.70 (m, 1H), 7.77 (t, 1H), 7.97 (d, 2H), 8.07-8.21 (m, 1H), 8.57 (s, 1H), 8.68 (s br, 1H), 9.00 (s, 1H), 10.41 (s br, 1H), 11.36 (s br, 1H).

Example 33

N-(6-{[1-(2,2-Difluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[1711] ##STR00154##

[1712] A mixture of 3-methyl-N-[6-(piperidin-3-yloxy)pyridin-3-yl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide [Example 32] (32 mg, 0.07 mmol, 1.0 eq), 1,1-difluoro-2-iodoethane (CAS 598-39-0) (40 mg, 0.21 mmol, 3 eq) and sodium carbonate (29 mg, 0.28 mmol, 4.0 eq) in 1.5 mL DMF was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 120° C. overnight. After cooling to rt all volatile components were removed in vacuo and the final purification of this crude material was achieved via preparative HPLC (Method A) to give 2.5 mg (6% yield of theory) of the title compound.

[1713] UPLC-MS (Method 3): R.sub.t=1.07 min; MS (El.sub.pos): m/z=526 [M+H].sup.+.

[1714] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.31-1.60 (m, 2H), 1.65-1.81 (m, 1H), 1.90-2.04 (m, 1H), 2.23-2.38 (m, 2H), 2.69-2.84 (m, 3H), 3.08 (d, 1H), 4.86-5.12 (m, 1H), 5.91-6.37 (m, 1H), 6.81 (d, 1H), 7.60 (s br, 1H), 7.75 (s br, 1H), 7.95 (s br, 2H), 8.08 (d, 1H), 8.53 (s, 1H), 8.99 (s br, 1H), 10.29 (s br, 1H), 11.36 (s br, 1H).

Example 34

tert-Butyl 3({5-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)piperidine-1-carboxylate

[1715] ##STR00155##

[1716] A mixture of tert-butyl 3-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]-amino}pyridin-2-yl)oxy]piperidine-1-carboxylate [Intermediate 17] (200 mg, 0.46 mmol, 1.2 eq), 2-chloroisonicotinonitrile (CAS-RN: 33252-30-1) (53 mg, 0.38 mmol, 1.0 eq) and cesium carbonate (288 mg, 0.9 mmol, 2.3 eq) in 3.8 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (9 mg, 0.04 mmol, 0.1 eq) and Xantphos (22 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification of 100 mg of the crude product was conducted via preparative HPLC (Method A) to give 10 mg (4% yield of theory) of the title compound. The other 300 mg of the crude product were used without further purification.

[1717] UPLC-MS (Method 1): Rt=1.39 min; MS (El.sub.pos): m/z=536 [M+H].sup.+.

[1718] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.27 (s br, 9 H), 1.41-1.55 (m, 1H), 1.65-1.82 (m., 2H), 1.86-2.00 (m, 1H), 2.46 (s br, 3H), 3.34-3.84 (m, 3H), 4.88-4.99 (m, 1H), 6.80 (d, 1H), 7.36 (d, 1H), 7.76 (s, 1H), 8.04 (d, 1H), 8.48 (s, 1H), 8.53-8.67 (m, 1H), 10.16 (s, 1H), 10.89 (s, 1H).

Example 35

5-[(4-Cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-3-yloxy)pyridin-3-yl]-1,2-thiazole-4-carboxamide

[1719] ##STR00156##

[1720] tert-Butyl 3-({5-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)piperidine-1-carboxylate [Example 34] (154 mg, 0.29 mmol, 1.0 eq) was suspended in 5.5 mL dichloromethane and trifluoro acetic acid (CAS-RN: 76-C.sub.5-1) (0.4 mL, 5.7 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. The volatile components were removed in vacuo and the purification was conducted via preparative HPLC (Method A) to give 12 mg (9% yield of theory) the title compound.

[1721] UPLC-MS (Method 1): R.sub.t=0.87 min; MS (El.sub.pos): m/z=436 [M+H].sup.+.

[1722] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.60-1.75 (m, 1H), 1.78-2.04 (m, 3H), 2.53 (s, 3H), 3.02-3.09 (m, 2H), 3.17-3.28 (m, 1H), 3.35-3.43 (m, 1H), 5.19-5.30 (m, 1H), 6.86 (d, 1H), 7.09 (s, br, 1H), 7.63 (s, 1H), 8.04-8.19 (m, 1H), 8.50 (d, 1H), 8.58 (s, 1H), 3×NH not detected.

Example 36

tert-Butyl 3-({5-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)piperidine-1-carboxylate

[1723] ##STR00157##

[1724] A mixture of tert-butyl 3-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-pyridin-2-yl)oxy]piperidine-1-carboxylate [Intermediate 17] (200 mg, 0.46 mmol, 1.2 eq), 6-chloronicotinonitrile (CAS-RN: 33252-28-7) (53 mg, 0.38 mmol, 1.0 eq) and cesium carbonate (288 mg, 0.9 mmol, 2.3 eq) in 3.8 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (9 mg, 0.04 mmol, 0.1 eq) and Xantphos (22 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification of 109 mg of the crude product was conducted via preparative HPLC (Method A) to give 36 mg (16% yield of theory) of the title compound. The other 271 mg of the crude product were used without further purification.

[1725] UPLC-MS (Method 1): Rt=1.37 min; MS (El.sub.pos): m/z=536 [M+H].sup.+.

[1726] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.27 (s br, 9 H), 1.41-1.56 (m, 1H), 1.65-1.84 (m, 2H), 1.85-2.04 (m, 1H), 2.44 (s br, 3H), 3.36-3.89 (m, 3H), 4.87-5.02 (m, 1H), 6.75-6.85 (m, 1H), 7.39-7.50 (m, 1H), 7.95-8.19 (m, 2H), 8.48 (d, 1H), 8.86 (d, 1H), 10.24 (s, 1H), 11.07 (s, 1H).

Example 37

5-[(5-Cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-3-yloxy)pyridin-3-yl]-1,2-thiazole-4-carboxamide

[1727] ##STR00158##

[1728] tert-Butyl 3-({5-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)piperidine-1-carboxylate [Example 36] (146 mg, 0.27 mmol, 1.0 eq) was suspended in 5.5 mL dichloromethane and trifluoro acetic acid (CAS-RN: 76-C.sub.5-1) (0.4 mL, 5.5 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. The volatile components were removed in vacuo and the purification was conducted via preparative HPLC (Method A) to give 92 mg (74% yield of theory) the title compound.

[1729] UPLC-MS (Method 3): R.sub.t=0.81 min; MS (El.sub.pos): m/z=436 [M+H].sup.+.

[1730] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.62-1.77 (m, 1H), 1.77-2.00 (m, 3H), 2.46 (s, 3H), 3.03-3.11 (m, 2H), 3.23 (dd, 1H), 3.38 (dd, 1H), 5.19-5.30 (m, 1H), 6.88 (d, 1H), 7.39 (s br, 1H), 7.96-8.23 (m, 2H), 8.52 (d, 1H), 8.67 (s br, 1H), 8.85 (s br, 1H), 10.30 (s br, 1H), 11.08 (s br, 1H).

Example 38

5-[(5-Cyanopyridin-2-yl)amino]-N-(6-{[1-(2-fluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-3-methyl-1,2-thiazole-4-carboxamide

[1731] ##STR00159##

[1732] A mixture of 5-[(5-cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-3-yloxy)-pyridin-3-yl]-1,2-thiazole-4-carboxamide [Example 37] (94 mg, 0.22 mmol, 1.0 eq), 2-fluoroethyl 4-methylbenzenesulfonate (CAS-RN: 383-50-6) (71 mg, 0.32 mmol, 1.5 eq), potassium carbonate (149 mg, 1.08 mmol, 5.0 eq) and potassium iodide (3.4 mg, 0.02 mmol, 0.1 eq) in 5 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. overnight. After cooling to rt all volatile components were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 41 mg (37% yield of theory) of the title compound.

[1733] UPLC-MS (Method 2): R.sub.t=0.85 min; MS (El.sub.pos): m/z=482 [M+H].sup.+.

[1734] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.32-1.45 (m, 1H), 1.45-1.60 (m, 1H), 1.67-1.78 (m, 1H), 1.92-2.03 (m, 1H), 2.09-2.27 (m, 2H), 2.62 (t, 1H), 2.67-2.76 (m, 2H), 3.05 (d, 1H), 4.46 (t, 1H), 4.58 (t, 1H), 4.89-5.10 (m, 1H), 6.76(d, 1H), 7.32 (s br, 1H), 7.77 (s br, 1H), 8.10 (d, 1H), 8.48 (d, 1H), 8.72 (s br., 1H) 10.24 (s br, 1H), 11.08 (s br, 1H) 1×CH.sub.3 obscured by solvent signal.

Example 39

5-[(5-Cyanopyridin-2-yl)amino]-N-(6-{[1-(2,2-difluoroethyl)piperidin-3-yl]oxy}-pyridin-3-yl)-3-methyl-1,2-thiazole-4-carboxamide

[1735] ##STR00160##

[1736] A mixture of 5-[(5-cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-3-yloxy)-pyridin-3-yl]-1,2-thiazole-4-carboxamide [Example 37] (34 mg, 85% purity, 0.07 mmol, 1.0 eq), 1,1-difluoro-2-iodoethane (CAS-RN: 598-39-0) (25 mg, 0.13 mmol, 2 eq) and sodium carbonate (14 mg, 0.13 mmol, 2 eq) in 2 mL DMF was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 60° C. for 3 h and at 120° C. overnight. After cooling to rt all volatile components were removed in vacuo and the final purification of this crude material was achieved via preparative HPLC (Method A) to give 7 mg (18% yield of theory) of the title compound.

[1737] UPLC-MS (Method 3): R.sub.t=0.93 min; MS (El.sub.pos): m/z=500 [M+H].sup.+.

[1738] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.28-1.62 (m, 2H), 1.72 (dd, 1H), 1.88-2.09 (m, 1H), 2.17-2.41 (m, 2H), 2.45 (s, 3H), 2.64-2.87 (m, 3H), 3.01-3.13 (m, 1H), 4.98 (tt, 1H), 5.88-6.37 (m, 1H), 6.80 (d, 1H), 7.22-7.51 (m, 1H), 7.88-8.18 (m, 2H), 8.48 (d, 1H), 8.85 (s br, 1H), 10.27 (s br, 1H), 11.09 (s br, 1 H).

Example 40

5-[(5-Cyanopyridin-2-yl)amino]-3-methyl-N-(6-{[1-(2,2,2-trifluoroethyl)piperidin-3-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide

[1739] ##STR00161##

[1740] A mixture of 5-[(5-cyanopyridin-2-yl)amino]-3-methyl-N-[6-(piperidin-3-yloxy)-pyridin-3-yl]-1,2-thiazole-4-carboxamide [Example 37] (94 mg, 0.22 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (75 mg, 0.32 mmol, 1.5 eq) potassium carbonate (149 mg, 1.08 mmol, 5.0 eq) and potassium iodide (3.6 mg, 0.02 mmol, 0.1 eq) in 5 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. Final purification was conducted via preparative HPLC (Method B) to give 40 mg (34% yield of theory) of the title compound.

[1741] UPLC-MS (Method 2): R.sub.t=0.95 min; MS (El.sub.pos): m/z=518 [M+H].sup.+.

[1742] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.31-1.62 (m, 2H), 1.64-1.83 (m, 1H), 1.91-2.05 (m, 1H), 2.68-2.87(m, 1H), 3.06-3.16 (m, 1H), 3.17-3.28 (m, 2H), 4.98 (tt, 1H), 6.79 (d, 1H), 7.38 (s br, 1H), 7.94-8.2 (m, 2H), 8.48 (d, 1H), 8.81 (s br, 1H), 10.25 (s br, 1H), 11.09 (s br, 1H) 1×CH.sub.2 and 1×CH.sub.3 obscured by solvent signal.

Example 41

tert-Butyl 3-{[5-({[3-methyl-5-(pyrazin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-pyridin-2-yl]oxy}piperidine-1-carboxylate

[1743] ##STR00162##

[1744] A mixture of tert-butyl 3-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]-amino}pyridin-2-yl)oxy]piperidine-1-carboxylate [Intermediate 17] (200 mg, 0.46 mmol, 1.2 eq), 2-chloropyrazine (CAS-RN: 14508-49-7) (44 mg, 0.38 mmol, 1.0 eq)and cesium carbonate (288 mg, 0.9 mmol, 2.3 eq) in 3.8 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (9 mg, 0.04 mmol, 0.1 eq) and Xantphos (22 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification of 120 mg of the crude product was conducted via preparative HPLC (Method A) to give 5 mg (2% yield of theory) of the title compound. The other 160 mg of the crude product were used without further purification.

[1745] UPLC-MS (Method 1): Rt=1.29 min; MS (El.sub.pos): m/z=512 [M+H].sup.+.

[1746] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.11-1.41 (m, 9 H), 1.43-1.54 (m, 1H), 1.64-1.81 (m, 2H), 1.86-2.13 (m, 1H), 2.46 (s, 3H), 3.06-3.24 (m, 1H), 3.35-3.84 (m, 3H), 4.89-5.04 (m, 1H), 6.80 (d, 1H), 8.05 (d, 1H), 8.17 (d, 1H), 8.34 -8.42 (m, 1H), 8.49 (s br, 1H), 8.74 (s, 1H), 10.17 (s, 1H), 10.93 (s, 1H).

Example 42

tert-Butyl (3-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)pyridin-2-yl]oxy}propyl)carbamate

[1747] ##STR00163##

[1748] A mixture of tert-butyl {3-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]-amino}pyridin-2-yl)oxy]propyl}carbannate [Intermediate 20] (200 mg, 0.49 mmol, 1.2 eq), 2-chloroquinoxaline (CAS-RN: 1448-87-9) (67 mg, 0.41 mmol, 1.0 eq) and cesium carbonate (307 mg, 0.9 mmol, 2.3 eq) in 4.2 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (9 mg, 0.04 mmol, 0.1 eq) and Xantphos (24 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification of 100 mg of the crude product was conducted via preparative HPLC (Method A) to give 41 mg (18% yield of theory) of the title compound. The other 165 mg of the crude product were used without further purification.

[1749] UPLC-MS (Method 1): Rt=1.34 min; MS (El.sub.pos): m/z=536 [M+H].sup.+.

[1750] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.37 (s, 9 H), 1.77-1.89 (m, 2H), 3.01-3.13 (m, 2H), 4.18-4.30 (m, 2H), 6.78-6.94 (m, 2H), 7.55-7.69 (m, 1H), 7.78(t, 1H), 7.92-8.03 (m, 2H), 8.06 (d, 1H), 8.52 (s br, 1H), 9.04 (s, 1H), 10.25 (s br, 1H), 11.32 (s br, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 43

tert-Butyl [3-({5-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)propyl]carbamate

[1751] ##STR00164##

[1752] A mixture of tert-butyl {3-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]-amino}pyridin-2-yl)oxy]propyl}carbannate [Intermediate 20] (200 mg, 0.46 mmol, 1.2 eq), 2-chloroisonicotinonitrile (CAS-RN: 33252-30-1) (57 mg, 0.41 mmol, 1.0 eq) and cesium carbonate (307 mg, 0.9 mmol, 2.3 eq) in 4.2 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (9 mg, 0.04 mmol, 0.1 eq) and Xantphos (24 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification of 100 mg of the crude product was conducted via preparative HPLC (Method A) to give 28 mg (12% yield of theory) of the title compound. The other 350 mg of the crude product were used without further purification.

[1753] UPLC-MS (Method 1): Rt=1.27 min; MS (El.sub.pos): m/z=510 [M+H].sup.+.

[1754] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.37 (s, 9 H), 1.73-1.91 (m, 2H), 2.93-3.15 (m, 2H), 4.15-4.33 (m, 2H), 6.74-6.93 (m, 2H), 7.36 (s, br, 1H), 7.76 (s, 1H), 8.02 (d, 1H), 8.48 (s br, 1H), 8.60 (d, 1H), 10.14 (s br, 1H), 10.89 (s br, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 44

N-[6-(3-Aminopropoxy)pyridin-3-yl]-5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazole-4-carboxamide

[1755] ##STR00165##

[1756] tert-Butyl [3-({5-[({5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)propyl]carbamate [Example 43] (162 mg, 0.32 mmol, 1.0 eq) was suspended in 6 mL dichloromethane and trifluoro acetic acid (CAS-RN: 76-C.sub.5-1) (0.5 mL, 6.4 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. The volatile components were removed in vacuo and the purification was conducted via preparative HPLC (Method A) to give the 90 mg (66% yield of theory) title compound.

[1757] UPLC-MS (Method 1): R.sub.t=0.81 min; MS (El.sub.pos): m/z=410 [M+H].sup.+.

[1758] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.86-2.12 (m, 2H), 2.85-3.08 (m, 2H), 4.18-4.41 (m, 2H), 6.73-6.89 (m, 1H), 7.08 (s br, 1H), 7.62 (s br, 1H), 7.65-7.86 (m, 2H), 8.05-8.18 (m, 1H), 8.50 (d, 1H), 8.54-8.67 (m, 1H), 2xNH not detected, 1×CH.sub.3 obscured by the solvent signal.

Example 45

5-[(4-Cyanopyridin-2-yl)amino]-N-(6-{3-[(2,2-difluoroethyl)amino]propoxy}pyridin-3-yl)-3-methyl-1,2-thiazole-4-carboxamide

[1759] ##STR00166##

[1760] A mixture of N-[6-(3-aminopropoxy)pyridin-3-yl]-5-[(4-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazole-4-carboxamide [Example 44] (33 mg, 0.08 mmol, 1.0 eq), 1,1-difluoro-2-iodoethane (CAS-RN: 598-39-0) (31 mg, 0.16 mmol, 2 eq) and sodium carbonate (17 mg, 0.16 mmol, 2 eq) in 2 mL DMF was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 60° C. for 3 h and at 120° C. overnight. After cooling to rt all volatile components were removed in vacuo and the final purification of this crude material was achieved via preparative HPLC (Method A) to give 4 mg (10% yield of theory) of the title compound.

[1761] UPLC-MS (Method 3): R.sub.t=0.83 min; MS (El.sub.pos): m/z=474 [M+H].sup.+.

[1762] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.78-1.90 (m, 2H), 2.66-2.80 (m, 2H), 2.82-3.04 (m, 2H), 4.27 (t, 2H), 5.77-6.25 (m, 1H), 6.82 (d, 1H), 7.28 (s, br, 1H), 7.74 (s, 1H), 8.05 (dd, 1H), 8.39-8.66 (m, 2H), 10.52 (s br, 1H), 2xNH and 1×CH.sub.3 obscured by solvent signal.

Example 46

tert-Butyl [3-({5-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}-carbonyl)amino]pyridin-2-yl}oxy)propyl]carbamate

[1763] ##STR00167##

[1764] A mixture of tert-butyl {3-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]-amino}pyridin-2-yl)oxy]propyl}carbannate [Intermediate 20] (200 mg, 0.49 mmol, 1.2 eq), 6-chloronicotinonitrile (CAS-RN: 33252-28-7) (57 mg, 0.41 mmol, 1.0 eq) and cesium carbonate (307 mg, 0.9 mmol, 2.3 eq) in 4.2 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (9 mg, 0.04 mmol, 0.1 eq) and Xantphos (24 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification of 100 mg of the crude product was conducted via preparative HPLC (Method A) to give 26 mg (12% yield of theory) of the title compound. The other 161 mg of the crude product were used without further purification.

[1765] UPLC-MS (Method 1): Rt=1.24 min; MS (El.sub.neg): m/z=508 [M−H].sup.−.

[1766] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.37 (s, 9 H), 1.73-1.90 (m, 2H), 2.45 (s, 3H), 3.00-3.12 (m, 2H), 4.15-4.29 (m, 2H), 6.75-6.94 (m, 2H), 7.31-7.58 (m, 1H), 7.93-8.23 (m, 2H), 8.48 (d, 1H), 8.86 (s, 1H), 10.22 (s br, 1H), 11.07 (s br, 1H).

Example 47

tert-Butyl (3-{[5-({[3-methyl-5-(pyrazin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)pyridin-2-yl]oxy}propyl)carbamate

[1767] ##STR00168##

[1768] A mixture of tert-butyl {3-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]-amino}pyridin-2-yl)oxy]propyl}carbamate [Intermediate 20] (200 mg, 0.46 mmol, 1.2 eq), 2-chloropyrazine (CAS-RN: 14508-49-7) (47 mg, 0.41 mmol, 1.0 eq) and cesium carbonate (307 mg, 0.9 mmol, 2.3 eq) in 4.2 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (9 mg, 0.04 mmol, 0.1 eq) and Xantphos (24 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification of 100 mg of the crude product was conducted via preparative HPLC (Method A) to give 4 mg (2% yield of theory) of the title compound. The other 128 mg of the crude product were used without further purification.

[1769] UPLC-MS (Method 1): Rt=1.16 min; MS (El.sub.pos): m/z=486 [M+H].sup.+.

[1770] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.37 (s, 9 H), 1.75-1.88 (m, 2H), 2.46 (s, 3H), 3.01-3.10 (m, 2H), 4.19-4.28 (m, 2H), 6.76-6.97 (m, 2H), 8.03 (d, 1H), 8.18 (br. s., 1H), 8.35-8.42 (dd, 1H), 8.49 (s br, 1H), 8.67-8.80 (m, 1H), 10.15(s, 1H), 10.93 (s, 1H).

Example 48

N-[6-(3-Aminopropoxy)pyridin-3-yl]-3-methyl-5-(pyrazin-2-ylamino)-1,2-thiazole-4-carboxamide

[1771] ##STR00169##

[1772] tert-Butyl (3-{[5-({[3-methyl-5-(pyrazin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)pyridin-2-yl]oxy}propyl)carbamate [Example 47] (128 mg, 0.26 mmol, 1.0 eq) was suspended in 5 mL dichloromethane and trifluoro acetic acid (CAS-RN: 76-05-1) (0.4 mL, 5.3 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. The volatile components were removed in vacuo and the purification was conducted via preparative HPLC (Method A) to give the 7 mg (7% yield of theory) title compound.

[1773] UPLC-MS (Method 1): R.sub.t=0.71 min; MS (El.sub.pos): m/z=386 [M+H].sup.+.

[1774] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.87-2.10 (m, 2H), 2.46 (s, 3H), 2.80-3.14 (m, 2H), 4.31 (t, 2H), 6.77-6.98 (m, 1H), 7.71 (s br, 2H), 8.05 (dd, 1H), 8.18 (d, 1H), 8.40 (dd, 1H), 8.51 (d, 1H), 8.73 (d, 1H), 10.18 (s, 1H), 10.93 (s, 1H).

Example 49

tert-Butyl 3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoate

[1775] ##STR00170##

[1776] A mixture of tert-butyl 3-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-benzoate [Intermediate 21] (107 mg, 0.32 mmol, 1.2 eq), 2-chloroquinoxaline (CAS-RN: 1448-87-9) (44 mg, 0.27 mmol, 1.0 eq) and cesium carbonate (200 mg, 0.62 mmol, 2.3 eq) in 2.7 mL dioxane/DMF (5/1) was placed in a round bottom flusk that was flushed with argon. Then, palladium(II) acetate (6 mg, 0.027 mmol, 0.1 eq) and Xantphos (15.5 mg, 0.027 mmol, 0.1 eq) were added. Afterwards, the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification purification of this crude material was achieved via preparative HPLC (Method 1) to give 72 mg (58% yield of theory) of the title compound.

[1777] UPLC-MS (Method 1): Rt=1.50 min; MS (El.sub.pos): m/z=462 [M+H].sup.+.

[1778] .sup.1H NMR (300 MHz, DMSO-d.sub.6) δ [ppm]=1.55 (s, 9 H), 7.49 (t, 1H), 7.65 (d, 2H), 7.77 (d, 1H), 7.93-8.05 (m, 2H), 8.41 (s, 1H), 9.02 (s, 1H), 10.49 (s br, 1H), 11.35 (s br, 1H), 1×CH.sub.3 obscured by solvent signal.

[1779] In a larger batch a mixture of tert-butyl 3-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}benzoate [Intermediate 21] (9.3 g, 27.9 mmol, 1.2 eq), 2-chloroquinoxaline (CAS-RN: 1448-87-9) (3.8 g, 23.2 mmol, 1.0 eq) and cesium carbonate (17.4 g, 53.5 mmol, 2.3 eq) in 235 mL dioxane/DMF (5/1) was placed in a round bottom flusk that was flushed with argon. Then, palladium(II) acetate (522 mg, 2.3 mmol, 0.1 eq) and Xantphos (1.3 g, 2.3 mmol, 0.1 eq) were added. Afterwards, the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification purification of this crude material was achieved via preparative MPLC (Biotage Isolera) dichloromethane/ethanol gradient) to give 9.4 g (88% yield of theory) of the title compound.

Example 50

Methyl 3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoate

[1780] ##STR00171##

[1781] A mixture of methyl 3-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-benzoate [Intermediate 22] (65 mg, 0.22 mmol, 1.2 eq), 2-chloroquinoxaline (CAS-RN: 1448-87-9) (31 mg, 0.19 mmol, 1.0 eq) and cesium carbonate (139 mg, 53.5 mmol, 2.3 eq) in 2 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (4 mg, 0.02 mmol, 0.1 eq) and Xantphos (11 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification of the crude product was conducted via preparative HPLC (Method A) to give 28 mg (32% yield of theory) of the title compound.

[1782] UPLC-MS (Method 3): Rt=1.30 min; MS (ESlpos): m/z=420 [M+H]+.

[1783] .sup.1H NMR (300 MHz, DMSO-d.sub.6) δ [ppm]=3.88 (s, 3H), 7.48-7.57 (m, 1H), 7.58-7.85 (m, 3H), 7.90-8.07 (m, 3H), 8.54 (s, 1H), 9.03 (s, 1H), 10.52 (s, 1H), 11.37 (s, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 51

3-({[3-Methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)benzoic acid

[1784] ##STR00172##

[1785] Example 50 (58 mg, 0.14 mmol, 1.0 eq) was dissolved in 2.8 mL THF/water (2:1) and hydrolized with lithium hydroxide (10 mg, 0.42 mmol, 3.0 eq). All volatile components were removed in vacuo and reaction mixture was re-dissolved in water and the pH was adjusted at a pH of 3. Then the aqueous solution was extracted three times with dichloromethane. After drying with sodium sulphate the volume of the combined organic phases was reduced until dryness. Final purification of the crude product was conducted via preparative HPLC (Method A) to give 7 mg (11% yield of theory) of the title compound.

[1786] UPLC-MS (Method 1): Rt=1.13 min; MS (El.sub.neg): m/z=404 [M−H].sup.−.

[1787] .sup.1H NMR (300 MHz, DMSO-d.sub.6) δ [ppm]=7.45-7.54 (m, 1H), 7.58-7.67 (m, 1H), 7.70 (d, 1H), 7.78 (t, 1H), 7.90-8.03 (m, 4H), 8.49 (s, 1H), 9.03 (s, 1H), 10.44(s br, 1H), 11.35 (s br, 1H), 12.96 (s br, 1H), 1×CH.sub.3 was obscured by the solvent signal.

Example 51-1

3-({[3-Methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)benzoic acid, salt with trifluoro acetic acid

[1788] ##STR00173##

[1789] tert-Butyl 3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoate [Example 49] (9.43 g, 20.4 mmol, 1.0 eq) was suspended in 400 mL dichloromethane then 31.5 mL trifluoro acetic acid (409 mmol, 20.0 eq) were added and the reaction mixture was stirred at rt overnight. The volatile components were removed in vacuo. After the addition of toluene all volatile components were removed again. 15.1 g of a trifluoroacetate salt were isolated and used without further purification.

Example 52

3-Methyl-N-[3-(morpholin-4-ylcarbonyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[1790] ##STR00174##

[1791] The crude TFA salt of 3-({[3-Methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]-carbonyl}amino)benzoic acid [Example 51-1] (150 mg, 0.37 mmol, 1.0 eq) was dissolved im DMF (2 mL), then HATU (CAS-RN: 148893-10-1) (47 mg, 0.41 mmol, 1.0 eq) and N,N-Diisopropylethylamin (97 μL, 0.56 mmol, 1.5 eq) were added and the mixture was stirred for 10 min at rt. Afterwards morpholine (97 μL, 1.1 mmol, 3 eq) dissolved im 1 mL DMF was added and the reaction mixture was stirred for 3 h at rt. The volatile components of the reaction mixture were removed in vacuo. Final purification of the crude product was conducted via preparative HPLC (Method A) to give 59 mg (33% yield of theory) of the title compound.

[1792] UPLC-MS (Method 1): Rt=1.10 min; MS (El.sub.pos): m/z=475 [M+H].sup.+.

[1793] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=3.36-3.50 (m, 2H), 3.52-3.79 (m, 6H), 7.15 (d, 1H), 7.44 (t, 1H), 7.52-7.70 (m, 1H), 7.72-7.83 (m, 2H), 7.90 (s, 1H), 7.99 (d, 2H), 9.03 (s, 1H), 10.44 (s, 1H), 11.36 (s, 1H), 1×CH.sub.3 was obscured by the solvent signal.

[1794] The following examples were prepared in analogy to Example 52, employing the appropriate primary or secondary amines:

TABLE-US-00003 TABLE 1 Example No, amine Structure, Name, yield of theory Analytical data Example 53 amine: 2- methylpropan- 2-amine [CAS- RN: 75-64-9] [00175] UPLC-MS (Method 1): Rt = 1.28 min; MS (ESI.sub.pos): m/z = 461 [M + H].sup.+. .sup.1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 1.38 (s, 9 H), 2.53 (s, 3 H), 7.41 (t, 1 H), 7.52 (d, 1 H), 7.63 (t, 1 H), 7.72 (s, 1 H), 7.75-7.85 (m, 1 H), 7.89 (d, 1 H), 7.99 (d, 2 H), 8.15 (s, 1 H), 9.05 (s, 1 H), 10.33 (s, 1 H), 11.33 (s, 1 H). N-[3-(tert-Butylcarbamoyl)-phenyl]-3-methyl-5-(quinoxalin-2- ylamino)-1,2-thiazole-4-carboxamide, 30% Example 54 amine: tert-butyl glycinate [CAS-RN: 6456- 74-2] [00176] UPLC-MS (Method 3): Rt = 1.27 min; MS (ESI.sub.pos): m/z = 519 [M + H].sup.+. .sup.1H NMR (300 MHz, DMSO-d6): δ [ppm] = 1.42 (s, 9 H), 2.44 (s, 3 H), 3.90 (d, 2 H), 7.42-7.52 (m, 1 H), 7.60 (d, 2 H), 7.78 (s, 1 H), 7.98 (d, 3 H), 8.30 (s, 1 H), 8.83 (s, 1 H), 9.05 (s, 1 H), 10.43 (s br, 1 H), 11.37 (s br, 1 H). tert-Butyl N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2- thiazol-4-yl]carbonyl}amino)-benzoyl]glycinate, 12% Example 55 amine: tert-butyl piperazine-1- carboxylate [CAS-RN: 57260-71-6] [00177] UPLC-MS (Method 3): Rt = 1.32 min; MS (ESIpos): m/z = 574 [M + H]+. .sup.1H NMR (300 MHz, DMSO-d6) δ [ppm] = 1.40 (s, 9 H), 2.44 (s, 3 H), 3.32-3.39 (m, 8 H), 7.15 (d, 1 H), 7.45 (t, 1 H), 7.62 (s, 1 H), 7.72-7.85 (m, 2 H), 7.90 (s br, 1 H), 7.98 (d, 2 H), 9.03 (s, 1 H), 10.44 (s br, 1 H), 11.36 (s, br, 1 H). tert-Butyl 4-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2- thiazol-4-yl]carbonyl}amino)-benzoyl]piperazine-1-carboxylate, 14% Example 56 amine: tert-butyl L- glutaminate hydrochloride (1:1) [CAS-RN: 39741-62-3] [00178] UPLC-MS (Method 2): Rt = 1.17 min; MS (ESIpos): m/z = 590 [M + H]+. .sup.1H NMR (300 MHz, DMSO-d6) δ [ppm] = 1.42 (s, 9 H), 1.99 (d, 2 H), 2.23 (t, 2 H), 2.44 (s, 3 H), 4.17-4.37 (m, 1 H), 6.81-6.87 (m, 1 H), 7.32-7.38 (m, 1 H), 7.47 (t, 1 H), 7.64 (d, 2 H), 7.78 (s, 1 H), 7.88-8.03 (m, 3 H), 8.26 (s, 1 H), 8.74 (d, 1 H), 9.05 (s, 1 H), 10.41 (s, 1 H), 11.36 (s, 1 H). tert-butyl N.sup.2-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2- thiazol-4-yl]carbonyl}amino)-benzoyl]glutaminate, 12% Example 57 amine: tert-butyl O- tert-butyl-L- threoninate [CAS-RN: 5854- 78-4] [00179] UPLC-MS (Method 2): Rt = 1.56 min; (MS) ESIpos: m/z = 619 [M + H]+. .sup.1H NMR (300 MHz, DMSO-d6) δ [ppm] = 1.12-1.19 (m, 12 H), 1.43 (s, 9 H), 4.11-4.22 (m, 1 H), 2.44 (s, 3 H), 4.35-4.44 (m, 1 H), 7.44-7.83 (m, 5 H), 7.91-7.85 (m, 3 H), 8.26 (s, 1 H), 9.03 (s, 1 H), 10.46 (s, 1 H), 11.36 (s, 1 H). tert-Butyl O-tert-butyl-N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)- 1,2-thiazol-4 yl]carbonyl}amino)-benzoyl]threoninate, 10%

Example 58

N-(3-{[2-(Dimethylamino)ethyl](methyl)carbamoyl}phenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[1795] ##STR00180##

[1796] To a mixture of 61 mg (0.15 mmol) of the crude TFA salt of 3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)benzoic acid [Example 51-1] and 50 mg (0.39 mmol) N,N-diisopropylethylamine in 1 mL of DMF were added 20 mg (0.195 mmol) N,N,N′-trimethylethane-1,2-diamine in 0.34 mL DMF and 84 mg (0.195 mmol) COMU in 0.4 mL DMF. The mixture was shaked for 16 h at room temperature. Precipitated material was filtered off. Methanol was added to adjust the volume of the mixture to 2 mL.

[1797] This mixture was subjected to HPLC purification to give 5 mg of the title compound as solid material.

[1798] UPLC-MS (Method 6): Rt=0.91 min; (MS) ESIpos: m/z=490[M+H].sup.+.

[1799] The following examples were prepared in analogy to Example 58, employing the appropriate primary or secondary amines:

TABLE-US-00004 TABLE 2 Example Analytical No, Structure, Name data Example 59 [00181] UPLC-MS (Method 6): Rt = 1.12 min; (MS) ESIpos: m/z = 463[M + H]+. N-{3-[(2-hydroxyethyl)(methyl)carbamoyl]phenyl}-3-methyl-5-(quinoxalin- 2-ylamino)-1,2-thiazole-4-carboxamide Example 60 [00182] UPLC-MS (Method 6): Rt = 1.2 min; (MS) ESIpos: m/z = 530[M + H]+. 3-Methyl-N-(3-{[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl}phenyl)- 5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 61 [00183] UPLC-MS (Method 6): Rt = 0.95 min; (MS) ESIpos: m/z = 556[M + H]+. N-[3-(1,4′-Bipiperidin-1′-ylcarbonyl)phenyl]-3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 62 [00184] UPLC-MS (Method 6): Rt = 1.3 min; (MS) ESIpos: m/z = 457[M + H]+. 3-Methyl-N-{3-[methyl(prop-2-yn-1-yl)carbamoyl]phenyl}- 5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 63 [00185] UPLC-MS (Method 6): Rt = 1.4 min; (MS) ESIpos: m/z = 525[M + H]+. N-[3-(1,3-Benzodioxol-5-ylcarbamoyl)phenyl]-3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 64 [00186] UPLC-MS (Method 6): Rt = 1.33 min; (MS) ESIpos: m/z = 487[M + H]+. 3-Methyl-5-(quinoxalin-2-ylamino)-N-{3-[(2,2,2-trifluoro- ethyl)carbamoyl]phenyl}-1,2-thiazole-4-carboxamide Example 65 [00187] UPLC-MS (Method 6): Rt = 1.37 min; (MS) ESIpos: m/z = 566[M + H]+. 3-Methyl-N-(3-{[4-(morpholin-4-yl)phenyl]carbamoyl}phenyl)- 5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 66 [00188] UPLC-MS (Method 6): Rt = 1.11 min; (MS) ESIpos: m/z = 490[M + H]+. N-(3-{[2-(Acetylamino)ethyl]carbamoyl}phenyl)-3-methyl- 5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 67 [00189] UPLC-MS (Method 6): Rt = 1.3 min; (MS) ESIpos: m/z = 447[M + H]+. N-{3-[Ethyl(methyl)carbamoyl]phenyl}-3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 68 [00190] UPLC-MS (Method 6): Rt = 0.92 min; (MS) ESIpos: m/z = 504[M + H]+. N-(3-{[3-(Dimethylamino)propyl](methyl)carbamoyl}-phenyl)-3- methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 69 [00191] UPLC-MS (Method 6): Rt = 1.35 min; (MS) ESIpos: m/z = 585[M + H]+. 3-Methyl-5-(quinoxalin-2-ylamino)-N-{3-[(3,4,5-trimethoxy- benzyl)carbamoyl]phenyl}-1,2-thiazole-4-carboxamide Example 70 [00192] UPLC-MS (Method 6): Rt = 1.14 min; (MS) ESIpos: m/z = 516[M + H]+. N-{3-[(4-Acetylpiperazin-1-yl)carbonyl]phenyl}-3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 71 [00193] UPLC-MS (Method 6): Rt = 0.93 min; (MS) ESIpos: m/z = 518[M + H]+. 3-Methyl-N-(3-{[2-(morpholin-4-yl)ethyl]carbamoyl}-phenyl)- 5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 72 [00194] UPLC-MS (Method 6): Rt = 0.94 min; (MS) ESIpos: m/z = 502[M + H]+. 3-Methyl-N-(3-{[2-(pyrrolidin-1-yl)ethyl]carbamoyl}phenyl)- 5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 73 [00195] UPLC-MS (Method 6): Rt = 1.25 min; (MS) ESIpos: m/z = 443[M + H]+. 3-Methyl-N-[3-(prop-2-yn-1-ylcarbamoyl)phenyl]-5- (quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 74 [00196] UPLC-MS (Method 6): Rt = 1.24 min; (MS) ESIpos: m/z = 491[M + H]+. Methyl N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2- thiazol-4-yl]carbonyl}amino)benzoyl]-β-alaninate Example 75 [00197] UPLC-MS (Method 6): Rt = 0.92 min; (MS) ESIpos: m/z = 476[M + H]+. N-(3-{[2-(dimethylamino)ethyl]carbamoyl}phenyl)-3-methyl- 5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 76 [00198] UPLC-MS (Method 6): Rt = 1.26 min; (MS) ESIpos: m/z = 491[M + H]+. Methyl N-methyl-N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)- 1,2-thiazol-4-yl]carbonyl}amino)benzoyl]-glycinate Example 77 [00199] UPLC-MS (Method 6): Rt = 1.39 min; (MS) ESIpos: m/z = 571[M + H]+. 3-Methyl-5-(quinoxalin-2-ylamino)-N-{3-[(3,4,5-trimethoxy- phenyl)carbamoyl]phenyl}-1,2-thiazole-4-carboxamide Example 78 [00200] UPLC-MS (Method 6): Rt = 1.51 min; (MS) ESIpos: m/z = 568[M + H]+. N-(3-{[4-(2-Fluorophenyl)piperazin-1-yl]carbonyl}phenyl)-3- methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 79 [00201] UPLC-MS (Method 6): Rt = 1.28 min; (MS) ESIpos: m/z = 552[M + H]+. 3-Methyl-N-(3-{[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl}- phenyl)-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 80 [00202] UPLC-MS (Method 6): Rt = 1.45 min; (MS) ESIpos: m/z = 575[M + H]+. N-(3-{[4-(2-Cyanophenyl)piperazin-1-yl]carbonyl}phenyl)-3- methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 81 [00203] UPLC-MS (Method 6): Rt = 0.95 min; (MS) ESIpos: m/z = 516[M + H]+. 3-Methyl-N-(3-{[3-(pyrrolidin-1-yl)propyl]carbamoyl}-phenyl)- 5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 82 [00204] UPLC-MS (Method 6): Rt = 0.98 min; (MS) ESIpos: m/z = 524[M + H]+. 3-Methyl-N-(3-{methyl[2-(pyridin-4-yl)ethyl]carbamoyl}- phenyl)-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 83 [00205] UPLC-MS (Method 6): Rt = 0.9 min; (MS) ESIpos: m/z = 502[M + H]+. 3-Methyl-N-{3-[(4-methyl-1,4-diazepan-1-yl)carbonyl]- phenyl}-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 84 [00206] UPLC-MS (Method 6): Rt = 1.29 min; (MS) ESIpos: m/z = 538[M + H]+. N-(3-{[2-(Acetylamino)phenyl]carbamoyl}phenyl)-3-methyl- 5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 85 [00207] UPLC-MS (Method 6): Rt = 1.26 min; (MS) ESIpos: m/z = 477[M + H]+. N-{3-[(3-Methoxypropyl)carbamoyl]phenyl}-3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 86 [00208] UPLC-MS (Method 6): Rt = 1.11 min; (MS) ESIpos: m/z = 516[M + H]+. N-(3-{[(3S)-3-(acetylamino)pyrrolidin-1-yl]carbonyl}-phenyl)- 3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 87 [00209] UPLC-MS (Method 6): Rt = 1.5 min; (MS) ESIpos: m/z = 568[M + H]+. N-(3-{[4-(3-Fluorophenyl)piperazin-1-yl]carbonyl}phenyl)- 3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 88 [00210] UPLC-MS (Method 6): Rt = 1.3 min; (MS) ESIpos: m/z = 578[M + H].sup.+. N-{3-[(4-Benzoylpiperazin-1-yl)carbonyl]phenyl}-3-methyl- 5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 89 [00211] UPLC-MS (Method 6): Rt = 1.21 min; (MS) ESIpos: m/z = 545[M + H]+. N,N-Dimethyl-4-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2- thiazol-4-yl]carbonyl}amino)benzoyl]piperazine-1-carboxamide Example 90 [00212] UPLC-MS (Method 6): Rt = 0.92 min; (MS) ESIpos: m/z = 545[M + H]+. N-[3-({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)-phenyl]- 3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 91 [00213] UPLC-MS (Method 6): Rt = 0.92 min; (MS) ESIpos: m/z = 532 [M + H]+. N-(3-{[4-(2-Methoxyethyl)piperazin-1-yl]carbonyl}phenyl)- 3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 92 [00214] UPLC-MS (Method 6): Rt = 0.92 min; (MS) ESIpos: m/z = 559[M + H]+. N-[3-({4-[2-(Dimethylamino)-2-oxoethyl]piperazin-1-yl}-carbonyl)phenyl]- 3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 93 [00215] UPLC-MS (Method 6): Rt = 1.03 min; (MS) ESIpos: m/z = 582[M + H]+. N-(3-{[4-(4-Fluorobenzyl)piperazin-1-yl]carbonyl}phenyl)-3- methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 94 [00216] UPLC-MS (Method 6): Rt = 0.97 min; (MS) ESIpos: m/z = 579[M + H]+. 3-Methyl-N-[3-({4-[2-(pyridin-2-yl)ethyl]piperazin-1-yl}- carbonyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide Example 95 [00217] UPLC-MS (Method 6): Rt = 0.93 min; (MS) ESIpos: m/z = 532[M + H]+. 3-Methyl-N-(3-{[3-(morpholin-4-yl)propyl]carbamoyl}- phenyl)-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

Example 96

tert-Butyl 4-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}benzoate

[1800] ##STR00218##

[1801] A mixture of tert-butyl 4-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-benzoate [Intermediate 23] (300 mg, 0.9 mmol, 1.2 eq), 2-chloro-5-(trifluoro-methyl)pyrazine (CAS-RN: 799557-87-2) (137 mg, 0.9 mmol, 1.0 eq) and cesium carbonate (562 mg, 8.3 mmol, 2.3 eq) in 7.5 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (17 mg, 0.075 mmol, 0.1 eq) and Xantphos (43 mg, 0.075 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. After cooling to rt all volatile components were removed in vacuo. The final purification of this crude material was achieved via preparative HPLC (Method 1) to give 53 mg (14% yield of theory) of the title compound.

[1802] UPLC-MS (Method 2): Rt=1.03 min; MS (El.sub.pos): m/z=480 [M+H].sup.+.

[1803] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.55 (s, 9 H), 2.53 (s, 3H), 7.76-8.02 (m, 4H), 8.29-8.97 (m, 2H), 11.56 (s br, 1H), 13.68 (s br, 1H).

[1804] In a larger batch tert-butyl 4-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-benzoate [Intermediate 23] (1440 mg, 4.3 mmol, 1.2 eq), 2-chloro-5-(trifluoro-methyl)pyrazine (CAS-RN: 799557-87-2) (657 mg, 3.6 mmol, 1.0 eq) and cesium carbonate (2.7 g, 8.3 mmol, 2.3 eq) in 36.5 mL dioxane/DMF (6/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (81 mg, 0.36 mmol, 0.1 eq) and Xantphos (208 mg, 0.36 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). Purification of this crude material was achieved via preparative MPLC (Biotage Isolera; 25 g SNAP cartridge: dicloromethane.fwdarw.dichloromethane/ethanol 97:3) to give 1.6 g (92% yield of theory) of the title compound.

Example 97

4-{[(3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbony]-amino}benzoic acid

[1805] ##STR00219##

[1806] tert-Butyl 4-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}benzoate [Example 96] (284 mg, 0.59 mmol, 1.0 eq) was suspended in 11.5 mL dichloromethane, then 0.9 mL trifluoro acetic acid (11.9 mmol, 20.0 eq) were added and the reaction mixture was stirred at rt overnight. The volatile components were removed in vacuo. The crude product was redissolved with a mixture of dichloromethane and toluene (1:1) and the volume was reduced in vacuo until dryness. The final purification of the title compound was achieved via preperative HPLC (Method 1) to give 186 mg (67% yield of the theory) of the title compound.

[1807] UPLC-MS (Method 1): Rt=1.15 min; MS (El.sub.pos): m/z=424 [M+H].sup.+.

[1808] .sup.1H NMR (300 MHz, DMSO-d.sub.6) δ [ppm]=2.46 (s, 3H), 7.81-8.00 (m, 4H), 8.81 (s, 1H), 8.90 (s, 1H), 10.63 (s br, 1H), 11.50 (s br, 1H), 12.74 (s br, 1H).

Example 97-1

4-{[(3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}benzoic acid, salt with trifluora acetic acid

[1809] ##STR00220##

[1810] In a larger batch tert-Butyl 4-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}benzoate [Example 96] (1.58 g, 3.3 mmol, 1.0 eq) was suspended in 64 mL dichloromethane, then 5 mL trifluoro acetic acid (66 mmol, 20.0 eq) were added and the reaction mixture was stirred at rt overnight. The volatile components were removed in vacuo. The crude product was re-dissolved with a mixture of dichloromethane and toluene (1:1) and the volume was reduced in vacuo until dryness to give 1.85 g of a trifluoro acetate salt of the title compound.

Example 98

tert-Butyl 4-[({5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazol-4-yl}carbonyl)-amino]benzoate

[1811] ##STR00221##

[1812] A mixture of tert-butyl 4-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-benzoate [Intermediate 23] (300 mg, 0.9 mmol, 1.2 eq), 6-chloronicotinonitrile (CAS-RN: 33252-28-7) (104 mg, 0.75 mmol, 1.0 eq) and cesium carbonate (562 m g, 1.73 mmol, 2.3 eq) in 7.5 mL dioxane/DMF (6/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (17 mg, 0.08 mmol, 0.1 eq) and Xantphos (43 mg, 0.08 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. All volatile components were removed in vacuo. Purification of this crude material was achieved via preparative HPLC (Method A) to give 49 mg (14% yield of theory) of the title compound.

[1813] UPLC-MS (Method 2): Rt=0.97 min; MS (El.sub.pos): m/z=436 [M+H].sup.+.

[1814] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.56 (s, 9 H), 2.56 (s, 3H), 6.99 (d, 1H), 7.64 (d, 1H), 7.76-7.93 (m, 4H), 8.21 (s, 1H), 8.57 (d, 1H), 13.75 (s br, 1H).

Example 99

[1815] N-[3-({[3-Methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)benzoy]-glycine

##STR00222##

tert-Butyl N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)benzoyl]glycinate [Example 54] (190 mg, 0.37 mmol, 1 eq) was suspended in 7 mL dichloromethane and 0.6 mL trifluoroacetic acid (CAS-RN: 76-C.sub.5-1) were added. The reaction mixture was stirred at rt overnight. All volatile components were removed in vacuo. Purification of this crude material was achieved via preparative HPLC (Method A) to give 50 mg (27% yield of theory) of the title compound.

[1816] UPLC-MS (Method 1): Rt=1.02 min; MS (El.sub.pos): m/z=463 [M+H].sup.+.

[1817] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=2.52 (s, 3H), 3.93 (d, 2H), 7.39-7.53 (m, 1H), 7.60 (d, 2H), 7.72-7.83 (m, 1H), 7.87-8.09 (m, 3H), 8.31 (s, 1H), 8.81 (t, 1H), 9.03 (s, 1H), 10.43 (s br, 1H), 11.37 (s br, 1H), 12.59 (s br, 1H).

Example 100

Methyl N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoyl]glycinate

[1818] ##STR00223##

[1819] N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoyl]glycine [Example 99] (43 mg, 0.09 mmol, 1 eq) was dissolved 2 mL methanol and 7 μL thionyl dichloride (CAS-RN: 7719-09-7) (0.09 mmol, 1 eq) were added. The reaction mixture was stirred at rt overnight. Another 0.5 eq of thionyl dichloride (CAS-RN: 7719-09-7) (3 μL, 0.05 mmol), 0.5 mL of methanol were added and the reaction mixture was stirred at 35° C. for another 3 hours, cooled down to rt and stirred at rt fot 72 h. All volatile components were removed in vacuo. Purification of this crude material was achieved via preparative HPLC (Method A) to give 10 mg (22% yield of theory) of the title compound.

[1820] UPLC-MS (Method 1): Rt=1.10 min; MS (El.sub.pos): m/z=477 [M+H].sup.+.

[1821] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=2.53 (s br, 3H), 3.66 (s, 3H), 4.02 (d, 2 H), 7.41-7.56 (m, 1H), 7.56-7.68 (m, 2H), 7.78 (t, 1H), 7.85-8.06 (m, 3H), 8.31 (s, 1H), 8.92 (t, 1H), 9.04 (s, 1H), 10.41 (s br, 1H), 11.36 (s br, 1H).

Example 101

3-Methyl-N-[3-(piperazin-1-ylcarbonyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[1822] ##STR00224##

[1823] tert-Butyl 4-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)benzoyl]piperazine-1-carboxylate [Example 55] (190 mg, 0.33 mmol, 1 eq) was suspended in 6 mL dichloromethane and 0.5 mL trifluoroacetic acid (CAS-RN: 76-C.sub.5-1) were added. The reaction mixture was stirred at rt overnight. All volatile components were removed in vacuo. Purification of this crude material was achieved via preparative HPLC (Method A) to give 52 mg (32% yield of theory) of the title compound.

[1824] UPLC-MS (Method 1): Rt=0.90 min; MS (El.sub.pos): m/z=474 [M+H].sup.+.

[1825] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=2.53 (s br, 3H), 3.11-3.26 (m, 4H), 3.55-3.91 (m, 4H), 7.18 (d, 1H), 7.46 (t, 1H), 7.55 (s br, 1H), 7.67-7.77 (m, 1H), 7.78-7.88 (m, 1H), 7.92 (s br, 2H), 7.99 (s br, 1H), 8.95 (s br, 2H), 10.54 (s br, 1H), 11.35 (s br, 1H).

Example 102

3-Methyl-N-{3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[1826] ##STR00225##

[1827] 3-Methyl-N-[3-(piperazin-1-ylcarbonyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide [Example 101] (45 mg, 0.1 mmol, 1 eq), formaldehyde (27 mg, 0.9 mmol, 9.5 eq) (CAS-RN: 50-00-0) and sodium cyanoborohydride (CAS-RN: 25895-60-7) (39 mg, 0.6 mmol, 6.5 eq) were suspended in 3 mL methanol and stirred at rt for 3.5 h. The reaction mixture was filtered and all volatile components were removed in vacuo. Purification of this crude material was achieved via preparative HPLC (Method A) to give 13 mg (25% yield of theory) of the title compound.

[1828] UPLC-MS (Method 1): Rt=0.89 min; MS (El.sub.pos): m/z=488 [M+H].sup.+.

[1829] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=2.35 (s, 3H), 2.52 (s br, 3H), 2.55-2.69 (m, 4H), 3.40-3.55 (m, 2H), 3.57-3.80 (m, 2H), 7.10 (d, 1H), 7.44 (t, 1H), 7.49-7.63 (m, 1H), 7.66-7.76 (m, 1H), 7.77-7.84 (m, 1H),7.85-8.02 (m, 3H), 8.95 (s br, 1H), 10.47 (s br, 1H), 11.30 (s br, 1H).

Example 103

N.SUP.2.-[3-({[3-Methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoyl]glutamine

[1830] ##STR00226##

[1831] tert-butyl N.sup.2-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}-amino)benzoyl]glutaminate [Example 56] (50 mg, 0.09 mmol, 1 eq) was suspended in 1.5 mL dichloromethane and 130 μL trifluoroacetic acid (CAS-RN: 76-C.sub.5-1) were added. The reaction mixture was stirred at rt overnight. The reaction mixture was diluted with a mixture of methanol and dichloromethane (1:1) and the volume was reduced in vacuo until dryness. The precipitate was suspended with diethyl ether and isolated by filtration to give 30 mg (63% yield of theory) as a pale yellow solid of the title compound.

[1832] UPLC-MS (Method 1): Rt=0.96 min; MS (El.sub.pos): m/z=534 [M+H].sup.+.

[1833] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.89-2.04 (m, 1H), 2.04-2.15 (m, 1H), 2.18-2.28 (m, 2H), 2.51 (s, 3H), 4.25-4.47 (m, 1H), 6.82 (s br, 1H), 7.33 (s br, 1H), 7.47 (t, 1H), 7.54-7.73 (m, 2H), 7.73-7.86 (m, 1H), 7.86-8.06 (m, 3H), 8.27 (s, 1H), 8.71 (d, 1H), 9.05 (s, 1H), 10.39 (s, 1H), 11.34 (s, 1H), 12.62 (s br, 1H).

Example 104

O-tert-Butyl-N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]-carbonyl}amino)benzoyl]threonine

[1834] ##STR00227##

[1835] tert-Butyl O-tert-butyl-N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4 yl]-carbonyl}amino)benzoyl]threoninate [Example 57] (185 mg, 0.3 mmol, 1 eq) was suspended in 6 mL dichloromethane and 0.5 mL trifluoroacetic acid (CAS-RN: 76-05-1) were added. The reaction mixture was stirred at rt for 6.5 h. The reaction mixture was diluted with a mixture of methanol and toluene (1:1) and the volume was reduced in vacuo until dryness. Then, the reaction mixture was partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate (3×) and the combined organic phases were washed with brine. The organic phase were passed through a Whatman filter and concentrated in vacuo. Purification of this crude material was achieved via preparative HPLC (Method A) to give 24 mg (14% yield of theory) of the title compound and 23 mg (14% yield of theory) 0-deprotected hydroxy compound [Example 105]

[1836] UPLC-MS (Method 1): Rt=1.25 min; MS (El.sub.pos): m/z=563 [M+H].sup.+.

[1837] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.12 (d, 3H), 1.43 (m, 9 H), 2.55 (s, 3H), 4.06-4.26 (m, 1H), 4.37 (dd, 1H), 4.92 (d, 1H), 7.37-7.57 (m, 1H), 7.62 (s br, 2 H), 7.77 (s br, 1H), 7.85-8.10 (m, 4H), 8.31 (s, 1H), 9.03 (s br, 1H), 10.45 (s br, 1H), 11.37 (s br, 1H).

Example 105

N-[3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-benzoyl]threonine

[1838] ##STR00228##

[1839] UPLC-MS (Method 1): Rt=1.02 min; MS (El.sub.pos): m/z=507 [M+H].sup.+.

[1840] .sup.1H NMR (300 MHz, DMSO-d.sub.6) d ppm 1.17 (d, 3H), 2.57 (s, 3H), 4.10-4.29 (m, 1H), 4.30-4.52 (m, 1H), 7.10 (s br, 2H), 7.36 (t, 1H), 7.41-7.55 (m, 2H), 7.55-7.66 (m, 1H), 7.71-7.85 (m, 2H), 7.99 (d, 2H), 8.33 (s, 1H), 8.74 (s br, 1H), 13.68 (s br, 1H), 1NH not detected.

Example 106

3-Methyl-N-[3-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[1841] ##STR00229##

[1842] The crude TFA salt of 3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]-carbonyl}amino)benzoic acid [Example 51] (200 mg, 0.49 mmol, 1.0 eq) was dissolved im DMF (3 mL), then 1-Hydroxybenzotriazole (CAS-RN: 2592-95-2) (200 mg, 1.48 mmol, 3.0 eq), N-[3-(dimethylamino)propyl]-N′-ethylcarbodiimide hydrochloride (CAS-RN: 25952-53-8) (284 mg, 1.48 mmol, 3.0 eq) and N-hydroxyethanimidamide (CAS-RN: 25952-53-8) (110 mg, 1.48 mmol, 3.0 eq) were added and the mixture was stirred overnight at 100° C. Of each of the three reagents were 3 eq. more added and the reaction mixture was stirred for additional 3 hours at 100° C. The volatile components of the reaction mixture were removed in vacuo. Then, the reaction mixture was partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate (3×) and the combined organic phases were washed with brine. The organic phase were passed through a Whatman filter and concentrated in vacuo. Final purification of the crude product was conducted via preparative HPLC (Method B) to give 8 mg (3% yield of theory) of the title compound.

[1843] UPLC-MS (Method 2): Rt=0.82 min; MS (El.sub.pos): m/z=444 [M+H].sup.+.

[1844] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=2.44 (m, 3H), 7.51-7.68 (m, 2H), 7.68-7.87 (m, 2H), 7.88-8.05 (m, 3H), 8.78 (s br, 1H), 9.00 (s br, 1H), 10.62 (s br, 1H), 11.41 (s br, 1H), 1×CH.sub.3 was obscured by the solvent signal.

Example 107

N-[3-(5-tert-Butyl-1,3,4-oxadiazol-2-yl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[1845] ##STR00230##

[1846] The crude TFA salt of 3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)benzoic acid [Example 51] (200 mg, 0.49 mmol, 1.0 eq) and 2,2-dimethylpropanehydrazide (CAS-RN: 42826-42-6) (172 mg, 1.48 mmol, 3.0 eq) were dissolved im ethyl acetate (3 mL), then triethylamine (CAS-RN: 121-44-8) (0.3 mL, 2.5 mmol, 5.0 eq) and 1.3 mL T3P-solution (50% in DMF)(CAS-RN: 68957-94-8) (2.2 mmol, 4.5 eq) were added and the mixture was stirred overnight at 80° C. The volatile components of the reaction mixture were removed in vacuo. Then, the reaction mixture was partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate (3×) and the combined organic phases were washed with brine. The organic phase were passed through a Whatman filter and concentrated in vacuo. Final purification of the crude product was conducted via preparative HPLC (Method A) to give 7 mg (17% yield of theory) of the title compound.

[1847] UPLC-MS (Method 1): Rt=1.39 min; MS (El.sub.pos): m/z=486 [M+H].sup.+.

[1848] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.43 (s, 9 H), 7.54-7.68 (m, 2H), 7.71-7.86 (m, 2H), 7.88-8.07 (m, 3H), 8.57 (s br, 1H), 9.03 (s, 1H), 10.58 (s br, 1H), 11.40 (s br, 1H), 1×CH.sub.3 was obscured by the solvent signal.

Example 108

N-[3-(3-tert-Butyl-1,2,4-oxadiazol-5-yl)phenyl]-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[1849] ##STR00231##

[1850] The crude TFA salt of 3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)benzoic acid [Example 51] (200 mg, 0.49 mmol, 1.0 eq) and 2,2-dimethylpropionamidoxime (CAS-RN: 42956-75-2) (172 mg, 1.48 mmol, 3.0 eq) were dissolved im ethyl acetate (3 mL), then triethylamine (CAS-RN: 121-44-8) (0.3 mL, 2.5 mmol, 5.0 eq) and 1.3 mL T3P-solution (50% in DMF)(CAS-RN: 68957-94-8)) (2.2 mmol, 4.5 eq) were added and the mixture was stirred overnight at 80° C. The volatile components of the reaction mixture were removed in vacuo. Then, the reaction mixture was partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate (3×) and the combined organic phases were washed with brine. The organic phase were passed through a Whatman filter and concentrated in vacuo. Final purification of the crude product was conducted via preparative HPLC (Method A) to give 31 mg (12% yield of theory) of the title compound.

[1851] UPLC-MS (Method 1): Rt=1.55 min; MS (El.sub.pos): m/z=486 [M+H].sup.+.

[1852] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.38 (s, 9 H), 7.51-7.70 (m, 2H), 7.73-7.90 (m, 2H), 7.94-8.02 (m, 3H), 8.70 (s br, 1H), 9.03 (s, 1H), 10.61 (s br, 1H), 11.40 (s br, 1H), 1×CH.sub.3 was obscured by the solvent signal.

Example 109

tert-Butyl 3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate

[1853] ##STR00232##

[1854] A mixture of tert-butyl 3-{[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbony]-amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate [Intermediate 26] (305 mg, 0.7 mmol, 1.2 eq), 2-chloro-5-(trifluoromethyl)pyrazine (CAS-RN: 799557-87-2) (107 mg, 0.59 mmol, 1.0 eq) and cesium carbonate (439 mg, 1.35 mmol, 2.3 eq) in 6 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (13 mg, 0.06 mmol, 0.1 eq) and Xantphos (34 mg, 0.06 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). After filtration all volatile components were removed in vacuo. Purification of this crude material was achieved via preparative MPLC (Biotage Isolera; 25 g SNAP cartridge: dicloromethan.fwdarw.dichloromethane/ethanol 9:1). to give 125 mg (33% yield of theory) of the title compound.

[1855] UPLC-MS (Method 2): Rt=1.01 min; MS (El.sub.pos): m/z=580 [M+H].sup.+.

[1856] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.39 (s, 9 H), 1.60-1.77 (m, 1H), 1.89-2.05 (m, 1H), 2.56-2.68 (m, 1H), 3.02-3.13 (m, 1H), 3.15-3.27 (m, 1H), 3.33 -3.52 (m, 2H), 4.12-4.30 (m, 2H), 6.87 (d, 1H), 8.06 (d, 1H), 8.51 (s br, 1H), 8.83 (s, 1H), 8.90 (s, 1H), 10.30 (s br, 1H), 11.45 (s br, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 110

tert-Butyl 3-{[(5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate

[1857] ##STR00233##

[1858] A mixture of tert-butyl 3-{[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbony]-amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate [Intermediate 26] (305 mg, 0.7 mmol, 1.2 eq), 2-iodo-6-(trifluoromethyl)pyrazine (CAS-RN: 141492-94-6) (161 mg, 0.59 mmol, 1.0 eq) and cesium carbonate (439 mg, 1.35 mmol, 2.3 eq) in 6 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (13 mg, 0.06 mmol, 0.1 eq) and Xantphos (34 mg, 0.06 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). After filtration all volatile components were removed in vacuo. Purification of this crude material was achieved via preparative MPLC (Biotage Isolera; 25 g SNAP cartridge: dicloromethan.fwdarw.dichloromethane/ethanol 9:1) to give 92 mg (24% yield of theory) of the title compound.

[1859] UPLC-MS (Method 2): Rt=0.98 min; MS (El.sub.pos): m/z=580 [M+H].sup.+.

[1860] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.39 (s, 9 H), 1.61-1.77 (m, 1H), 1.89-2.07 (m, 1H), 2.57-2.68 (m, 1H), 3.01-3.13 (m, 1H), 3.15-3.28 (m, 1H), 3.31-3.51 (m, 2H), 4.10-4.31 (m, 2H), 6.87 (d, 1H), 8.06 (d, 1H), 8.51 (s br, 1H), 8.64 (s br, 1H), 8.98 (s br, 1H), 10.27 (s br, 1H), 11.40 (s br, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 111

3-Methyl-N-[4-(methylsulfannoyl)phenyl]-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[1861] ##STR00234##

[1862] A mixture of 5-amino-3-methyl-N-[4-(methylsulfannoyl)phenyl]-1,2-thiazole-4-carboxamide [Intermediate 27] (55 mg, 0.17 mmol, 1.2 eq), 2-chloroquinoxaline (CAS-RN: 1448-87-9) (23 mg, 0.14 mmol, 1.0 eq) and cesium carbonate (105 mg, 0.32 mmol, 2.3 eq) in 1.4 mL dioxane/DMF (6:1) was placed in a microwave vial and flushed with argon. Then, palladium(II) acetate (3 mg, 0.014 mmol, 0.1 eq) and Xantphos (8 mg, 0.014 mmol, 0.1 eq) were added. The vial was capped and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. After cooling to rt the crude product was purified via MPLC (Biotage Isolera: dicloromethan.fwdarw.dichloromethane/ethanol 94:6). The product fractions obtained were purified via preperative HPLC (Method 1) to give 3 mg (5% yield of theory) of the title compound.

[1863] UPLC-MS (Method 2): R.sub.t=0.72 min; MS (Elne.sub.g): m/z=455 [M+H].sup.+.

[1864] .sup.1H-NMR (500 MHz, DMSO-d.sub.6): δ [ppm]=2.41 (d, 3H), 7.34 (q, 1H), 7.59-7.67 (m, 1H), 7.78 (d, 3H), 7.99 (d, 4H), 9.01 (s, 1H), 10.68 (s br, 1H), 11.37 (s br, 1H), 1×CH.sub.3 was obscured by the solvent signal.

[1865] The compounds listed in Table 3 were prepared according to the procedure outlined below from the starting materials named in the following SM1 and SM2. A typical reaction was usually run on 0.5 mmol scale:

[1866] A mixture of SM1 (0.5 mmol, 1.0 eq), SM2 (0.8-1.2 eq) and cesium carbonate (2.3 eq) in −5.5 mL dioxane/DMF (7/1) was placed in a microwave vial and flushed with argon. Then, palladium(II) acetate (0.1 eq) and Xantphos (0.1 eq) were added. The vial was capped and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was partitioned between dichloromethane and water. After filtration over Celite, the organic phase was separated and concentrated in vacuo. The crude product was usually purified via preparative HPLC or via crystallization from a suitable solvent.

TABLE-US-00005 TABLE 3 Example No, SM1, SM2 Structure, Name, yield of theory Analytical data Example 112 SM1: Intermediate 11 SM2: 2-chloro-4- (trifluoro- methyl)-1,3- benzothiazole [CAS-RN: 898748-15-7] [00235] UPLC-MS (Method 1): Rt = 1.29 min; MS (EI.sub.neg): m/z = 549 [M − H].sup.−. .sup.1H-NMR (400 MHz, DMSO-d6): δ [ppm] = 1.98 (s, 1.5H), 2.01 (s, 1.5H), 2.44 (s, 3H), 2.84 (s, 1.5H), 3.03 (s, 1.5H), 3.62 (t, 1H), 3.67 (t, 1H), 4.33 (t, 1H), 4.42 (t, 1H), 6.86 (dd, 1H), 7.40 (m, 1H), 7.74 (m, 1H), 8.05 (dt, 1H), 8.23 (m, 1H), 8.51 (s br, 1H), 10.43 (s br, 1H), 12.09 (s br, 1H). N-(6-{2-[Acetyl(methyl)amino]- ethoxy}pyridin-3-yl)-3-methyl-5- {[4-(trifluoromethyl)-1,3- benzothiazol-2-yl]amino}-1,2- thiazole-4-carboxamide, 4% Example 113 SM1: Intermediate 28 SM2: 2- chloro- quinoxaline (CAS-RN: 1448-87-9) [00236] UPLC-MS (Method 2): Rt = 1.18 min; MS (ESI.sub.pos): m/z = 459 [M + H].sup.+. .sup.1H NMR (300 MHz, CDCl.sub.3-d) δ [ppm] = 1.79-2.01 (m, 4 H), 2.78 (s, 3 H), 3.44 (t, 2 H), 3.59 (t, 2 H), 7.27 (d, 1 H), 7.38 (t, 1 H), 7.49-7.59 (m, 1 H), 7.62-7.75 (m, 3 H), 7.85 (s, 1 H), 7.91- 8.02 (m, 2 H), 8.63 (s, 1 H), 11.93 (s br, 1 H). 3-Methyl-N-[3-(pyrrolidin-1- ylcarbonyl)phenyl]-5-(quinoxalin- 2-ylamino)-1,2-thiazole-4- carboxamide, 3% Example 114 SM1: Intermediate 28 SM2: 2- chloroiso- nicotinonitrile (CAS- RN: 33252-30- 1) [00237] UPLC-MS (Method 2): Rt = 1.11 min; MS (ESI.sub.pos): m/z = 433 [M + H]+. .sup.1H NMR (300 MHz, DMSO-d.sub.6) δ [ppm] = 1.73-1.94 (m, 4 H), 2.46 (s, 3 H), 3.36-3.56 (m, 4 H), 7.25 (s, 1 H), 7.29- 7.46 (m, 2 H), 7.68-7.81 (m, 2 H), 7.95 (s br, 1 H), 8.60 (d, 1 H), 10.24- 10.33 (m, 1 H), 10.86- 10.95 (m, 1 H). 5-[(4-Cyanopyridin-2-yl)amino]-3- methyl-N-[3-(pyrrolidin-1- ylcarbonyl)phenyl]-1,2-thiazole-4- carboxamide, 32% Example 115 SM1: Intermediate 29 SM2: 2- chloro- quinoxaline (CAS-RN: 1448-87-9) [00238] UPLC-MS (Method 2): Rt = 0.76 min; MS (ESIpos): m/z = 440 [M + H]+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ [ppm] = 2.54 (s, 3 H), 3.18 (s, 3 H), 7.43-7.58 (m, 1 H), 7.63-7.75 (m, 1 H), 7.90 (d, 4 H), 8.05 (d, 2 H), 8.91 (s br, 1 H), 11.34- 11.54 (m, 1 H). 3-Methyl-N-[4- (methylsulfonyl)phenyl]-5- (quinoxalin-2-ylamino)-1,2- thiazole-4-carboxamide, 84% Example 116 SM1: Intermediate 30 SM2: 2- chloro- quinoxaline (CAS-RN: 1448-87-9) [00239] UPLC-MS (Method 2): Rt = 1.19 min; MS (ESI.sub.pos): m/z = 469 [M + H].sup.+. .sup.1H NMR (300 MHz, DMSO-d.sub.6) δ [ppm] = 0.98 (t, 3 H), 2.74-2.83 (m, 2 H), 2.45 (s, 3 H), 7.46 (t, 1 H), 7.58-7.67 (m, 1 H), 7.74-7.84 (m, 3 H), 7.90-8.05 (m, 4 H), 9.02 (s, 1 H), 10.68 (s br, 1 H), 11.38 (s br, 1 H). N-[4-(Ethylsulfamoyl)phenyl]-3- methyl-5-(quinoxalin-2-ylamino)- 1,2-thiazole-4-carboxamide, 10% Example 117 SM1: Intermediate 31 SM2: 2- chloro- quinoxaline (CAS-RN: 1448-87-9) [00240] UPLC-MS (Method 2): Rt = 0.96 min; MS (ESI.sub.pos): m/z = 523 [M + H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3-d) δ [ppm] = 2.80 (s, 3 H), 7.02 (d, 1 H), 7.15-7.24 (m, 2 H), 7.50-7.64 (m, 4 H), 7.69 (td, 1 H), 7.93-8.03 (m, 2 H), 8.11 (d, 1 H), 8.24 (d, 1 H), 8.64 (s, 1 H), 11.77- 12.06 (m, 1 H). 3-Methyl-5-(quinoxalin-2-ylamino)- N-{6-[3- (trifluoromethyl)phenoxy]pyridin- 3-yl}-1,2-thiazole-4-carboxamide, 7% Example 118 SM1: Intermediate 31 SM2: 6- chloro- nicotinonitrile (CAS- RN: 33252-28- 7) [00241] UPLC-MS (Method 1): Rt = 1.39 min; MS (ESI.sub.pos): m/z = 497 [M + H].sup.+. .sup.1H NMR (400 MHz, DMSO-d.sub.6) δ [ppm] = 2.45 (s, 3 H), 7.21 (d, 1 H), 7.29 (m, 2 H), 7.43 (d, 1 H), 7.77 (m, 2 H), 8.13 (dd, 1 H), 8.21-8.32 (m, 1 H), 8.56 (d, 1 H), 8.87 (d, 1 H), 10.47 (s, 1 H), 11.09 (s, 1 H). 5-[(5-Cyanopyridin-2-yl)amino]-3- methyl-N-{6-[3- (trifluoromethyl)phenoxy]pyridin- 3-yl}-1,2-thiazole-4-carboxamide, 37% Example 119 SM1: Intermediate 32 SM2: 2- chloroiso-nicotinonitrile (CAS- RN: 33252-30- 1) [00242] UPLC-MS (Method 1): Rt = 1.05 min; MS (ESIpos): m/z = 430 [M + H]+. .sup.1H NMR (400 MHz, DMSO- d6) δ [ppm] = 2.57 (s, 3 H), 7.19 (d, 1 H), 7.36 (s br, 1 H), 7.47 (dd, 1 H), 7.54-7.66 (m, 1 H), 7.68-7.84 (m, 1 H), 8.14-8.32 (m, 1 H), 8.36- 8.54 (m, 3 H), 8.60 (d, 1 H), 10.35 (s br, 1 H), 10.90 (s br, 1 H). 5-[(4-Cyanopyridin-2-yl)amino]-3- methyl-N-[6-(pyridin-3- yloxy)pyridin-3-yl]-1,2-thiazole-4- carboxamide, 5%

Example 120

3-Methyl-N-[6-(pyrrolidin-3-ylmethoxy)pyridin-3-yl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoroacetic acid

[1867] ##STR00243##

[1868] tert-Butyl 3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate [Example 109] (1.8 g, 3.1 mmol, 1.0 eq) was suspended in 60 mL dichloromethane and trifluoroacetic acid (CAS-RN: 76-C.sub.5-1) (4.8 mL, 62.1 mmol, 20 eq) was added.

[1869] The reaction mixture was stirred at room temperature overnight in a sealed vial. The crude reaction mixture was dissolved in a mixture of dichloromethane and methanol (1:1) mixed with toluene and the volatile components were removed in vacuo. The crude trifluoro acetate salt of the title compound was used for further derivatization without further purification.

[1870] UPLC-MS (Method 2): Rt=0.93 min; MS (El.sub.pos): m/z=480 [M+H].sup.+.

[1871] .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.66-1.83 (m, 1H), 2.02-2.18 (m, 1H), 2.68-2.81 (m, 1H), 2.98-3.09 (m, 1H), 3.11-3.40 (m, 3H), 4.17-4.34 (m, 2

[1872] H), 6.89 (d, 1H), 8.07 (d, 1H), 8.53 (s br, 1H), 8.68-8.79 (s br, 2H), 8.83 (s, 1H), 8.93 (s, 1H), 10.34 (s br, 1H), 11.48 (s br, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 121

N-(6-{[1-(2-fluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1873] ##STR00244##

[1874] A mixture of the crude salt of 3-methyl-N-[6-(pyrrolidin-3-ylmethoxy)pyridin-3-yl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 120] (390 mg, 0.81 mmol, 1.0 eq), 2-fluoroethyl 4-methylbenzenesulfonate (CAS-RN: 383-50-6) (266.3 mg, 1.22 mmol, 1.5 eq), potassium carbonate (562 mg, 4.1 mmol, 5.0 eq) and potassium iodide (13.5 mg, 0.08 mmol, 0.1 eq) in 12.6 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. The Volume of the reaction mixture was reduced in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 167 mg (37% yield of theory) of the title compound.

[1875] UPLC-MS (Method 2): R.sub.t=0.84 min; MS (El.sub.pos): m/z=526 [M+H].sup.+.

[1876] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.53-1.66 (m, 1H), 1.91-2.10 (m, 1H), 2.57 (s, 3H), 2.59-2.69 (m, 2H), 2.70-2.89 (m, 2H), 2.82-3.01 (m, 3H), 4.09-4.25 (m, 2H), 4.52 (t, 1H), 4.64 (t, 1H), 6.81 (d, 1H), 8.19 (dd, 1H), 8.42 (s, 1H), 8.57 (d, 2H), 13.29 (s br, 1H), 1 NH not detected.

Example 122

N-(6-{[1-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1877] ##STR00245##

[1878] A mixture of the crude salt of 3-methyl-N-{6-[(3R)-pyrrolidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-oxazole-4-carboxamide with trifluoroacetic acid [Example 120] (390 mg, 0.81 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate [CAS-RN: 74427-22-8] (261 mg, 1.22 mmol, 1.5 eq), potassium carbonate (562 mg, 4.1 mmol, 5.0 eq) and potassium iodide (13.5 mg, 0.085 mmol, 0.1 eq) in 12.5 mL acetonitrile was placed in a microwave vial that was flushed with argon and stirred for 17h at 70° C. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration and purification was conducted via preparative HPLC (Method B). Final purification was achieved via preparative MPLC (Biotage Isolera; 25 g SNAP cartridge: dicloromethane.fwdarw.dichloromethane/ethanol 9:10) to give 50 mg (11% yield of theory) of the title compound.

[1879] UPLC-MS (Method 2): R.sub.t=0.94 min; MS (El.sub.pos): m/z=544 [M+H].sup.+.

[1880] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.50-1.65 (m, 1H), 1.87-2.07 (m, 1H), 2.55-2.66 (m, 2H), 2.69-2.82 (m, 2H), 2.83-3.13 (m, 3H), 4.07-4.26 (m, 2H), 6.00-6.32 (m, 1H), 6.86 (d, 1H), 8.02-8.16 (m, 1H), 8.53 (s br, 1H), 8.80 (s, 1H), 8.88 (s br, 1H), 10.33 (s br, 1H), 11.45 (s br, 1H) 1CH.sub.3 and 1H dot obscured by the solvent signal.

[1881] [α].sub.D.sup.20 (c=10 mg/mL, CHCl3) 0.3°+/−0.2°.

Example 123

3-Methyl-N-(6-{[1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1882] ##STR00246##

[1883] A mixture of the crude salt of 3-methyl-N-[6-(pyrrolidin-3-ylmethoxy)pyridin-3-yl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 120] (390 mg, 0.81 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate [CAS-RN: 6226-25-1] (283 mg, 1.2 mmol, 1.5 eq), potassium carbonate (562 mg, 4.1 mmol, 5.0 eq) and potassium iodide (13.5 mg, 0.08 mmol, 0.1 eq) in 12.6 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1).

[1884] The volatile components were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 140 mg (29% yield of theory) of the title compound.

[1885] UPLC-MS (Method 2): R.sub.t=0.93 min; MS (El.sub.pos): m/z=562 [M+H].sup.+.

[1886] .sup.1H NMR (300 MHz, DMSO-d.sub.6): δ [ppm]=1.46-1.59 (m, 1H), 1.87-2.02 (m, 1H), 2.53-2.63 (m, 2H), 2.64-2.78 (m, 2H), 2.80-2.91 (m, 1H), 3.19-3.29 (m, 2H), 4.04-4.23 (m, 2H), 6.86 (d, 1H), 8.06 (d, 1H), 8.51 (s br, 1H), 8.82 (s, 1H), 8.90 (s, 1H), 10.32 (s br, 1H), 11.47 (s br, 1H) 1CH.sub.3 got obscured by the solvent signal.

[1887] [α].sub.D.sup.20 (c=10 mg/mL, CHCl.sub.3)+0.2°+/−0.3°.

Example 124

3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide

[1888] ##STR00247##

[1889] A mixture of the crude salt of 3-methyl-N-[6-(pyrrolidin-3-ylmethoxy)pyridin-3-yl]-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 120] (390 mg, 0.81 mmol, 1.0 eq), 3,3,3-trifluoropropyl 4-methylbenzenesulfonate [CAS-RN: 2342-67-8] (327 mg, 1.2 mmol, 1.5 eq), potassium carbonate (562 mg, 4.1 mmol, 5.0 eq) and potassium iodide (13.5 mg, 0.08 mmol, 0.1 eq) was taken up in 12.6 mL acetonitrile. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. for overnight under an atmosphere of argon. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 147 mg (30% yield of theory) of the title compound.

[1890] UPLC-MS (Method 1): R.sub.t=0.98 min; MS (El.sub.neg): m/z=574 [M−H].sup.−.

[1891] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.59-1.76 (m, 1H), 1.98-2.15 (m, 1H), 2.52 (s, 3H), 2.57-2.78 (m, 3H), 2.92-3.19 (m, 4H), 3.21-3.44 (m, 2H), 4.13-4.28 (m, 2H), 6.83 (d, 1H), 8.09-8.16 (m, 1H), 8.55 (s, 1H), 8.59 (s br, 2H), 8.71 (s br, 1H), 11.65 (s br, 1H).

[1892] [α].sub.D.sup.20 (c=10 mg/mL, CHCl.sub.3) −0.1°+/−0.1°.

Example 125

tert-Butyl (3R)-3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate

[1893] ##STR00248##

[1894] A mixture of tert-butyl (3R)-3-{[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate [Intermediate 35] (500 mg, 1.2 mmol, 1.0 eq), 2-chloro-5-(trifluoromethyl)pyrazine [CAS-RN: 799557-87-2] (210 mg, 1.2 mmol, 1.0 eq) and cesium carbonate (864 mg, 2.7 mmol, 2.3 eq) in 11.5 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (26 mg, 0.11 mmol, 0.1 eq) and Xantphos (67 mg, 0.11 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 25 g SNAP cartridge: dicloromethane.fwdarw.dichloromethane/ethanol 90:10) to give 597 mg (89% yield of the theory) of the title compound.

[1895] UPLC-MS (Method 2): Rt=0.96 min; MS (El.sub.pos): m/z=580 [M+H].sup.+.

Example 126

3-Methyl-N-{6-[(3R)-pyrrolidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with hydrochloric acid

[1896] ##STR00249##

[1897] tert-Butyl (3R)-3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate [Example 125] (597 mg, 1.0 mmol, 1.0 eq) was suspended in 26 mL dioxane and 5.2 mL hydrogen chloride solution (4.0 M) in dioxane (CAS-RN: 7647-01-0) (1.5 mL, 20.6 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. The precipitate of the crude hydrochloride acid salt of the title compound was isolated by filtration (350 mg) and used for further derivatization without further purification.

[1898] UPLC-MS (Method 2): R.sub.t=0.87 min; MS (El.sub.pos): m/z=480 [M+H].sup.+.

Example 127

[1899] N-(6-{[(3R)-1-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

##STR00250##

[1900] A mixture of the crude salt of 3-methyl-N-{6-[(3R)-pyrrolidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with HCl [Example 126] (224 mg, purity 74%, 0.34 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate [CAS-RN: 74427-22-8] (110 mg, 0.52 mmol, 1.5 eq), potassium carbonate (237 mg, 1.7 mmol, 5.0 eq) and potassium iodide (5.7 mg, 0.03 mmol, 0.1 eq) in 9 mL acetonitrile was placed in a microwave vial that was flushed with argon and stirred for 17h at 70° C. Another 0.5 equ 2,2-difluoroethyl trifluoromethanesulfonate [CAS-RN: 74427-22-8] (37 mg) were added and the reaction mixture was stirred for 5 h at 70° C. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. Final purification was conducted via preparative HPLC (Method B) to give 62 mg (30% yield of theory) of the title compound.

[1901] UPLC-MS (Method 2): R.sub.t=0.89 min; MS (El.sub.pos): m/z=544 [M+H].sup.+.

[1902] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.48-1.64 (m, 1H), 1.89-2.04 (m, 1H), 2.55-2.66 (m, 2H), 2.66-2.75 (m, 2H), 2.77-3.01 (m, 3H), 4.05-4.25 (m, 2H), 5.97-6.31 (m, 1H), 6.85 (d, 1H), 8.05-8.20 (m, 1H), 8.54 (s br, 1H), 8.63-8.96 (m, 2H), 10.35 (s br, 1H), 11.46 (s br, 1H) 1CH.sub.3 obscured by the solvent signal.

[1903] [α].sub.D.sup.20 (c=10 mg/mL, DMSO) 0.1°+/−0.2°.

Example 128

3-Methyl-N-(6-{[(3R)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1904] ##STR00251##

[1905] A mixture of the crude salt of 3-methyl-N-{6-[(3R)-pyrrolidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with HCl [Example 126] (224 mg, purity 74%, 0.34 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate [CAS-RN: 6226-25-1] (120 mg, 0.52 mmol, 1.5 eq), potassium carbonate (237 mg, 1.7 mmol, 5.0 eq) and potassium iodide (5.7 mg, 0.03 mmol, 0.1 eq) in 9 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 hours. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The volatile components were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 45 mg (21% yield of theory) of the title compound.

[1906] UPLC-MS (Method 2): R.sub.t=0.94 min; MS (El.sub.pos): m/z=562 [M+H].sup.+.

[1907] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.46-1.63 (m, 1H), 1.90-2.01 (m, 1H), 2.54-2.63 (m, 2H), 2.69-2.79 (m, 2H), 2.83-2.92 (m, 1H), 3.21-3.31 (m, 2H), 4.07-4.27 (m, 2H), 6.85 (d, 1H), 8.10 (s br, 1H), 8.54 (s br, 1H), 8.80 (s, 1H), 8.90 (s, 1H), 10.33 (s br, 1H), 11.50 (s br, 1H), 1CH.sub.3 got obscured by the solvent signal.

[1908] [α].sub.D.sup.20 (c=10 mg/mL, DMSO)+0.9°+/−0.2°.

Example 129

3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3R)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide

[1909] ##STR00252##

[1910] A mixture of the crude salt of 3-methyl-N-{6-[(3R)-pyrrolidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with HCl [Example 126] (224 mg, purity 74%, 0.34 mmol, 1.0 eq), 3,3,3-trifluoropropyl 4-methylbenzenesulfonate [CAS-RN: 2342-67-8] (138 mg, 0.52 mmol, 1.5 eq), potassium carbonate (237 mg, 1.7 mmol, 5.0 eq) and potassium iodide (5.7 mg, 0.03 mmol, 0.1 eq) was taken up in 5 mL acetonitrile. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. for 17 hunder an atmosphere of argon. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 45 mg (20% yield of theory) of the title compound.

[1911] UPLC-MS (Method 2): R.sub.t=0.94 min; MS (El.sub.pos): m/z=576 [M+H].sup.+.

[1912] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.52-1.73 (m, 1H), 1.93-2.10 (m, 1H), 2.53 (s, 3H), 2.54-2.74 (m, 3H), 2.75-3.10 (m, 4H), 4.09-4.30 (m, 2H), 6.82 (d, 1H), 8.11-8.22 (m, 1H), 8.49 (s br, 1H), 8.57 (s br, 2H), 8.64 (s br, 1H), 13.3 (s br, 1H), 1CH.sub.2 obscured by water signal.

[1913] [α].sub.D.sup.20 (c=10 mg/mL, DMSO)−0.6°+/−0.3°.

Example 130

tert-Butyl (3S)-3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate

[1914] ##STR00253##

[1915] A mixture of tert-butyl (3S)-3-{[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate [Intermediate 38] (645 mg, 1.5 mmol, 1.0 eq), 2-chloro-5-(trifluoromethyl)pyrazine [CAS-RN: 799557-87-2] (272 mg, 1.5 mmol, 1.0 eq) and cesium carbonate (1115 mg, 3.4 mmol, 2.3 eq) in 15 mL dioxane/DMF (6/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (33 mg, 0.15 mmol, 0.1 eq) and Xantphos (86 mg, 0.15 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 25 g SNAP cartridge: dicloromethane.fwdarw.dichloromethane/ethanol 90:10) to give 670 mg (78% yield of the theory) of the title compound.

[1916] UPLC-MS (Method 2): Rt=1.02 min; MS (El.sub.pos): m/z=580 [M+H].sup.+.

Example 131

3-Methyl-N-{6-[(3S)-pyrrolidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with hydrochloric acid

[1917] ##STR00254##

[1918] tert-butyl (3S)-3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}pyrrolidine-1-carboxylate [Example 130] (495 mg, 0.9 mmol, 1.0 eq) was suspended in 222 mL dioxane and 4.3 mL hydrogen chloride solution (4.0 M) in dioxane (CAS-RN: 7647-01-0) (17.1 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature for 3 h in a sealed vial. The precipitate of the crude hydrochloride acid salt of the title compound was isolated by filtration (670 mg) and used for further derivatization without further purification.

[1919] UPLC-MS (Method 2): R.sub.t=0.86 min; MS (El.sub.pos): m/z=480 [M+H].sup.+.

Example 132

N-(6-{[(3S)-1-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1920] ##STR00255##

[1921] A mixture of the crude salt of 3-methyl-N-{6-[(3S)-pyrrolidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with HCl [Example 131] (223 mg, purity 61%, 0.28 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate [CAS-RN: 74427-22-8] (91 mg, 0.43 mmol, 1.5 eq), potassium carbonate (196 mg, 1.4 mmol, 5.0 eq) and potassium iodide (4. mg, 0.03 mmol, 0.1 eq) in 7.5 mL acetonitrile and 0.6 mL DMF was placed in a microwave vial that was flushed with argon and stirred for 17h at 70° C. Another 0.5 equ 2,2-difluoroethyl trifluoromethanesulfonate [CAS-RN: 74427-22-8] (30 mg) were added and the reaction mixture was stirred for 4 h at 70° C. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. Final purification was conducted via preparative HPLC (Method B) to give 51 mg (30% yield of theory) of the title compound.

[1922] UPLC-MS (Method 2): R.sub.t=0.92 min; MS (El.sub.pos): m/z=544 [M+H].sup.+.

[1923] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.43-1.59 (m, 1H), 1.97-2.13 (m, 1H), 2.61-2.92 (m, 3H), 2.93-3.11 (m, 1H), 2.77-3.01 (m, 3H), 3.83-4.06 (m, 2H), 5.96-6.40 (m, 1H), 7.11-7.37 (m, 2H), 7.63-7.84 (m, 1H), 8.64-8.96 (m, 2H), 10.34 (s br, 1H), 11.46 (s br, 1H) 1CH.sub.3 obscured by the solvent signal.

[1924] [α].sub.D.sup.20 (c=10 mg/mL, DMSO)−1.4°+/−0.4°.

Example 133

3-Methyl-N-(6-{[(SR)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1925] ##STR00256##

[1926] A mixture of the crude salt of 3-methyl-N-{6-[(3S)-pyrrolidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with HCl [Example 131] (223 mg, purity 61%, 0.28 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate [CAS-RN: 6226-25-1] (99 mg, 0.43 mmol, 1.5 eq), potassium carbonate (96 mg, 1.4 mmol, 5.0 eq) and potassium iodide (4.7 mg, 0.03 mmol, 0.1 eq) in 7.5 mL acetonitrile and 0.6 mL DMF was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 hours. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The volatile components were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 83 mg (52% yield of theory) of the title compound.

[1927] UPLC-MS (Method 2): R.sub.t=0.96 min; MS (El.sub.pos): m/z=562 [M+H].sup.+.

[1928] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.47-1.59 (m, 1H), 1.90-2.03 (m, 1H), 2.54-2.65 (m, 2H), 2.70-2.79 (m, 2H), 2.83-2.92 (m, 1H), 3.21-3.30 (m, 2H), 4.08-4.24 (m, 2H), 6.86 (d, 1H), 8.9 (d, 1H), 8.53 (s br, 1H), 8.79 (s, 1H), 8.86 (s, 1H), 10.34 (s br, 1H), 11.51 (s br, 1H), 1CH.sub.3 got obscured by the solvent signal.

[1929] [α].sub.D.sup.20 (c=10 mg/mL, DMSO)−2.6°+/−0.3°.

Example 134

3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3S)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide

[1930] ##STR00257##

[1931] A mixture of the crude salt of 3-methyl-N-{6-[(3S)-pyrrolidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with HCl [Example 131] (223 mg, purity 61%, 0.28 mmol, 1.0 eq), 3,3,3-trifluoropropyl 4-methylbenzenesulfonate [CAS-RN: 2342-67-8] (114 mg, 0.43 mmol, 1.5 eq), potassium carbonate (196 mg, 1.42 mmol, 5.0 eq) and potassium iodide (4.7 mg, 0.03 mmol, 0.1 eq) was taken up in 7.5 mL acetonitrile and 0.6 mL DMF. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h under an atmosphere of argon. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 70 mg (39% yield of theory) of the title compound.

[1932] UPLC-MS (Method 2): R.sub.t=0.96 min; MS (El.sub.pos): m/z=576 [M+H].sup.+.

[1933] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.60-1.84 (m, 1H), 1.94-2.22 (m, 1H), 2.54 (s, 3H), 2.60-2.82 (m, 3H), 2.83-3.22 (m, 4H), 4.11-4.35 (m, 2H), 6.84 (d, 1H), 8.05-8.26 (m, 1H), 8.57 (s, 1H), 8.71 (s br, 2H), 8.64 (s br, 1H), 11.40 (s br, 1H), 1CH.sub.2 obscured by water signal.

[1934] [α].sub.D.sup.20 (c=10 mg/mL, DMSO)−2.0°+/−0.4°.

Example 135

tert-Butyl (3S,4R)-3-fluoro-4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate

[1935] ##STR00258##

[1936] A mixture of tert-butyl (3S,4R)-4-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]-3-fluoropiperidine-1-carboxylate [Intermediate 41] (400 mg, 0.9 mmol, 1.2 eq), 2-chloro-5-(trifluoromethyl)pyrazine (CAS-RN: 799557-87-2) (135 mg, 0.74 mmol, 1.0 eq) and cesium carbonate (553 mg, 1.7 mmol, 2.3 eq) in 7.5 mL dioxane/DMF (6/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (17 mg, 0.07 mmol, 0.1 eq) and Xantphos (43 mg, 0.07 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 25 g KP-cartridge: n-hexane/ethyl acetate: 100:0 15:85) to give 380 mg (86% yield of the theory) of the title compound.

[1937] UPLC-MS (Method 2): Rt=0.98 min; MS (El.sub.pos): m/z=598 [M+H].sup.+.

[1938] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.40 (s, 9 H), 1.73-1.97 (m, 2H), 2.96-3.25 (m, 2H), 3.87-4.01 (m, 1H), 4.10-4.26 (m, 1H), 4.88-5.08 (m, 1H), 5.16-5.33 (m, 1H), 6.92 (d, 1H), 8.09 (s br, 1H), 8.53 (s br, 1H), 8.84 (s br, 1H), 8.92 (s br, 1H), 10.37 (s br, 1H), 11.47 (s br, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 136

N-(6-{[(3S,4R)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoroacetic acid

[1939] ##STR00259##

[1940] Tert-butyl (3S,4R)-3-fluoro-4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate [Example 135] (380 mg, 0.64 mmol, 1.0 eq) was suspended in 12 mL dichloromethane and trifluoroacetic acid (CAS-RN: 76-C.sub.5-1) (1 mL, 12.7 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature for 4 h in a sealed vial. The crude reaction mixture was dissolved in a mixture of dichloromethane and methanol (1:1) and the volatile components were removed in vacuo. The crude trifluoro acetate salt of the title compound was used for further derivatization without further purification.

[1941] UPLC-MS (Method 2): R.sub.t=0.80 min; MS (El.sub.pos): m/z=498 [M+H].sup.+.

Example 137

[1942] N-(6-{[(3S,4R)-1-(2,2-difluoroethyl)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

##STR00260##

[1943] A mixture of the crude salt of N-(6-{[(3S,4R)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 136] (143 mg, 0.29 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (92 mg, 0.43 mmol, 1.5 eq), potassium carbonate (199 mg, 1.4 mmol, 5.0 eq) and potassium iodide (5 mg, 0.03 mmol, 0.1 eq) in 4.5 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 3 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. The volatile components of the collected fractions were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 41 mg (24% yield of theory) of the title compound.

[1944] UPLC-MS (Method 2): R.sub.t=0.93 min; MS (El.sub.pos): m/z=562 [M+H].sup.+.

[1945] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.79-2.08 (m, 2H), 2.62-2.94 (m, 4H), 3.03-3.20 (m, 1H), 4.81-5.03 (m, 1H), 5.09-5.26 (m, 1H), 5.98-6.33 (m, 1H), 6.88 (d, 1H), 8.14 (s br, 1H), 8.54 (s br, 1H), 8.77 (s br, 2H), 10.35 (s br, 1H), 11.51 (s br, 1H), 1H and 1×CH.sub.3 obscured by solvent signal.

Example 138

N-(6-{[(3S,4R)-3-fluoro-1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1946] ##STR00261##

[1947] A mixture of the crude salt of N-(6-{[(3S,4R)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 136] (143 mg, 0.29 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (100 mg, 0.43 mmol, 1.5 eq) potassium carbonate (199 mg, 1.4 mmol, 5.0 eq) and potassium iodide (5 mg, 0.03 mmol, 0.1 eq) in 4.5 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 6 h. Another 0.5 eq of 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (33 mg, 0.14 mmol) were added and the reaction mixture was stirred overnight at 70° C. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. Final purification was conducted via preparative HPLC (Method B) to give 50 mg (29% yield of theory) of the title compound.

[1948] UPLC-MS (Method 2): R.sub.t=0.98 min; MS (El.sub.pos): m/z=580 [M+H].sup.+.

[1949] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.79-2.08 (m, 2H), 2.64-2.74 (m, 1H), 2.78-2.98 (m, 2H), 3.12-3.22 (m, 1H), 4.82-5.03 (m, 1H), 5.10-5.26 (m, 1H), 6.91 (d, 1H), 8.11 (s br, 1H), 8.53 (s br, 1H), 8.74-8.97 (m, 2H), 10.37 (s br, 1H), 11.49 (s br, 1H), 1×CH.sub.2 and 1×CH.sub.3 obscured by solvent signal.

Example 139

N-(6-{[(3S,4R)-3-fluoro-1-(3,3, 3-trifluoropropyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1950] ##STR00262##

[1951] A mixture of the crude salt of N-(6-{[(3S,4R)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 136] (143 mg, 0.29 mmol, 1.0 eq), 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (116 mg, 0.43 mmol, 1.5 eq), potassium carbonate (199 mg, 1.44 mmol, 5.0 eq) and potassium iodide (5 mg, 0.03 mmol, 0.1 eq) was taken up in 4.5 mL acetonitrile.

[1952] Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. for 6 h under an atmosphere of argon. Another 0.5 eq of 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS 2342-67-8) (39 mg, 0.14 mmol) were added and the reaction mixture was stirred at 70° C. overnight. This was repeated with 0.5 eq and 0.2 eq of 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) and everytimed the reaction was stirred at 70° C. for another 24 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 50 mg (28% yield of theory) of the title compound.

[1953] UPLC-MS (Method 2): R.sub.t=0.96 min; MS (El.sub.pos): m/z=594 [M+H].sup.+.

[1954] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.82-2.03 (m, 2H), 2.33-2.44 (m, 1H), 2.60-2.71 (m, 3H), 2.72-2.84 (m, 1H), 2.98-3.13 (m, 1H), 4.82-5.04 (m, 1H), 5.09-5.24 (m, 1H), 6.89 (d, 1H), 8.09 (d, 1H), 8.51 (s br, 1H), 8.79 (s br, 1H), 8.88 (s br, 1H), 10.34 (s br, 1H), 11.45 (s br, 1H), 1×CH.sub.2 and 1×CH.sub.3 obscured by the solvent signal.

[1955] [α].sub.D.sup.20 (c=10 mg/mL, CHCl3)+8.4°+/−0.2°.

Example 140

N-(6-{[(3S,4R)-3-fluoro-1-propylpiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1956] ##STR00263##

[1957] A mixture of the crude salt of N-(6-{[(3S,4R)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 136] (190 mg, 0.38 mmol, 1.0 eq), propyl 4-methylbenzenesulfonate (CAS-RN: 599-91-7) (98 mg, 0.46 mmol, 1.5 eq), potassium carbonate (264 mg, 1.44 mmol, 5.0 eq) and potassium iodide (6 mg, 0.04 mmol, 0.1 eq) was taken up in 5 mL acetonitrile. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. overnight under an atmosphere of argon. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 54 mg (25% yield of theory) of the title compound.

[1958] UPLC-MS (Method 2): R.sub.t=0.93 min; MS (El.sub.pos): m/z=540 [M+H].sup.+.

[1959] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=0.86 (t, 3H), 1.38-1.61 (m, 2H), 1.78-2.06 (m, 2H), 2.25-2.46 (m, 2H), 2.54 (s, 3H), 2.69-2.94 (m, 1H), 2.94-3.21 (m, 1H), 4.82-5.08 (m, 1H), 5.09-5.26 (m, 1H), 6.84 (d, 1H), 8.18 (d, 1H), 8.43 (s br, 1H), 8.54 (s br, 1H), 8.58 (s br, 1H), 13.29 (s br, 1H), 1×CH.sub.2 and obscured by the solvent signal,1xNH not detected.

[1960] [α].sub.D.sup.20 (c=10 mg/mL, DMSO)+12.6°+/−0.3°.

Example 141

N-(6-{[(3S,4R)-1-butyl-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1961] ##STR00264##

[1962] A mixture of the crude salt of N-(6-{[(3S,4R)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 136] (190 mg, 0.38 mmol, 1.0 eq), butyl 4-methylbenzenesulfonate (CAS-RN: 778-28-9) (174 mg, 0.76 mmol, 2 eq), potassium carbonate (264 mg, 1.9 mmol, 5.0 eq) and potassium iodide (6 mg, 0.04 mmol, 0.1 eq) was taken up in 4.5 mL acetonitrile. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. for 5 h under an atmosphere of argon. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 51 mg (23% yield of theory) of the title compound.

[1963] UPLC-MS (Method 2): R.sub.t=0.97 min; MS (El.sub.pos): m/z=554 [M+H].sup.+.

[1964] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=0.89 (t, 3H), 1.18-1.37 (m, 3H), 1.40-1.62 (m, 2H), 1.90-2.12 (m, 2H), 2.76-3.14 (m, 2H), 4.80-5.30 (m, 2H), 6.88 (d, 1H), 8.16 (d, 1H), 8.40-8.75 (m, 3H), 9.65 (s br, 1H), 11,48 (s br, 1H), 1×CH.sub.3 obscured by the solvent signal, 3H not assigned.

[1965] [α].sub.D.sup.20 (c=10 mg/mL, DMSO)+14.1°+/−0.3°.

Example 142

tert-Butyl (3R,4S)-3-fluoro-4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate

[1966] ##STR00265##

[1967] A mixture of tert-butyl (3R,4S)-4-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]-3-fluoropiperidine-1-carboxylate [Intermediate 44] (650 mg, 1.4 mmol, 1.2 eq), 2-chloro-5-(trifluoromethyl)pyrazine (CAS-RN: 799557-87-2) (219 mg, 1.2 mmol, 1.0 eq) and cesium carbonate (899 mg, 2.8 mmol, 2.3 eq) in 12 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (27 mg, 0.12 mmol, 0.1 eq) and Xantphos (69 mg, 0.12 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo.

[1968] Purification of this crude material was done via preparative MPLC (Biotage Isolera; 25 g KP-cartridge: n-hexane/ethyl acetate: 100:0 15:85) to give 580 mg (81% yield of the theory) of the title compound.

[1969] UPLC-MS (Method 2): Rt=1.03 min; MS (El.sub.pos): m/z=598 [M+H].sup.+.

[1970] .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.42 (s, 9 H), 1.75-1.95 (m, 2H), 2.96-3.26 (m, 2H), 3.88-4.02 (m, 1H), 4.10-4.28 (m, 1H), 4.87-5.09 (m, 1H), 5.15-5.37 (m, 1H), 6.92 (d, 1H), 8.10 (s br, 1H), 8.53 (s br, 1H), 8.84 (s br, 1H), 8.92 (s br, 1H), 10.37 (s br, 1H), 11.47 (s br, 1H), 1×CH.sub.3 obscured by solvent signal.

Example 143

[1971] N-(6-{[(3R,4S)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoroacetic acid

##STR00266##

[1972] tert-butyl (3R,4S)-3-fluoro-4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]piperidine-1-carboxylate [Example 142] (580 mg, 0.97 mmol, 1.0 eq) was suspended in 19 mL dichloromethane and trifluoroacetic acid (CAS-RN: 76-C.sub.5-1) (1.5 mL, 19.4 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature for 4 h in a sealed vial. The crude reaction mixture was dissolved in a mixture of dichloromethane and methanol (1:1) and the volatile components were removed in vacuo. The crude trifluoro acetate salt of the title compound was used for further derivatization without further purification.

[1973] UPLC-MS (Method 2): Rt=0.79 min; MS (Elne.sub.g): m/z=496 [M−H].sup.−.

Example 144

[1974] N-(6-{[(3R,4S)-1-(2,2-difluoroethyl)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

##STR00267##

[1975] A mixture of the crude salt of N-(6-{[(3R,4S)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 143] (126 mg, 0.25 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (81 mg, 0.38 mmol, 1.5 eq), potassium carbonate (175 mg, 1.3 mmol, 5.0 eq) and potassium iodide (4 mg, 0.03 mmol, 0.1 eq) in 4 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. The volatile components of the collected fractions were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 45 mg (30% yield of theory) of the title compound.

[1976] UPLC-MS (Method 2): R.sub.t=0.91 min; MS (El.sub.pos): m/z=562 [M+H].sup.+.

[1977] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.79-2.08 (m, 2H), 2.64-2.92 (m, 4H), 3.04-3.20 (m, 1H), 4.81-5.04 (m, 1H), 5.10-5.26 (m, 1H), 5.97-6.36 (m, 1H), 6.89 (d, 1H), 8.14 (s br, 1H), 8.54 (s br, 1H), 8.77 (s br, 2H), 10.41 (s br, 1H), 11.52 (s br, 1H), 1H and 1×CH.sub.3 obscured by solvent signal.

Example 145

N-(6-{[(3R,4S)-3-fluoro-1-(2,2,2-trifluoroethyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1978] ##STR00268##

[1979] A mixture of the crude salt of N-(6-{[(3R,4S)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 143] (126 mg, 0.25 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (88 mg, 0.38 mmol, 1.5 eq) potassium carbonate (175 mg, 1.3 mmol, 5.0 eq) and potassium iodide (4 mg, 0.03 mmol, 0.1 eq) in 4 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 6 h. Another 0.5 eq of 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (58 mg, 0.13 mmol) were added and the reaction mixture was stirred overnight at 70° C. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. Final purification was conducted via preparative HPLC (Method B) to give 49 mg (32% yield of theory) of the title compound.

[1980] UPLC-MS (Method 2): R.sub.t=0.98 min; MS (El.sub.pos): m/z=580 [M+H].sup.+.

[1981] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.79-2.04 (m, 2H), 2.62-2.74 (m, 1H), 2.82-2.95 (m, 2H), 3.10-3.25 (m, 1H), 4.83-5.04 (m, 1H), 5.11-5.27 (m, 1 H), 6.91 (d, 1H), 8.10 (s br, 1H), 8.53 (s br, 1H), 8.71-9.00 (m, 2H), 10.37 (s br, 1H), 11.47 (s br, 1H), 1×CH.sub.2 and 1×CH.sub.3 obscured by solvent signal.

Example 146

N-(6-{[(3R,4S)-3-fluoro-1-(3,3,3-trifluoropropyl)piperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1982] ##STR00269##

[1983] A mixture of the crude salt of N-(6-{[(3R,4S)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 143] (126 mg, 0.25 mmol, 1.0 eq), 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (102 mg, 0.38 mmol, 1.5 eq), potassium carbonate (175 mg, 1.3 mmol, 5.0 eq) and potassium iodide (4 mg, 0.03 mmol, 0.1 eq) was taken up in 4 mL acetonitrile.

[1984] Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. for 6 h under an atmosphere of argon. Another 0.5 eq of 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS 2342-67-8) (39 mg, 0.14 mmol) were added and the reaction mixture was stirred at 70° C. overnight. This was repeated with 0.5 eq and 0.2 eq of 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) and everytimed the reaction was stirred at 70° C. for another 24 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 42 mg (27% yield of theory) of the title compound.

[1985] UPLC-MS (Method 2): R.sub.t=0.94 min; MS (El.sub.pos): m/z=594 [M+H].sup.+.

[1986] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=1.78-2.05 (m, 2H), 2.24-2.39 (m, 1H), 2.56-2.68 (m, 3H), 2.71-2.83 (m, 1H), 2.98-3.09 (m, 1H), 4.82-5.02 (m, 1 H), 5.07-5.22 (m, 1H), 6.88 (d, 1H), 8.12 (d, 1H), 8.52 (s br, 1H), 8.83 (s br, 2 H), 10.35 (s br, 1H), 11.46 (s br, 1H), 1×CH.sub.2 and 1×CH.sub.3 obscured by the solvent signal.

Example 147

N-(6-{[(3R,4S)-3-fluoro-1-propylpiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1987] ##STR00270##

[1988] A mixture of the crude salt of N-(6-{[(3R,4S)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 143] (180 mg, 0.36 mmol, 1.0 eq), propyl 4-methylbenzenesulfonate (CAS-RN: 599-91-7) (93 mg, 0.43 mmol, 1.2 eq), potassium carbonate (250 mg, 1.8 mmol, 5.0 eq) and potassium iodide (6 mg, 0.04 mmol, 0.1 eq) was taken up in 4.5 mL acetonitrile. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. overnight under an atmosphere of argon. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 57 mg (29% yield of theory) of the title compound.

[1989] UPLC-MS (Method 2): R.sub.t=0.95 min; MS (El.sub.pos): m/z=540 [M+H].sup.+.

[1990] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=0.86 (t, 3H), 1.38-1.58 (m, 2H), 1.85-2.09 (m, 2H), 2.24-2.46 (m, 2H), 2.54 (s, 3H), 2.59-3.24 (m, 3H), 4.80-5.33 (m, 2H), 6.84 (d, 1H), 8.19 (d, 1H), 8.46 (s br, 1H), 8.54 (s br, 1H), 8.59 (s br, 1H), 13.34 (s br, 1H), 1H not assigned,1xNH not detected.

[1991] [α].sub.D.sup.20 (c=10 mg/mL, DMSO)−13.6°+/−0.3°.

Example 148

N-(6-{[(3R,4S)-1-butyl-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1992] ##STR00271##

[1993] A mixture of the crude salt of N-(6-{[(3R,4S)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 143] (180 mg, 0.36 mmol, 1.0 eq), butyl 4-methylbenzenesulfonate (CAS-RN: 778-28-9) (165 mg, 0.72 mmol, 2 eq), potassium carbonate (250 mg, 1.8 mmol, 5.0 eq) and potassium iodide (6 mg, 0.04 mmol, 0.1 eq) was taken up in 4 mL acetonitrile. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. for 5 h under an atmosphere of argon. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 50 mg (24% yield of theory) of the title compound.

[1994] UPLC-MS (Method 2): R.sub.t=0.97 min; MS (El.sub.pos): m/z=554 [M+H].sup.+.

[1995] .sup.1H NMR (400 MHz, DMSO-d.sub.6): δ [ppm]=0.89 (t, 3H), 1.13-1.37 (m, 3H), 1.38-1.63 (m, 2H), 1.92-2.16 (m, 2H), 2.75-3.23 (m, 2H), 4.79-5.41 (m, 2H), 6.88 (d, 1H), 8.16 (d, 1H), 8.44-8.85 (m, 3H), 9.66 (s br, 1H), 11.32 (s br, 1H), 1×CH.sub.3 obscured by the solvent signal, 3H not assigned.

[1996] [α].sub.D.sup.20 (c=10 mg/mL, DMSO)−14.4°+/−0.2°.

[1997] The compounds listed in Table 3B were prepared in close anology to the compounds described above, employing the procedures described above, starting from commercially available starting materials, or according to literature which is known to the person skilled in the art.

TABLE-US-00006 TABLE 3B Example No Structure, Name Analytical data Example 149 [00272]   5-[(6-fluoroquinoxalin-2-yl)amino]-3- methyl-N-(4-sulfamoylphenyl)-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.73 min; MS (EI.sub.pos): m/z = 459 [M + H].sup.+. Example 150 [00273]   5-[(5-cyanopyridin-2-yl)amino]-3-methyl- N-[3-(methylsulfonyl)phenyl]-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.73 min; MS (ESI.sub.pos): m/z = 414 [M + H].sup.+. Example 151 [00274]   N-(3-carbamoyl-4-fluorophenyl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.09 min; MS (ESI.sub.pos): m/z = 441 [M + H].sup.+. Example 152 [00275]   N-(3-acetamido-4-fluorophenyl)-5-[(5- cyanopyridin-2-yl)amino]-3-methyl-1,2- thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 0.99 min; MS (ESI.sub.pos): m/z = 411 [M + H].sup.+. Example 153 [00276]   N-(4-{[2-(3,3-difluoropiperidin-1- yl)ethyl]carbamoyl}phenyl)-3-methyl-5- {[5-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.07 min; MS (ESI.sub.pos): m/z = 570 [M + H].sup.+. Example 154 [00277]   N-(4-{[4-(2,2-difluoroethyl)piperazin-1- yl]carbonyl}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.18 min; MS (ESI.sub.pos): m/z = 556 [M + H].sup.+. Example 155 [00278]   N-(4-{[2-(3-fluoropiperidin-1- yl)ethyl]carbamoyl}phenyl)-3-methyl-5- {[6-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 0.99 min; MS (ESI.sub.pos): m/z = 552 [M + H].sup.+. Example 156 [00279]   N-(4-{[2-(3,3-difluoropiperidin-1- yl)ethyl]carbamoyl}phenyl)-3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazole-4- carboxamide UPLC-MS (Method 1): Rt = 1.05 min; MS (ESI.sub.pos): m/z = 552 [M + H].sup.+. Example 157 [00280]   N-(4-{[4-(2,2-difluoroethyl)piperazin-1- yl]carbonyl}phenyl)-3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazole-4- carboxamide UPLC-MS (Method 1): Rt = 1.15 min; MS (ESI.sub.pos): m/z = 538 [M + H].sup.+. Example 158 [00281]   tert-butyl 3,3-difluoro-5-{[4-({[3-methyl- 5-(quinoxalin-2-ylamino)-1,2-thiazol-4- yl]carbonyl}amino)benzoyl]amino} piperidine-1-carboxylate UPLC-MS (Method 1): Rt = 1.36 min; MS (ESI.sub.pos): m/z = 624 [M + H].sup.+. Example 159 [00282]   3-methyl-5-(quinoxalin-2-ylamino)-N-(4- {4-(2,2,2-trifluoroethyl)-1,4-diazepan-1- yl]carbonyl}phenyl)-1,2-thiazole-4- carboxamide UPLC-MS (Method 1): Rt = 1.30 min; MS (ESI.sub.pos): m/z = 570 [M + H].sup.+. Example 160 [00283]   N-{6-[(1-isopropylpiperidin-4- yl)oxy]pyridin-3-yl}-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.89 min; MS (ESI.sub.pos): m/z = 522 [M + H].sup.+. Example 162 [00284]   N-(3-fluoro-4-{[1-(2- fluoroethyl)piperidin-4-yl]oxy}phenyl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 6): Rt = 1.07 min; MS (ESI.sub.pos): m/z = 543 [M + H].sup.+. Example 163 [00285]   N-(3-fluoro-4-{[1-(2,2,2- trifluoroethyl)piperidin-4-yl]oxy}phenyl)- 3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 6): Rt = 1.50 min; MS (ESI.sub.pos): m/z = 579 [M + H].sup.+. Example 164 [00286]   N-(4-{[1-(2,2-difluoroethyl)piperidin-4- yl]oxy}-3-fluorophenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.00 min; MS (ESI.sub.pos): m/z = 561 [M + H].sup.+. Example 165 [00287]   3-methyl-N-(4-{[1-(2,2,2- trifluoroethyl)piperidin-4- yl]carbamoyl}phenyl)-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 6): Rt = 0.90 min; MS (ESI.sub.pos): m/z = 588 [M + H].sup.+. Example 166 [00288]   tert-butyl 3-{[(5-{[(3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazol-4-yl)carbonyl]amino}pyridin-2- yl)oxy]methyl}piperidine-1-carboxylate UPLC-MS (Method 2): Rt = 0.99 min; MS (ESI.sub.pos): m/z = 594 [M + H].sup.+. Example 167 [00289]   3-methyl-N-(4-{[1-(2,2,2- trifluoroethyl)piperidin-4- yl]carbamoyl}phenyl)-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.88 min; MS (ESI.sub.pos): m/z = 588 [M + H].sup.+. Example 168 [00290]   tert-butyl 4-(2-fluoro-5-{[(3-methyl-5- {[6-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazol-4- yl)carbonyl]amino}phenoxy)piperidine-1- carboxylate UPLC-MS (Method 2): Rt = 1.04 min; MS (ESI.sub.pos): m/z = 597 [M + H].sup.+. Example 169 [00291]   3-methyl-N-[6-(morpholin-4-yl)pyridin-3- yl]-5-(quinoxalin-2-ylamino)-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.72 min; MS (ESI.sub.neg): m/z = 446 [M − H].sup.−. Example 170 [00292]   tert-butyl N-{5-[({5-[(5-cyanopyridin-2- yl)amino]-3-methyl-1,2-thiazol-4- yl}carbonyl)amino]pyridin-2-yl}alaninate UPLC-MS (Method 2): Rt = 0.92 min; MS (ESI.sub.neg): m/z = 478 [M − H].sup.−. Example 171 [00293]   tert-butyt 3-({5-[({5-[(5-cyanopyridin-2- yl)amino]-3-methyl-1,2-thiazol-4- yl}carbonyl)amino]pyridin-2- yl}amino)piperidine-1-carboxylate UPLC-MS (Method 2): Rt = 0.92 min; MS (ESI.sub.pos): m/z = 535 [M + H].sup.+. Example 172 [00294]   N-[6-(cyclopropylamino)pyridin-3-yl]-3- methyl-5-(quinoxalin-2-ylamino)-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.80 min; MS (ESI.sub.pos): m/z = 418 [M + H].sup.+. Example 173 [00295]   5-[(5-cyanopyridin-2-yl)amino]-N-[6- methoxy-2-(morpholin-4-yl)pyridin-3-yl]- 3-methyl-1,2-thiazole-4-carboxamide UPLC-MS (Method 3): Rt = 1.29 min; MS (ESI.sub.pos): m/z = 452 [M + H].sup.+. Example 174 [00296]   5-[(4-cyanopyridin-2-yl)amino]-N-(3-{[2- (diethylamino)ethyl]carbamoyl}phenyl)- 3-methyl-1,2-thiazole-4-carboxamide UPLC-MS (Method 3): Rt = 0.87 min; MS (ESI.sub.pos): m/z = 478 [M + H].sup.+. Example 175 [00297]   5-[(4-cyanopyridin-2-yl)amino]-N-[3- (cyclopropylcarbamoyl)phenyl]-3- methyl-1,2-thiazole-4-carboxamide UPLC-MS (Method 3): Rt = 1.07 min; MS (ESI.sub.pos): m/z = 419 [M + H].sup.+. Example 176 [00298]   methyl 3-{3-[({5-[(5-cyanopyridin-2- yl)amino]-3-methyl-1,2-thiazol-4- yl}carbonyl)amino]phenyl}propanoate UPLC-MS (Method 2): Rt = 0.85 min; MS (ESI.sub.pos): m/z = 422 [M + H].sup.+. Example 177 [00299]   tert-butyl {4-[({5-[(4-cyanopyridin-2- yl)amino]-3-methyl-1,2-thiazol-4- yl}carbonyl)amino]phenyl}carbamate UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 451 [M + H].sup.+. Example 178 [00300]   tert-butyl [3-({[3-methyl-5-(quinoxalin-2- ylamino)-1,2-thiazol-4- yl]carbonyl}amino)phenyl]carbamate UPLC-MS (Method 1): Rt = 1.38 min; MS (ESI.sub.pos): m/z = 477 [M + H].sup.+. Example 179 [00301]   tert-butyl {3-[({5-[(5-cyanopyridin-2- yl)amino]-3-methyl-1,2-thiazol-4- yl}carbonyl)amino]phenyl}carbamate UPLC-MS (Method 1): Rt = 1.28 min; MS (ESI.sub.pos): m/z = 451 [M + H].sup.+. Example 180 [00302]   N-(3-aminophenyl)-5-[(5-cyanopyridin-2- yl)amino]-3-methyl-1,2-thiazole-4- carboxamide UPLC-MS (Method 1): Rt = 0.91 min; MS (ESI.sub.pos): m/z = 351 [M + H].sup.+. Example 181 [00303]   tert-butyl 4-({[3-methyl-5-(quinoxalin-2- ylamino)-1,2-thiazol-4- yl]carbonyl}amino)benzoate % UPLC-MS (Method 1): Rt = 1.49 min; MS (ESI.sub.pos): m/z = 462 [M + H].sup.+. Example 182 [00304]   tert-butyl 4-[({5-[(4-cyanopyridin-2- yl)amino]-3-methyl-1,2-thiazol-4- yl}carbonyl)amino]benzoate UPLC-MS (Method 2): Rt = 0.96 min; MS (ESI.sub.pos): m/z = 436 [M + H].sup.+. Example 183 [00305]   5-[(4-cyanopyridin-2-yl)amino]-N-{3- [(2,2-dimethylpropanoyl)amino]phenyl}- 3-methyl-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.86 min; MS (ESI.sub.pos): m/z = 435 [M + H].sup.+. Example 184 [00306]   tert-butyl 4-({[3-methyl-5-(pyrazin-2- ylamino)-1,2-thiazol-4- yl]carbonyl}amino)benzoate UPLC-MS (Method 2): Rt = 0.83 min; MS (ESI.sub.pos): m/z = 412 [M + H].sup.+. Example 185 [00307]   N-{4-[(2,2- dimethylpropanoyl)amino]phenyl}-3- methyl-5-(quinoxalin-2-ylamino)-1,2- thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.26 min; MS (ESI.sub.pos): m/z = 461 [M + H].sup.+. Example 186 [00308]   N-{3-[(2,2- dimethylpropanoyl)amino]phenyl}-3- methyl-5-(quinoxalin-2-ylamino)-1,2- thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.29 min; MS (ESI.sub.pos): m/z = 461 [M + H].sup.+. Example 187 [00309]   4-({[3-methyl-5-(quinoxalin-2-ylamino)- 1,2-thiazol-4-yl]carbonyl}amino)benzoic acid UPLC-MS (Method 1): Rt = 1.13 min; MS (ESI.sub.pos): m/z = 406 [M + H].sup.+. Example 188 [00310]   3-methyl-N-[2-(methylsulfonyl)phenyl]-5- (quinoxalin-2-ylamino)-1,2-thiazole-4- carboxamide UPLC-MS (Method 1): Rt = 1.26 min; MS (ESI.sub.pos): m/z = 440 [M + H].sup.+. Example 189 [00311]   tert-butyl 3-[(5-{[(3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazol-4-yl)carbonyl]amino}pyridin-2- yl)oxy]piperidine-1-carboxylate UPLC-MS (Method 2): Rt = 0.95 min; MS (ESI.sub.pos): m/z = 580 [M + H].sup.+. Example 190 [00312]   tert-butyl {3-[(5-{[(3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazoL-4-yl)carbonyl]amino}pyridin-2- yl)oxy]propyl}carbamate UPLC-MS (Method 2): Rt = 0.89 min; MS (ESI.sub.pos): m/z = 554 [M + H].sup.+. Example 191 [00313]   tert-butyl {2-[(5-{[(3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazol-4-yl)carbonyl]amino}pyridin-2- yl)oxy]ethyl}carbamate UPLC-MS (Method 2): Rt = 0.87 min; MS (ESI.sub.pos): m/z = 540 [M + H].sup.+. Example 192 [00314]   tert-butyl {2-[(5-{[(3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazol-4-yl)carbonyl]amino}pyridin-2- yl)oxy]ethyl}carbamate UPLC-MS (Method 2): Rt = 0.90 min; MS (ESI.sub.pos): m/z = 540 [M + H].sup.+. Example 193 [00315]   tert-butyl tert-butyl 4-{[(3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazol-4-yl)carbonyl]amino}benzoate UPLC-MS (Method 1): Rt = 1.46 min; MS (ESI.sub.pos): m/z = 480 [M + H].sup.+. Example 194 [00316]   3-methyl-N-[3-(methylsulfonyl)phenyl]-5- {[6-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.76 min; MS (ESI.sub.pos): m/z = 458 [M + H].sup.+. Example 195 [00317]   3-methyl-N-[3-(methylsulfonyl)phenyl]-5- {[5-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.79 min; MS (ESI.sub.pos): m/z = 458 [M + H].sup.+. Example 196 [00318]   N-[6-(2-aminoethoxy)pyridin-3-yl]-3- methyl-5-{[6-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.71 min; MS (ESI.sub.pos): m/z = 440 [M + H].sup.+. Example 197 [00319]   N-[6-(2-aminoethoxy)pyridin-3-yl]-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.73 min; MS (ESI.sub.pos): m/z = 440 [M + H].sup.+. Example 198 [00320]   tert-butyl 3-{[5-({[3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazol-4- yl]carbonyl}amino)pyridin-2- yl]oxy}propanoate UPLC-MS (Method 2): Rt = 0.78 min; MS (ESI.sub.pos): m/z = 507 [M + H].sup.+. Example 199 [00321]   tert-butyl 3-({5-[({5-[(5-cyanopyridin-2- yl)amino]-3-methyl-1,2-thiazol-4- yl}carbonyl)amino]pyridin-2- yl}oxy)propanoate UPLC-MS (Method 2): Rt = 0.75 min; MS (ESI.sub.pos): m/z = 481 [M + H].sup.+. Example 200 [00322]   tert-butyl 3-({5-[({5-[(4-cyanopyridin-2- yl)amino]-3-methyl-1,2-thiazol-4- yl}carbonyl)amino]pyridin-2- yl}oxy)propanoate UPLC-MS (Method 2): Rt = 0.77 min; MS (ESI.sub.pos): m/z = 481 [M + H].sup.+. Example 201 [00323]   N-(4-carbamoyl-3-fluorophenyl)-3- methyl-5-(quinoxalin-2-ylamino)-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.71 min; MS (ESI.sub.pos): m/z = 423 [M + H].sup.+. Example 202 [00324]   N-(3-carbamoyl-4-fluorophenyl)-3- methyl-5-(quinoxalin-2-ylamino)-1,2- thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.05 min; MS (ESI.sub.pos): m/z = 423 [M + H].sup.+. Example 203 [00325]   N-(3-carbamoyl-4-fluorophenyl)-5-[(5- cyanopyridin-2-yl)amino]-3-methyl-1,2- thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 0.94 min; MS (ESI.sub.pos): m/z = 397 [M + H].sup.+. Example 204 [00326]   N-(3-carbamoyl-4-fluorophenyl)-3- methyl-5-{[6-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.05 min; MS (ESI.sub.pos): m/z = 441 [M + H].sup.+. Example 205 [00327]   N-(3-acetamido-4-fluorophenyl)-3- methyl-5-(pyrazin-2-ylamino)-1,2- thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 0.89 min; MS (ESI.sub.pos): m/z = 387 [M + H].sup.+. Example 206 [00328]   N-(3-acetamido-4-fluorophenyl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.14 min; MS (ESI.sub.pos): m/z = 455 [M + H].sup.+. Example 207 [00329]   N-[3-fluoro-4-(methylcarbamoyl)phenyl]- 3-methyl-5-(quinoxalin-2-ylamino)-1,2- thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.12 min; MS (ESI.sub.pos): m/z = 437 [M + H].sup.+. Example 208 [00330]   5-[(5-cyanopyridin-2-yl)amino]-N-[3- fluoro-4-(methylcarbamoyl)phenyl]-3- methyl-1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.00 min; MS (ESI.sub.pos): m/z = 411 [M + H].sup.+. Example 209 [00331]   N-[6-(3-aminopropoxy)pyridin-3-yl]-3- methyl-5-{[6-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.77 min; MS (ESI.sub.pos): m/z = 454 [M + H].sup.+. Example 210 [00332]   5-[(4-cyanopyridin-2-yl)amino]-3-methyl- N-[4-(methylsulfamoyl)phenyl]-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.78 min; MS (ESI.sub.pos): m/z = 429 [M + H].sup.+. Example 211 [00333]   3-methyl-N-[4-(methylsulfamoyl)phenyl]- 5-{[6-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.81 min; MS (ESI.sub.pos): m/z = 473 [M + H].sup.+. Example 212 [00334]   3-methyl-N-[4-(methylsulfamoyl)phenyl]- 5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.84 min; MS (ESI.sub.pos): m/z = 473 [M + H].sup.+. Example 213 [00335]   N-(4-{[2-(3-fluoropiperidin-1- yl)ethyl]carbamoyl}phenyl)-3-methyl-5- {[5-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.03 min; MS (ESI.sub.pos): m/z = 552 [M + H].sup.+. Example 214 [00336]   N-(4-{[2-(3,3-difluoropiperidin-1- yl)ethyl]carbamoyl}phenyl)-3-methyl-5- {[6-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.04 min; MS (ESI.sub.pos): m/z = 570 [M + H].sup.+. Example 215 [00337]   tert-butyl [2-(2-fluoro-4-{[(3-methyl-5- {[5-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazol-4- yl)carbonyl]amino}phenoxy)ethyl]carbamate UPLC-MS (Method 3): Rt = 1.47 min; MS (ESI.sub.pos): m/z = 557 [M + H].sup.+. Example 216 [00338]   tert-butyl [2-(2-fluoro-4-{[(3-methyl-5- {[6-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazol-4- yl)carbonyl]amino}phenoxy)ethyl]carbamate UPLC-MS (Method 1): Rt = 1.42 min; MS (ESI.sub.pos): m/z = 557 [M + H].sup.+. Example 217 [00339]   tert-butyl 4-(2-fluoro-4-{[(3-methyl-5- {[5-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazol-4- yl)carbonyl]amino}phenoxy)piperidine-1- carboxylate % UPLC-MS (Method 1): Rt = 1.52 min; MS (ESI.sub.pos): m/z = 597 [M + H].sup.+. Example 218 [00340]   N-{6-[(1-isopropylpiperidin-4- yl)oxy]pyridin-3-yl}-3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.87 min; MS (ESI.sub.pos): m/z = 522 [M + H].sup.+. Example 219 [00341]   3-methyl-N-{6-[(1-methylpiperidin-4- yl)oxy]pyridin-3-yl}-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.79 min; MS (ESI.sub.pos): m/z = 494 [M + H].sup.+. Example 220 [00342]   3-methyl-N-{6-[(1-methylpiperidin-4- yl)oxy]pyridin-3-yl}-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.81 min; MS (ESI.sub.pos): m/z = 494 [M + H].sup.+. Example 221 [00343]   3-N-[4-(2-aminoethoxy)-3-fluorophenyl]- 3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.79 min; MS (ESI.sub.pos): m/z = 457 [M + H].sup.+. Example 222 [00344]   tert-butyl 4-[(4-{[(3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazol-4- yl)carbonyl]amino}benzoyl)amino] piperidine-1-carboxylate UPLC-MS (Method 1): Rt = 1.29 min; MS (ESI.sub.pos): m/z = 606 [M + H].sup.+. Example 223 [00345]   N-(3-fluoro-4-{[1-(2- fluoroethyl)piperidin-4-yl]oxy}phenyl)-3- methyl-5-{[6-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 6): Rt = 1.07 min; MS (ESI.sub.pos): m/z = 543 [M + H].sup.+. Example 224 [00346]   N-(4-{[1-(2,2-difluoroethyl)piperidin-4- yl]oxy}-3-fluorophenyl)-3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.95 min; MS (ESI.sub.pos): m/z = 561 [M + H].sup.+. Example 225 [00347]   N-N-(4-{[1-(2,2-difluoroethyl)piperidin-4- yl]carbamoyl}phenyl)-3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.86 min; MS (ESI.sub.pos): m/z = 570 [M + H].sup.+. Example 226 [00348]   tert-butyl 4-{[(5-{[(3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazol-4-yl)carbonyl]amino}pyridin-2- yl)oxy]methyl}piperidine-1-carboxylate UPLC-MS (Method 2): Rt = 1.02 min; MS (ESI.sub.pos): m/z = 594 [M + H].sup.+. Example 227 [00349]   tert-butyl 4-{[(5-{[(3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazol-4-yl)carbonyl]amino}pyridin-2- yl)oxy]methyl}piperidine-1-carboxylate UPLC-MS (Method 2): Rt = 1.05 min; MS (ESI.sub.pos): m/z = 594 [M + H].sup.+. Example 228 [00350]   tert-butyl 3-{[(5-{[(3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazol-4-yl)carbonyl]amino}pyridin-2- yl)oxy]methyl}piperidine-1-carboxylate UPLC-MS (Method 2): Rt = 1.00 min; MS (ESI.sub.pos): m/z = 594 [M + H].sup.+. Example 229 [00351]   tert-butyl 4-(2-fluoro-5-{[(3-methyl-5- {[5-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazol-4- yl)carbonyl]amino}phenoxy)piperidine-1- carboxylate UPLC-MS (Method 2): Rt = 1.05 min; MS (ESI.sub.pos): m/z = 597 [M + H].sup.+. Example 230 [00352]   5-[(4-cyanopyridin-2-yl)amino]-3-methyl- N-{6-[3- (trifluoromethyl)phenoxy]pyridin-3-yl}- 1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.97 min; MS (ESI.sub.pos): m/z = 497 [M + H].sup.+. Example 231 [00353]   3-methyl-N-[6-(pyridin-3-yloxy)pyridin-3- yl]-5-(quinoxalin-2-ylamino)-1,2- thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.13 min; MS (ESI.sub.pos): m/z = 456 [M + H].sup.+. Example 233 [00354]   3-methyl-5-(quinoxalin-2-ylamino)-N-(6-{4- [(trifluoromethyl)sulfanyl]phenoxy} pyridin-3-yl)-1,2-thiazole-4-carboxamide UPLC-MS (Method 3): Rt = 1.51 min; MS (ESI.sub.pos): m/z = 555 [M + H].sup.+. Example 234 [00355]   tert-butyl 4-{[5-({[3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazol-4- yl]carbonyl}amino)pyridin-2- yl]amino}piperidine-1-carboxylate UPLC-MS (Method 2): Rt = 0.87 min; MS (ESI.sub.pos): m/z = 561 [M + H].sup.+. Example 235 [00356]   N-[2-(cyanomethyl)-6-methoxypyridin-3- yl]-3-methyl-5-(quinoxalin-2-ylamino)- 1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.21 min; MS (ESI.sub.pos): m/z = 432 [M + H].sup.+. Example 236 [00357]   tert-butyl N-[5-({[3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazol-4- yl]carbonyl}amino)pyridin-2-yl]-beta- alaninate UPLC-MS (Method 2): Rt = 0.92 min; MS (ESI.sub.pos): m/z = 506 [M + H].sup.+. Example 237 [00358]   dimethyl 5-({[3-methyl-5-(quinoxalin-2- ylamino)-1,2-thiazol-4- yl]carbonyl}amino)isophthalate UPLC-MS (Method 1): Rt = 1.34 min; MS (ESI.sub.pos): m/z = 478 [M + H].sup.+. Example 238 [00359]   tert-butyl 4-({[5-({[3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazol-4- yl]carbonyl}amino)pyridin-2- yl]amino}methyl)piperidine-1- carboxylate UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 575 [M + H].sup.+. Example 239 [00360]   tert-butyl 3-[({5-[(4-cyanopyridin-2- yl)amino]-3-methyl-1,2-thiazol-4- yl}carbonyl)amino]benzoate UPLC-MS (Method 1): Rt = 1.42 min; MS (ESI.sub.pos): m/z = 436 [M + H].sup.+. Example 240 [00361]   tert-butyl 3-[({5-[(5-cyanopyridin-2- yl)amino]-3-methyl-1,2-thiazol-4- yl}carbonyl)amino]benzoate UPLC-MS (Method 2): Rt = 1.01 min; MS (ESI.sub.pos): m/z = 436 [M + H].sup.+. Example 241 [00362]   tert-butyl 3-{[5-({[3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazol-4- yl]carbonyl}amino)pyridin-2- yl]amino}piperidine-1-carboxylate UPLC-MS (Method 2): Rt = 0.94 min; MS (ESI.sub.neg): m/z = 559 [M − H].sup.−. Example 242 [00363]   5-[(4-cyanopyridin-2-yl)amino]-3-methyl- N-[6-(piperidin-3-ylamino)pyridin-3-yl]- 1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 0.78 min; MS (ESI.sub.pos): m/z = 435 [M + H].sup.+. Example 243 [00364]   N-[2-(3,5-dimethyl-1H-pyrazol-1- yl)phenyl]-3-methyl-5-(quinoxalin-2- ylamino)-1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.45 min; MS (ESI.sub.pos): m/z = 456 [M + H].sup.+. Example 244 [00365]   tert-butyl (2-{[5-({[3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazol-4- yl]carbonyl}amino)pyridin-2- yl]amino}ethyl)carbamate UPLC-MS (Method 2): Rt = 0.84 min; MS (ESI.sub.pos): m/z = 521 [M + H].sup.+. Example 245 [00366]   N-{6-[(3,4-difluorophenyl)amino]pyridin- 3-yl}-3-methyl-5-(quinoxalin-2-ylamino)- 1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.90 min; MS (ESI.sub.pos): m/z = 490 [M + H].sup.+. Example 246 [00367]   5-[(5-cyanopyridin-2-yl)amino]-3-methyl- N-[4-(methylsulfonyl)phenyl]-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.73 min; MS (ESI.sub.pos): m/z = 414 [M + H].sup.+. Example 247 [00368]   N-(3-{[2- (diethylamino)ethyl]carbamoyl}phenyl)- 3-methyl-5-(pyrazin-2-ylamino)-1,2- thiazole-4-carboxamide UPLC-MS (Method 3): Rt = 0.76 min; MS (ESI.sub.pos): m/z = 454 [M + H].sup.+. Example 248 [00369]   tert-butyl 4-[5-({[3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazol-4- yl]carbonyl}amino)pyridin-2- yl]piperazine-1-carboxylate UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 547 [M + H].sup.+. Example 249 [00370]   N-[3-(cyclopropylcarbamoyl)phenyl]-3- methyl-5-(quinoxalin-2-ylamino)-1,2- thiazole-4-carboxamide UPLC-MS (Method 3): Rt = 1.15 min; MS (ESI.sub.pos): m/z = 445 [M + H].sup.+. Example 250 [00371]   5-[(5-cyanopyridin-2-yl)amino]-N-[3- (cyclopropylcarbamoyl)phenyl]-3- methyl-1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.03 min; MS (ESI.sub.pos): m/z = 419 [M + H].sup.+. Example 251 [00372]   N-[3-(ethylcarbamoyl)phenyl]-3-methyl- 5-(quinoxalin-2-ylamino)-1,2-thiazole-4- carboxamide UPLC-MS (Method 3): Rt = 1.14 min; MS (ESI.sub.pos): m/z = 433 [M + H].sup.+. Example 252 [00373]   5-[(5-cyanopyridin-2-yl)amino]-N-[3- (ethylcarbamoyl)phenyl]-3-methyl-1,2- thiazole-4-carboxamide UPLC-MS (Method 3): Rt = 1.03 min; MS (ESI.sub.pos): m/z = 407 [M + H].sup.+. Example 253 [00374]   N-[3-(isopropylcarbamoyl)phenyl]-3- methyl-5-(quinoxalin-2-ylamino)-1,2- thiazole-4-carboxamide UPLC-MS (Method 3): Rt = 1.20 min; MS (ESI.sub.pos): m/z = 447 [M + H].sup.+. Example 254 [00375]   5-[(4-cyanopyridin-2-yl)amino]-N-[3- (isopropylcarbamoyl)phenyl]-3-methyl- 1,2-thiazole-4-carboxamide UPLC-MS (Method 3): Rt = 1.13 min; MS (ESI.sub.pos): m/z = 421 [M + H].sup.+. Example 255 [00376]   5-[(5-cyanopyridin-2-yl)amino]-N-[3- (isopropylcarbamoyl)phenyl]-3-methyl- 1,2-thiazole-4-carboxamide UPLC-MS (Method 3): Rt = 1.10 min; MS (ESI.sub.pos): m/z = 421 [M + H].sup.+. Example 256 [00377]   methyl 4-{4-[({5-[(4-cyanopyridin-2- yl)amino]-3-methyl-1,2-thiazol-4- yl}carbonyl)amino]phenyl}butanoate UPLC-MS (Method 2): Rt = 0.87 min; MS (ESI.sub.pos): m/z = 436 [M + H].sup.+. Example 257 [00378]   methyl 3-[3-({[3-methyl-5-(quinoxalin-2- ylamino)-1,2-thiazol-4- yl]carbonyl}amino)phenyl]propanoate UPLC-MS (Method 2): Rt = 0.87 min; MS (ESI.sub.pos): m/z = 448 [M + H].sup.+. Example 258 [00379]   tert-butyl 4-{[3-({[3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazol-4- yl]carbonyl}amino)phenyl]sulfamoyl} piperidine-1-carboxylate UPLC-MS (Method 1): Rt = 1.35 min; MS (ESI.sub.pos): m/z = 624 [M + H].sup.+. Example 259 [00380]   N-(4-{[1-(2,2-difluoroethyl)piperidin-4- yl]carbamoyl}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.86 min; MS (ESI.sub.pos): m/z = 570 [M + H].sup.+. Example 260 [00381]   3-methyl-N-(4-{[4-(2,2,2- trifluoroethyl)piperazin-1- yl]carbonyl}phenyl)-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.88 min; MS (ESI.sub.pos): m/z = 574 [M + H].sup.+. Example 261 [00382]   N-{4-[(4-ethylpiperazin-1- yl)carbonyl]phenyl}-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.88 min; MS (ESI.sub.pos): m/z = 520 [M + H].sup.+. Example 262 [00383]   3-methyl-N-{4-[(4-methylpiperazin-1 yl)carbonyl]phenyl}-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.78 min; MS (ESI.sub.pos): m/z = 506 [M + H].sup.+. Example 263 [00384]   5-[(4-cyanopyridin-2-yl)amino]-N-(6-{[1- (2,2-difluoroethyl)piperidin-4- yl]oxy}pyridin-3-yl)-3-methyl-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.91 min; MS (ESI.sub.pos): m/z = 500 [M + H].sup.+. Example 264 [00385]   N-(4-fluoro-3-{[1-(2,2,2- trifluoroethyl)piperidin-4-yl]oxy}phenyl)- 3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.02 min; MS (ESI.sub.pos): m/z = 579 [M + H].sup.+. Example 265 [00386]   N-(3-{[1-(2,2-difluoroethyl)piperidin-4- yl]oxy}-4-fluorophenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.96 min; MS (ESI.sub.pos): m/z = 561 [M + H].sup.+. Example 266 [00387]   N-(4-fluoro-3-{[1-(2- fluoroethyl)piperidin-4-yl]oxy}phenyl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.92 min; MS (ESI.sub.pos): m/z = 543 [M + H].sup.+. Example 267 [00388]   N-(4-fluoro-3-{[1-(2,2,2- trifluoroethyl)piperidin-4-yl]oxy}phenyl)- 3-methyl-5-{[6-(trifluoromethyl)pyrazin- 2-yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.45 min; MS (ESI.sub.pos): m/z = 579 [M + H].sup.+. Example 268 [00389]   N-(3-{[1-(2,2-difluoroethyl)piperidin-4- yl]oxy}-4-fluorophenyl)-3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.95 min; MS (ESI.sub.pos): m/z = 561 [M + H].sup.+. Example 269 [00390]   N-(4-fluoro-3-{[1-(2- fluoroethyl)piperidin-4-yl]oxy}phenyl)-3- methyl-5-{[6-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.88 min; MS (ESI.sub.pos): m/z = 543 [M + H].sup.+. Example 270 [00391]   3-methyl-N-(4-{[1-(2,2,2- trifluoroethyl)azetidin-3- yl]carbamoyl}phenyl)-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.86 min; MS (ESI.sub.pos): m/z = 560 [M + H].sup.+. Example 271 [00392]   N-(4-{[1-(2,2-difluoroethyl)azetidin-3- yl]carbamoyl}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.85 min; MS (ESI.sub.pos): m/z = 542 [M + H].sup.+. Example 272 [00393]   3-methyl-N-(4-{[4-(2,2,2- trifluoroethyl)piperazin-1- yl]carbonyl}phenyl)-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.87 min; MS (ESI.sub.pos): m/z = 574 [M + H].sup.+. Example 273 [00394]   N-(4-{[4-(2,2-difluoroethyl)piperazin-1- yl]carbonyl}phenyl)-3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.81 min; MS (ESI.sub.pos): m/z = 556 [M + H].sup.+. Example 274 [00395]   N-(4-{[4-(2-fluoroethyl)piperazin-1- yl]carbonyl}phenyl)-3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.77 min; MS (ESI.sub.pos): m/z = 538 [M + H].sup.+. Example 275 [00396]   N-{4-[(4-ethylpiperazin-1- yl)carbonyl]phenyl}-3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.79 min; MS (ESI.sub.pos): m/z = 520 [M + H].sup.+. Example 276 [00397]   N-[6-(2-hydroxyethoxy)pyridin-3-yl]-3- methyl-5-{[6-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.72 min; MS (ESI.sub.pos): m/z = 441 [M + H].sup.+. Example 277 [00398]   N-[6-(2-hydroxyethoxy)pyridin-3-yl]-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.74 min; MS (ESI.sub.pos): m/z = 441 [M + H].sup.+. Example 278 [00399]   N-[6-(3-hydroxypropoxy)pyridin-3-yl]-3- methyl-5-{[6-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.76 min; MS (ESI.sub.pos): m/z = 455 [M + H].sup.+. Example 279 [00400]   N-[6-(3-hydroxypropoxy)pyridin-3-yl]-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.77 min; MS (ESI.sub.pos): m/z = 455 [M + H].sup.+. Example 280 [00401]   3-methyl-N-(4-{[1-(2,2,2- trifluoroethyl)azetidin-3- yl]carbamoyl}phenyl)-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.82 min; MS (ESI.sub.pos): m/z = 560 [M + H].sup.+. Example 281 [00402]   3-methyl-5-(quinoxalin-2-ylamino)-N-[3- ({[1-(2,2,2-trifluoroethyl)piperidin-4- yl]sulfonyl}amino)phenyl]-1,2-thiazole-4- carboxamide UPLC-MS (Method 3): Rt = 1.36 min; MS (ESI.sub.pos): m/z = 606 [M + H].sup.+. Example 282 [00403]   N-[3-({[1-(2,2-difluoroethyl)piperidin-4- yl]sulfonyl}amino)phenyl]-3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.76 min; MS (ESI.sub.pos): m/z = 588 [M + H].sup.+. Example 283 [00404]   3-methyl-5-(quinoxalin-2-ylamino)-N-[3- ({[1-(3,3,3-trifluoropropyl)piperidin-4- yl]sulfonyl}amino)phenyl]-1,2-thiazole-4- carboxamide UPLC-MS (Method 1): Rt = 1.04 min; MS (ESI.sub.pos): m/z = 620 [M + H].sup.+. Example 284 [00405]   3-tert-butyl (3-{[(3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazol-4- yl)carbonyl]amino}phenyl)carbamate UPLC-MS (Method 1): Rt = 1.41 min; MS (ESI.sub.pos): m/z = 495 [M + H].sup.+. Example 285 [00406]   3-methyl-5-(quinoxalin-2-ylamino)-N-[3- ({[1-(2,2,2-trifluoroethyl)azetidin-3- yl]sulfonyl}amino)phenyl]-1,2-thiazole-4- carboxamide UPLC-MS (Method 1): Rt = 1.26 min; MS (ESI.sub.pos): m/z = 578 [M + H].sup.+. Example 286 [00407]   N-[3-({[1-(2,2-difluoroethyl)azetidin-3- yl]sulfonyl}amino)phenyl]-3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazole-4- carboxamide UPLC-MS (Method 1): Rt = 1.15 min; MS (ESI.sub.pos): m/z = 560 [M + H].sup.+. Example 287 [00408]   N-[3-({[1-(2-fluoroethyl)azetidin-3- yl]sulfonyl}amino)phenyl]-3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.79 min; MS (ESI.sub.pos): m/z = 542 [M + H].sup.+. Example 288 [00409]   3-methyl-5-(quinoxalin-2-ylamino)-N-[3- ({[1-(3,3,3-trifluoropropyl)azetidin-3- yl]sulfonyl}amino)phenyl]-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.71 min; MS (ESI.sub.pos): m/z = 592 [M + H].sup.+. Example 289 [00410]   3-methyl-5-(quinoxalin-2-ylamino)-N-[3- ({[1-(2,2,2-trifluoroethyl)pyrrolidin-3- yl]sulfonyl}amino)phenyl]-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.77 min; MS (ESI.sub.pos): m/z = 592 [M + H].sup.+. Example 290 [00411]   tert-butyl 3-{[3-({[3-methyl-5- (quinoxalin-2-ylamino)-1,2-thiazol-4- yl]carbonyl}amino)phenyl]sulfamoyl} pyrrolidine-1-carboxylate UPLC-MS (Method 1): Rt = 1.33 min; MS (ESI.sub.pos): m/z = 610 [M + H].sup.+. Example 291 [00412]   benzyl 3-{[3-({[3-methyl-5-(quinoxalin- 2-ylamino)-1,2-thiazol-4- yl]carbonyl}amino)phenyl]sulfamoyl} piperidine-1-carboxylate UPLC-MS (Method 3): Rt = 1.41 min; MS (ESI.sub.pos): m/z = 658 [M + H].sup.+. Example 292 [00413]   3-methyl-N-(6-{3-[(2,2,2- trifluoroethyl)amino]propoxy}pyridin-3- yl)-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.85 min; MS (ESI.sub.pos): m/z = 536 [M + H].sup.+. Example 293 [00414]   N-(6-{3-[(2,2- difluoroethyl)amino]propoxy}pyridin-3- yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.82 min; MS (ESI.sub.pos): m/z = 518 [M + H].sup.+. Example 294 [00415]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{3-[(3,3,3- trifluoropropyl)amino]propoxy}pyridin-3- yl)-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.86 min; MS (ESI.sub.pos): m/z = 550 [M + H].sup.+. Example 295 [00416]   N-(6-{[1-(2-fluoroethyl)pyrrolidin-3- yl]oxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.82 min; MS (ESI.sub.pos): m/z = 512 [M + H].sup.+. Example 296 [00417]   N-(6-{[1-(2,2-difluoroethyl)pyrrolidin-3- yl]oxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.88 min; MS (ESI.sub.pos): m/z = 530 [M + H].sup.+. Example 297 [00418]   3-methyl-N-(6-{[1-(2,2,2- trifluoroethyl)pyrrolidin-3-yl]oxy}pyridin- 3-yl)-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.91 min; MS (ESI.sub.pos): m/z = 548 [M + H].sup.+. Example 298 [00419]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{[1-(3,3,3- trifluoropropyl)pyrrolidin-3- yl]oxy}pyridin-3-yl)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.91 min; MS (ESI.sub.pos): m/z = 562 [M + H].sup.+. Example 299 [00420]   N-[4-(dimethylamino)-3-{3- [methyl(2,2,2- trifluoroethyl)amino]propoxy}phenyl]-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.98 min; MS (ESI.sub.pos): m/z = 592 [M + H].sup.+. Example 300 [00421]   N-[4-(dimethylamino)-3-{3- [methyl(3,3,3- trifluoropropyl)amino]propoxy}phenyl]-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.97 min; MS (ESI.sub.pos): m/z = 606 [M + H].sup.+. Example 301 [00422]   N-(3-{3-[(2,2- difluoroethyl)(methyl)amino]propoxy}-4- fluorophenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.95 min; MS (ESI.sub.pos): m/z = 549 [M + H].sup.+. Example 302 [00423]   N-(4-fluoro-3-{3-[methyl(2,2,2- trifluoroethyl)amino]propoxy}phenyl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.99 min; MS (ESI.sub.pos): m/z = 567 [M + H].sup.+. Example 303 [00424]   N-(4-fluoro-3-{3-[methyl(3,3,3- trifluoropropyl)amino]propoxy}phenyl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.11 min; MS (ESI.sub.pos): m/z = 579 [M − H].sup.−. Example 304 [00425]   3-methyl-5-{[6-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{[1-(3,3,3- trifluoropropyl)piperidin-4- yl]oxy}pyridin-3-yl)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.89 min; MS (ESI.sub.pos): m/z = 576 [M + H].sup.+. Example 305 [00426]   N-(6-{2-[(2,2- difluoroethyl)amino]ethoxy}pyridin-3-yl)- 3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.80 min; MS (ESI.sub.pos): m/z = 504 [M + H].sup.+. Example 306 [00427]   N-(4-fluoro-3-{3-[(2,2,2- trifluoroethyl)amino]propoxy}phenyl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.92 min; MS (ESI.sub.pos): m/z = 553 [M + H].sup.+. Example 307 [00428]   N-(4-fluoro-3-{3-[(3,3,3- trifluoropropyl)amino]propoxy}phenyl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.94 min; MS (ESI.sub.pos): m/z = 567 [M + H].sup.+. Example 308 [00429]   N-(3-{[1-(2,2-difluoroethyl)piperidin-4- yl]methoxy}-4-fluorophenyl)-3-methyl-5- {[5-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.00 min; MS (ESI.sub.pos): m/z = 575 [M + H].sup.+. Example 309 [00430]   N-(4-fluoro-3-{[1-(2- fluoroethyl)piperidin-4- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.94 min; MS (ESI.sub.pos): m/z = 557 [M + H].sup.+. Example 310 [00431]   N-(4-fluoro-3-{[1-(2,2,2- trifluoroethyl)piperidin-4- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.49 min; MS (ESI.sub.pos): m/z = 593 [M + H].sup.+. Example 311 [00432]   N-(4-fluoro-3-{[1-(3,3,3- trifluoropropyl)piperidin-4- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.01 min; MS (ESI.sub.pos): m/z = 607 [M + H].sup.+. Example 312 [00433]   N-(3-{[1-(1,3-difluoropropan-2- yl)piperidin-4-yl]methoxy}-4- fluorophenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.96 min; MS (ESI.sub.pos): m/z = 589 [M + H].sup.+. Example 313 [00434]   N-(6-{[1-(1,3-difluoropropan-2- yl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.88 min; MS (ESI.sub.pos): m/z = 544 [M + H].sup.+. Example 314 [00435]   N-(3-{[1-(2,2-difluoroethyl)pyrrolidin-3- yl]oxy}-4-fluorophenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 547 [M + H].sup.+. Example 315 [00436]   N-(4-fluoro-3-{[1-(2,2,2- trifluoroethyl)pyrrolidin-3- yl]oxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.96 min; MS (ESI.sub.pos): m/z = 565 [M + H].sup.+. Example 316 [00437]   N-(3-{[1-(2,2-difluoroethyl)pyrrolidin-3- yl]methoxy}-4-fluorophenyl)-3-methyl-5- {[5-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.95 min; MS (ESI.sub.pos): m/z = 561 [M + H].sup.+. Example 317 [00438]   N-(4-fluoro-3-{[1-(2- fluoroethyl)pyrrolidin-3- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.90 min; MS (ESI.sub.pos): m/z = 543 [M + H].sup.+. Example 318 [00439]   N-(4-fluoro-3-{[1-(2,2,2- trifluoroethyl)pyrrolidin-3- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.98 min; MS (ESI.sub.pos): m/z = 579 [M + H].sup.+. Example 319 [00440]   N-(4-fluoro-3-{[1-(3,3,3- trifluoropropyl)pyrrolidin-3- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.99 min; MS (ESI.sub.pos): m/z = 593 [M + H].sup.+. Example 320 [00441]   N-(3-{[1-(1,3-difluoropropan-2- yl)pyrrolidin-3-yl]methoxy}-4- fluorophenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 1): Rt = 1.14 min; MS (ESI.sub.pos): m/z = 575 [M + H].sup.+. Example 321 [00442]   N-(6-{2-[(2- fluoroethyl)amino]ethoxy}pyridin-3-yl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.81 min; MS (ESI.sub.pos): m/z = 486 [M + H].sup.+. Example 322 [00443]   3-methyl-N-(6-{2-[(2,2,2- trifluoroethyl)amino]ethoxy}pyridin-3- yl)-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.82 min; MS (ESI.sub.pos): m/z = 522 [M + H].sup.+. Example 323 [00444]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{2-[(3,3,3- trifluoropropyl)amino]ethoxy}pyridin-3- yl)-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.86 min; MS (ESI.sub.pos): m/z = 536 [M + H].sup.+. Example 324 [00445]   N-(6-{[1-(1,3-difluoropropan-2- yl)piperidin-4-yl]oxy}pyridin-3-yl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 558 [M + H].sup.+. Example 325 [00446]   N-(6-{[1-(2-fluoroethyl)piperidin-3- yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.88 min; MS (ESI.sub.pos): m/z = 540 [M + H].sup.+. Example 326 [00447]   3-methyl-N-(6-{[1-(2,2,2- trifluoroethyl)piperidin-3- yl]methoxy}pyridin-3-yl)-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.97 min; MS (ESI.sub.pos): m/z = 576 [M + H].sup.+. Example 327 [00448]   N-(6-{[1-(2,2-difluoroethyl)piperidin-3- yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.92 min; MS (ESI.sub.pos): m/z = 558 [M + H].sup.+. Example 328 [00449]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{[1-(3,3,3- trifluoropropyl)piperidin-3- yl]methoxy}pyridin-3-yl)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.96 min; MS (ESI.sub.pos): m/z = 590 [M + H].sup.+. Example 329 [00450]   N-(6-{[1-(2-fluoroethyl)piperidin-3- yl]oxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 526 [M + H].sup.+. Example 330 [00451]   N-(6-{[1-(2,2-difluoroethyl)piperidin-3- yl]oxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.97 min; MS (ESI.sub.pos): m/z = 544 [M + H].sup.+. Example 331 [00452]   3-methyl-N-(6-{[1-(2,2,2- trifluoroethyl)piperidin-3-yl]oxy}pyridin- 3-yl)-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.02 min; MS (ESI.sub.pos): m/z = 562 [M + H].sup.+. Example 332 [00453]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{[1-(3,3,3- trifluoropropyl)piperidin-3- yl]oxy}pyridin-3-yl)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.98 min; MS (ESI.sub.pos): m/z = 576 [M + H].sup.+. Example 333 [00454]   N-(6-{[1-(1,3-difluoropropan-2- yl)piperidin-3-yl]oxy}pyridin-3-yl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.91 min; MS (ESI.sub.pos): m/z = 558 [M + H].sup.+. Example 334 [00455]   N-(3-{[1-(2,2-difluoroethyl)piperidin-3- yl]methoxy}-4-fluorophenyl)-3-methyl-5- {[5-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.97 min; MS (ESI.sub.pos): m/z = 575 [M + H].sup.+. Example 335 [00456]   N-(3-{[1-(2,2-difluoroethyl)piperidin-3- yl]methoxy}-4-fluorophenyl)-3-methyl-5- {[5-(trifluoromethyl)pyrazin-2-yl]amino}- 1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.94 min; MS (ESI.sub.pos): m/z = 589 [M + H].sup.+. Example 336 [00457]   N-(4-fluoro-3-{[1-(2- fluoroethyl)piperidin-3- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 557 [M + H].sup.+. Example 337 [00458]   N-(4-fluoro-3-{[1-(2,2,2- trifluoroethyl)piperidin-3- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.03 min; MS (ESI.sub.pos): m/z = 593 [M + H].sup.+. Example 338 [00459]   N-(4-fluoro-3-{[1-(3,3,3- trifluoropropyl)piperidin-3- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.01 min; MS (ESI.sub.pos): m/z = 607 [M + H].sup.+. Example 339 [00460]   N-(4-fluoro-3-{[(3R)-1-(2,2,2- trifluoroethyl)pyrrolidin-3- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.00 min; MS (ESI.sub.pos): m/z = 579 [M + H].sup.+. Example 340 [00461]   N-(4-fluoro-3-{[(3R)-1-(3,3,3- trifluoropropyl)pyrrolidin-3- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.03 min; MS (ESI.sub.pos): m/z = 593 [M + H].sup.+. Example 341 [00462]   N-(3-{[(3R)-1-(2,2- difluoroethyl)piperidin-3-yl]methoxy}-4- fluorophenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.00 min; MS (ESI.sub.pos): m/z = 575 [M + H].sup.+. Example 342 [00463]   N-(4-fluoro-3-{[(3R)-1-(2,2,2- trifluoroethyl)piperidin-3- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.04 min; MS (ESI.sub.pos): m/z = 593 [M + H].sup.+. Example 343 [00464]   N-(4-fluoro-3-{[1-(3,3,3- trifluoropropyl)piperidin-4- yl]oxy}phenyl)-3-methyl-5-{[6- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.00 min; MS (ESI.sub.pos): m/z = 593 [M + H].sup.+. Example 344 [00465]   N-(6-{[1-(2-fluoroethyl)piperidin-4- yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 540 [M + H].sup.+. Example 345 [00466]   N-(6-{[1-(2,2-difluoroethyl)piperidin-4- yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.95 min; MS (ESI.sub.pos): m/z = 558 [M + H].sup.+. Example 346 [00467]   3-methyl-N-(6-{[1-(2,2,2- trifluoroethyl)piperidin-4- yl]methoxy}pyridin-3-yl)-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.01 min; MS (ESI.sub.pos): m/z = 576 [M + H].sup.+. Example 347 [00468]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{[1-(3,3,3- trifluoropropyl)piperidin-4- yl]methoxy}pyridin-3-yl)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 1.00 min; MS (ESI.sub.pos): m/z = 590 [M + H].sup.+. Example 348 [00469]   N-(6-{2-[(2- fluoroethyl)(methyl)amino]ethoxy}pyridin- 3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.85 min; MS (ESI.sub.pos): m/z = 500 [M + H].sup.+. Example 349 [00470]   N-(6-{2-[(2,2- difluoroethyl)(methyl)amino]ethoxy}pyridin- 3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.89 min; MS (ESI.sub.pos): m/z = 518 [M + H].sup.+. Example 350 [00471]   3-methyl-N-(6-{2-[methyl(2,2,2- trifluoroethyl)amino]ethoxy}pyridin-3- yl)-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.94 min; MS (ESI.sub.pos): m/z = 536 [M + H].sup.+. Example 351 [00472]   3-methyl-N-(6-{2-[methyl(3,3,3- trifluoropropyl)amino]ethoxy}pyridin-3- yl)-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.97 min; MS (ESI.sub.pos): m/z = 550 [M + H].sup.+. Example 352 [00473]   N-(6-{3-[(2- fluoroethyl)(methyl)amino]propoxy}pyridin- 3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.87 min; MS (ESI.sub.pos): m/z = 514 [M + H].sup.+. Example 353 [00474]   N-(6-{3-[(2,2- difluoroethyl)(methyl)amino]propoxy} pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.92 min; MS (ESI.sub.pos): m/z = 532 [M + H].sup.+. Example 354 [00475]   3-methyl-N-(6-{3-[methyl(2,2,2- trifluoroethyl)amino]propoxy}pyridin-3- yl)-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.97 min; MS (ESI.sub.pos): m/z = 550 [M + H].sup.+. Example 355 [00476]   3-methyl-N-(6-{3-[methyl(3,3,3- trifluoropropyl)amino]propoxy}pyridin-3- yl)-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.98 min; MS (ESI.sub.pos): m/z = 564 [M + H].sup.+. Example 356 [00477]   N-(6-{2-[1-(2,2-difluoroethyl)piperidin-4- yl]ethyl}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 556 [M + H].sup.+. Example 357 [00478]   N-{6-[1-(2,2-difluoroethyl)piperidin-4 yl]pyridin-3-yl}-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.89 min; MS (ESI.sub.pos): m/z = 528 [M + H].sup.+. Example 358 [00479]   3-methyl-N-{6-[1-(2,2,2- trifluoroethyl)piperidin-4-yl]pyridin-3- yl}-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.92 min; MS (ESI.sub.pos): m/z = 546 [M + H].sup.+. Example 359 [00480]   N-{6-[4-(2,2-difluoroethyl)piperazin-1- yl]pyridin-3-yl}-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.88 min; MS (ESI.sub.pos): m/z = 529 [M + H].sup.+. Example 360 [00481]   3-methyl-N-{6-[4-(2,2,2- trifluoroethyl)piperazin-1-yl]pyridin-3- yl}-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.94 min; MS (ESI.sub.pos): m/z = 547 [M + H].sup.+. Example 361 [00482]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-{6-[4-(3,3,3- trifluoropropyl)piperazin-1-yl]pyridin-3- yl}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.94 min; MS (ESI.sub.pos): m/z = 561 [M + H].sup.+. Example 362 [00483]   N-(6-{[(3S,4S)-1-(2,2-difluoroethyl-3- fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 562 [M + H].sup.+. Example 363 [00484]   N-(6-{[(3S,4S)-3-fluoro-1-(2,2,2- trifluoroethyl)piperidin-4-yl]oxy}pyridin- 3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.98 min; MS (ESI.sub.pos): m/z = 580 [M + H].sup.+. Example 364 [00485]   N-(6-{[(3S,4S)-3-fluoro-1-(3,3,3- trifluoropropyl)piperidin-4- yl]oxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.00 min; MS (ESI.sub.pos): m/z = 594 [M + H].sup.+. Example 365 [00486]   N-(6-{[(3S,4S)-1-ethyl-3-fluoropiperidin- 4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.90 min; MS (ESI.sub.pos): m/z = 526 [M + H].sup.+. Example 366 [00487]   N-(6-{[(3R,4R)-1-(2,2-difluoroethyl)-3- fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.94 min; MS (ESI.sub.pos): m/z = 562 [M + H].sup.+. Example 367 [00488]   N-(6-{[(3R,4R)-3-fluoro-1-(2,2,2- trifluoroethyl)piperidin-4-yl]oxy}pyridin- 3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.99 min; MS (ESI.sub.pos): m/z = 580 [M + H].sup.+. Example 368 [00489]   N-(6-{[(3R,4R)-3-fluoro-1-(3,3,3- trifluoropropyl)piperidin-4- yl]oxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.99 min; MS (ESI.sub.pos): m/z = 594 [M + H].sup.+. Example 369 [00490]   N-(6-{[(3R,4R)-1-ethyl-3-fluoropiperidin- 4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.89 min; MS (ESI.sub.pos): m/z = 526 [M + H].sup.+. Example 370 [00491]   N-(6-{[(3S,4S)-3-fluoro-1-propylpiperidin- 4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.94 min; MS (ESI.sub.pos): m/z = 540 [M + H].sup.+. Example 371 [00492]   N-(6-{[(3R,4R)-3-fluoro-1- propylpiperidin-4-yl]oxy}pyridin-3-yl)-3- methyl-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.95 min; MS (ESI.sub.pos): m/z = 540 [M + H].sup.+. Example 372 [00493]   N-{5-[4-(2,2-difluoroethyl)piperazin-1- yl]pyridin-2-yl}-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.83 min; MS (ESI.sub.pos): m/z = 529 [M + H].sup.+. Example 373 [00494]   3-methyl-N-{5-[4-(2,2,2- trifluoroethyl)piperazin-1-yl]pyridin-2- yl}-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.90 min; MS (ESI.sub.pos): m/z = 547 [M + H].sup.+. Example 374 [00495]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-{5-[4-(3,3,3- trifluoropropyl)piperazin-1-yl]pyridin-2- yl}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.88 min; MS (ESI.sub.pos): m/z = 561 [M + H].sup.+. Example 375 [00496]   N-(6-{[(3R)-1-(2,2- difluoroethyl)piperidin-3- yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.95 min; MS (ESI.sub.pos): m/z = 558 [M + H].sup.+. Example 376 [00497]   3-methyl-N-(6-{[(3R)-1-(2,2,2- trifluoroethyl)piperidin-3- yl]methoxy}pyridin-3-yl)-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.00 min; MS (ESI.sub.pos): m/z = 576 [M + H].sup.+. Example 377 [00498]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{[(3R)-1-(3,3,3- trifluoropropyl)piperidin-3- yl]methoxy}pyridin-3-yl)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 1.02 min; MS (ESI.sub.pos): m/z = 590 [M + H].sup.+. Example 378 [00499]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{[(3S)-1-(3,3,3- trifluoropropyl)piperidin-3- yl]methoxy}pyridin-3-yl)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.98 min; MS (ESI.sub.pos): m/z = 590 [M + H].sup.+. Example 379 [00500]   N-(6-{[(3R)-1-(2,2- difluoroethyl)pyrrolidin-3-yl]oxy}pyridin- 3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.88 min; MS (ESI.sub.pos): m/z = 530 [M + H].sup.+. Example 380 [00501]   3-methyl-N-(6-{[(3R)-1-(2,2,2- trifluoroethyl)pyrrolidin-3-yl]oxy}pyridin- 3-yl)-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 548 [M + H].sup.+. Example 381 [00502]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{[(3R)-1-(3,3,3- trifluoropropyl)pyrrolidin-3- yl]oxy}pyridin-3-yl)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 562 [M + H].sup.+. Example 382 [00503]   N-(6-{[(3S)-1-(2,2- difluoroethyl)pyrrolidin-3-yl]oxy}pyridin- 3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.89 min; MS (ESI.sub.pos): m/z = 530 [M + H].sup.+. Example 383 [00504]   3-methyl-N-(6-{[(3S)-1-(2,2,2- trifluoroethyl)pyrrolidin-3-yl]oxy}pyridin- 3-yl)-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.92 min; MS (ESI.sub.pos): m/z = 548 [M + H].sup.+. Example 384 [00505]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{[(3S)-1-(3,3,3- trifluoropropyl)pyrrolidin-3- yl]oxy}pyridin-3-yl)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.93 min; MS (ESI.sub.pos): m/z = 562 [M + H].sup.+. Example 385 [00506]   N-(6-{[(3R)-1-(2,2- difluoroethyl)piperidin-3-yl]oxy}pyridin- 3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.94 min; MS (ESI.sub.pos): m/z = 544 [M + H].sup.+. Example 386 [00507]   3-methyl-N-(6-{[(3R)-1-(2,2,2- trifluoroethyl)piperidin-3-yl]oxy}pyridin- 3-yl)-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.97 min; MS (ESI.sub.pos): m/z = 562 [M + H].sup.+. Example 387 [00508]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{[(3R)-1-(3,3,3- trifluoropropyl)piperidin-3- yl]oxy}pyridin-3-yl)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.96 min; MS (ESI.sub.pos): m/z = 576 [M + H].sup.+. Example 388 [00509]   N-(6-{[(3S)-1-(2,2- difluoroethyl)piperidin-3-yl]oxy}pyridin- 3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.91 min; MS (ESI.sub.pos): m/z = 544 [M + H].sup.+. Example 389 [00510]   3-methyl-N-(6-{[(3S)-1-(2,2,2- trifluoroethyl)piperidin-3-yl]oxy}pyridin- 3-yl)-5-{[5-(trifluoromethyl)pyrazin-2- yl]amino}-1,2-thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.97 min; MS (ESI.sub.pos): m/z = 562 [M + H].sup.+. Example 390 [00511]   3-methyl-5-{[5-(trifluoromethyl)pyrazin- 2-yl]amino}-N-(6-{[(3S)-1-(3,3,3- trifluoropropyl)piperidin-3- yl]oxy}pyridin-3-yl)-1,2-thiazole-4- carboxamide UPLC-MS (Method 2): Rt = 0.96 min; MS (ESI.sub.pos): m/z = 576 [M + H].sup.+. Example 392 [00512]   N-(6-{[3,3-difluoro-1-(2,2,2- trifluoroethyl)piperidin-4- yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.98 min; MS (ESI.sub.pos): m/z = 612 [M + H].sup.+. Example 393 [00513]   N-{6-[(1-ethyl-3,3-difluoropiperidin-4- yl)methoxy]pyridin-3-yl}-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.91 min; MS (ESI.sub.pos): m/z = 558 [M + H].sup.+. Example 394 [00514]   N-{6-[(3,3-difluoro-1-propylpiperidin-4- yl)methoxy]pyridin-3-yl}-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.97 min; MS (ESI.sub.pos): m/z = 572 [M + H].sup.+. Example 395 [00515]   N-(4-fluoro-3-{[(3R)-1-(3,3,3- trifluoropropyl)piperidin-3- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.06 min; MS (ESI.sub.pos): m/z = 607 [M + H].sup.+. Example 396 [00516]   N-{6-[(1-butyl-3,3-difluoropiperidin-4- yl)methoxy]pyridin-3-yl}-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.04 min; MS (ESI.sub.pos): m/z = 586 [M + H].sup.+. Example 397 [00517]   N-(3-{[(3S)-1-(2,2- difluoroethyl)pyrrolidin-3-yl]methoxy}-4- fluorophenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.03 min; MS (ESI.sub.pos): m/z = 561 [M + H].sup.+. Example 398 [00518]   N-(4-fluoro-3-{[(3S)-1-(2,2,2- trifluoroethyl)pyrrolidin-3- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.06 min; MS (ESI.sub.pos): m/z = 579 [M + H].sup.+. Example 399 [00519]   N-(4-fluoro-3-{[(3S)-1-(3,3,3- trifluoropropyl)pyrrolidin-3- yl]methoxy}phenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.08 min; MS (ESI.sub.pos): m/z = 593 [M + H].sup.+. Example 400 [00520]   N-(3-{[(3S)-1-(2,2- difluoroethyl)piperidin-3-yl]methoxy}-4- fluorophenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.06 min; MS (ESI.sub.pos): m/z = 575 [M + H].sup.+. Example 401 [00521]   N-(6-{[1-(2,2-difluoroethyl)-3,3- difluoropiperidin-4-yl]methoxy}pyridin-3- yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.94 min; MS (ESI.sub.pos): m/z = 594 [M + H].sup.+. Example 402 [00522]   N-(6-{[3,3-difluoro-1-(3,3,3- trifluoropropyl)piperidin-4- yl]methoxy}pyridin-3-yl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 1.00 min; MS (ESI.sub.pos): m/z = 626 [M + H].sup.+. Example 403 [00523]   N-(3-{[(3R)-1-(2,2- difluoroethyl)pyrrolidin-3-yl]methoxy}-4- fluorophenyl)-3-methyl-5-{[5- (trifluoromethyl)pyrazin-2-yl]amino}-1,2- thiazole-4-carboxamide UPLC-MS (Method 2): Rt = 0.95 min; MS (ESI.sub.pos): m/z = 561 [M + H].sup.+.

Example 404

3-Methyl-N-(6-{[(3S)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[1998] ##STR00524##

[1999] A mixture of 5-amino-3-methyl-N-(6-{[(3S)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide [Intermediate 55] (100 mg, 0.22 mmol, 1.0 eq), 2-chloro-5-(trifluoromethyl)pyrazine (CAS-RN: 799557-87-2) (61 mg, 0.33 mmol, 1.5 eq) and cesium carbonate (144 mg, 0.44 mmol, 2.0 eq) in 2.4 mL dioxane/DMF (3.5:1) was placed in a microwave vial and flushed with argon. Then, palladium(II) acetate (5 mg, 0.02 mmol, 0.1 eq) and Xantphos (13 mg, 0.02 mmol, 0.1 eq) were added. The vial was capped and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. After cooling to rt the crude product was purified via MPLC (Biotage Isolera: 10 g SNAP-cartridge: hexane.fwdarw.hexane/ethyl acetate 1:1) to give 70 mg (51% yield of theory) of the title compound.

[2000] UPLC-MS (Method 1): R.sub.t=1.46 min; MS (El.sub.neg): m/z=460 [M−H].sup.−.

[2001] .sup.1H-NMR (500 MHz, DMSO-d.sub.6): δ [ppm]=1.60 (m, 1H), 1.76 (m, 2H), 1.94 (m, 1H), 2.55 (q, 1H), 3.13 (m, 2H), 3.24 (m, 1H), 3.66 (m, 1H), 4.07 (dd, 1H), 4.19 (dd, 1H), 6.85 (d, 1H), 8.06 (d, 1H), 8.50 (s, 1H), 8.83 (s, 1H), 8.90 (s, 1H), 10.29 (s, 1H), 11.45 (s, 1H), 1×CH.sub.3 not assigned.

Example 405

5-[(5-Cyanopyridin-2-yl)amino]-3-methyl-N-(6-{[(35)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide

[2002] ##STR00525##

[2003] A mixture of 5-amino-3-methyl-N-(6-{[(35)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide [Intermediate 55] (100 mg, 0.22 mmol, 1.0 eq), 6-chloronicotinonitrile (CAS-RN: 33252-28-7) (46 mg, 0.33 mmol, 1.5 eq) and cesium carbonate (144 mg, 0.44 mmol, 2.0 eq) in 2.4 mL dioxane/DMF (3.5:1) was placed in a microwave vial and flushed with argon. Then, palladium(II) acetate (5 mg, 0.02 mmol, 0.1 eq) and Xantphos (13 mg, 0.02 mmol, 0.1 eq) were added. The vial was capped and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. After cooling to rt the crude product was purified via MPLC (Biotage Isolera: lOg SNAP-cartridge: hexane/ethylacetate 4/1.fwdarw.hexane/ethyl acetate 1/4) to give 70 mg (57% yield of theory) of the title compound.

[2004] UPLC-MS (Method 1): R.sub.t=1.33 min; MS (El.sub.neg): m/z=516 [M−H].sup.−.

[2005] .sup.1H-NMR (500 MHz, DMSO-d.sub.6): δ [ppm]=1.61 (m, 1H), 1.77 (m, 2H), 1.94 (m, 1H), 3.13 (m, 2H), 3.26 (m, 1H), 3.68 (m, 1H), 4.07 (dd, 1H), 4.20 (dd, 1H), 6.85 (d, 1H), 7.45 (d, 1H), 8.06 (d, 1H), 8.14 (d, 1H), 8.50 (d, 1H), 8.88 (d, 1H), 10.26 (s, 1H), 11.10 (s, 1H), 5H's not assigned.

Example 406

N-{6-[(1-Ethyl-3,3-difluoropiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2006] ##STR00526##

[2007] A mixture of 5-amino-N-{6-[(1-ethyl-3,3-difluoropiperidin-4-yl)oxy]pyridin-3-yl}-3-methyl-1,2-thiazole-4-carboxamide [Intermediate 60] (240 mg, 0.60 mmol, 1.0 eq), 2-chloro-5-(trifluoromethyl)pyrazine (CAS-RN: 799557-87-2) (165 mg, 0.91 mmol, 1.5 eq) and cesium carbonate (394 mg, 1.21 mmol, 2.0 eq) in 6.7 mL dioxane/DMF (3.5/1) was placed in a microwave vial and flushed with argon. Then, palladium(II) acetate (14 mg, 0.06 mmol, 0.1 eq) and Xantphos (35 mg, 0.06 mmol, 0.1 eq) were added. The vial was capped and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. After cooling to rt the crude product was purified via MPLC (Biotage Isolera: 25 g SNAP-cartridge: dichloromethane.fwdarw.dichloromethane/ethanol 95/5) to give 32 mg (10% yield of theory) of the title compound.

[2008] UPLC-MS (Method 1): R.sub.t=1.05 min; MS (El.sub.neg): m/z=542 [M−H].sup.−.

[2009] .sup.1H-NMR (500 MHz, DMSO-d.sub.6): δ [ppm]=1.03 (t, 3H), 1.83 (m, 1H), 2.07 (m, 1H), 2.74 (m, 1H), 3.05 (m, 1H), 5.40 (m, 1H), 6.95 (d, 1H), 8.11 (m, 1H), 8.53 (s br, 1H), 8.80 (s br, 1H), 8.89 (s br, 1H), 10.36 (s br, 1H), 11.45 (s br, 1H), 7H's not assigned.

Example 407

[2010] N-{6-[2-(4,4-Difluoropiperidin-1-yl)ethoxy]pyridin-3-yl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

##STR00527##

[2011] A mixture of 5-amino-N-{6-[2-(4,4-difluoropiperidin-1-yl)ethoxy]pyridin-3-yl}-3-methyl-1,2-thiazole-4-carboxamide [Intermediate 63] (685 mg, 1.47 mmol, 1.0 eq), 2-chloro-5-(trifluoromethyl)pyrazine (CAS-RN: 799557-87-2) (294 mg, 1.61 mmol, 1.1 eq) and cesium carbonate (1.09 gg, 3.37 mmol, 2.3 eq) in 14.3 mL dioxane/DMF (7/1) was placed in a microwave vial and flushed with argon. Then, palladium(II) acetate (33 mg, 0.15 mmol, 0.1 eq) and Xantphos (85 mg, 0.15 mmol, 0.1 eq) were added. The vial was capped and the reaction mixture was stirred at an environmental temperature of 110° C. for 5 h. The reaction mixture was partitioned between water and isopropanol/dichloromethane (4/1). The organic phase was washed with brine and the phases were separated by the use of a

[2012] Whatman filter. The volatile components of the organic phase were removed in vacuo. The crude product was purified via MPLC (Biotage Isolera: 25 g SNAP-cartridge: hexane.fwdarw.hexane/ethyl acetate 2/1). The product observed this way was forwarded to a MPLC for a second time (Biotage Isolera: 25 g SNAP-cartridge: hexane.fwdarw.ethyl acetate) to give 80 mg (10% yield of theory) of the title compound.

[2013] UPLC-MS (Method 1): R.sub.t=1.06 min; MS (El.sub.neg): m/z=542 [M−H].sup.−.

[2014] .sup.1H-NMR (500 MHz, DMSO-d.sub.6): δ [ppm]=2.01 (m, 4H), 2.60-3.11 (m, 6H), 4.40 (m, 2H), 6.86 (d, 1H), 8.08 (m, 1H), 8.53 (s, 1H), 8.81 (s br, 1H), 8.87 (s br, 1H), 10.30 (s br, 1H), 11.44 (s br, 1H), 3H′s not assigned.

Example 408

N-(6-{[(3R,4S)-4-Fluoro-1-propylpyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2015] ##STR00528##

[2016] A mixture of the crude salt of N-(6-{[(3R,4S)-4-fluoropyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with hydrochloric acid [Example 437] (91 mg, 87% purity, 0.17 mmol, 1.0 eq), propyl 4-methylbenzenesulfonate (CAS-RN: 599-91-7) (53 mg, 0.25 mmol, 1.5 eq), potassium carbonate (114 mg, 0.82 mmol, 5.0 eq) and potassium iodide (2.7 mg, 0.02 mmol, 0.1 eq) was taken up in 4 mL acetonitrile and 0.5 mL DMF. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h under an atmosphere of argon. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 22 mg (24% yield of theory) of the title compound.

[2017] UPLC-MS (Method 2): Rt=0.86 min; MS (El.sub.pos): m/z=526 [M+H].sup.+.

[2018] 1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 0.821 (0.45), 0.840 (1.03), 0.855 (6.84), 0.873 (16.00), 0.892 (7.71), 1.210 (0.49), 1.496 (0.98), 1.514 (1.54), 1.515 (1.59), 1.534 (1.59), 1.553 (0.98), 2.295 (0.47), 2.299 (1.01), 2.304 (1.47), 2.309 (1.07), 2.314 (0.51), 2.435 (0.40), 2.637 (0.65), 2.642 (1.21), 2.646 (1.65), 2.651 (1.27), 2.656 (0.74), 3.162 (0.42), 5.357 (0.56), 5.484 (0.54), 6.887 (2.17), 6.910 (2.28), 8.109 (0.76), 8.123 (0.74), 8.150 (0.72), 8.565 (2.03), 8.567 (1.97).

[2019] [α]D 20 (c=1.8 mg/mL, DMSO) 9.0°+/−0.65°.

Example 409

N-(6-{[(3R,4S)-4-Fluoro-1-(3,3, 3-trifluoropropyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2020] ##STR00529##

[2021] A mixture of the crude salt of N-(6-{[(3R,4S)-4-fluoropyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with hydrochloricic acid [Example 437] (91 mg, 87% purity, 0.17 mmol, 1.0 eq), 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (66 mg, 0.25 mmol, 1.5 eq), potassium carbonate (114 mg, 0.8 mmol, 5.0 eq) and potassium iodide (2.7 mg, 0.02 mmol, 0.1 eq) was taken up in 4 mL acetonitrile an 0.5 ,mL DMF. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h under an atmosphere of argon. Another 0.5 eq of 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS 2342-67-8) (22 mg, 0.08 mmol) were added and the reaction mixture was stirred at 70° C. for 17 h. This was repeated with 0.5 eq of 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) and the reaction was stirred at 70° C. for another 4 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 34 mg (34% yield of theory) of the title compound.

[2022] UPLC-MS (Method 2): R.sub.t=0.76 min; MS (El.sub.pos): m/z=580 [M+H].sup.+.

[2023] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 0.874 (0.83), 1.255 (2.46), 2.009 (0.48), 2.029 (0.59), 2.339 (0.56), 2.343 (1.20), 2.349 (1.74), 2.353 (1.31), 2.358 (0.62), 2.452 (0.75), 2.471 (1.79), 2.481 (2.22), 2.544 (16.00), 2.548 (12.33), 2.557 (6.15), 2.561 (5.46), 2.576 (2.01), 2.681 (0.88), 2.685 (1.50), 2.691 (2.49), 2.695 (1.79), 2.700 (0.96), 2.708 (1.26), 2.720 (2.09), 2.738 (3.56), 2.743 (2.97), 2.757 (2.25), 2.763 (3.40), 2.773 (1.15), 2.782 (1.58), 2.793 (1.15), 2.812 (0.54), 2.836 (1.58), 2.852 (1.98), 2.860 (2.35), 2.877 (2.86), 2.902 (1.47), 2.905 (1.58), 2.907 (1.53), 2.939 (0.91), 2.942 (1.02), 2.969 (1.55), 2.973 (1.71), 2.979 (1.53), 2.989 (1.34), 3.008 (0.83), 3.018 (0.80), 3.055 (2.62), 3.067 (2.03), 3.072 (2.65), 3.079 (2.30), 3.096 (2.11), 5.249 (0.67), 5.254 (0.78), 5.261 (1.47), 5.267 (1.50), 5.273 (1.28), 5.278 (1.04), 5.291 (0.96), 5.307 (1.61), 5.320 (1.23), 5.325 (1.10), 5.332 (0.91), 5.337 (0.86), 5.344 (1.28), 5.349 (1.26), 5.361 (1.71), 5.378 (1.04), 5.387 (1.12), 5.392 (1.23), 5.398 (1.61), 5.404 (1.53), 5.411 (0.96), 5.416 (0.80), 6.911 (2.01), 6.933 (2.09), 8.129 (1.02), 8.153 (1.42), 8.567 (3.10), 8.571 (3.26), 8.574 (3.02), 8.608 (0.48), 11.517 (0.51).

[2024] [α].sub.D.sup.20 (c=2.6 mg/mL, DMSO) 10.8°+/−0.62°.

Example 410

N-(6-{[(3R,4S)-4-Fluoro-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2025] ##STR00530##

[2026] A mixture of the crude salt of N-(6-{[(3R,4S)-4-fluoropyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with hydrochloricic acid [Example 437] (91 mg, 87% purity, 0.17 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (57 mg, 0.25 mmol, 1.5 eq) potassium carbonate (114 mg, 0.8 mmol, 5.0 eq) and potassium iodide (2.7 mg, 0.02 mmol, 0.1 eq) in 4 mL acetonitrile and 0.5 mL DMF was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. Final purification was conducted via preparative HPLC (Method B) to give 43 mg (44% yield of theory) of the title compound.

[2027] UPLC-MS (Method 2): R.sub.t=0.88 min; MS (El.sub.pos): m/z=566 [M+H].sup.+.

[2028] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 0.842 (0.61), 0.860 (1.50), 0.877 (0.56), 1.242 (4.41), 1.248 (3.66), 1.299 (0.56), 1.430 (0.61), 1.463 (0.47), 1.996 (0.94), 2.015 (1.03), 2.033 (0.66), 2.039 (0.47), 2.325 (0.94), 2.329 (2.02), 2.334 (3.00), 2.339 (2.25), 2.344 (1.08), 2.530 (16.00), 2.547 (3.43), 2.667 (1.03), 2.672 (2.21), 2.676 (3.10), 2.681 (2.25), 2.686 (1.08), 2.985 (1.74), 3.004 (2.49), 3.009 (2.53), 3.012 (2.53), 3.029 (2.44), 3.047 (1.22), 3.052 (1.41), 3.077 (2.11), 3.082 (2.21), 3.113 (1.41), 3.117 (1.45), 3.143 (2.21), 3.147 (2.06), 3.161 (1.64), 3.172 (1.83), 3.191 (1.08), 3.201 (1.08), 3.246 (3.66), 3.255 (2.16), 3.265 (3.43), 3.271 (3.38), 3.289 (2.91), 3.354 (2.21), 3.366 (2.53), 3.379 (1.50), 3.391 (4.83), 3.414 (5.40), 3.425 (0.99), 3.439 (4.36), 3.451 (1.31), 3.465 (1.27), 3.477 (1.03), 3.636 (0.52), 3.669 (1.08), 3.695 (0.89), 3.727 (1.08), 3.791 (0.52), 4.010 (0.52), 4.029 (0.75), 4.036 (0.84), 4.055 (0.99), 4.060 (0.66), 4.712 (1.27), 4.734 (3.75), 4.757 (3.71), 4.780 (1.22), 5.255 (0.80), 5.259 (0.94), 5.266 (1.83), 5.271 (1.83), 5.277 (1.45), 5.282 (1.17), 5.303 (1.03), 5.314 (0.84), 5.321 (2.06), 5.332 (1.74), 5.339 (1.08), 5.350 (1.31), 5.360 (1.13), 5.367 (1.22), 5.378 (2.21), 5.394 (2.39), 5.396 (2.39), 5.404 (2.02), 5.408 (2.02), 5.415 (1.45), 5.419 (1.36), 5.540 (0.56), 5.556 (0.84), 6.934 (2.82), 6.956 (2.96), 6.978 (0.94), 7.000 (0.84), 8.092 (1.13), 8.113 (1.31), 8.140 (0.94), 8.552 (3.10), 8.556 (2.96), 8.583 (1.36), 8.821 (1.69), 8.912 (1.55), 11.480 (1.27).

[2029] [α].sub.D.sup.20 (c=2.4 mg/mL, DMSO) 8.7°+/−0.64°.

Example 411

N-(6-{[(3R,4S)-1-(2,2-Difluoroethyl)-4-fluoropyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2030] ##STR00531##

[2031] A mixture of the crude salt of N-(6-{[(3R,4S)-4-fluoropyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with hydrochloricic acid [Example 437] (91 mg, 87% purity, 0.17 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (53 mg, 0.25 mmol, 1.5 eq), potassium carbonate (114 mg, 0.8 mmol, 5.0 eq) and potassium iodide (2.7 mg, 0.02 mmol, 0.1 eq) in 4 mL acetonitrile and 0.5 mL DMF was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. Another 0.5 eq of 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (17 mg, 0.08 mmol) was added and the reaction mixture was stirred at an environmental temperature of 70° C. for another 17 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. The volatile components of the collected fractions were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 35 mg (37% yield of theory) of the title compound.

[2032] UPLC-MS (Method 2): R.sub.t=0.85 min; MS (El.sub.pos): m/z=548 [M+H].sup.+.

[2033] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 1.242 (0.64), 2.178 (0.55), 2.325 (0.87), 2.330 (1.92), 2.334 (2.79), 2.339 (2.06), 2.344 (0.96), 2.530 (16.00), 2.547 (4.34), 2.667 (0.91), 2.672 (2.01), 2.676 (2.79), 2.681 (1.92), 2.686 (0.96), 2.874 (0.50), 2.885 (0.50), 2.909 (1.74), 2.920 (3.89), 2.925 (1.83), 2.936 (4.07), 2.942 (3.93), 2.948 (5.21), 2.959 (7.45), 2.971 (1.46), 2.976 (3.52), 2.987 (6.90), 2.992 (3.52), 2.998 (2.01), 3.011 (1.42), 3.016 (1.97), 3.022 (2.79), 3.027 (3.15), 3.052 (4.43), 3.057 (3.20), 3.063 (2.93), 3.082 (1.23), 3.092 (1.28), 3.130 (3.89), 3.148 (4.30), 3.154 (3.38), 3.163 (1.74), 3.172 (3.57), 5.234 (0.96), 5.238 (1.01), 5.245 (2.01), 5.250 (2.01), 5.257 (1.60), 5.262 (1.28), 5.282 (1.14), 5.294 (0.96), 5.300 (2.06), 5.312 (1.65), 5.317 (1.33), 5.324 (1.01), 5.329 (1.19), 5.337 (1.37), 5.342 (1.42), 5.354 (2.33), 5.371 (2.42), 5.377 (1.78), 5.383 (2.10), 5.388 (1.97), 5.395 (1.05), 5.400 (0.91), 5.971 (1.19), 5.982 (2.51), 5.992 (1.19), 6.110 (2.33), 6.121 (5.21), 6.132 (2.61), 6.250 (1.10), 6.260 (2.42), 6.271 (1.23), 6.918 (2.83), 6.940 (2.93), 8.088 (1.19), 8.114 (1.33), 8.139 (0.69), 8.549 (3.70), 8.552 (3.52), 8.586 (0.50), 8.808 (1.05), 8.903 (1.05), 11.489 (0.87).

[2034] [α].sub.D.sup.20 (c=2.3 mg/mL, MeOH) 10.7°+/−1.46°.

Example 412

[2035] N-(3-{[(3R)-1-(2,2-Difluoroethyl)pyrrolidin-3-yl]oxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

##STR00532##

[2036] A mixture of the crude salt of tert-butyl (3R)-3-(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)-pyrrolidine-1-carboxylate with trifluoroacetic acid [Example 439] (250 mg, 75% purity, 0.39 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (125 mg, 0.58 mmol, 1.5 eq), potassium carbonate (269 mg, 1.9 mmol, 5.0 eq) and potassium iodide (6.5 mg, 0.04 mmol, 0.1 eq) in 5 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The precipitate observed was isolated by filtration. The volatile components of the collected fractions were removed in vacuo. Final purification was conducted via preparative HPLC (Method A) to give 30 mg (13% yield of theory) of the title compound.

[2037] UPLC-MS (Method 2): R.sub.t=0.90 min; MS (El.sub.pos): m/z=547 [M+H].sup.+.

[2038] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 1.216 (1.00), 1.235 (2.44), 1.254 (1.10), 1.648 (0.48), 1.845 (1.00), 1.864 (2.10), 1.878 (2.44), 1.883 (2.44), 1.900 (2.44), 1.902 (2.34), 1.919 (1.19), 2.050 (2.72), 2.085 (1.24), 2.256 (0.91), 2.275 (2.15), 2.290 (2.91), 2.309 (2.91), 2.318 (1.91), 2.323 (3.82), 2.327 (4.44), 2.331 (2.87), 2.337 (1.43), 2.343 (0.86), 2.431 (0.86), 2.449 (2.72), 2.470 (11.27), 2.523 (7.88), 2.540 (16.00), 2.581 (1.58), 2.600 (2.58), 2.623 (2.58), 2.659 (1.67), 2.665 (2.67), 2.669 (3.34), 2.674 (2.48), 2.678 (1.77), 2.680 (1.39), 2.699 (0.96), 2.718 (0.53), 2.725 (0.57), 2.799 (0.67), 2.818 (1.10), 2.838 (0.91), 2.874 (5.35), 2.914 (7.45), 2.959 (2.77), 2.983 (2.96), 2.998 (3.01), 3.025 (1.81), 4.869 (2.48), 5.989 (1.00), 6.000 (1.91), 6.011 (1.00), 6.129 (2.01), 6.139 (3.87), 6.150 (2.05), 6.268 (0.96), 6.278 (1.91), 6.289 (1.00), 7.023 (0.38), 7.046 (1.15), 7.053 (0.38), 7.188 (3.44), 7.210 (5.40), 7.216 (4.16), 7.238 (5.06), 7.296 (2.96), 7.303 (3.96), 7.306 (4.16), 7.313 (3.53), 7.319 (2.72), 7.325 (2.96), 7.329 (3.10), 7.335 (2.29), 7.349 (0.62), 7.352 (0.62), 7.359 (0.57), 7.386 (0.43), 7.571 (2.20), 7.573 (2.39), 7.597 (2.72), 7.822 (0.43), 8.464 (0.53), 8.470 (0.48), 8.576 (0.53), 8.828 (3.53), 8.904 (4.78), 9.606 (0.62), 10.333 (2.01), 11.465 (2.63).

[2039] [α].sub.D.sup.20 (c=6.1 mg/mL, DMSO): −6.1°+/−0.40°.

Example 413

N-(4-Fluoro-3-{[(3R)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2040] ##STR00533##

[2041] A mixture of the crude salt of tert-butyl (3R)-3-(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)pyrrolidine-1-carboxylate with trifluoroacetic acid [Example 439] (250 mg, 75% purity, 0.4 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (135 mg, 0.6 mmol, 1.5 eq) potassium carbonate (269 mg, 1.9 mmol, 5.0 eq) and potassium iodide (6.5 mg, 0.04 mmol, 0.1 eq) in 5 mL acetonitrile and 0.5 mL DMF was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. overnight. All volatile components were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 60 mg (27% yield of theory) of the title compound.

[2042] UPLC-MS (Method 2): R.sub.t=0.94 min; MS (El.sub.pos): m/z=565 [M+H].sup.+.

[2043] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 1.234 (0.60), 1.876 (1.03), 1.883 (1.16), 1.895 (2.01), 1.910 (2.35), 1.917 (2.31), 1.925 (1.93), 1.931 (2.35), 1.944 (1.33), 1.951 (1.20), 2.085 (3.85), 2.246 (1.20), 2.265 (2.91), 2.280 (3.98), 2.299 (3.68), 2.314 (2.70), 2.318 (2.78), 2.323 (2.40), 2.327 (2.99), 2.332 (2.78), 2.337 (1.33), 2.523 (6.59), 2.540 (5.52), 2.569 (0.47), 2.659 (1.03), 2.665 (2.01), 2.669 (2.74), 2.674 (1.93), 2.678 (1.03), 2.692 (2.10), 2.706 (2.78), 2.711 (3.94), 2.714 (3.76), 2.725 (3.47), 2.729 (4.06), 2.734 (3.17), 2.748 (2.14), 2.904 (3.64), 2.910 (3.85), 2.919 (2.99), 2.930 (5.18), 2.937 (8.86), 2.954 (3.47), 2.959 (3.85), 2.977 (1.67), 3.100 (4.71), 3.114 (5.30), 3.126 (4.11), 3.141 (3.64), 3.294 (6.67), 3.345 (16.00), 3.370 (4.96), 4.132 (0.43), 4.906 (2.05), 7.178 (1.84), 7.200 (3.29), 7.202 (3.34), 7.228 (2.78), 7.290 (2.40), 7.298 (3.38), 7.322 (2.27), 7.328 (1.71), 7.601 (1.97), 7.620 (2.05), 8.132 (0.47), 11.484 (0.94).

[2044] [α].sub.D.sup.20 (c=5.3 mg/mL, DMSO): −6.3°+/−0.29°.

Example 414

N-(4-Fluoro-3-{[(3R)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2045] ##STR00534##

[2046] A mixture of the crude salt of tert-butyl (3R)-3-(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)-pyrrolidine-1-carboxylate with trifluoroacetic acid [Example 439] (250 mg, 75% purity, 0.4 mmol, 1.0 eq), 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (156 mg, 0.6 mmol, 1.5 eq), potassium carbonate (269 mg, 1.9 mmol, 5.0 eq) and potassium iodide (6.5 mg, 0.04 mmol, 0.1 eq) was taken up in 5 mL acetonitrile. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. overnight under an atmosphere of argon. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 54 mg (22% yield of theory) of the title compound.

[2047] UPLC-MS (Method 2): R.sub.t=0.95 min; MS (El.sub.pos): m/z=579 [M+H].sup.+.

[2048] [α].sub.D.sup.20 (c=6.3 mg/mL, DMSO)−4.7°+/−0.42°.

Example 415

[2049] N-(4-Fluoro-3-{[(3S)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

##STR00535##

[2050] A mixture of the crude salt of N-{4-fluoro-3-[(3R)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 441] (200 mg, 0.4 mmol, 1.0 eq), 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (167 mg, 0.6 mmol, 1.5 eq), potassium carbonate (286 mg, 2.1 mmol, 5.0 eq) and potassium iodide (6.8 mg, 0.04 mmol, 0.1 eq) was taken up in 5 mL acetonitrile. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. overnight under an atmosphere of argon. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 48 mg (20% yield of theory) of the title compound.

[2051] UPLC-MS (Method 2): R.sub.t=0.95 min; MS (El.sub.pos): m/z=579 [M+H].sup.+.

[2052] [α].sub.D.sup.20 (c=5.8 mg/mL, DMSO) 2.8°+/−0.21°.

Example 416

[2053] N-(4-Fluoro-3-{[(35)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]oxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

##STR00536##

[2054] A mixture of the crude salt of N-{4-fluoro-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 441] (200 mg, 0.4 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (144 mg, 0.6 mmol, 1.5 eq) potassium carbonate (286 mg, 2.1 mmol, 5.0 eq) and potassium iodide (6.8 mg, 0.04 mmol, 0.1 eq) in 5 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. overnight. All volatile components were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 70 mg (27% yield of theory) of the title compound.

[2055] UPLC-MS (Method 2): R.sub.t=0.95 min; MS (El.sub.pos): m/z=565 [M+H].sup.+.

[2056] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 1.234 (0.69), 1.877 (1.02), 1.896 (2.07), 1.911 (2.43), 1.918 (2.43), 1.926 (2.00), 1.931 (2.39), 1.945 (1.38), 1.951 (1.23), 2.246 (1.20), 2.265 (2.87), 2.280 (3.95), 2.299 (3.81), 2.314 (2.65), 2.318 (2.76), 2.323 (2.10), 2.327 (2.65), 2.332 (2.50), 2.337 (1.27), 2.450 (1.20), 2.523 (6.53), 2.539 (8.38), 2.659 (0.83), 2.665 (1.67), 2.669 (2.29), 2.674 (1.56), 2.678 (0.76), 2.692 (2.07), 2.707 (2.83), 2.712 (3.95), 2.714 (3.81), 2.729 (4.10), 2.734 (3.08), 2.749 (2.10), 2.905 (3.63), 2.911 (3.92), 2.919 (3.01), 2.931 (5.26), 2.938 (9.03), 2.955 (3.56), 2.959 (3.85), 2.977 (1.74), 3.100 (4.79), 3.114 (5.26), 3.126 (4.17), 3.141 (3.77), 3.269 (0.47), 3.294 (6.39), 3.345 (16.00), 3.370 (4.64), 4.908 (2.18), 7.176 (2.10), 7.198 (3.59), 7.226 (3.05), 7.288 (2.43), 7.295 (3.41), 7.322 (1.96), 7.605 (2.14), 7.626 (2.00), 8.132 (0.40).

[2057] [α].sub.D.sup.20 (c=5.9 mg/mL, DMSO):: 4.1°+/−0.30°.

Example 417

N-(3-{[(3S)-1-(2,2-Difluoroethyl)pyrrolidin-3-yl]oxy}-4-fluorophenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2058] ##STR00537##

[2059] A mixture of the crude salt of N-{4-fluoro-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 441] (200 mg, 0.4 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (133 mg, 0.6 mmol, 1.5 eq), potassium carbonate (286 mg, 2.1 mmol, 5.0 eq) and potassium iodide (6.9 mg, 0.04 mmol, 0.1 eq) in 5 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The volatile components of the reaction mixture were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 55 mg (22% yield of theory) of the title compound.

[2060] UPLC-MS (Method 2): R.sub.t=0.93 min; MS (El.sub.pos): m/z=547 [M+H].sup.+.

[2061] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 0.852 (0.69), 1.234 (2.41), 1.354 (0.69), 1.792 (0.69), 1.807 (1.03), 1.814 (1.03), 1.827 (0.95), 1.840 (1.81), 1.848 (1.98), 1.859 (2.75), 1.861 (2.75), 1.874 (3.01), 1.877 (2.92), 1.882 (3.10), 1.896 (3.01), 1.899 (3.01), 1.916 (1.55), 1.918 (1.46), 2.171 (0.86), 2.190 (1.38), 2.205 (1.89), 2.224 (1.98), 2.239 (1.46), 2.244 (1.29), 2.254 (1.89), 2.268 (2.75), 2.273 (3.61), 2.287 (5.08), 2.292 (3.35), 2.306 (4.73), 2.318 (3.61), 2.322 (6.62), 2.327 (7.14), 2.331 (4.56), 2.337 (2.75), 2.523 (11.70), 2.540 (11.18), 2.569 (3.61), 2.589 (5.51), 2.608 (4.90), 2.610 (4.47), 2.625 (2.06), 2.627 (2.06), 2.659 (1.72), 2.665 (3.96), 2.669 (5.42), 2.674 (3.61), 2.678 (1.72), 2.774 (1.03), 2.797 (1.46), 2.832 (1.63), 2.839 (2.15), 2.850 (3.53), 2.861 (8.17), 2.865 (9.20), 2.871 (9.89), 2.879 (8.69), 2.889 (11.70), 2.900 (16.00), 2.911 (11.10), 2.927 (4.22), 2.941 (6.11), 2.952 (5.08), 2.970 (5.68), 2.986 (5.42), 2.998 (3.61), 3.012 (3.10), 3.499 (0.95), 4.725 (0.86), 4.733 (0.86), 4.740 (1.20), 4.745 (1.20), 4.752 (1.03), 4.759 (0.86), 4.878 (2.84), 5.970 (0.52), 5.981 (1.63), 5.984 (1.98), 5.994 (3.96), 6.005 (1.81), 6.031 (1.20), 6.037 (1.55), 6.039 (1.55), 6.046 (1.38), 6.052 (1.38), 6.058 (1.81), 6.061 (1.63), 6.067 (1.55), 6.109 (1.12), 6.120 (3.35), 6.124 (4.04), 6.134 (8.09), 6.145 (3.87), 6.247 (2.58), 6.253 (2.49), 6.259 (1.89), 6.265 (3.53), 6.273 (5.33), 6.284 (1.89), 6.783 (3.01), 6.804 (2.92), 6.812 (3.01), 6.834 (2.92), 7.179 (2.75), 7.201 (5.08), 7.207 (4.39), 7.229 (4.39), 7.289 (3.35), 7.296 (4.90), 7.305 (4.47), 7.322 (3.35), 7.328 (2.58), 7.588 (2.92), 7.608 (3.01), 8.891 (2.41).

[2062] [α].sub.D.sup.20 (c=5.1 mg/mL, DMSO): 4.3°+/−0.28°.

Example 418

N-(4-Fluoro-3-{[(3S)-1-(3,3,3-trifluoropropyl)piperidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2063] ##STR00538##

[2064] A mixture of the crude salt of N-{4-fluoro-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 443] (200 mg, 0.39 mmol, 1.0 eq), 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (158 mg, 0.6 mmol, 1.5 eq), potassium carbonate (270 mg, 2.0 mmol, 5.0 eq) and potassium iodide (6.5 mg, 0.04 mmol, 0.1 eq) was taken up in 4.9 mL acetonitrile. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. overnight under an atmosphere of argon. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 98 mg (39% yield of theory) of the title compound.

[2065] UPLC-MS (Method 2): R.sub.t=1.08 min; MS (El.sub.pos): m/z=607 [M+H].sup.+.

[2066] [α].sub.D.sup.20 (c=5 mg/mL, DMSO):: 0.6°+/−0.25°.

Example 419

[2067] N-(4-Fluoro-3-{[(3S)-1-(2,2,2-trifluoroethyl)piperidin-3-yl]methoxy}phenyl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

##STR00539##

[2068] A mixture of the crude salt of N-{4-fluoro-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 443] (200 mg, 0.39 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (136 mg, 0.6 mmol, 1.5 eq) potassium carbonate (271 mg, 2 mmol, 5.0 eq) and potassium iodide (6.5 mg, 0.04 mmol, 0.1 eq) in 5 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. overnight. All volatile components were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 114 mg (47% yield of theory) of the title compound.

[2069] UPLC-MS (Method 2): Rt=1.09 min; MS (El.sub.pos): m/z=593 [M+H].sup.+.

[2070] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 1.074 (1.10), 1.090 (1.98), 1.101 (2.44), 1.123 (2.61), 1.133 (2.31), 1.150 (1.32), 1.161 (1.10), 1.210 (1.02), 1.446 (1.02), 1.474 (2.20), 1.479 (2.20), 1.497 (2.11), 1.507 (2.83), 1.517 (1.76), 1.534 (1.54), 1.542 (1.56), 1.597 (2.44), 1.607 (3.62), 1.616 (3.07), 1.630 (2.14), 1.639 (2.44), 1.642 (2.14), 1.649 (1.89), 1.690 (2.77), 1.699 (2.72), 1.720 (2.63), 1.729 (2.47), 2.036 (2.52), 2.062 (2.52), 2.145 (0.58), 2.237 (3.57), 2.263 (5.43), 2.288 (3.40), 2.300 (2.63), 2.304 (3.92), 2.310 (3.54), 2.313 (2.83), 2.332 (4.20), 2.334 (4.06), 2.339 (4.09), 2.359 (2.44), 2.368 (2.03), 2.458 (16.00), 2.556 (1.89), 2.637 (0.77), 2.642 (1.43), 2.646 (1.84), 2.651 (1.34), 2.656 (0.71), 2.795 (3.62), 2.822 (3.51), 2.989 (3.49), 2.994 (3.38), 3.012 (3.21), 3.017 (3.29), 3.098 (0.85), 3.111 (2.66), 3.117 (2.72), 3.136 (7.33), 3.143 (7.27), 3.162 (7.30), 3.168 (7.25), 3.181 (1.95), 3.188 (2.74), 3.194 (2.58), 3.233 (0.47), 3.845 (1.95), 3.868 (5.16), 3.887 (5.60), 3.889 (5.54), 3.894 (5.74), 3.908 (5.30), 3.918 (2.88), 3.932 (2.09), 7.154 (3.13), 7.176 (6.23), 7.182 (3.68), 7.203 (6.20), 7.221 (3.46), 7.228 (4.42), 7.232 (4.53), 7.238 (3.98), 7.243 (2.88), 7.249 (2.61), 7.255 (2.17), 7.260 (1.87), 7.659 (2.72), 7.681 (2.91), 8.800 (3.18), 8.874 (4.75), 11.437 (1.56).

[2071] [α].sub.D.sup.20 (c=5.4 mg/mL, DMSO): −5.4°+/−0.25°.

Example 420

3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{2-[1-(3,3,3-trifluoro-propyl)piperidin-4-yl]ethyl}pyridin-3-yl)-1,2-thiazole-4-carboxamide

[2072] ##STR00540##

[2073] A mixture of the crude salt of N-{4-fluoro-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with hydrochloric acid [Example 445] (109 mg, 0.22 mmol, 1.0 eq), 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (89 mg, 0.33 mmol, 1.5 eq), potassium carbonate (153 mg, 1.1 mmol, 5.0 eq) and potassium iodide (3.7 mg, 0.02 mmol, 0.1 eq) was taken up in 20 mL acetonitrile. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h under an atmosphere of argon. Another 0.5 eq 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (30 mg, 0.11 mmol) were added and the reaction mixture was stirred for another 5 h at 70° C. The the reaction mixture was allow to cool down to rt and was stirred overnight at rt. The reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 12 mg (8% yield of theory) of the title compound.

[2074] UPLC-MS (Method 2): R.sub.t=0.98 min; MS (El.sub.pos): m/z=588 [M+H].sup.+.

[2075] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 0.969 (0.58), 1.109 (10.55), 1.146 (0.55), 1.226 (1.22), 1.232 (1.57), 1.297 (1.51), 1.350 (1.12), 1.391 (0.90), 1.425 (0.74), 1.629 (2.73), 1.648 (2.73), 1.854 (1.70), 2.318 (0.93), 2.323 (1.73), 2.327 (2.28), 2.332 (1.67), 2.337 (0.93), 2.523 (15.65), 2.540 (16.00), 2.659 (2.05), 2.665 (2.92), 2.669 (3.46), 2.674 (2.85), 2.678 (2.15), 2.716 (4.91), 2.732 (5.55), 2.735 (6.16), 2.739 (5.77), 2.755 (4.36), 3.507 (0.48), 4.177 (0.48), 7.239 (2.89), 7.260 (2.98), 8.146 (1.51), 8.168 (1.41), 8.836 (4.26), 8.843 (3.82).

Example 421

3-Methyl-N-(6-{[(3R)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2076] ##STR00541##

[2077] A mixture of the crude salt of 3-methyl-N-{6-[(3R)-pyrrolidin-3-yloxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with hydrochloric acid [Example 447] (150 mg, 87% purity, 0.3 mmol, 1.0 eq), 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS-RN: 6226-25-1) (98 mg, 0.4 mmol, 1.5 eq), potassium carbonate (195 mg, 1.4 mmol, 5.0 eq) and potassium iodide (4.7 mg, 0.03 mmol, 0.1 eq) in 7.5 mL acetonitrile and 0.5 mL DMF was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. All volatile components were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 62 mg (36% yield of theory) of the title compound.

[2078] UPLC-MS (Method 2): R.sub.t=0.93 min; MS (El.sub.pos): m/z=548 [M+H].sup.+.

[2079] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 1.652 (1.54), 1.811 (0.97), 1.830 (1.83), 1.845 (2.31), 1.852 (2.27), 1.865 (2.19), 1.886 (1.10), 2.227 (1.22), 2.246 (2.88), 2.261 (4.14), 2.280 (3.94), 2.295 (2.76), 2.314 (1.50), 2.322 (2.03), 2.327 (2.60), 2.331 (1.91), 2.336 (0.93), 2.479 (16.00), 2.523 (9.18), 2.539 (4.18), 2.652 (2.07), 2.664 (3.13), 2.669 (5.69), 2.674 (5.44), 2.690 (4.14), 2.709 (2.03), 2.818 (3.74), 2.826 (3.57), 2.845 (4.47), 2.852 (4.39), 2.905 (2.07), 2.924 (4.06), 2.940 (3.45), 2.943 (3.57), 2.962 (1.58), 3.077 (4.10), 3.092 (4.67), 3.104 (3.90), 3.119 (3.57), 3.263 (5.04), 3.289 (15.19), 3.340 (5.77), 5.329 (1.42), 5.337 (2.60), 5.344 (3.17), 5.352 (3.90), 5.363 (3.21), 5.371 (2.72), 5.378 (1.42), 6.853 (8.61), 6.875 (8.89), 7.373 (1.06), 7.389 (1.66), 7.400 (1.26), 8.045 (2.40), 8.068 (2.44), 8.505 (4.95), 8.509 (5.28), 8.835 (8.37), 8.912 (12.91), 10.307 (3.74), 11.446 (4.10).

[2080] [α].sub.D.sup.20 (c=7.8 mg/mL, DMSO): : 9.4°+/−0.12°.

Example 422

3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3R)-1-(3,3,3-trifluoropropyl)piperidin-3-yl]methoxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide

[2081] ##STR00542##

[2082] A mixture of the crude salt of 3-methyl-N-{6-[(3R)-piperidin-3-ylmethoxy]pyridin-3-yl}-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with hydrochloric acid [Example 449] (226 mg, 77% purity, 0.35 mmol, 1.0 eq), 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (142 mg, 0.5 mmol, 1.5 eq), potassium carbonate (244 mg, 1.8 mmol, 5.0 eq) and potassium iodide (5.8 mg, 0.04 mmol, 0.1 eq) in 9 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. Another 0.5 eq 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (47 mg, 0.17 mmol) were added and the reaction mixture was stirred for another 24 h at 70° C. All volatile components were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 62 mg (27% yield of theory) of the title compound.

[2083] UPLC-MS (Method 2): R.sub.t=1.02 min; MS (El.sub.pos): m/z=590 [M+H].sup.+.

[2084] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 1.740 (2.73), 1.776 (1.80), 2.317 (1.51), 2.322 (2.79), 2.327 (3.84), 2.331 (2.91), 2.336 (1.57), 2.523 (16.00), 2.537 (15.01), 2.539 (15.13), 2.660 (1.92), 2.664 (3.14), 2.669 (4.25), 2.674 (3.20), 2.679 (1.86), 4.071 (1.63), 4.098 (2.91), 4.115 (2.56), 4.158 (2.27), 4.172 (2.39), 4.200 (1.11), 6.819 (3.37), 6.841 (3.37), 8.132 (1.92), 8.541 (4.60).

[2085] [α].sub.D.sup.20 (c=5.8 mg/mL, DMSO): 5.8°+/−0.18°.

Example 423

3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[(3R)-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide

[2086] ##STR00543##

[2087] A mixture of the crude salt of 3-methyl-N-{6-[(3R)-pyrrolidin-3-yloxy]pyridin-3-yl}-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with hydrochloric acid [Example 447] (150 mg, 87% purity, 0.3 mmol, 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (113 mg, 0.4 mmol, 1.5 eq), potassium carbonate (195 mg, 1.4 mmol, 5.0 eq) and potassium iodide (4.7 mg, 0.03 mmol, 0.1 eq) in 7.4 mL acetonitrile and 0.5 mL DMF was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. Another 0.5 eq 3,3,3-trifluoropropyl 4-methylbenzenesulfonate (CAS-RN: 2342-67-8) (38 mg, 0.14 mmol) were added and the reaction mixture was stirred for another 5 h at 70° C. All volatile components were removed in vacuo. Final purification was conducted via preparative HPLC (Method B) to give 38 mg (22% yield of theory) of the title compound.

[2088] UPLC-MS (Method 2): R.sub.t=0.93 min; MS (El.sub.pos): m/z=562 [M+H].sup.+.

[2089] .sup.1H-NMR (300 MHz, DMSO-d.sub.6) delta [ppm]: 2.264 (0.80), 2.270 (1.13), 2.277 (1.13), 2.302 (0.96), 2.327 (0.96), 2.348 (0.71), 2.530 (16.00), 2.540 (9.43), 2.579 (3.03), 2.720 (1.17), 2.726 (1.46), 2.733 (1.41), 5.376 (1.26), 6.802 (2.43), 6.831 (2.51), 8.133 (1.24), 8.155 (0.98), 8.539 (2.94), 8.548 (2.84).

[2090] [α].sub.D.sup.20 (c=5.7 mg/mL, DMSO): 10.5°+/−0.27°.

Example 424

N-(6-{[(3R,4S)-1-Ethyl-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2091] ##STR00544##

[2092] A mixture of the crude salt of N-(6-{[(3R,4S)-3-fluoropiperidin-4-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 143] (126 mg, 0.25 mmol, 1.0 eq), ethyl 4-methylbenzenesulfonate (CAS-RN: 80-40-0) (51 mg, 0.25 mmol, 1 eq), potassium carbonate (175 mg, 1.26 mmol, 5.0 eq) and potassium iodide (4 mg, 0.03 mmol, 0.1 eq) was taken up in 6 mL acetonitrile. Afterwards the reaction mixture was stirred at an environmental temperature of 70° C. for 6 h under an atmosphere of argon. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo and the final purification was conducted via preparative HPLC (Method B) to give 46 mg (33% yield of theory) of the title compound.

[2093] UPLC-MS (Method 2): R.sub.t=0.85 min; MS (EI.sub.pos): m/z=526 [M+H].sup.+.

[2094] 1H-NMR (400 MHz, THF) delta [ppm]: 0.000 (7.24), 1.042 (2.32), 1.059 (4.87), 1.077 (2.49), 1.726 (15.81), 2.405 (0.63), 2.423 (1.83), 2.441 (1.81), 2.455 (1.23), 2.459 (0.72), 2.664 (10.03), 3.577 (14.31), 3.580 (16.00), 3.582 (14.43), 6.763 (1.30), 6.785 (1.35), 8.086 (0.83), 8.093 (0.88), 8.109 (0.85), 8.115 (0.87), 8.450 (1.32), 8.456 (1.31), 8.557 (1.23), 8.561 (1.31), 8.638 (1.36).

Example 425

3-Methyl-N-(6-{2-[(trifluoroacetyl)amino]ethoxy}pyridin-3-yl)-5-{[5-(trifluoro-methyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2095] ##STR00545##

[2096] In the synthesis of N-(6-{2-[(2,2-difluoroethyl)amino]ethoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide [Example 305] the title coumpound was collected as a by-product. Starting from a mixture of the crude salt of N-[6-(2-aminoethoxy)pyridin-3-yl]-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 197] (147 mg, purity 36%, 0.12 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (37 mg, 0.18 mmol, 1.5 eq), potassium carbonate (82 mg, 0.6 mmol, 5.0 eq) and potassium iodide (2 mg, 0.01 mmol, 0.1 eq) in 3 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The volatile components of the reaction mixture were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 25 g cartridge: dichloromethane/ethanol). Final purification was conducted via preparative HPLC to give 10 mg (15% yield of theory) of the title compound.

[2097] UPLC-MS (Method 2): R.sub.t=0.83 min; MS (El.sub.pos): m/z=536 [M+H].sup.+.

[2098] 1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 1.109 (5.76), 1.225 (0.82), 1.234 (1.12), 1.257 (0.61), 2.318 (0.92), 2.322 (1.89), 2.327 (2.75), 2.331 (2.04), 2.337 (0.92), 2.480 (10.70), 2.523 (16.00), 2.539 (8.31), 2.659 (1.17), 2.665 (2.24), 2.669 (3.01), 2.673 (2.19), 2.678 (1.12), 2.757 (0.71), 3.379 (1.94), 3.392 (1.32), 3.567 (1.94), 3.581 (5.30), 3.596 (5.40), 3.609 (2.09), 4.363 (4.69), 4.377 (8.76), 4.391 (4.43), 6.856 (3.46), 6.878 (3.57), 8.058 (1.12), 8.082 (1.22), 8.525 (2.34), 8.529 (2.14), 8.833 (3.57), 8.913 (3.06), 9.618 (1.27), 9.631 (2.24), 9.646 (1.22), 10.339 (1.99), 11.473 (2.19).

Example 426

3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[1-(3,3,3-trifluoro-propyl)piperidin-4-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide, Salt with Hydrochloric Acid

[2099] ##STR00546##

[2100] 3-Methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-N-(6-{[1-(3,3,3-trifluoropropyl)-piperidin-4-yl]oxy}pyridin-3-yl)-1,2-thiazole-4-carboxamide [Example 10] (84 mg, 0.15 mmol, 1.0 eq) was dissolved in 1 mL dioxane and 37 μL hydrogen chloride solution (4.0 M) in dioxane (CAS-RN: 7647-01-0) (0.15 mmol, 1 eq) was added to the solution. After 1 h another 1 eq hydrogen chloride solution (4.0 M) in dioxane (CAS-RN: 7647-01-0) (37 μL, 0.15 mmol, 1 eq) were put into the reaction mixture. The mixture was stirred for 3 h, n-hexane was added and the precipitate was isolated by filtration and dryed in vacuo to give 84 mg (85% yield of theory) of the title compound.

[2101] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 1.960 (0.50), 1.991 (0.57), 2.145 (1.25), 2.185 (0.57), 2.279 (0.77), 2.317 (0.87), 2.322 (1.02), 2.327 (1.04), 2.331 (0.76), 2.475 (3.39), 2.478 (4.22), 2.523 (2.62), 2.539 (0.80), 2.664 (0.59), 2.669 (0.80), 2.674 (0.59), 2.994 (0.98), 3.020 (0.63), 3.162 (0.77), 3.192 (1.09), 3.222 (0.77), 3.325 (0.50), 3.366 (0.71), 3.385 (0.77), 3.398 (0.71), 3.424 (0.62), 3.462 (0.80), 3.494 (0.62), 3.565 (16.00), 3.609 (0.87), 3.640 (0.74), 3.922 (2.07), 5.136 (0.46), 5.273 (0.71), 6.873 (1.26), 6.895 (1.36), 6.906 (1.15), 6.928 (1.08), 8.090 (0.42), 8.545 (1.43), 8.838 (1.43), 8.925 (2.09), 10.405 (0.76), 11.488 (0.97).

Example 427

N-(4-Fluoro-3-{3-[(trifluoroacetyl)amino]propoxy}phenyl)-3-methyl-5-{[5-(trifluoro-methyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2102] ##STR00547##

[2103] Starting from a mixture of the crude salt of N-[3-(3-aminopropoxy)-4-fluorophenyl]-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid (120 mg, 0.26 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (82 mg, 0.38 mmol, 1.5 eq), potassium carbonate (177 mg, 1.23 mmol, 5.0 eq) and potassium iodide (4.2 mg, 0.03 mmol, 0.1 eq) in 3 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The volatile components of the reaction mixture were removed in vacuo. Purification was conducted via preparative HPLC (Method B) to give 29 mg (19% yield of theory) of the title compound.

[2104] UPLC-MS (Method 2): R.sub.t=1.35 min; MS (EI.sub.pos): m/z=567 [M+H].sup.+.

[2105] 1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 0.833 (0.75), 0.851 (1.45), 1.108 (0.81), 1.232 (5.74), 1.297 (0.75), 1.907 (0.87), 1.923 (1.16), 1.939 (0.87), 1.971 (1.97), 1.988 (6.26), 2.004 (9.16), 2.020 (5.97), 2.036 (1.91), 2.085 (1.51), 2.322 (2.43), 2.327 (3.25), 2.332 (2.32), 2.523 (16.00), 2.660 (1.28), 2.664 (2.32), 2.669 (3.30), 2.674 (2.49), 3.188 (1.16), 3.204 (1.10), 3.220 (0.64), 3.367 (3.71), 3.385 (8.41), 3.400 (8.23), 3.417 (3.13), 4.059 (4.58), 4.076 (7.01), 4.091 (3.88), 4.190 (0.64), 4.229 (1.10), 4.237 (1.16), 6.201 (0.64), 6.534 (0.58), 7.178 (1.68), 7.201 (3.54), 7.226 (3.36), 7.247 (4.29), 7.273 (1.80), 7.606 (0.64), 7.717 (2.14), 8.132 (1.86), 9.509 (2.20), 9.525 (4.06), 9.540 (2.14).

Example 428

3-Methyl-N-(6-{3-[(trifluoroacetyl)amino]propoxy}pyridin-3-yl)-5-{[5-(trifluoro-methyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2106] ##STR00548##

[2107] In the synthesis of N-(6-{3-[(2,2-difluoroethyl)amino]propoxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide [Example 293] the title coumpound was collected as a by-product. Starting from a mixture of the crude salt of N-[6-(3-aminopropoxy)pyridin-3-yl]-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 293] (80 mg, 0.18 mmol, 1.0 eq), 2,2-difluoroethyl trifluoromethanesulfonate (CAS-RN: 74427-22-8) (57 mg, 0.27 mmol, 1.5 eq), potassium carbonate (122 mg, 0.89 mmol, 5.0 eq) and potassium iodide (3 mg, 0.02 mmol, 0.1 eq) in 4.6 mL acetonitrile was placed in a microwave vial that was flushed with argon. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 70° C. for 17 h. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1). The volatile components of the reaction mixture were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 25 g cartridge: dichloromethane/ethanol). Final purification was conducted via preparative HPLC to give 20 mg (21% yield of theory) of the title compound.

[2108] UPLC-MS (Method 2): R.sub.t=0.84 min; MS (EI.sub.pos): m/z=549 [M+H].sup.+.

[2109] .sup.1H-NMR (400 MHz, CHLOROFORM-d) delta [ppm]: 1.182 (0.90), 1.989 (0.53), 2.005 (0.77), 2.020 (0.60), 2.142 (13.88), 2.147 (15.65), 2.149 (16.00), 2.753 (3.48), 3.450 (0.70), 3.465 (0.71), 4.357 (0.76), 4.371 (1.38), 4.386 (0.79), 8.667 (0.85), 8.669 (0.94).

Example 429

tert-Butyl methyl{2-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]ethyl}carbannate

[2110] ##STR00549##

[2111] A mixture of tert-butyl {2-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]ethyl}methylcarbannate [Intermediate 87] (355 mg, 0.9 mmol, 1.2 eq), 2-chloro-5-(trifluoromethyl)pyrazine [CAS-RN: 799557-87-2] (133 mg, 0.7 mmol, 1.0 eq) and cesium carbonate (544 mg, 1.7 mmol, 2.3 eq) in 21 mL dioxane/DMF (6/1) was placed in a round bottom flask that was flushed with argon. Then, palladium(II) acetate (16 mg, 0.07 mmol, 0.1 eq) and Xantphos (42 mg, 0.07 mmol, 0.1 eq) were added. Afterwards the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 25 g cartridge: dichloromethane/ethanol). Final purification was conducted via preparative HPLC to give 230 mg (52% yield of theory) of the title compound.

[2112] UPLC-MS (Method 2): Rt=1.01 min; MS (El.sub.neg): m/z=554 [M+H].sup.+.

[2113] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 1.347 (16.00), 1.390 (9.43), 1.393 (8.79), 2.317 (0.95), 2.322 (2.28), 2.327 (3.13), 2.332 (2.23), 2.336 (1.06), 2.480 (11.92), 2.523 (8.90), 2.660 (1.06), 2.665 (2.28), 2.669 (3.23), 2.674 (2.28), 2.679 (1.06), 2.832 (6.30), 2.861 (3.60), 3.519 (2.65), 3.536 (5.19), 3.551 (2.81), 4.378 (3.97), 6.842 (3.39), 6.865 (3.44), 6.938 (0.48), 7.194 (0.42), 8.055 (1.54), 8.079 (1.48), 8.517 (3.18), 8.838 (7.10), 8.910 (6.73), 10.309 (2.60), 11.460 (3.02).

Example 430

tert-Butyl methyl{2-[(5-{[(3-methyl-5-{[6-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]ethyl}carbannate

[2114] ##STR00550##

[2115] A mixture of tert-butyl {2-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]ethyl}methylcarbannate [Intermediate 87] (355 mg, 0.9 mmol, 1.2 eq), 2-iodo-6-(trifluoromethyl)pyrazine (CAS-RN: 141492-94-6) (199 mg, 0.7 mmol, 1.0 eq) and cesium carbonate (544 mg, 1.7 mmol, 2.3 eq) in 21 mL dioxane/DMF (6/1) was placed in a round bottom flask that was flushed with argon. Then, palladium(II) acetate (16 mg, 0.07 mmol, 0.1 eq) and Xantphos (42 mg, 0.07 mmol, 0.1 eq) were added. Afterwards the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 25 g cartridge: dichloromethane/ethanol). Final purification was conducted via preparative HPLC to give 168 mg (42% yield of theory) of the title compound.

[2116] UPLC-MS (Method 2): Rt=0.95 min; MS (El.sub.neg): m/z=554 [M+H].sup.+.

[2117] .sup.1H-NMR (300 MHz, DMSO-d.sub.6) delta [ppm]: 1.350 (16.00), 1.388 (9.49), 2.270 (0.99), 2.276 (0.77), 2.525 (7.00), 2.720 (0.81), 2.727 (1.01), 2.732 (0.77), 2.837 (7.50), 3.515 (2.87), 3.534 (5.37), 3.553 (3.04), 4.376 (4.15), 4.395 (2.37), 6.838 (3.50), 6.867 (3.62), 8.047 (1.70), 8.080 (1.73), 8.514 (3.33), 8.518 (3.21), 8.651 (4.45), 9.009 (5.96), 10.281 (3.39), 11.412 (3.72).

Example 431

N-[3-Fluoro-4-(piperidin-4-yloxy)phenyl]-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide

[2118] ##STR00551##

[2119] tert-butyl 4-(2-fluoro-4-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)piperidine-1-carboxylate [Example 217] (480 mg, 0.8 mmol, 1.0 eq) was suspended in 15.5 mL dioxane and 1.2 mL trifluoro acetic acid were added (16 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 50 g KP cartridge: dichloromethane/ethanol). Final purification was conducted via preparative HPLC to give 395 mg (94% yield of theory) of the title compound.

[2120] UPLC-MS (Method 2): R.sub.t=0.82 min; MS (EI.sub.pos): m/z=497 [M+H].sup.+.

[2121] .sup.1H-NMR (300 MHz, DMSO-d.sub.6) delta [ppm]: 0.852 (1.02), 1.233 (3.48), 1.822 (3.99), 1.854 (4.63), 1.869 (4.07), 1.894 (2.08), 2.006 (1.06), 2.045 (4.03), 2.117 (2.89), 2.270 (2.93), 2.459 (14.05), 2.525 (16.00), 2.726 (2.84), 2.889 (0.76), 4.569 (3.69), 7.249 (2.84), 7.279 (6.41), 7.310 (4.20), 7.411 (4.41), 7.441 (3.14), 7.796 (2.55), 7.838 (2.50), 8.820 (9.25), 8.912 (8.49), 10.418 (2.63), 11.466 (3.01).

Example 432

3-Methyl-5-(quinoxalin-2-ylamino)-N-{3-[(trifluoroacetyl)amino]phenyl}-1,2-thiazole-4-carboxamide

[2122] ##STR00552##

[2123] To a mixture of the crude salt of N-(3-aminophenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide with trifluoroacetic acid [Example 450] (250 mg, 0.7 mmol, 1.0 eq) and tert-butyl 3-(chlorosulfonyl)azetidine-1-carboxylate (CAS-RN: 1310732-18-3) (340 mg, 1.3 mmol, 2 eq) in 10 mL dichloromethane were 0.4 mL of pyridine (4.7 mmol, 7 eq) added and the reaction mixture was stirred at an room temperature overnight. The reaction mixture was diluted in dichloromethane and ethanol (9/1). The volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera) to give 210 mg (60% yield of theory) of the title compound.

[2124] UPLC-MS (Method 1): R.sub.t=1.27 min; MS (El.sub.pos): m/z=473 [M+H].sup.+.

[2125] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: -0.008 (2.34), 0.009 (2.47), 0.855 (0.72), 1.160 (2.34), 1.178 (5.30), 1.196 (2.83), 1.207 (1.57), 1.235 (3.87), 1.261 (1.21), 1.299 (0.67), 1.368 (16.00), 1.384 (1.03), 1.910 (0.72), 1.988 (4.27), 2.321 (0.76), 2.326 (1.62), 2.331 (2.38), 2.335 (1.66), 2.340 (0.76), 2.527 (10.20), 2.593 (0.76), 2.664 (0.67), 2.669 (1.66), 2.673 (2.25), 2.678 (1.62), 2.682 (0.85), 3.369 (1.57), 3.384 (0.90), 3.390 (0.72), 4.022 (0.90), 4.040 (1.03), 7.375 (1.93), 7.395 (5.39), 7.414 (4.99), 7.428 (3.73), 7.449 (1.62), 7.611 (3.87), 7.631 (5.08), 7.652 (2.11), 7.769 (1.84), 7.773 (1.89), 7.791 (3.55), 7.807 (1.93), 7.811 (1.93), 7.974 (3.24), 7.983 (4.31), 7.987 (4.36), 7.993 (3.10), 8.003 (3.96), 8.254 (4.18), 8.324 (4.63), 9.036 (7.46), 10.447 (4.13), 11.361 (6.07), 11.363 (6.07), 11.369 (5.53).

Example 433

5-[(5-Cyanopyridin-2-yl)amino]-N-{6-[(3,4-difluorophenyl)amino]pyridin-3-yl}-3-methyl-1,2-thiazole-4-carboxamide

[2126] ##STR00553##

[2127] A mixture of 5-amino-N-{6-[(3,4-difluorophenyl)amino]pyridin-3-yl}-3-methyl-1,2-thiazole-4-carboxamide [Intermediate 88] (106 mg, 0.29 mmol, 1.2 eq), 6-chloropyridine-3-carbonitrile (CAS-RN: 33252-28-7) (34 mg, 0.24 mmol, 1.0 eq) and cesium carbonate (183 mg, 0.56 mmol, 2.3 eq) in 2.5 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (5.5 mg, 0.24 mmol, 0.1 eq) and Xantphos (14 mg, 0.24 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. Final purification of this material was achieved via preparative MPLC (Biotage Isolera: 11 g NH cartridge, dichloromethane/eethanol) to give 85 mg (68% yield of theory) of the title compound.

[2128] UPLC-MS (Method 2): Rt=0.92 min; MS (El.sub.pos): m/z=464 [M+H].sup.+.

[2129] .sup.1H-NMR (300 MHz, DMSO-d.sub.6) delta [ppm]: 1.055 (0.65), 2.270 (0.43), 2.466 (16.00), 2.720 (0.41), 2.726 (0.51), 6.854 (3.73), 6.884 (3.85), 7.265 (3.27), 7.272 (3.40), 7.279 (2.47), 7.287 (4.63), 7.294 (4.35), 7.319 (1.94), 7.349 (0.55), 7.436 (2.90), 7.468 (3.14), 7.932 (1.25), 7.956 (1.53), 7.976 (2.74), 8.000 (2.58), 8.008 (2.48), 8.113 (2.81), 8.120 (2.81), 8.142 (2.51), 8.150 (2.59), 8.523 (2.94), 8.527 (3.02), 8.534 (2.74), 8.867 (3.40), 8.873 (3.66), 8.876 (3.56), 9.254 (4.99), 10.186 (4.28), 11.091 (4.16).

Example 434

tert-Butyl methyl(2-{[5-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)pyridin-2-yl]amino}ethyl)carbamate

[2130] ##STR00554##

[2131] A mixture of tert-butyl {2-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)amino]ethyl}methylcarbamate [Intermediate 89] (214 mg, 0.53 mmol, 1.2 eq), 2-chloroquinoxaline (CAS-RN: 1448-87-9) (72 mg, 0.44 mmol, 1.0 eq) and cesium carbonate (329 mg, 1 mmol, 2.3 eq) in 4.5 mL dioxane/DMF (5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (10 mg, 0.04 mmol, 0.1 eq) and Xantphos (25 mg, 0.04 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. The volatile components of the reaction mixture were removed in vacuo. The final purification of this material was achieved via preparative MPLC (Biotage Isolera: 11 g NH cartridge, dichloromethane/methanol) to give 187 mg (80% yield of theory) of the title compound.

[2132] UPLC-MS (Method 2): Rt=0.88 min; MS (El.sub.pos): m/z=535 [M+H].sup.+.

[2133] .sup.1H-NMR (400 MHz, CHLOROFORM-d) delta [ppm]: 1.487 (16.00), 1.701 (0.50), 2.853 (3.91), 2.922 (3.40), 3.514 (1.29), 5.307 (2.07), 7.550 (0.61), 7.614 (0.52), 7.735 (0.47), 7.739 (0.44), 7.757 (0.60), 8.029 (0.64), 8.032 (0.57), 8.050 (1.27), 8.069 (0.62), 8.163 (0.68), 8.170 (0.66), 8.677 (1.40), 12.138 (0.51).

Example 435

[2134] N-(6-Acetamidopyridin-3-yl)-5-[(5-cyanopyridin-2-yl)amino]-3-methyl-1,2-thiazole-4-carboxamide

##STR00555##

[2135] A mixture of N-(6-acetamidopyridin-3-yl)-5-amino-3-methyl-1,2-thiazole-4-carboxamide [Intermediate 90] (120 mg, 0.41 mmol, 1.2 eq), 6-chloropyridine-3-carbonitrile (CAS-RN: 33252-28-7) (48 mg, 0.34 mmol, 1.0 eq) and cesium carbonate (257 mg, 0.79 mmol, 2.3 eq) in 3.5 mL dioxane/DMF (6/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (8 mg, 0.03 mmol, 0.1 eq) and Xantphos (20 mg, 0.03 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. All volatile components were removed in vacuo and the residue was partitioned between dichloromethane/2-propanol (4:1) and water. The combined organic phases were washed with brine and dryed by the use of a Whatman filter. The volatile components of the organic phase were removed in vacuo). Final purification was conducted via preparative HPLC (Method B) to give 5 mg (3% yield of theory) of the title compound.

[2136] UPLC-MS (Method 2): Rt=0.62 min; MS (El.sub.pos): m/z=394 [M+H].sup.+.

[2137] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) delta [ppm]: 1.235 (0.62), 2.073 (1.33), 2.084 (16.00), 2.144 (1.01), 2.214 (1.03), 2.236 (0.42), 2.322 (0.59), 2.327 (0.78), 2.332 (0.57), 2.404 (0.42), 2.460 (10.81), 2.523 (2.26), 2.540 (0.99), 2.648 (1.07), 2.664 (0.56), 2.669 (0.77), 2.674 (0.55), 6.671 (0.90), 6.696 (0.92), 7.436 (1.77), 7.458 (1.88), 7.794 (0.82), 7.801 (0.82), 7.818 (0.79), 7.825 (0.82), 8.026 (1.03), 8.028 (1.04), 8.047 (1.14), 8.049 (1.12), 8.080 (4.04), 8.118 (1.45), 8.124 (1.45), 8.140 (1.33), 8.146 (1.36), 8.551 (0.81), 8.556 (0.93), 8.572 (0.82), 8.578 (0.99), 8.685 (1.42), 8.689 (2.16), 8.693 (1.60), 8.780 (0.92), 8.786 (0.99), 8.871 (2.19), 8.877 (2.23), 9.141 (0.90), 9.143 (0.96), 9.146 (0.96), 10.342 (2.33), 10.463 (2.30), 11.093 (2.26).

Example 436

tert-Butyl (3S,4R)-3-fluoro-4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]pyrrolidine-1-carboxylate

[2138] ##STR00556##

[2139] A mixture of tert-butyl (3R,4S)-3-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]-4-fluoropyrrolidine-1-carboxylate [Intermediate 66] (290 mg, 0.7 mmol, 1.0 eq), 2-chloro-5-(trifluoromethyl)pyrazine [CAS-RN: 799557-87-2] (121 mg, 0.7 mmol, 1.0 eq) and cesium carbonate (497 mg, 1.5 mmol, 2.3 eq) in 6.7 mL dioxane/DMF (5.5/1) was placed in a microwave vial that was flushed with argon. Then, palladium(II) acetate (15 mg, 0.07 mmol, 0.1 eq) and Xantphos (38 mg, 0.07 mmol, 0.1 eq) were added. Afterwards, the vial was sealed and the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 25 g SNAP cartridge: dicloromethane.fwdarw.dichloromethane/ethanol 90:10) to give 385 mg (99% yield of the theory) of the title compound.

[2140] UPLC-MS (Method 2): Rt=0.93 min; MS (El.sub.pos): m/z=584 [M+H].sup.+.

Example 437

N-(6-{[(3R,4S)-4-Fluoropyrrolidin-3-yl]oxy}pyridin-3-yl)-3-methyl-5-{[5-(trifluoro-methyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with hydrochloric acid

[2141] ##STR00557##

[2142] tert-butyl (3S,4R)-3-fluoro-4-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]-amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]pyrrolidine-1-carboxylate [Example 436] (385 mg, 0.7 mmol, 1.0 eq) was suspended in 28 mL dioxane and 3.3 mL hydrogen chloride solution (4.0 M) in dioxane (CAS-RN: 7647-01-0) (13.2 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature for 72 h in a sealed vial. Afterwards all volatile components were removed in vacuo. The crude hydrochloride acid salt of the title compound was isolated by filtration (365 mg) and used for further derivatization without further purification.

[2143] UPLC-MS (Method 2): R.sub.t=0.86 min; MS (El.sub.pos): m/z=480 [M+H].sup.+.

Example 438

tert-Butyl (3R)-3-(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)pyrrolidine-1-carboxylate

[2144] ##STR00558##

[2145] A mixture of tert-butyl (3R)-3-(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-2-fluorophenoxy)pyrrolidine-1-carboxylate [Intermediate 69] (2.3 g, 5.3 mmol, 1.2 eq), 2-chloro-5-(trifluoromethyl)pyrazine [CAS-RN: 799557-87-2] (801 mg, 4.4 mmol, 1.0 eq) and cesium carbonate (3.3 g, 10.1 mmol, 2.3 eq) in 44 mL dioxane/DMF (5/1) was placed in a round bottom flusk that was flushed with argon. Then, palladium(II) acetate (99 mg, 0.4 mmol, 0.1 eq) and Xantphos (254 mg, 0.4 mmol, 0.1 eq) were added. Afterwards the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 100 g KP cartridge: n-hexane/ethyl acetate) to give 1.7 g (66% yield of the theory) of the title compound.

[2146] UPLC-MS (Method 2): Rt=0.96 min; MS (El.sub.pos): m/z=583 [M+H].sup.+.

Example 439

N-{4-Fluoro-3-[(3R)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoro acetic acid

[2147] ##STR00559##

[2148] tert-butyl (3R)-3-(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)pyrrolidine-1-carboxylate [Example 438] (1.7 g, 2.9 mmol, 1.0 eq) was suspended in 56 mL dioxane and 4.5 mL trifluoro acetic acid were added. The reaction mixture was stirred at room temperature overnight in a sealed vial. Afterwards all volatile components were removed in vacuo. The crude trifluoro acetic acid salt of the title compound was isolated (1.9 g) and used for further derivatization without further purification.

[2149] UPLC-MS (Method 2): R.sub.t=0.82 min; MS (El.sub.pos): m/z=483 [M+H].sup.+.

Example 440

tert-Butyl (3R)-3-(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)pyrrolidine-1-carboxylate

[2150] ##STR00560##

[2151] A mixture of tert-butyl (3S)-3-(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-2-fluorophenoxy)pyrrolidine-1-carboxylate [Intermediate 72] (2.5 g, 5.7 mmol, 1.2 eq), 2-chloro-5-(trifluoromethyl)pyrazine [CAS-RN: 799557-87-2] (871 mg, 4.7 mmol, 1.0 eq) and cesium carbonate (3.6 g, 11 mmol, 2.3 eq) in 48 mL dioxane/DMF (6/1) was placed in a round bottom flask that was flushed with argon. Then, palladium(II) acetate (107 mg, 0.5 mmol, 0.1 eq) and Xantphos (276 mg, 0.5 mmol, 0.1 eq) were added. Afterwards the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 100 g KP cartridge: n-hexane/ethyl acetate) to give 1.8 g (65% yield of the theory) of the title compound.

[2152] UPLC-MS (Method 2): Rt=0.98 min; MS (El.sub.pos): m/z=583 [M+H].sup.+.

Example 441

N-{4-Fluoro-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoro acetic acid

[2153] ##STR00561##

[2154] tert-butyl (3R)-3-(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)pyrrolidine-1-carboxylate [Example 440] (1.8 g, 3.1 mmol, 1.0 eq) was suspended in 60 mL dichloromethane and 4.8 mL trifluoro acetic acid were added. The reaction mixture was stirred at room temperature overnight in a sealed vial. Afterwards all volatile components were removed in vacuo. The crude trifluoro acetic acid salt of the title compound was isolated (1.5 g) and used for further derivatization without further purification.

[2155] UPLC-MS (Method 2): R.sub.t=0.83 min; MS (El.sub.pos): m/z=483 [M+H].sup.+.

Example 442

tert-Butyl (3S)-3-[(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]-amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)methyl]piperidine-1-carboxylate

[2156] ##STR00562##

[2157] A mixture of tert-butyl (3S)-3-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}-2-fluorophenoxy)methyl]piperidine-1-carboxylate [Intermediate 75] (1.8 g, 3.9 mmol, 1.2 eq), 2-chloro-5-(trifluoromethyl)pyrazine [CAS-RN: 799557-87-2] (589 mg, 3.2 mmol, 1.0 eq) and cesium carbonate (2.4 g, 7.4 mmol, 2.3 eq) in 33 mL dioxane/DMF (5.5/1) was placed in a round bottom flask that was flushed with argon. Then, palladium(II) acetate (72 mg, 0.3 mmol, 0.1 eq) and Xantphos (187 mg, 0.3 mmol, 0.1 eq) were added. Afterwards the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 50 g KP cartridge: n-hexane/ethyl acetate) to give 1.72 g (87% yield of the theory) of the title compound.

[2158] UPLC-MS (Method 2): Rt=1.15 min; MS (El.sub.pos): m/z=611 [M+H].sup.+.

Example 443

N-{4-Fluoro-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoro acetic acid

[2159] ##STR00563##

[2160] tert-butyl (3S)-3-[(2-fluoro-5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]-amino}-1,2-thiazol-4-yl)carbonyl]amino}phenoxy)methyl]piperidine-1-carboxylate [Example 442] (1.7 g, 2.9 mmol, 1.0 eq) was suspended in 54 mL dichloromethane and 4.3 mL trifluoro acetic acid were added. The reaction mixture was stirred at room temperature for 2.5 h in a sealed vial. Afterwards all volatile components were removed in vacuo. The crude trifluoro acetic acid salt of the title compound was isolated (1.74 g) and used for further derivatization without further purification.

[2161] UPLC-MS (Method 2): R.sub.t=0.96 min; MS (El.sub.pos): m/z=511 [M+H].sup.+.

Example 444

tert-Butyl 4-[2-(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)ethyl]piperidine-1-carboxylate

[2162] ##STR00564##

[2163] A mixture of tert-butyl 4-[2-(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)ethyl]piperidine-1-carboxylate [Intermediate 78] (0.71 g, 1.6 mmol, 1.05 eq), 2-chloro-5-(trifluoromethyl)pyrazine [CAS-RN: 799557-87-2] (277 mg, 1.5 mmol, 1.0 eq) and cesium carbonate (1137 mg, 3.5 mmol, 2.3 eq) in 15 mL dioxane/DMF (6/1) was placed in a round bottom flask that was flushed with argon. Then, palladium(II) acetate (34 mg, 0.15 mmol, 0.1 eq) and Xantphos (88 mg, 0.15 mmol, 0.1 eq) were added. Afterwards the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 50 g cartridge: n-hexane/ethyl acetate) to give 504 mg (56% yield of the theory) of the title compound.

[2164] UPLC-MS (Method 2): Rt=1.00 min; MS (El.sub.pos): m/z=592 [M+H].sup.+.

Example 445

N-{4-Fluoro-3-[(3S)-pyrrolidin-3-yloxy]phenyl}-3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with trifluoro acetic acid

[2165] ##STR00565##

[2166] tert-butyl 4-[2-(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)ethyl]piperidine-1-carboxylate [Example 444] (532 mg, 0.9 mmol, 1.0 eq) was suspended in 23 mL dioxane and 4.5 mL hydrogen chloride solution (4.0 M) in dioxane (CAS-RN: 7647-01-0) (13.2 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. All volatile components were removed in vacuo. The crude hydrochloride acid salt of the title compound was isolated (327 mg, 56% yield of the theory) and used for further derivatization without further purification.

[2167] UPLC-MS (Method 2): Rt=0.89 min; MS (El.sub.pos): m/z=492 [M+H].sup.+.

Example 446

tert-Butyl (3R)-3-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]pyrrolidine-1-carboxylate

[2168] ##STR00566##

[2169] A mixture of tert-butyl (3R)-3-[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]pyrrolidine-1-carboxylate [Intermediate 81] (500 mg, 1.2 mmol, 1.0 eq), 2-chloro-5-(trifluoromethyl)pyrazine [CAS-RN: 799557-87-2] (218 mg, 1.2 mmol, 1.0 eq) and cesium carbonate (893 mg, 2.7 mmol, 2.3 eq) in 12 mL dioxane/DMF (5/1) was placed in a round bottom flusk that was flushed with argon. Then, palladium(II) acetate (27 mg, 0.1 mmol, 0.1 eq) and Xantphos (69 mg, 0.1 mmol, 0.1 eq) were added. Afterwards the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 25 g cartridge: dichloromethane/ethanol) to give 480 mg (71% yield of the theory) of the title compound.

[2170] UPLC-MS (Method 2): Rt=0.94 min; MS (El.sub.neg): m/z=564 [M−H].sup.−.

Example 447

3-Methyl-N-{6-[(3R)-pyrrolidin-3-yloxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with hydrochloric acid

[2171] ##STR00567##

[2172] tert-butyl (3R)-3-[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]pyrrolidine-1-carboxylate [Example 446] (480 mg, 0.9 mmol, 1.0 eq) was suspended in 22 mL dioxane and 4.2 mL hydrogen chloride solution (4.0 M) in dioxane (CAS-RN: 7647-01-0) (17 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. All volatile components were removed in vacuo. The crude hydrochloride acid salt of the title compound was isolated (452 mg) and used for further derivatization without purification.

[2173] UPLC-MS (Method 2): R.sub.t=0.80 min; MS (EI.sub.pos): m/z=466 [M+H].sup.+.

Example 448

tert-Butyl (3R)-3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}piperidine-1-carboxylate

[2174] ##STR00568##

[2175] A mixture of tert-butyl (3R)-3-{[(5-{[(5-amino-3-methyl-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}piperidine-1-carboxylate [Intermediate 84] (500 mg, 1.1 mmol, 1.0 eq), 2-chloro-5-(trifluoromethyl)pyrazine [CAS-RN: 799557-87-2] (204 mg, 1.1 mmol, 1.0 eq) and cesium carbonate (837 mg, 2.6 mmol, 2.3 eq) in 11 mL dioxane/DMF (5/1) was placed in a round bottom flask that was flushed with argon. Then, palladium(II) acetate (25 mg, 0.1 mmol, 0.1 eq) and Xantphos (65 mg, 0.1 mmol, 0.1 eq) were added. Afterwards the reaction mixture was stirred at an environmental temperature of 110° C. overnight. On cooling, the reaction mixture was diluted in dichloromethane and ethanol (9/1) and filtered. All volatile components were removed in vacuo. Purification of this crude material was done via preparative MPLC (Biotage Isolera; 25 g cartridge: dichloromethane/ethanol) to give 623 mg (94% yield of the theory) of the title compound.

[2176] UPLC-MS (Method 2): Rt=0.99 min; MS (El.sub.neg): m/z=594 [M−H].sup.−.

[2177] [α].sub.D.sup.20 (c=6.7 mg/mL, CHCl.sub.3): −16.3°+/−0.45°.

Example 449

3-Methyl-N-{6-[(3R)-piperidin-3-ylmethoxy]pyridin-3-yl}-5-{[5-(trifluoromethyl)-pyrazin-2-yl]amino}-1,2-thiazole-4-carboxamide, salt with hydrochloric acid

[2178] ##STR00569##

[2179] tert-butyl (3R)-3-{[(5-{[(3-methyl-5-{[5-(trifluoromethyl)pyrazin-2-yl]amino}-1,2-thiazol-4-yl)carbonyl]amino}pyridin-2-yl)oxy]methyl}piperidine-1-carboxylate [Example 448] (632 mg, 1.1 mmol, 1.0 eq) was suspended in 27 mL dioxane and 5.3 mL hydrogen chloride solution (4.0 M) in dioxane (CAS-RN: 7647-01-0) (17 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. All volatile components were removed in vacuo. The crude hydrochloride acid salt of the title compound was isolated (678 mg) and used for further derivatization without purification.

[2180] UPLC-MS (Method 2): R.sub.t=0.90 min; MS (El.sub.pos): m/z=494 [M+H].sup.+.

Example 450

N-(3-Aminophenyl)-3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazole-4-carboxamide

[2181] ##STR00570##

[2182] tert-butyl [3-({[3-methyl-5-(quinoxalin-2-ylamino)-1,2-thiazol-4-yl]carbonyl}amino)-phenyl]carbamate [Example 178] (10.3 g, 21.6 mmol, 1.0 eq) was suspended in 400 mL dioxane and 33.3 mL trifluoro acetic acid were added (432 mmol, 20 eq) was added. The reaction mixture was stirred at room temperature overnight in a sealed vial. All volatile components were removed in vacuo to give 12.8 mg of the title compound as salt with trifluoro acetic acid. This crude product was used without further purification.

[2183] A Sample of the TFA salt was dissolved in a mixture of dichloromethane and methanol and triethylamine was added. The volatile components were removed in vacuo and the purification was conducted via preparative HPLC (Method B) to give the title compound as free base.

[2184] UPLC-MS (Method 1): R.sub.t=1.05 min; MS (El.sub.pos): m/z=377 [M+H].sup.+.

[2185] .sup.1H-NMR (300 MHz, DMSO-d.sub.6) delta [ppm]: 0.830 (0.78), 0.852 (1.26), 1.172 (1.07), 1.233 (4.62), 1.753 (1.65), 1.983 (1.02), 2.007 (1.22), 2.032 (0.68), 2.270 (3.16), 2.540 (14.54), 2.726 (3.16), 6.317 (8.02), 6.342 (8.36), 6.348 (6.22), 6.907 (3.84), 6.934 (8.07), 6.958 (12.98), 6.983 (15.03), 7.010 (5.45), 7.095 (12.64), 7.593 (3.11), 7.619 (6.47), 7.646 (4.62), 7.754 (4.77), 7.781 (8.17), 7.806 (4.67), 7.960 (13.23), 7.964 (16.00), 7.975 (12.11), 7.987 (11.23), 7.992 (12.40), 8.002 (10.21), 9.045 (15.17), 9.982 (3.26), 11.320 (3.50).

[2186] Further, the compounds of formula (I) of the present invention can be converted to any salt as described herein, by any method which is known to the person skilled in the art. Similarly, any salt of a compound of formula (I) of the present invention can be converted into the free compound, by any method which is known to the person skilled in the art.

[2187] Pharmaceutical Ccompositions of the Compounds of the Invention

[2188] This invention also relates to pharmaceutical compositions containing one or more compounds of the present invention. These compositions can be utilised to achieve the desired pharmacological effect by administration to a patient in need thereof. A patient, for the purpose of this invention, is a mammal, including a human, in need of treatment for the particular condition or disease. Therefore, the present invention includes pharmaceutical compositions that are comprised of a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound, or salt thereof, of the present invention. A pharmaceutically acceptable carrier is preferably a carrier that is relatively non-toxic and innocuous to a patient at concentrations consistent with effective activity of the active ingredient so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the active ingredient. A pharmaceutically effective amount of compound is preferably that amount which produces a result or exerts an influence on the particular condition being treated. The compounds of the present invention can be administered with pharmaceutically-acceptable carriers well known in the art using any effective conventional dosage unit forms, including immediate, slow and timed release preparations, orally, parenterally, topically, nasally, ophthalmically, optically, sublingually, rectally, vaginally, and the like.

[2189] For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, troches, lozenges, melts, powders, solutions, suspensions, or emulsions, and may be prepared according to methods known to the art for the manufacture of pharmaceutical compositions. The solid unit dosage forms can be a capsule that can be of the ordinary hard- or soft-shelled gelatine type containing, for example, surfactants, lubricants, and inert fillers such as lactose, sucrose, calcium phosphate, and corn starch.

[2190] In another embodiment, the compounds of this invention may be tableted with conventional tablet bases such as lactose, sucrose and cornstarch in combination with binders such as acacia, corn starch or gelatine, disintegrating agents intended to assist the break-up and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch, and guar gum, gum tragacanth, acacia, lubricants intended to improve the flow of tablet granulation and to prevent the adhesion of tablet material to the surfaces of the tablet dies and punches, for example talc, stearic acid, or magnesium, calcium or zinc stearate, dyes, colouring agents, and flavouring agents such as peppermint, oil of wintergreen, or cherry flavouring, intended to enhance the aesthetic qualities of the tablets and make them more acceptable to the patient. Suitable excipients for use in oral liquid dosage forms include dicalcium phosphate and diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent or emulsifying agent. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance tablets, pills or capsules may be coated with shellac, sugar or both.

[2191] Dispersible powders and granules are suitable for the preparation of an aqueous suspension. They provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example those sweetening, flavouring and colouring agents described above, may also be present.

[2192] The pharmaceutical compositions of this invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil such as liquid paraffin or a mixture of vegetable oils. Suitable emulsifying agents may be (1) naturally occurring gums such as gum acacia and gum tragacanth, (2) naturally occurring phosphatides such as soy bean and lecithin, (3) esters or partial esters derived form fatty acids and hexitol anhydrides, for example, sorbitan monooleate, (4) condensation products of said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

[2193] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil such as, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent such as, for example, beeswax, hard paraffin, or cetyl alcohol. The suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxybenzoate; one or more colouring agents; one or more flavouring agents; and one or more sweetening agents such as sucrose or saccharin.

[2194] Syrups and elixirs may be formulated with sweetening agents such as, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, and preservative, such as methyl and propyl parabens and flavouring and colouring agents.

[2195] The compounds of this invention may also be administered parenterally, that is, subcutaneously, intravenously, intraocularly, intrasynovially, intramuscularly, or interperitoneally, as injectable dosages of the compound in preferably a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid or mixture of liquids such as water, saline, aqueous dextrose and related sugar solutions, an alcohol such as ethanol, isopropanol, or hexadecyl alcohol, glycols such as propylene glycol or polyethylene glycol, glycerol ketals such as 2,2-dimethyl-1,1-dioxolane-4-methanol, ethers such as poly(ethylene glycol) 400, an oil, a fatty acid, a fatty acid ester or, a fatty acid glyceride, or an acetylated fatty acid glyceride, with or without the addition of a pharmaceutically acceptable surfactant such as a soap or a detergent, suspending agent such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agent and other pharmaceutical adjuvants.

[2196] Illustrative of oils which can be used in the parenteral formulations of this invention are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, sesame oil, cottonseed oil, corn oil, olive oil, petrolatum and mineral oil. Suitable fatty acids include oleic acid, stearic acid, isostearic acid and myristic acid. Suitable fatty acid esters are, for example, ethyl oleate and isopropyl myristate. Suitable soaps include fatty acid alkali metal, ammonium, and triethanolamine salts and suitable detergents include cationic detergents, for example dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and alkylamine acetates; anionic detergents, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates; non-ionic detergents, for example, fatty amine oxides, fatty acid alkanolamides, and poly(oxyethylene-oxypropylene)s or ethylene oxide or propylene oxide copolymers; and amphoteric detergents, for example, alkyl-beta-aminopropionates, and 2-alkylimidazoline quarternary ammonium salts, as well as mixtures.

[2197] The parenteral compositions of this invention will typically contain from about 0.5% to about 25% by weight of the active ingredient in solution. Preservatives and buffers may also be used advantageously. In order to minimise or eliminate irritation at the site of injection, such compositions may contain a non-ionic surfactant having a hydrophile-lipophile balance (HLB) preferably of from about 12 to about 17. The quantity of surfactant in such formulation preferably ranges from about 5% to about 15% by weight. The surfactant can be a single component having the above HLB or can be a mixture of two or more components having the desired HLB.

[2198] Illustrative of surfactants used in parenteral formulations are the class of polyethylene sorbitan fatty acid esters, for example, sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.

[2199] The pharmaceutical compositions may be in the form of sterile injectable aqueous suspensions. Such suspensions may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents which may be a naturally occurring phosphatide such as lecithin, a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate, a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadeca-ethyleneoxycetanol, a condensation product of ethylene oxide with a partial ester derived form a fatty acid and a hexitol such as polyoxyethylene sorbitol monooleate, or a condensation product of an ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride, for example polyoxyethylene sorbitan monooleate.

[2200] The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent. Diluents and solvents that may be employed are, for example, water, Ringer's solution, isotonic sodium chloride solutions and isotonic glucose solutions. In addition, sterile fixed oils are conventionally employed as solvents or suspending media. For this purpose, any bland, fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be used in the preparation of injectables.

[2201] A composition of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are, for example, cocoa butter and polyethylene glycol.

[2202] Another formulation employed in the methods of the present invention employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art (see, e.g., US Pat. No. 5,023,252, issued Jun. 11, 1991, incorporated herein by reference). Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

[2203] Controlled release formulations for parenteral administration include liposomal, polymeric microsphere and polymeric gel formulations that are known in the art.

[2204] It may be desirable or necessary to introduce the pharmaceutical composition to the patient via a mechanical delivery device. The construction and use of mechanical delivery devices for the delivery of pharmaceutical agents is well known in the art. Direct techniques for, for example, administering a drug directly to the brain usually involve placement of a drug delivery catheter into the patient's ventricular system to bypass the blood-brain barrier. One such implantable delivery system, used for the transport of agents to specific anatomical regions of the body, is described in U.S. Pat. No. 5,011,472, issued Apr. 30, 1991.

[2205] The compositions of the invention can also contain other conventional pharmaceutically acceptable compounding ingredients, generally referred to as carriers or diluents, as necessary or desired. Conventional procedures for preparing such compositions in appropriate dosage forms can be utilized.

[2206] Such ingredients and procedures include those described in the following references, each of which is incorporated herein by reference: Powell, M. F. et al., “Compendium of Excipients for Parenteral Formulations” PDA Journal of Pharmaceutical Science a Technology 1998, 52(5), 238-311; Strickley, R. G “Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)-Part-1” PDA Journal of Pharmaceutical Science a Technology 1999, 53(6), 324-349; and Nema, S. et al., “Excipients and Their Use in Injectable Products” PDA Journal of Pharmaceutical Science a Technology 1997, 51(4), 166-171.

[2207] Commonly used pharmaceutical ingredients that can be used as appropriate to formulate the composition for its intended route of administration include:

[2208] acidifying agents (examples include but are not limited to acetic acid, citric acid, fumaric acid, hydrochloric acid, nitric acid);

[2209] alkalinizing agents (examples include but are not limited to ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, triethanolamine, trolamine);

[2210] adsorbents (examples include but are not limited to powdered cellulose and activated charcoal);

[2211] aerosol propellants (examples include but are not limited to carbon dioxide, CCl.sub.2F.sub.2, F.sub.2ClC—CClF.sub.2 and CClF.sub.3)

[2212] air displacement agents (examples include but are not limited to nitrogen and argon);

[2213] antifungal preservatives (examples include but are not limited to benzoic acid, butylparaben, ethylparaben, methylparaben, propylparaben, sodium benzoate);

[2214] antimicrobial preservatives (examples include but are not limited to benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate and thimerosal);

[2215] antioxidants (examples include but are not limited to ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorus acid, monothioglycerol, propyl gallate, sodium ascorbate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite);

[2216] binding materials (examples include but are not limited to block polymers, natural and synthetic rubber, polyacrylates, polyurethanes, silicones, polysiloxanes and styrene-butadiene copolymers);

[2217] buffering agents (examples include but are not limited to potassium metaphosphate, dipotassium phosphate, sodium acetate, sodium citrate anhydrous and sodium citrate dihydrate)

[2218] carrying agents (examples include but are not limited to acacia syrup, aromatic syrup, aromatic elixir, cherry syrup, cocoa syrup, orange syrup, syrup, corn oil, mineral oil, peanut oil, sesame oil, bacteriostatic sodium chloride injection and bacteriostatic water for injection)

[2219] chelating agents (examples include but are not limited to edetate disodium and edetic acid)

[2220] colourants (examples include but are not limited to FD&C Red No. 3, FD&C Red No. 20, FD&C Yellow No. 6, FD&C Blue No. 2, D&C Green No. 5, D%C Orange No. 5, D&C Red No. 8, caramel and ferric oxide red);

[2221] clarifying agents (examples include but are not limited to bentonite); emulsifying agents (examples include but are not limited to acacia, cetomacrogol, cetyl alcohol, glyceryl monostearate, lecithin, sorbitan monooleate, polyoxyethylene 50 monostearate);

[2222] encapsulating agents (examples include but are not limited to gelatin and cellulose acetate phthalate)

[2223] flavourants (examples include but are not limited to anise oil, cinnamon oil, cocoa, menthol, orange oil, peppermint oil and vanillin);

[2224] humectants (examples include but are not limited to glycerol, propylene glycol and sorbitol);

[2225] levigating agents (examples include but are not limited to mineral oil and glycerin);

[2226] oils (examples include but are not limited to arachis oil, mineral oil, olive oil, peanut oil, sesame oil and vegetable oil);

[2227] ointment bases (examples include but are not limited to lanolin, hydrophilic ointment, polyethylene glycol ointment, petrolatum, hydrophilic petrolatum, white ointment, yellow ointment, and rose water ointment);

[2228] penetration enhancers (transdermal delivery) (examples include but are not limited to monohydroxy or polyhydroxy alcohols, mono-or polyvalent alcohols, saturated or unsaturated fatty alcohols, saturated or unsaturated fatty esters, saturated or unsaturated dicarboxylic acids, essential oils, phosphatidyl derivatives, cephalin, terpenes, amides, ethers, ketones and ureas)

[2229] plasticizers (examples include but are not limited to diethyl phthalate and glycerol);

[2230] solvents (examples include but are not limited to ethanol, corn oil, cottonseed oil, glycerol, isopropanol, mineral oil, oleic acid, peanut oil, purified water, water for injection, sterile water for injection and sterile water for irrigation);

[2231] stiffening agents (examples include but are not limited to cetyl alcohol, cetyl esters wax, microcrystalline wax, paraffin, stearyl alcohol, white wax and yellow wax);

[2232] suppository bases (examples include but are not limited to cocoa butter and polyethylene glycols (mixtures));

[2233] surfactants (examples include but are not limited to benzalkonium chloride, nonoxynol 10, oxtoxynol 9, polysorbate 80, sodium lauryl sulfate and sorbitan mono-palmitate);

[2234] suspending agents (examples include but are not limited to agar, bentonite, carbomers, carboxymethylcellulose sodium, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, kaolin, methylcellulose, tragacanth and veegum);

[2235] sweetening agents (examples include but are not limited to aspartame, dextrose, glycerol, mannitol, propylene glycol, saccharin sodium, sorbitol and sucrose);

[2236] tablet anti-adherents (examples include but are not limited to magnesium stearate and talc);

[2237] tablet binders (examples include but are not limited to acacia, alginic acid, carboxymethylcellulose sodium, compressible sugar, ethylcellulose, gelatin, liquid glucose, methylcellulose, non-crosslinked polyvinyl pyrrolidone, and pregelatinized starch);

[2238] tablet and capsule diluents (examples include but are not limited to dibasic calcium phosphate, kaolin, lactose, mannitol, microcrystalline cellulose, powdered cellulose, precipitated calcium carbonate, sodium carbonate, sodium phosphate, sorbitol and starch);

[2239] tablet coating agents (examples include but are not limited to liquid glucose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, cellulose acetate phthalate and shellac);

[2240] tablet direct compression excipients (examples include but are not limited to dibasic calcium phosphate);

[2241] tablet disintegrants (examples include but are not limited to alginic acid, carboxymethylcellulose calcium, microcrystalline cellulose, polacrillin potassium, cross-linked polyvinylpyrrolidone, sodium alginate, sodium starch glycollate and starch);

[2242] tablet glidants (examples include but are not limited to colloidal silica, corn starch and talc);

[2243] tablet lubricants (examples include but are not limited to calcium stearate, magnesium stearate, mineral oil, stearic acid and zinc stearate);

[2244] tablet/capsule opaquants (examples include but are not limited to titanium dioxide),

[2245] tablet polishing agents (examples include but are not limited to carnuba wax and white wax);

[2246] thickening agents (examples include but are not limited to beeswax, cetyl alcohol and paraffin);

[2247] tonicity agents (examples include but are not limited to dextrose and sodium chloride);

[2248] viscosity increasing agents (examples include but are not limited to alginic acid, bentonite, carbomers, carboxymethylcellulose sodium, methylcellulose, polyvinyl pyrrolidone, sodium alginate and tragacanth); and

[2249] wetting agents (examples include but are not limited to heptadecaethylene oxycetanol, lecithins, sorbitol monooleate, polyoxyethylene sorbitol monooleate, and polyoxyethylene stearate).

[2250] Pharmaceutical compositions according to the present invention can be illustrated as follows:

[2251] Sterile IV Solution: A 5 mg/mL solution of the desired compound of this invention can be made using sterile, injectable water, and the pH is adjusted if necessary.

[2252] The solution is diluted for administration to 1-2 mg/mL with sterile 5% dextrose and is administered as an IV infusion over about 60 min.

[2253] Lyophilised powder for IV administration: A sterile preparation can be prepared with (i) 100-1000 mg of the desired compound of this invention as a lyophilised powder, (ii) 32-327 mg/mL sodium citrate, and (iii) 300-3000 mg Dextran 40. The formulation is reconstituted with sterile, injectable saline or dextrose 5% to a concentration of 10 to 20 mg/mL, which is further diluted with saline or dextrose 5% to 0.2-0.4 mg/mL, and is administered either IV bolus or by IV infusion over 15-60 min.

[2254] Intramuscular suspension: The following solution or suspension can be prepared, for intramuscular injection:

TABLE-US-00007 50 mg/mL of the desired, water-insoluble compound of this invention 5 mg/mL sodium carboxymethylcellulose 4 mg/mL TWEEN 80 9 mg/mL sodium chloride 9 mg/mL benzyl alcohol

[2255] Hard Shell Capsules: A large number of unit capsules are prepared by filling standard two-piece hard galantine capsules each with 100 mg of powdered active ingredient, 150 mg of lactose, 50 mg of cellulose and 6 mg of magnesium stearate.

[2256] Soft Gelatin Capsules: A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into molten gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules are washed and dried. The active ingredient can be dissolved in a mixture of polyethylene glycol, glycerin and sorbitol to prepare a water miscible medicine mix.

[2257] Tablets: A large number of tablets are prepared by conventional procedures so that the dosage unit is 100 mg of active ingredient, 0.2 mg. of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 98.8 mg of lactose. Appropriate aqueous and non-aqueous coatings may be applied to increase palatability, improve elegance and stability or delay absorption.

[2258] Immediate Release Tablets/Capsules: These are solid oral dosage forms made by conventional and novel processes. These units are taken orally without water for immediate dissolution and delivery of the medication. The active ingredient is mixed in a liquid containing ingredient such as sugar, gelatin, pectin and sweeteners. These liquids are solidified into solid tablets or caplets by freeze drying and solid state extraction techniques. The drug compounds may be compressed with viscoelastic and thermoelastic sugars and polymers or effervescent components to produce porous matrices intended for immediate release, without the need of water.

[2259] Combination Therapies

[2260] The term “combination” in the present invention is used as known to persons skilled in the art and may be present as a fixed combination, a non-fixed combination or kit-of-parts.

[2261] A “fixed combination” in the present invention is used as known to persons skilled in the art and is defined as a combination wherein the said first active ingredient and the said second active ingredient are present together in one unit dosage or in a single entity. One example of a “fixed combination” is a pharmaceutical composition wherein the said first active ingredient and the said second active ingredient are present in admixture for simultaneous administration, such as in a formulation. Another example of a “fixed combination” is a pharmaceutical combination wherein the said first active ingredient and the said second active ingredient are present in one unit without being in admixture.

[2262] A non-fixed combination or “kit-of-parts” in the present invention is used as known to persons skilled in the art and is defined as a combination wherein the said first active ingredient and the said second active ingredient are present in more than one unit. One example of a non-fixed combination or kit-of-parts is a combination wherein the said first active ingredient and the said second active ingredient are present separately. The components of the non-fixed combination or kit-of-parts may be administered separately, sequentially, simultaneously, concurrently or chronologically staggered.

[2263] The compounds of this invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutical agents where the combination causes no unacceptable adverse effects. The present invention relates also to such combinations. For example, the compounds of this invention can be combined with known chemotherapeutic agents or anti-cancer agents, e.g. anti-hyper-proliferative or other indication agents, and the like, as well as with admixtures and combinations thereof. Other indication agents include, but are not limited to, anti-angiogenic agents, mitotic inhibitors, alkylating agents, anti-metabolites, DNA-intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, toposisomerase inhibitors, biological response modifiers, or anti-hormones.

[2264] The term “chemotherapeutic anti-cancer agents”, includes but is not limited to

[2265] 131I-chTNT, abarelix, abiraterone, aclarubicin, ado-trastuzumab emtansine, afatinib, aflibercept, aldesleukin, alemtuzumab, Alendronic acid, alitretinoin, altretamine, amifostine, aminoglutethimide, Hexyl aminolevulinate,amrubicin, amsacrine, anastrozole, ancestim, anethole dithiolethione, angiotensin II, antithrombin III, aprepitant, arcitumomab, arglabin, arsenic trioxide, asparaginase, axitinib, azacitidine, basiliximab, belotecan, bendamustine, belinostat, bevacizumab, bexarotene, bicalutamide, bisantrene, bleomycin, bortezomib, buserelin, bosutinib, brentuximab vedotin, busulfan, cabazitaxel, cabozantinib, calcium folinate, calcium levofolinate, capecitabine, capromab, carboplatin, carfilzomib, carmofur, carmustine, catumaxomab, celecoxib, celmoleukin, ceritinib, cetuximab, chlorambucil, chlormadinone, chlormethine, cidofovir, cinacalcet, cisplatin, cladribine, clodronic acid, clofarabine, copanlisib , crisantaspase, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, darbepoetin alfa, dabrafenib, dasatinib, daunorubicin, decitabine, degarelix, denileukin diftitox, denosumab, depreotide, deslorelin, dexrazoxane, dibrospidium chloride, dianhydrogalactitol, diclofenac, docetaxel, dolasetron, doxifluridine, doxorubicin, doxorubicin+estrone, dronabinol, eculizumab, edrecolomab, elliptinium acetate, eltrombopag, endostatin, enocitabine, enzalutamide, epirubicin, epitiostanol, epoetin alfa, epoetin beta, epoetin zeta, eptaplatin, eribulin, erlotinib, esomeprazole, estradiol, estramustine, etoposide, everolimus, exemestane, fadrozole, fentanyl, filgrastim, fluoxymesterone, floxuridine, fludarabine, fluorouracil, flutamide, folinic acid, formestane, fosaprepitant, fotemustine, fulvestrant, gadobutrol, gadoteridol, gadoteric acid meglumine, gadoversetamide, gadoxetic acid, gallium nitrate, ganirelix, gefitinib, gemcitabine, gemtuzumab, Glucarpidase, glutoxim, GM-CSF, goserelin, granisetron, granulocyte colony stimulating factor, histamine dihydrochloride, histrelin, hydroxycarbamide, I-125 seeds, lansoprazole, ibandronic acid, ibritumomab tiuxetan, ibrutinib, idarubicin, ifosfamide, imatinib, imiquimod, improsulfan, indisetron, incadronic acid, ingenol mebutate, interferon alfa, interferon beta, interferon gamma, iobitridol, iobenguane (123I), iomeprol, ipilimumab, irinotecan, Itraconazole, ixabepilone, lanreotide, lapatinib, lasocholine, lenalidomide, lenograstim, lentinan, letrozole, leuprorelin, levamisole, levonorgestrel, levothyroxine sodium, lisuride, lobaplatin, lomustine, lonidamine, masoprocol, medroxyprogesterone, megestrol, melarsoprol, melphalan, mepitiostane, mercaptopurine, mesna, methadone, methotrexate, methoxsalen, methylaminolevulinate, methylprednisolone, methyltestosterone, metirosine, mifamurtide, miltefosine, miriplatin, mitobronitol, mitoguazone, mitolactol, mitomycin, mitotane, mitoxantrone, mogamulizumab, molgramostim, mopidamol, morphine hydrochloride, morphine sulfate, nabilone, nabiximols, nafarelin, naloxone+pentazocine, naltrexone, nartograstim, nedaplatin, nelarabine, neridronic acid, nivolumabpentetreotide, nilotinib, nilutamide, nimorazole, nimotuzumab, nimustine, nitracrine, nivolumab, obinutuzumab, octreotide, ofatumumab, omacetaxine mepesuccinate, omeprazole, ondansetron, oprelvekin, orgotein, orilotimod, oxaliplatin, oxycodone, oxymetholone, ozogamicine, p53 gene therapy, paclitaxel, palifermin, palladium-103 seed, palonosetron, pamidronic acid, panitumumab, pantoprazole, pazopanib, pegaspargase, PEG-epoetin beta (methoxy PEG-epoetin beta), pembrolizumab, pegfilgrastim, peginterferon alfa-2b, pemetrexed, pentazocine, pentostatin, peplomycin, Perflubutane, perfosfamide, Pertuzumab, picibanil, pilocarpine, pirarubicin, pixantrone, plerixafor, plicamycin, poliglusam, polyestradiol phosphate, polyvinylpyrrolidone+sodium hyaluronate, polysaccharide-K, pomalidomide, ponatinib, porfimer sodium, pralatrexate, prednimustine, prednisone, procarbazine, procodazole, propranolol, quinagolide, rabeprazole, racotumomab, radium-223 chloride, radotinib, raloxifene, raltitrexed, ramosetron, ramucirumab, ranimustine, rasburicase, razoxane, refametinib , regorafenib, risedronic acid, rhenium-186 etidronate, rituximab, romidepsin, romiplostim, romurtide, roniciclib , samarium (153Sm) lexidronam, sargramostim, satumomab, secretin, sipuleucel-T, sizofiran, sobuzoxane, sodium glycididazole, sorafenib, stanozolol, streptozocin, sunitinib, talaporfin, tamibarotene, tamoxifen, tapentadol, tasonermin, teceleukin, technetium (99mTc) nofetumomab merpentan, 99mTc-HYNIC-[Tyr3]-octreotide, tegafur, tegafur+gimeracil+oteracil, temoporfin, temozolomide, temsirolimus, teniposide, testosterone, tetrofosmin, thalidomide, thiotepa, thymalfasin, thyrotropin alfa, tioguanine, tocilizumab, topotecan, toremifene, tositumomab, trabectedin, tramadol, trastuzumab, trastuzumab emtansine, treosulfan, tretinoin, trifluridine+tipiracil, trilostane, triptorelin, trametinib, trofosfamide, thrombopoietin, tryptophan, ubenimex, valrubicin, vandetanib, vapreotide, vemurafenib, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vismodegib, vorinostat, vorozole, yttrium-90 glass microspheres, zinostatin, zinostatin stimalamer, zoledronic acid, zorubicin.

[2266] The compounds of the invention may also be administered in combination with protein therapeutics. Such protein therapeutics suitable for the treatment of cancer or other angiogenic disorders and for use with the compositions of the invention include, but are not limited to, an interferon (e.g., interferon .alpha., .beta., or .gamma.) supraagonistic monoclonal antibodies, Tuebingen, TRP-1 protein vaccine, Colostrinin, anti-FAP antibody, YH-16, gemtuzumab, infliximab, cetuximab, trastuzumab, denileukin diftitox, rituximab, thymosin alpha 1, bevacizumab, mecasermin, mecasermin rinfabate, oprelvekin, natalizumab, rhMBL, MFE-CP1+ZD-2767-P, ABT-828, ErbB2-specific immunotoxin, SGN-35, MT-103, rinfabate, AS-1402, B43-genistein, L-19 based radioimmunotherapeutics, AC-9301, NY-ESO-1 vaccine, IMC-1C.sub.11, CT-322, rhCC.sub.10, r(m)CRP, MORAb-009, aviscumine, MDX-1307, Her-2 vaccine, APC-8024, NGR-hTNF, rhH1.3, IGN-311, Endostatin, volociximab, PRO-1762, lexatumumab, SGN-40, pertuzumab, EMD-273063, L19-IL-2 fusion protein, PRX-321, CNTO-328, MDX-214, tigapotide, CAT-3888, labetuzumab, alpha-particle-emitting radioisotope-llinked lintuzumab, EM-1421, HyperAcute vaccine, tucotuzumab celmoleukin, galiximab, HPV-16-E7, Javelin—prostate cancer, Javelin—melanoma, NY-ESO-1 vaccine, EGF vaccine, CYT-004-MelQbG10, WT1 peptide, oregovomab, ofatumumab, zalutumumab, cintredekin besudotox, WX-G250, Albuferon, aflibercept, denosumab, vaccine, CTP-37, efungumab, or 1311-chTNT-1/B. Monoclonal antibodies useful as the protein therapeutic include, but are not limited to, muromonab-CD3, abciximab, edrecolomab, daclizumab, gentuzumab, alemtuzumab, ibritumomab, cetuximab, bevicizumab, efalizumab, adalimumab, omalizumab, muromomab-CD3, rituximab, daclizumab, trastuzumab, palivizumab, basiliximab, and infliximab.

[2267] A compound of general formula (I) as defined herein can optionally be administered in combination with one or more of the following: ARRY-162, ARRY-300, ARRY-704, AS-703026, AZD-5363, AZD-8055, BEZ-235, BGT-226, BKM-120, BYL-719, CAL-101, CC-223, CH-5132799, deforolimus, E-6201, enzastaurin , GDC-0032, GDC-0068, GDC-0623, GDC-0941, GDC-0973, GDC-0980, GSK-2110183, GSK-2126458, GSK-2141795, MK-2206, novolimus, OSI-027, perifosine, PF-04691502, PF-05212384, PX-866, rapamycin, RG-7167, RO-4987655, RO-5126766, selumetinib, TAK-733, trametinib, triciribine, UCN-01, WX-554, XL-147, XL-765, zotarolimus, ZSTK-474.

[2268] Generally, the use of cytotoxic and/or cytostatic agents in combination with a compound or composition of the present invention will serve to:

[2269] (1) yield better efficacy in reducing the growth of a tumor or even eliminate the tumor as compared to administration of either agent alone,

[2270] (2) provide for the administration of lesser amounts of the administered chemo-therapeutic agents,

[2271] (3) provide for a chemotherapeutic treatment that is well tolerated in the patient with fewer deleterious pharmacological complications than observed with single agent chemotherapies and certain other combined therapies,

[2272] (4) provide for treating a broader spectrum of different cancer types in mammals, especially humans,

[2273] (5) provide for a higher response rate among treated patients,

[2274] (6) provide for a longer survival time among treated patients compared to standard chemotherapy treatments,

[2275] (7) provide a longer time for tumor progression, and/or

[2276] (8) yield efficacy and tolerability results at least as good as those of the agents used alone, compared to known instances where other cancer agent combinations produce antagonistic effects.

[2277] Methods of Sensitizing Cells to Radiation

[2278] In a distinct embodiment of the present invention, a compound of the present invention may be used to sensitize a cell to radiation. That is, treatment of a cell with a compound of the present invention prior to radiation treatment of the cell renders the cell more susceptible to DNA damage and cell death than the cell would be in the absence of any treatment with a compound of the invention. In one aspect, the cell is treated with at least one compound of the invention.

[2279] Thus, the present invention also provides a method of killing a cell, wherein a cell is administered one or more compounds of the invention in combination with conventional radiation therapy.

[2280] The present invention also provides a method of rendering a cell more susceptible to cell death, wherein the cell is treated with one or more compounds of the invention prior to the treatment of the cell to cause or induce cell death. In one aspect, after the cell is treated with one or more compounds of the invention, the cell is treated with at least one compound, or at least one method, or a combination thereof, in order to cause DNA damage for the purpose of inhibiting the function of the normal cell or killing the cell.

[2281] In one embodiment, a cell is killed by treating the cell with at least one DNA damaging agent. That is, after treating a cell with one or more compounds of the invention to sensitize the cell to cell death, the cell is treated with at least one DNA damaging agent to kill the cell. DNA damaging agents useful in the present invention include, but are not limited to, chemotherapeutic agents (e.g., cisplatinum), ionizing radiation (X-rays, ultraviolet radiation), carcinogenic agents, and mutagenic agents.

[2282] In another embodiment, a cell is killed by treating the cell with at least one method to cause or induce DNA damage. Such methods include, but are not limited to, activation of a cell signalling pathway that results in DNA damage when the pathway is activated, inhibiting of a cell signalling pathway that results in DNA damage when the pathway is inhibited, and inducing a biochemical change in a cell, wherein the change results in DNA damage. By way of a non-limiting example, a DNA repair pathway in a cell can be inhibited, thereby preventing the repair of DNA damage and resulting in an abnormal accumulation of DNA damage in a cell.

[2283] In one aspect of the invention, a compound of the invention is administered to a cell prior to the radiation or other induction of DNA damage in the cell. In another aspect of the invention, a compound of the invention is administered to a cell concomitantly with the radiation or other induction of DNA damage in the cell. In yet another aspect of the invention, a compound of the invention is administered to a cell immediately after radiation or other induction of DNA damage in the cell has begun.

[2284] In another aspect, the cell is in vitro. In another embodiment, the cell is in vivo.

[2285] As mentioned supra, the compounds of the present invention have surprisingly been found to effectively inhibit the spindle assembly checkpoint and may therefore be used for the treatment or prophylaxis of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, or diseases which are accompanied with uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses are affected by inhibition of the spindle assembly checkpoint, such as, for example, haematological tumours, solid tumours, and/or metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

[2286] In accordance with another aspect therefore, the present invention covers a compound of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, as described and defined herein, for use in the treatment or prophylaxis of a disease, as mentioned supra.

[2287] Another particular aspect of the present invention is therefore the use of a compound of general formula (I), described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the prophylaxis or treatment of a disease.

[2288] Another particular aspect of the present invention is therefore the use of a compound of general formula (I) described supra for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

[2289] The diseases referred to in the two preceding paragraphs are diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, or diseases which are accompanied with uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, such as, for example, haematological tumours, solid tumours, and/or metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

[2290] The term “inappropriate” within the context of the present invention, in particular in the context of “inappropriate cellular immune responses, or inappropriate cellular inflammatory responses”, as used herein, is to be understood as meaning a response which is less than, or greater than normal, and which is associated with, responsible for, or results in, the pathology of said diseases.

[2291] Preferably, the use is in the treatment or prophylaxis of diseases, wherein the diseases are haemotological tumours, solid tumours and/or metastases thereof.

[2292] Method of Treating Hyper-Proliferative Disorders

[2293] The present invention relates to a method for using the compounds of the present invention and compositions thereof, to treat mammalian hyper-proliferative disorders. Compounds can be utilized to inhibit, block, reduce, decrease, etc., cell proliferation and/or cell division, and/or produce apoptosis. This method comprises administering to a mammal in need thereof, including a human, an amount of a compound of this invention, or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof; etc. which is effective to treat the disorder. Hyperproliferative disorders include but are not limited, e.g., psoriasis, keloids, and other hyperplasias affecting the skin, benign prostate hyperplasia (BPH), solid tumours, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases. Those disorders also include lymphomas, sarcomas, and leukaemias.

[2294] Example s of breast cancer include, but are not limited to invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.

[2295] Examples of cancers of the respiratory tract include, but are not limited to small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.

[2296] Examples of brain cancers include, but are not limited to brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumour.

[2297] Tumours of the male reproductive organs include, but are not limited to prostate and testicular cancer. Tumours of the female reproductive organs include, but are not limited to endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.

[2298] Tumours of the digestive tract include, but are not limited to anal, colon, colorectal, oesophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.

[2299] Tumours of the urinary tract include, but are not limited to bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers.

[2300] Eye cancers include, but are not limited to intraocular melanoma and retinoblastoma.

[2301] Examples of liver cancers include, but are not limited to hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.

[2302] Skin cancers include, but are not limited to squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.

[2303] Head-and-neck cancers include, but are not limited to laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, lip and oral cavity cancer and squamous cell. Lymphomas include, but are not limited to AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.

[2304] Sarcomas include, but are not limited to sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.

[2305] Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.

[2306] These disorders have been well characterized in humans, but also exist with a similar etiology in other mammals, and can be treated by administering pharmaceutical compositions of the present invention.

[2307] The term “treating” or “treatment” as stated throughout this document is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of, etc., of a disease or disorder, such as a carcinoma.

[2308] Methods of Treating Angiogenic Disorders

[2309] The present invention also provides methods of treating disorders and diseases associated with excessive and/or abnormal angiogenesis.

[2310] Inappropriate and ectopic expression of angiogenesis can be deleterious to an organism. A number of pathological conditions are associated with the growth of extraneous blood vessels. These include, e.g., diabetic retinopathy, ischemic retinal-vein occlusion, and retinopathy of prematurity [Aiello et al. New Engl. J. Med. 1994, 331, 1480; Peer et al. Lab. Invest. 1995, 72, 638], age-related macular degeneration [AMD; see, Lopez et al. Invest. Opththalmol. Vis. Sci. 1996, 37, 855], neovascular glaucoma, psoriasis, retrolental fibroplasias, angiofibroma, inflammation, rheumatoid arthritis (RA), restenosis, in-stent restenosis, vascular graft restenosis, etc. In addition, the increased blood supply associated with cancerous and neoplastic tissue, encourages growth, leading to rapid tumour enlargement and metastasis. Moreover, the growth of new blood and lymph vessels in a tumour provides an escape route for renegade cells, encouraging metastasis and the consequence spread of the cancer. Thus, compounds of the present invention can be utilized to treat and/or prevent any of the aforementioned angiogenesis disorders, e.g., by inhibiting and/or reducing blood vessel formation; by inhibiting, blocking, reducing, decreasing, etc. endothelial cell proliferation or other types involved in angiogenesis, as well as causing cell death or apoptosis of such cell types.

[2311] Dose and Administration

[2312] Based upon standard laboratory techniques known to evaluate compounds useful for the treatment of hyper-proliferative disorders and angiogenic disorders, by standard toxicity tests and by standard pharmacological assays for the determination of treatment of the conditions identified above in mammals, and by comparison of these results with the results of known medicaments that are used to treat these conditions, the effective dosage of the compounds of this invention can readily be determined for treatment of each desired indication. The amount of the active ingredient to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.

[2313] The total amount of the active ingredient to be administered will generally range from about 0.001 mg/kg to about 200 mg/kg body weight per day, and preferably from about 0.01 mg/kg to about 20 mg/kg body weight per day. Clinically useful dosing schedules will range from one to three times a day dosing to once every four weeks dosing. In addition, “drug holidays” in which a patient is not dosed with a drug for a certain period of time, may be beneficial to the overall balance between pharmacological effect and tolerability. A unit dosage may contain from about 0.5 mg to about 1500 mg of active ingredient, and can be administered one or more times per day or less than once a day. The average daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily. The transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg. The average daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.

[2314] Of course the specific initial and continuing dosage regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound employed, the age and general condition of the patient, time of administration, route of administration, rate of excretion of the drug, drug combinations, and the like. The desired mode of treatment and number of doses of a compound of the present invention or a pharmaceutically acceptable salt or ester or composition thereof can be ascertained by those skilled in the art using conventional treatment tests.

[2315] Preferably, the diseases of said method are haematological tumours, solid tumour and/or metastases thereof.

[2316] The compounds of the present invention can be used in particular in therapy and prevention, i.e. prophylaxis, of tumour growth and metastases, especially in solid tumours of all indications and stages with or without pre-treatment of the tumour growth.

[2317] Methods of testing for a particular pharmacological or pharmaceutical property are well known to persons skilled in the art.

[2318] The example testing experiments described herein serve to illustrate the present invention and the invention is not limited to the examples given.

[2319] Biological Assays:

[2320] Examples were tested in selected biological assays one or more times. When tested more than once, data are reported as either average values or as median values, wherein [2321] the average value, also referred to as the arithmetic mean value, represents the sum of the values obtained divided by the number of times tested, and [2322] the median value represents the middle number of the group of values when ranked in ascending or descending order. If the number of values in the data set is odd, the median is the middle value. If the number of values in the data set is even, the median is the arithmetic mean of the two middle values.

[2323] Examples were synthesized one or more times. When synthesized more than once, data from biological assays represent average values or median values calculated utilizing data sets obtained from testing of one or more synthetic batch.

[2324] Spindle Assembly Checkpoint (SAC) Assays

[2325] The spindle assembly checkpoint assures the proper segregation of chromosomes during mitosis. Upon entry into mitosis, chromosomes begin to condensate which is accompanied by the phosphorylation of histone H3 on serine 10. Dephosphorylation of histone H3 on serine 10 begins in anaphase and ends at early telophase. Accordingly, phosphorylation of histone H3 on serine 10 can be utilized as a marker of cells in mitosis. Nocodazole is a microtubule destabilizing substance. Paclitaxel is a microtubule stabilizing compound. Thus, nocodazole as well as paclitaxel interfere with microtubule dynamics and mobilize the spindle assembly checkpoint. The cells arrest in mitosis at G2/M transition and exhibit phosphorylated histone H3 on serine 10. An inhibition of the spindle assembly checkpoint overrides the mitotic blockage in the presence of nocodazole or paclitaxel, the cells complete mitosis prematurely, and their nuclei typically exhibit a multilobed phenotype. The mitotic breakthrough can be detected by the decrease of cells with phosphorylation of histone H3 on serine 10. This decline is used as a marker to determine the capability of compounds of the present invention to induce a mitotic breakthrough. The typical morphological alteration of nuclei with a prematurely completed mitosis after SAC-inhibition can be monitored via image analysis routines supporting those findings.

[2326] The nocodazole and paclitaxel variations were used to focus on compounds that are capable of inhibiting a SAC induced by both microtubule destabilization as well as microtubule stabilization. When SAC inducing agents and compounds are given simultaneously inhibitors that effectively block the SAC during formation or abrogation are identified. When cells are incubated with a SAC inducing agent and the SAC interfering compound is given after a defined time, inhibitors are identified that effectively block SAC abrogation.

[2327] SAC-Formation—Nocodazole-Induced Assay

[2328] Cultivated cells of the human cervical tumor cell line HeLa (ATCC CCL-2) were plated at a density of 1000 cells/well in a 1536-well microtiter plate in 2 μl PAA Ham's F12 Medium supplemented with 1% (v/v) glutamine, 1% (v/v) penicillin, 1% (v/v) streptomycin and 10% (v/v) fetal calf serum. After incubation overnight at 37° C., 10 μl/well nocodazole at a final concentration of 0.1 μg/ml were added to cells. Test compounds solubilized in dimethyl sulfoxide (DMSO) were added at various concentrations (0 μM, as well as in the range of 0.005 μM-20 μM; the final concentration of the solvent DMSO was 0.5% (v/v)). Cells were incubated for 24 h at 37° C. in the presence of test compounds in combination with nocodazole. Thereafter, cells were fixed in 4% (v/v) paraformaldehyde in phosphate buffered saline (PBS) at 4° C. overnight then permeabilized in 0.1% (v/v) Triton X™ 100 in PBS at room temperature for 20 min and blocked in 0.5% (v/v) bovine serum albumin (BSA) in PBS at room temperature for 15 min. After washing with PBS, 5 μl/well antibody solution (anti-phospho-histone H3 clone 3H10, FITC; Millipore, Cat#16-222; 1:1000 dilution) was added to cells, which were incubated for 2 h at room temperature. Afterwards, cells were washed with PBS and 5 μl/well solution of HOECHST 33342 dye (5 μg/ml) was added to cells and cells were incubated 15 min at room temperature in the dark. Cells were washed twice with PBS then covered with PBS and stored at 4° C. until analysis. Images were acquired with a PERKIN ELMER OPERA™ High-Content Analysis reader. Images were analyzed with image analysis software MetaXpress™ from Molecular devices utilizing the Mitotic Index application module. In this assay both labels HOECHST 33342 and phosphorylated Histone H3 on serine 10 were measured. HOECHST 33342 labels the DNA and is used to count the cell number. The staining of phosphorylated Histone H3 on serine 10 determines the number of mitotic cells. After 24 h incubation, inhibition of SAC in presence of nocodazole decreases the number of mitotic cells indicating an inappropriate mitotic progression. Otherwise cells were arrested at G2/M phase of the cell cycle progression. The raw assay data were further analyzed by four-parametric hill equation using Genedata's Assay Analyzer and Condoseo software.

TABLE-US-00008 TABLE 4 SAC-Formation - Nocodazole-Induced Assay Example No. IC.sub.50 [mol/l] 1 7.2E−8 2 5.6E−7 3 2.3E−7 4 9.8E−7 5 4.3E−8 6 1.4E−5 7 6.0E−7 8 1.5E−6 9 2.2E−7 10 2.6E−7 11 1.0E−6 12 2.2E−7 13 4.6E−6 14 9.4E−7 15 1.0E−7 16 4.1E−8 17 2.1E−7 18 4.4E−8 19 3.2E−7 20 5.3E−8 21 6.1E−8 22 5.8E−7 23 4.9E−8 24 2.0E−5 25 1.6E−8 26 2.4E−6 27 1.5E−7 28 1.1E−5 29 1.6E−5 30 6.2E−7 31 2.2E−7 32 4.0E−6 33 1.4E−6 34 2.8E−7 35 1.5E−5 36 2.1E−7 37 4.2E−6 38 1.8E−6 39 1.5E−8 40 1.5E−7 41 2.4E−7 42 8.2E−7 43 1.3E−7 44 2.0E−5 45 3.5E−6 46 4.1E−8 47 3.6E−6 48 5.8E−6 49 2.9E−8 50 4.5E−6 51 2.0E−5 52 2.8E−8 53 9.5E−7 54 9.9E−7 55 9.3E−7 56 1.2E−6 57 3.4E−7 58 3.0E−6 59 3.4E−6 60 3.1E−7 61 3.1E−8 62 4.4E−7 63 1.9E−7 64 3.2E−7 65 4.1E−7 66 7.2E−7 67 1.6E−8 68 1.1E−7 69 8.7E−7 70 2.2E−6 71 1.4E−6 72 5.2E−8 73 2.5E−7 74 1.3E−6 75 1.5E−8 76 5.0E−6 77 2.2E−6 78 4.7E−7 79 9.0E−7 80 1.8E−6 81 1.0E−5 82 3.7E−6 83 5.0E−8 84 9.6E−8 85 1.8E−8 86 3.2E−6 87 3.9E−7 88 3.1E−8 89 2.9E−6 90 7.9E−7 91 4.2E−8 92 9.4E−7 93 7.1E−7 94 9.4E−7 95 6.8E−8 96 1.8E−9 97 2.4E−8 98 3.8E−9 99 1.1E−6 100 1.5E−6 101 1.8E−6 102 4.9E−6 103 1.3E−5 104 1.8E−6 105 2.0E−5 106 1.4E−7 107 1.1E−8 108 1.9E−8 109 7.0E−9 110 3.5E−8 111 1.1E−7 112 2.3E−7 113 2.1E−7 114 2.1E−7 115 1.2E−6 116 8.1E−7 117 1.9E−7 118 1.1E−7 119 4.5E−6 120 121 3.4E−07 122 3.9E−08 123 1.2E−08 124 2.4E−08 125 126 127 5.3E−08 128 1.5E−08 129 3.2E−08 130 131 132 2.7E−08 133 2.7E−08 134 3.6E−08 135 136 137 3.4E−08 138 1.1E−07 139 1.6E−08 140 6.0E−08 141 3.6E−08 142 143 144 3.6E−08 145 1.3E−08 146 6.3E−08 147 5.9E−09 148 2.1E−07 149 4.7E−07 150 1.6E−07 151 2.9E−07 152 8.4E−06 153 6.5E−08 154 7.1E−07 155 1.7E−06 156 2.1E−06 157 1.7E−06 158 2.4E−07 159 1.5E−06 160 2.0E−06 162 1.6E−07 163 6.1E−08 164 8.4E−08 165 2.4E−07 166 5.2E−08 167 9.1E−08 168 1.7E−08 169 2.5E−06 170 2.3E−06 171 7.1E−08 172 3.5E−06 173 1.9E−06 174 5.8E−06 175 2.2E−06 176 2.3E−07 177 3.9E−06 178 2.1E−07 179 3.2E−07 180 1.3E−06 181 2.6E−07 182 2.5E−08 183 1.5E−06 184 8.8E−08 185 1.6E−06 186 6.3E−07 187 2.2E−06 188 2.3E−07 189 1.5E−07 190 7.5E−08 191 5.9E−08 192 3.7E−08 193 4.7E−07 194 2.3E−07 195 6.6E−07 196 1.3E−06 197 1.0E−06 198 1.0E−06 199 9.5E−07 200 4.6E−07 201 5.2E−07 202 2.2E−07 203 1.3E−06 204 4.9E−07 205 6.0E−06 206 1.1E−07 207 2.0E−07 208 3.3E−07 209 2.1E−06 210 3.2E−06 211 9.6E−08 212 2.0E−06 213 2.7E−06 214 3.2E−07 215 2.1E−07 216 1.4E−07 217 8.6E−07 218 3.8E−07 219 9.1E−07 220 1.1E−06 221 9.2E−08 222 7.7E−07 223 1.8E−07 224 1.1E−07 225 3.1E−07 226 1.2E−07 227 5.8E−08 228 1.8E−07 229 1.4E−07 230 8.9E−08 231 5.8E−08 233 4.7E−06 234 1.0E−06 235 5.3E−07 236 3.0E−06 237 5.8E−07 238 3.5E−06 239 5.1E−07 240 1.3E−07 241 1.4E−06 242 2.6E−06 243 1.8E−06 244 3.7E−06 245 1.8E−06 246 3.3E−07 247 1.2E−06 248 7.3E−07 249 9.6E−07 250 7.9E−07 251 1.5E−06 252 5.3E−07 253 8.3E−07 254 2.8E−06 255 3.7E−06 256 1.6E−06 257 5.5E−07 258 6.0E−07 259 4.0E−07 260 8.7E−08 261 1.1E−06 262 2.6E−07 263 9.2E−07 264 3.5E−08 265 1.9E−07 266 1.5E−07 267 4.7E−08 268 3.8E−08 269 1.2E−07 270 9.5E−07 271 1.1E−06 272 2.3E−07 273 1.1E−06 274 1.4E−07 275 8.4E−07 276 3.5E−07 277 6.5E−07 278 1.9E−07 279 1.2E−07 280 6.7E−07 281 1.2E−06 282 6.7E−06 283 3.3E−06 284 7.6E−08 285 2.2E−06 286 4.1E−06 287 7.2E−06 288 7.7E−06 289 1.9E−06 290 2.0E−06 291 1.4E−06 292 9.8E−07 293 3.1E−06 294 4.5E−07 295 5.9E−07 296 1.8E−07 297 8.0E−08 298 8.0E−08 299 2.1E−07 300 4.4E−07 301 1.1E−07 302 7.0E−08 303 5.1E−08 304 1.3E−07 305 5.1E−07 306 2.4E−08 307 9.9E−08 308 3.1E−08 309 1.3E−07 310 5.9E−08 311 1.3E−07 312 8.2E−08 313 1.4E−07 314 5.3E−08 315 4.3E−09 316 2.8E−08 317 8.8E−08 318 4.2E−08 318 4.1E−07 320 5.5E−08 321 1.4E−07 322 6.9E−08 323 3.0E−08 324 7.1E−08 325 1.1E−07 326 5.6E−09 327 6.3E−09 328 1.8E−09 329 3.5E−08 330 2.3E−08 331 6.2E−09 332 7.1E−09 333 7.3E−08 334 4.7E−08 335 5.5E−08 336 4.9E−08 337 6.1E−08 338 2.7E−08 339 4.0E−08 340 3.3E−08 341 2.7E−08 342 7.2E−08 343 2.1E−07 344 2.9E−07 345 2.8E−08 346 3.3E−08 347 4.0E−08 348 3.1E−07 349 8.1E−08 350 9.9E−08 351 9.8E−08 352 4.7E−07 353 9.6E−08 354 1.1E−07 355 1.5E−07 356 5.0E−08 357 4.4E−08 358 3.0E−08 359 2.9E−08 360 3.6E−08 361 6.8E−08 362 2.3E−09 363 1.1E−07 364 1.2E−08 365 3.4E−08 366 5.8E−08 367 2.7E−08 368 1.6E−08 369 5.8E−08 370 2.2E−08 371 2.7E−08 372 1.2E−07 373 2.6E−07 374 1.2E−07 375 4.0E−08 376 5.0E−08 377 4.0E−08 378 379 3.4E−08 380 3.4E−07 381 4.7E−08 382 2.4E−08 383 2.7E−08 384 6.2E−08 385 1.8E−07 386 4.1E−08 387 7.0E−08 388 3.7E−08 389 9.3E−08 390 1.1E−07 392 7.4E−08 393 1.4E−08 395 3.5E−08 396 1.4E−08 397 3.1E−08 398 2.8E−08 399 2.9E−08 400 8.1E−08 401 2.7E−08 402 1.2E−06 403 3.0E−08 404 6.3E−08 405 8.6E−08 406 3.3E−08 407 3.9E−08 408 3.1E−09 409 2.1E−08 410 1.0E−08 411 2.4E−008 412 1.3E−08 413 1.7E−08 414 3.9E−08 415 1.8E−08 416 4.2E−09 417 9.4E−09 418 2.1E−07 419 3.8E−08 420 1.2E−07 421 3.4E−07 422 4.0E−08 423 4.7E−08 424 7.4E−08 425 7.2E−07 426 3.0E−08 427 7.0E−07 428 8.9E−07 429 1.6E−08 430 1.1E−08 431 1.0E−05 432 1.7E−07 433 2.1E−07 434 9.7E−07 435 1.2E−05 450 1.2E−5

[2329] SAC-Formation - Paclitaxel-Induced Assay

[2330] Cultivated cells of the human cervical tumor cell line HeLa (ATCC CCL-2) were plated at a density of 1000 cells/well in a 1536-well microtiter plate in 2 μl PAA

[2331] Ham's F12 Medium supplemented with 1% (v/v) glutamine, 1% (v/v) penicillin, 1% (v/v) streptomycin and 10% (v/v) fetal calf serum. After incubation overnight at 37° C., 10 μl/well paclitaxel at a final concentration of 0.05 μM were added to cells. Test compounds solubilized in dimethyl sulfoxide (DMSO) were added at various concentrations (0 μM, as well as in the range of 0.005 μM -20 μM; the final concentration of the solvent DMSO was 0.5% (v/v)). Cells were incubated for 24 h at 37° C. in the presence of test compounds in combination with paclitaxel. Thereafter, cells were fixed in 4% (v/v) paraformaldehyde in phosphate buffered saline (PBS) at 4° C. overnight then permeabilized in 0.1% (v/v) Triton X™ 100 in PBS at room temperature for 20 min and blocked in 0.5% (v/v) bovine serum albumin (BSA) in PBS at room temperature for 15 min. After washing with PBS, 5 μl/well antibody solution (anti-phospho-histone H3 clone 3H10, FITC; Millipore, Cat#16-222; 1:1000 dilution) was added to cells, which were incubated for 2 h at room temperature. Afterwards, cells were washed with PBS and 5 μl/well solution of HOECHST 33342 dye (5 μg/ml) was added to cells and cells were incubated 15 min at room temperature in the dark. Cells were washed twice with PBS then covered with PBS and stored at 4° C. until analysis. Images were acquired with a PERKIN ELMER OPERA™ High-Content Analysis reader. Images were analyzed with image analysis software MetaXpress™ from Molecular devices utilizing the Mitotic Index application module. In this assay both labels HOECHST 33342 and phosphorylated Histone H3 on serine 10 were measured. HOECHST 33342 labels the DNA and is used to count the cell number. The staining of phosphorylated Histone H3 on serine 10 determines the number of mitotic cells. After 24 h incubation, inhibition of SAC in presence of paclitaxel decreases the number of mitotic cells indicating an inappropriate mitotic progression. Otherwise cells were arrested at G2/M phase of the cell cycle progression. The raw assay data were further analyzed by four-parametric hill equation using Genedata's Assay Analyzer and Condoseo software.

TABLE-US-00009 TABLE 5 SAC-Formation - Paclitaxel-Induced Assay Example No. IC.sub.50 [mol/l] 1 9.4E−8 2 4.6E−7 3 1.3E−7 4 9.8E−7 5 1.1E−7 6 1.9E−5 7 7.7E−7 8 1.5E−6 9 3.6E−7 10 3.4E−7 11 1.5E−7 12 2.3E−7 13 1.3E−5 14 6.3E−7 15 8.7E−8 16 4.2E−7 17 3.0E−7 18 5.9E−8 19 2.1E−6 20 1.8E−7 21 1.5E−7 22 2.1E−6 23 3.2E−8 24 2.0E−5 25 6.6E−8 26 2.0E−5 27 1.3E−7 28 2.0E−5 29 2.0E−5 30 4.2E−7 31 6.1E−7 32 1.1E−5 33 7.4E−8 34 9.9E−7 35 2.0E−5 36 5.9E−7 37 5.2E−6 38 1.3E−5 39 2.4E−8 40 3.9E−7 41 1.8E−6 42 1.7E−6 43 3.0E−7 44 2.0E−5 45 2.0E−5 46 2.5E−7 47 1.3E−5 48 6.6E−6 49 4.1E−7 50 6.2E−7 51 2.0E−5 52 7.8E−7 53 1.1E−6 54 1.3E−6 55 3.1E−6 56 4.3E−6 57 1.2E−6 58 7.3E−6 59 2.0E−5 60 2.4E−7 61 2.8E−7 62 1.5E−6 63 4.4E−7 64 1.3E−6 65 7.4E−6 66 2.0E−5 67 6.7E−7 68 1.1E−6 69 2.6E−6 70 1.0E−5 71 2.0E−5 72 1.0E−5 73 5.3E−6 74 5.3E−6 75 1.0E−5 76 1.8E−5 77 1.0E−5 78 2.0E−6 79 3.7E−6 80 3.5E−6 81 1.1E−5 82 1.4E−5 83 9.4E−7 84 8.4E−6 85 9.7E−7 86 1.3E−5 87 1.5E−6 88 4.8E−7 89 1.1E−5 90 1.7E−5 91 2.3E−7 92 2.0E−5 93 2.7E−6 94 8.4E−6 95 1.0E−5 96 3.9E−8 97 2.0E−5 98 7.9E−9 99 2.0E−5 100 2.0E−5 101 2.0E−5 102 7.5E−6 103 2.0E−5 104 3.2E−6 105 2.0E−5 106 1.3E−7 107 2.1E−7 108 5.3E−8 109 3.7E−8 110 1.5E−7 111 1.3E−7 112 8.0E−7 113 1.7E−6 114 1.3E−6 115 3.7E−6 116 1.5E−6 117 1.5E−6 118 5.3E−8 119 2.0E−5 120 121 4.3E−08 122 3.0E−08 123 2.4E−08 124 3.8E−08 125 126 127 8.3E−08 128 7.0E−08 129 8.4E−08 130 131 132 133 134 135 136 137 3.2E−08 138 1.7E−07 139 8.9E−08 140 1.1E−07 141 1.2E−07 142 143 144 9.4E−08 145 3.7E−08 146 1.1E−07 147 3.0E−08 148 3.1E−07 149 1.6E−06 150 2.5E−07 151 1.3E−06 152 8.8E−06 153 3.7E−07 154 1.2E−06 155 2.0E−05 156 4.0E−06 157 9.0E−07 158 2.8E−06 159 1.0E−05 160 3.6E−06 162 1.2E−07 163 3.9E−08 164 1.4E−07 165 5.9E−07 166 1.7E−07 167 3.4E−07 168 7.5E−08 169 1.4E−05 170 1.1E−06 171 4.0E−06 172 2.3E−06 173 6.7E−06 174 5.5E−07 175 2.6E−06 176 2.4E−07 177 1.1E−05 178 2.6E−07 179 2.2E−06 180 4.3E−06 181 1.0E−07 182 1.9E−08 183 4.9E−06 184 1.4E−07 185 4.7E−06 186 3.8E−06 187 1.4E−06 188 1.0E−05 189 4.5E−07 190 8.9E−08 191 3.7E−08 192 1.8E−07 193 5.1E−07 194 2.9E−07 195 5.2E−07 196 1.3E−06 197 6.0E−07 198 7.4E−07 199 1.1E−07 200 1.2E−06 201 2.2E−07 202 1.3E−07 203 8.5E−06 204 4.5E−07 205 2.0E−05 206 7.5E−08 207 7.6E−08 208 4.1E−08 209 2.3E−06 210 7.7E−06 211 4.7E−08 212 4.1E−06 213 2.9E−06 214 1.6E−06 215 7.2E−08 216 1.4E−07 217 4.1E−07 218 3.9E−06 219 6.6E−07 220 9.7E−07 221 5.0E−07 222 8.2E−07 223 1.1E−07 224 1.8E−07 225 5.7E−07 226 2.1E−07 227 3.0E−07 228 4.8E−08 229 3.6E−07 230 8.2E−08 231 2.6E−07 233 4.1E−06 234 1.0E−05 235 1.5E−06 236 2.0E−05 237 2.0E−05 238 9.7E−06 239 6.3E−07 240 7.0E−08 241 2.3E−06 242 3.3E−06 243 6.5E−06 244 3.9E−06 245 1.7E−06 246 7.7E−08 247 1.4E−07 248 9.4E−07 249 1.1E−06 250 4.7E−06 251 3.0E−06 252 1.2E−07 253 2.2E−06 254 2.3E−06 255 1.0E−05 256 3.6E−06 257 2.7E−06 258 2.0E−06 259 4.4E−06 260 4.0E−07 261 2.9E−06 262 4.8E−06 263 3.5E−06 264 7.2E−08 265 1.5E−07 266 1.6E−07 267 2.0E−08 268 1.1E−07 269 2.1E−07 270 1.0E−05 271 2.1E−06 272 2.4E−06 273 4.8E−06 274 9.0E−06 275 4.4E−06 276 1.9E−06 277 1.0E−05 278 1.4E−06 279 7.2E−07 280 3.7E−06 281 3.9E−06 282 3.5E−06 283 7.1E−06 284 1.2E−07 285 6.1E−06 286 6.5E−06 287 8.2E−06 288 6.1E−06 289 3.3E−06 290 3.6E−06 291 4.8E−06 292 4.2E−07 293 4.0E−06 294 5.6E−07 295 1.2E−06 296 3.0E−07 297 5.6E−08 298 7.4E−07 299 1.9E−07 300 2.0E−06 301 8.1E−07 302 4.3E−07 303 3.2E−08 304 9.0E−08 305 2.2E−07 306 9.5E−08 307 3.8E−07 308 5.1E−08 309 6.1E−07 310 4.9E−08 311 4.8E−07 312 313 5.5E−08 314 7.8E−08 315 6.0E−08 316 4.5E−08 317 6.1E−07 318 9.0E−08 318 2.6E−07 320 2.9E−07 321 1.1E−06 322 1.5E−07 323 8.0E−07 324 8.7E−07 325 5.3E−08 326 2.3E−06 327 5.7E−08 328 3.7E−08 329 1.8E−07 330 2.5E−08 331 2.3E−08 332 2.5E−08 333 2.0E−07 334 5.6E−08 335 9.8E−08 336 6.1E−08 337 5.1E−08 338 7.9E−08 339 1.2E−08 340 3.5E−08 341 3.7E−08 342 1.1E−07 343 2.1E−07 344 2.8E−07 345 2.1E−08 346 3.2E−08 347 6.4E−08 348 5.2E−07 349 5.0E−08 350 5.7E−08 351 2.1E−07 352 5.2E−07 353 1.5E−07 354 1.2E−07 355 1.9E−07 356 2.5E−07 357 9.9E−08 358 6.8E−08 359 1.1E−07 360 7.5E−08 361 1.2E−07 362 5.9E−08 363 4.7E−08 364 4.0E−08 365 1.5E−07 366 9.8E−08 367 3.7E−08 368 6.4E−08 369 1.5E−07 370 3.1E−08 371 5.1E−08 372 3.3E−07 373 1.9E−07 374 2.1E−07 375 2.0E−07 376 4.4E−08 377 8.8E−08 378 2.9E−08 379 9.6E−08 380 3.3E−07 381 1.4E−07 382 4.5E−08 383 2.7E−08 384 3.2E−08 385 3.0E−07 386 5.7E−08 387 1.3E−07 388 8.0E−08 389 1.6E−07 390 1.1E−07 392 3.0E−08 392 2.7E−08 393 4.4E−07 394 1.9E−07 395 3.5E−08 395 2.7E−08 396 1.8E−08 397 8.2E−08 398 5.6E−08 398 5.6E−08 399 5.9E−08 399 2.7E−08 400 5.9E−08 401 2.7E−08 401 6.3E−08 402 3.4E−06 403 2.7E−08 403 4.2E−08 404 2.0E−08 405 1.6E−07 405 7.4E−08 406 4.9E−08 407 7.9E−08 408 4.7E−08 409 3.9E−08 410 4.2E−08 411 3.9E−08 412 1.1E−08 413 4.2E−08 414 4.4E−08 415 5.3E−08 416 2.7E−08 417 3.2E−08 418 1.4E−07 419 1.3E−07 420 2.4E−07 421 3.3E−07 422 8.8E−08 423 1.4E−07 424 3.2E−07 425 3.5E−07 426 3.2E−08 427 9.2E−07 428 6.2E−07 429 2.6E−07 430 4.5E−08 431 1.0E−05 432 1.2E−06 433 1.3E−06 434 3.5E−06 435 2.0E−05 450 2.0E−05

[2332] SAC-Multilobed Assay

[2333] Cultivated cells of the human cervical tumor cell line HeLa (ATCC CCL-2) were plated at a density of 1000 cells/well in a 1536-well microtiter plate in 2 μl PAA Ham's F12 Medium supplemented with 1% (v/v) glutamine, 1% (v/v) penicillin, 1% (v/v) streptomycin and 10% (v/v) fetal calf serum. After incubation overnight at 37° C., 10 μl/well nocodazole at a final concentration of 0.1 μg/ml were added to cells. Test compounds solubilized in dimethyl sulfoxide (DMSO) were added at various concentrations (0 μM, as well as in the range of 0.005 μM-20 μM; the final concentration of the solvent DMSO was 0.5% (v/v)). Cells were incubated for 24 h at 37° C. in the presence of test compounds in combination with nocodazole. Thereafter, cells were fixed in 4% (v/v) paraformaldehyde in phosphate buffered saline (PBS) at 4° C. overnight then permeabilized in 0.1% (v/v) Triton X™ 100 in PBS at room temperature for 20 min and blocked in 0.5% (v/v) bovine serum albumin (BSA) in PBS at room temperature for 15 min. Afterwards, cells were washed with PBS and 5 μl/well solution of HOECHST 33342 dye (5 μg/ml) was added to cells and cells were incubated 15 min at room temperature in the dark. Cells were washed twice with PBS then covered with PBS and stored at 4° C. until analysis. Images were acquired with a PERKIN ELMER OPERA™ High-Content Analysis reader. Images were analyzed with image analysis software MetaXpress™ from Molecular devices utilizing an image analysis routine that quantifies number of nuclei showing a multilobed shape. This number was related to the number of all nuclei counted with Count Nuclei application module resulting in a multilobed index. In this assay nuclei were identified via DNA staining with HOECHST 33342. After 24 h incubation, inhibition of SAC in presence of nocodazole increases the multilobed index i.e. number of nuclei with a multilobed shape related to all nuclei indicating an inappropriate mitotic progression. The raw assay data were further analyzed by four-parametric hill equation using Genedata's Assay Analyzer and Condoseo software.

[2334] SAC-Abrogation Assay

[2335] HeLa (cervical tumor; ATCC CCL-2) cells were plated at a density of 1000 cells/well in a 1536 well microtiter plate in 2 μl growth medium. After incubation overnight at 37° C., 2 μl/well nocodazole at a final concentration of 0.1 μg/ml was added to cells. After 24 h incubation, cells are arrested at G2/M phase of the cell cycle progression. Test compounds solubilized in DMSO were added at various concentrations (0 μM, as well as in the range of 0.005 μM-10 μM; the final concentration of the solvent DMSO was 0.5% (v/v)). Cells were incubated for 4 h at 37° C. in the presence of test compounds. Thereafter, cells were fixed in 4% (v/v) paraformaldehyde in phosphate buffered saline (PBS) at 4° C. overnight then permeabilized in 0.1% (v/v) Triton X-™ 100 in PBS at room temperature for 20 min and blocked in 0.5% (v/v) bovine serum albumin (BSA) in PBS at room temperature for 15 min. After washing with PBS, 5 μl/well antibody solution (anti-phospho-histone H3 clone 3H10, FITC; Millipore, Cat#16-222; 1:1000 dilution) was added to cells, which were incubated for 2 h at room temperature. Afterwards, cells were washed with PBS and 5 μl/well solution of HOECHST 33342 dye (5 μg/ml) was added to cells and cells were incubated 15 min at room temperature in the dark. Cells were washed twice with PBS then covered with PBS and stored at 4° C. until analysis. Images were acquired with a PERKIN ELMER OPERA™ High-Content Analysis reader. Images were analyzed with image analysis software MetaXpress™ from Molecular devices utilizing the Mitotic Index application module. In this assay both labels HOECHST 33342 and phosphorylated Histone H3 on serine 10 were measured. HOECHST 33342 labels the DNA and is used to count the cell number. The staining of phosphorylated Histone H3 on serine 10 determines the number of mitotic cells. After 24 h incubation, inhibition of SAC in presence of paclitaxel decreases the number of mitotic cells indicating an inappropriate mitotic progression. Otherwise cells were arrested at G2/M phase of the cell cycle progression. The raw assay data were further analyzed by four-parametric hill equation using Genedata's Assay Analyzer and Condoseo software.

[2336] M-Arrest-Assay

[2337] HeLa (cervical tumor; ATCC CCL-2) cells were plated at a density of 1000 cells/well in a 1536 well microtiter plate in 2 μl growth medium. After incubation overnight at 37° C., test compounds solubilized in DMSO were added at various concentrations (0 μM, as well as in the range of 0.005 μM-10 μM; the final concentration of the solvent DMSO was 0.5% (v/v)). Cells were incubated for 24 h at 37° C. in the presence of test compounds. Thereafter, cells were fixed in 4% (v/v) paraformaldehyde in phosphate buffered saline (PBS) at 4° C. overnight then permeabilized in 0.1% (v/v) Triton X™ 100 in PBS at room temperature for 20 min and blocked in 0.5% (v/v) bovine serum albumin (BSA) in PBS at room temperature for 15 min. After washing with PBS, 5 μl/well antibody solution (anti-phospho-histone H3 clone 3H10, FITC; Millipore, Cat#16-222; 1:1000 dilution) was added to cells, which were incubated for 2 h at room temperature. Afterwards, cells were washed with PBS and 5 μl/well solution of HOECHST 33342 dye (5 μg/ml) was added to cells and cells were incubated 15 min at room temperature in the dark. Cells were washed twice with PBS then covered with PBS and stored at 4° C. until analysis. Images were acquired with a PERKIN ELMER OPERA™ High-Content Analysis reader. Images were analyzed with image analysis software MetaXpress™ from Molecular devices utilizing the Mitotic Index application module. In this assay both labels HOECHST 33342 and phosphorylated Histone H3 on serine 10 were measured. HOECHST 33342 labels the DNA and is used to count the cell number. The staining of phosphorylated Histone H3 on serine 10 determines the number of mitotic cells. After 24 h incubation, the majority of the cells have entered mitosis. A compound that is able to arrest cells in M-phase will increase the number of nuclei with phosphorylated histone H3 on serine 10, which will be reflected by an increase of the Mitotic Index. The assay was used to exclude compounds that lead to a considerable G2/M-arrest after 24h incubation. The raw assay data were further analyzed by four-parametric hill equation using Genedata's Assay Analyzer and Condoseo software.

Induction of Cellular Multinucleation by SAC Inhibition

[2338] An abnormal mitosis by abrogating the mitotic spindle checkpoint can result in polyploidy and multi-nucleation in cells. Inhibition of SAC function by competent compounds impairs checkpoint activity and induces failures during cytokinesis. This is consequently associated with nuclear enlargement, multilobulation of nuclei and multinucleated cells resulting in extreme cellular phenotypes after several cell cycle turns with blocked SAC activity as depicted. Osteosarcoma cells U-2 OS (ATCC: HTB-96) were plated at a density of 2500 cells/well in a 384 well microtiter plate in 20 μl growth medium. After incubation overnight at 37° C., 20 μl/well SAC inhibitors at varying concentrations were added to cells in triplicates. Cells were incubated for 0 h, 24 h, 48 h and 72 h at 37° C. in the presence of test compounds.

[2339] Thereafter, cells were fixed, then permeabilized and blocked. Nuclei were marked by a DNA label and alpha-tubulin structures were detected by antibody labeling. Images were acquired with a PERKIN ELMER OPERA™ High-Content Analysis reader. The images were used for a qualitative assessment of the multinucleation state in tested cells after SAC inhibition.

[2340] CDK2/CycE kinase assay

[2341] CDK2/CycE -inhibitory activity of compounds of the present invention was quantified employing the CDK2/CycE TR-FRET assay as described in the following paragraphs.

[2342] Recombinant fusion proteins of GST and human CDK2 and of GST and human CycE, expressed in insect cells (Sf9) and purified by Glutathion-Sepharose affinity chromatography, were purchased from ProQinase GmbH (Freiburg, Germany). As substrate for the kinase reaction biotinylated peptide biotin-Ttds-YISPLKSPYKISEG (C-terminus in amid form) was used which can be purchased e.g. form the company JERINI peptide technologies (Berlin, Germany).

[2343] For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384we11 microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of CDK2/CycE in aqueous assay buffer [50 mM Tris/HCl pH 8.0, 10 mM MgCl.sub.2, 1.0 mM dithiothreitol, 0.1 mM sodium ortho-vanadate, 0.01% (v/v) Nonidet-P40 (Sigma)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.25 μM=>final conc. in the 5 μl assay volume is 0.75 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 25 min at 22° C. The concentration of CDK2/CycE was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical concentrations were in the range of 130 ng/ml. The reaction was stopped by the addition of 5 μl of a solution of TR-FRET detection reagents (0.2 μM streptavidine-XL665 [Cisbio Bioassays, Codolet, France] and 1 nM anti-RB(pSer807/pSer811)-antibody from BD Pharmingen [#558389] and 1.2 nM LANCE EU-W1024 labeled anti-mouse IgG antibody [Perkin-Elmer, product no. AD0077, as an alternative a Terbium-cryptate-labeled anti-mouse IgG antibody from Cisbio Bioassays can be used]) in an aqueous EDTA-solution (100 mM EDTA, 0.2% (w/v) bovine serum albumin in 100 mM HEPES/NaOH pH 7.0).

[2344] The resulting mixture was incubated 1 h at 22° C. to allow the formation of complex between the phosphorylated biotinylated peptide and the detection reagents. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the Eu-chelate to the streptavidine-XL. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a TR-FRET reader, e.g. a Rubystar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Usually the test compounds were tested on the same microtiterplate in 11 different concentrations in the range of 20 μM to 0.1 nM (20 μM, 5.9 μM, 1.7 μM, 0.51 μM, 0.15 μM, 44 nM, 13 nM, 3.8 nM, 1.1 nM, 0.33 nM and 0.1 nM, the dilution series prepared separately before the assay on the level of the 100fold concentrated solutions in DMSO by serial 1:3.4 dilutions) in duplicate values for each concentration and IC.sub.50 values were calculated by a 4 parameter fit.

[2345] Mps-1 Kinase Assay

[2346] The human kinase Mps-1 phosphorylates a biotinylated substrate peptide. Detection of the phosphorylated product is achieved by time-resolved fluorescence resonance energy transfer (TR-FRET) from Europium-labelled anti-phospho-Serine/Threonine antibody as donor to streptavidin labelled with cross-linked allophycocyanin (SA-XLent) as acceptor. Compounds are tested for their inhibition of the kinase activity.

[2347] N-terminally GST-tagged human full length recombinant Mps-1 kinase (purchased from Invitrogen, Karslruhe, Germany, cat. no PV4071) was used. As substrate for the kinase reaction a biotinylated peptide of the amino-acid sequence biotin-Ahx-PWDPDDADITEILG (C-terminus in amide form, purchased from Biosyntan GmbH, Berlin) was used.

[2348] For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384we11 microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Mps-1 in assay buffer [0.1 mM sodium-ortho-vanadate, 10 mM MgCl2,2 mM DTT, 25 mM Hepes pH 7.7, 0.05% BSA (w/v), 0.001% Pluronic F-127] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to Mps-1 before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of 16.7 μM adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and peptide substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22° C. The concentration of Mps-1 in the assay was adjusted to the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical enzyme concentrations were in the range of about 0.5 nM (final conc. in the 5 μl assay volume). The reaction was stopped by the addition of 5 μl of a solution of TR-FRET detection reagents (100 mM Hepes pH 7.4, 0.1% BSA, 40 mM EDTA, 140 nM Streptavidin-XLent [#61GSTXLB, Fa. Cis Biointernational, Marcoule, France], 1.5 nM anti-phospho(Ser/Thr)-Europium-antibody [#AD0180, PerkinElmer LAS, Rodgau-Jugesheinn, Germany]. Instead of the 1.5 nM anti-phospho(Ser/Thr)-Europium-antibody a mixture of 2 nM unlabeled anti-phospho ser/thr-pro antibody MPM-2 [Millipore cat. #05-368] and 1 nM LANCE EU-W1024 labeled anti-mouse IgG antibody [Perkin-Elmer, product no. AD0077] can be used).

[2349] The resulting mixture was incubated 1 h at 22° C. to allow the binding of the phosphorylated peptide to the anti-phospho(Ser/Thr)-Europium-antibody. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the Europium-labelled anti-phospho(Ser/Thr) antibody to the Streptavidin-XLent. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a Viewlux TR-FRET reader (PerkinElmer LAS, Rodgau-Jugesheinn, Germany). The “blank-corrected normalized ratio” (a Viewlux specific readout, similar to the traditional ratio of the emissions at 665 nm and at 622 nm, in which blank and Eu-donor crosstalk are subtracted from the 665 nm signal before the ratio is calculated) was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Usually the test compounds were tested on the same microtiterplate in 11 different concentrations in the range of 20 μM to 0.1 nM (20 μM, 5.9 μM, 1.7 μM, 0.51 μM, 0.15 μM, 44 nM, 13 nM, 3.8 nM, 1.1 nM, 0.33 nM and 0.1 nM, the dilution series prepared separately before the assay on the level of the 100fold concentrated solutions in DMSO by serial 1:3.4 dilutions) in duplicate values for each concentration and IC.sub.50 values were calculated by a 4 parameter fit.

[2350] Bubl Kinase Assay

[2351] Bub1-inhibitory activity of compounds of the present invention was quantified employing the Bub1 TR-FRET assay as described in the following paragraphs.

[2352] N-terminally His6-tagged recombinant catalytic domain of human Bub1 (amino acids 704-1085), expressed in insect cells (Hi5) and purified by Ni-NTA affinity chromatography and subsequent size exclusion chromatography, was used as enzyme. As substrate for the kinase reaction the biotinylated peptide biotin-Ahx-VLLPKKSFAEPG (C-terminus in amid form) was used which can be purchased e.g. form the company Biosyntan (Berlin, Germany).

[2353] For the assay 50 nl of a 100fold concentrated solution of the test compound in DMSO was pipetted into a black low volume 384well microtiter plate (Greiner Bio-One, Frickenhausen, Germany), 2 μl of a solution of Bub1 in aqueous assay buffer [50 mM Tris/HCl pH 7.5, 10 mM magnesium chloride (MgCl2), 200 mM potassium chloride (KCl), 1.0 mM dithiothreitol (DTT), 0.1 mM sodium ortho-vanadate, 1% (v/v) glycerol, 0.01% (w/v) bovine serum albumine (BSA), 0.005% (v/v) Trition X-100 (Sigma), 1× Complete EDTA-free protease inhibitor mixture (Roche)] were added and the mixture was incubated for 15 min at 22° C. to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μl of a solution of adenosine-tri-phosphate (ATP, 16.7 μM=>final conc. in the 5 μl assay volume is 10 μM) and substrate (1.67 μM=>final conc. in the 5 μl assay volume is 1 μM) in assay buffer and the resulting mixture was incubated for a reaction time of 60 min at 22° C. The concentration of Bub1 was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical concentrations were in the range of 200 ng/ml. The reaction was stopped by the addition of 5 μl of a solution of TR-FRET detection reagents (0.2 μM streptavidine-XL665 [Cisbio Bioassays, Codolet, France] and 1 nM anti-phosho-Serine antibody [Merck Millipore, cat. #35-001] and 0.4 nM LANCE EU-W1024 labeled anti-mouse IgG antibody [Perkin-Elmer, product no. AD0077, as an alternative a Terbium-cryptate-labeled anti-mouse IgG antibody from Cisbio Bioassays can be used]) in an aqueous EDTA-solution (50 mM EDTA, 0.2% (w/v) bovine serum albumin in 100 mM HEPES pH 7.5).

[2354] The resulting mixture was incubated 1 h at 22° C. to allow the formation of complex between the phosphorylated biotinylated peptide and the detection reagents. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the Eu-chelate to the streptavidine-XL. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a TR-FRET reader, e.g. a Rubystar or Pherastar (both from BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor=0% inhibition, all other assay components but no enzyme=100% inhibition). Usually the test compounds were tested on the same microtiterplate in 11 different concentrations in the range of 20 μM to 0.1 nM (20 μM, 5.9 μM, 1.7 μM, 0.51 μM, 0.15 μM, 44 nM, 13 nM, 3.8 nM, 1.1 nM, 0.33 nM and 0.1 nM, the dilution series prepared separately before the assay on the level of the 100fold concentrated solutions in DMSO by serial 1:3.4 dilutions) in duplicate values for each concentration and IC.sub.50 values were calculated by a 4 parameter fit.

TABLE-US-00010 TABLE 6 IC.sub.50 data for Bub1, CDK2 and Mps1 kinase assays Bub1 CDK2 Mps1 avg avg avg Example No. (IC.sub.50 [mol/l]) (IC.sub.50 [mol/l]) (IC.sub.50 [mol/l]) 1 2.0E−5 2.0E−5 2.0E−5 2 2.0E−5 2.0E−5 2.0E−5 3 2.0E−5 2.0E−5 4 2.0E−5 2.0E−5 2.0E−5 5 2.0E−5 2.0E−5 2.0E−5 6 2.0E−5 2.0E−5 2.0E−5 7 2.0E−5 2.0E−5 2.0E−5 8 2.0E−5 2.0E−5 2.0E−5 9 2.0E−5 2.0E−5 2.0E−5 10 2.0E−5 2.0E−5 2.0E−5 11 2.0E−5 2.0E−5 2.0E−5 12 2.0E−5 2.0E−5 2.0E−5 13 2.0E−5 2.0E−5 2.0E−5 14 2.0E−5 1.3E−5 2.0E−5 15 2.0E−5 2.0E−5 2.0E−5 16 2.0E−5 2.0E−5 2.0E−5 17 2.0E−5 2.0E−5 1.8E−5 18 2.0E−5 2.0E−5 2.0E−5 19 2.0E−5 2.0E−5 2.0E−5 20 2.0E−5 2.0E−5 2.0E−5 21 2.0E−5 2.0E−5 2.0E−5 22 2.0E−5 2.0E−5 2.0E−5 23 2.0E−5 2.0E−5 1.7E−5 24 2.0E−5 2.0E−5 9.0E−6 25 2.0E−5 2.0E−5 2.0E−5 26 2.0E−5 2.0E−5 2.0E−5 27 2.0E−5 2.0E−5 1.0E−5 28 2.0E−5 2.0E−5 2.0E−5 29 2.0E−5 2.0E−5 2.0E−5 30 2.0E−5 2.0E−5 2.0E−5 31 2.0E−5 2.0E−5 2.0E−5 32 2.0E−5 2.0E−5 1.5E−5 33 2.0E−5 2.0E−5 2.0E−5 34 2.0E−5 2.0E−5 2.0E−5 35 2.0E−5 2.0E−5 2.0E−5 36 2.0E−5 2.0E−5 2.0E−5 37 2.0E−5 2.0E−5 2.0E−5 38 2.0E−5 2.0E−5 2.0E−5 39 2.0E−5 2.0E−5 2.0E−5 40 2.0E−5 2.0E−5 2.0E−5 41 2.0E−5 2.0E−5 2.0E−5 42 2.0E−5 2.0E−5 2.0E−5 43 2.0E−5 2.0E−5 2.0E−5 44 2.0E−5 2.0E−5 2.0E−5 45 2.0E−5 2.0E−5 2.0E−5 46 2.0E−5 2.0E−5 2.0E−5 47 2.0E−5 2.0E−5 2.0E−5 48 2.0E−5 2.0E−5 2.0E−5 49 2.0E−5 2.0E−5 2.0E−5 50 2.0E−5 2.0E−5 2.5E−6 51 1.9E−6 2.0E−5 52 9.0E−6 2.0E−5 1.8E−5 53 9.0E−6 2.0E−5 2.0E−5 54 1.6E−5 2.0E−5 1.0E−5 55 2.0E−5 2.0E−5 2.0E−5 56 2.0E−5 2.0E−5 57 2.0E−5 2.0E−5 2.0E−5 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 2.0E−5 2.0E−5 2.0E−5 97 2.9E−6 2.0E−5 2.0E−5 98 2.0E−5 2.0E−5 2.0E−5 99 2.7E−6 2.0E−5 9.0E−6 100 9.0E−6 2.0E−5 1.2E−5 101 7.6E−6 2.0E−5 1.8E−5 102 1.9E−5 2.0E−5 2.0E−5 103 2.0E−5 2.0E−5 1.3E−5 104 2.0E−5 2.0E−5 1.6E−5 105 1.9E−5 2.0E−5 6.5E−6 106 2.0E−5 2.0E−5 2.0E−5 107 2.0E−5 2.0E−5 2.0E−5 108 2.0E−5 2.0E−5 2.0E−5 109 2.0E−5 2.0E−5 2.0E−5 110 2.0E−5 2.0E−5 2.0E−5 111 2.0E−5 2.0E−5 2.0E−5 112 2.0E−5 2.0E−5 2.0E−5 113 1.8E−5 2.0E−5 1.2E−5 114 2.0E−5 2.0E−5 2.0E−5 115 8.9E−6 2.0E−5 2.0E−5 116 2.0E−5 2.0E−5 2.0E−5 117 2.0E−5 2.0E−5 2.0E−5 118 2.0E−5 2.0E−5 2.0E−5 119 2.0E−5 2.0E−5 2.0E−5 120 121 2.0E−05 2.0E−05 122 2.0E−05 2.0E−05 2.0E−05 123 2.0E−05 2.0E−05 2.0E−05 124 2.0E−05 2.0E−05 2.0E−05 125 126 127 2.0E−05 >2.0E−05 128 >2.0E−05 >2.0E−05 >2.0E−05 129 >2.0E−05 >2.0E−05 >2.0E−05 130 131 132 >2.0E−05 >2.0E−05 133 >2.0E−05 >2.0E−05 134 >2.0E−05 >2.0E−05 135 136 137 >2.0E−05 >2.0E−05 >2.0E−05 138 >2.0E−05 >2.0E−05 >2.0E−05 139 >2.0E−05 >2.0E−05 >2.0E−05 140 >2.0E−05 >2.0E−05 >2.0E−05 141 2.0E−05 >2.0E−05 142 143 144 >2.0E−05 >2.0E−05 >2.0E−05 145 >2.0E−05 >2.0E−05 >2.0E−05 146 >2.0E−05 >2.0E−05 >2.0E−05 147 >2.0E−05 >2.0E−05 >2.0E−05 148 >2.0E−05 >2.0E−05 149 >2.0E−5 >2.0E−5 >2.0E−5 150 >2.0E−5 >2.0E−5 >2.0E−5 151 4.3E−06 >2.0E−5 >2.0E−5 152 >2.0E−5 >2.0E−5 >2.0E−5 153 1.4E−05 >2.0E−5 >2.0E−5 154 >2.0E−5 >2.0E−5 >2.0E−5 155 >2.0E−5 4.1E−06 1.8E−05 156 1.9E−05 >2.0E−5 >2.0E−5 156 >2.0E−05 157 >2.0E−5 >2.0E−5 >2.0E−5 158 >2.0E−5 >2.0E−5 >2.0E−5 159 >2.0E−5 >2.0E−5 >2.0E−5 160 >2.0E−5 >2.0E−5 >2.0E−5 162 >2.0E−5 >2.0E−5 >2.0E−5 163 >2.0E−5 >2.0E−5 >2.0E−5 164 >2.0E−5 >2.0E−5 >2.0E−5 165 >2.0E−5 >2.0E−5 >2.0E−5 166 >2.0E−5 >2.0E−5 >2.0E−5 167 >2.0E−5 >2.0E−5 >2.0E−5 168 >2.0E−5 >2.0E−5 >2.0E−5 169 >2.0E−5 >2.0E−5 >2.0E−5 170 >2.0E−5 >2.0E−5 >2.0E−5 171 >2.0E−5 >2.0E−5 >2.0E−5 172 >2.0E−05 >2.0E−5 >2.0E−5 172 1.8E−05 173 >2.0E−5 >2.0E−5 >2.0E−5 174 >2.0E−5 >2.0E−5 >2.0E−5 175 >2.0E−5 >2.0E−5 176 >2.0E−5 >2.0E−5 >2.0E−5 177 >2.0E−5 >2.0E−5 >2.0E−5 178 >2.0E−5 >2.0E−5 >2.0E−5 179 >2.0E−5 >2.0E−5 >2.0E−5 180 >2.0E−5 >2.0E−5 >2.0E−5 181 >2.0E−5 >2.0E−5 >2.0E−5 182 >2.0E−5 >2.0E−5 >2.0E−5 183 >2.0E−5 >2.0E−5 >2.0E−5 184 >2.0E−5 >2.0E−5 >2.0E−5 185 >2.0E−5 >2.0E−5 >2.0E−5 186 >2.0E−5 >2.0E−5 >2.0E−5 187 3.8E−06 >2.0E−5 5.4E−06 188 >2.0E−5 >2.0E−5 >2.0E−5 189 >2.0E−5 >2.0E−5 >2.0E−5 190 >2.0E−5 >2.0E−5 >2.0E−5 191 >2.0E−5 1.8E−05 >2.0E−5 192 >2.0E−5 >2.0E−5 >2.0E−5 193 >2.0E−5 1.2E−05 >2.0E−5 194 >2.0E−05 >2.0E−05 >1.0E−5 194 1.1E−05 7.8E−06 194 1.9E−05 195 >2.0E−5 >2.0E−5 196 >2.0E−5 >2.0E−5 >2.0E−5 197 9.1E−06 >2.0E−5 >2.0E−5 198 >2.0E−5 >2.0E−5 4.6E−06 199 >2.0E−5 >2.0E−5 >2.0E−5 200 >2.0E−5 >2.0E−5 >2.0E−5 201 >2.0E−5 >2.0E−5 >2.0E−5 202 >2.0E−5 >2.0E−5 5.8E−06 203 >2.0E−5 >2.0E−5 >2.0E−5 204 >2.0E−05 >2.0E−5 1.7E−05 204 1.6E−05 205 >2.0E−5 >2.0E−5 >2.0E−5 206 1.3E−05 >2.0E−5 >2.0E−5 207 >2.0E−5 >2.0E−5 >2.0E−5 208 >2.0E−5 >2.0E−5 >2.0E−5 209 >2.0E−5 >2.0E−5 >2.0E−5 210 >2.0E−5 >2.0E−5 >2.0E−5 211 4.3E−06 1.5E−05 >2.0E−05 211 1.9E−05 212 >2.0E−5 >2.0E−5 >2.0E−5 213 1.7E−05 >2.0E−5 >2.0E−5 214 >2.0E−5 >2.0E−5 215 >2.0E−5 >2.0E−5 >2.0E−5 216 >2.0E−5 >2.0E−5 >2.0E−5 217 >2.0E−5 >2.0E−5 >2.0E−5 218 >2.0E−5 >2.0E−5 >2.0E−5 219 >2.0E−5 >2.0E−5 >2.0E−5 220 >2.0E−5 >2.0E−5 >2.0E−5 221 >2.0E−5 >2.0E−5 >2.0E−5 222 >2.0E−5 >2.0E−5 >2.0E−5 223 >2.0E−5 >2.0E−5 >2.0E−5 224 >2.0E−5 >2.0E−5 >2.0E−5 225 >2.0E−5 >2.0E−5 >2.0E−5 226 >2.0E−5 >2.0E−5 >2.0E−5 227 >2.0E−5 >2.0E−5 >2.0E−5 228 >2.0E−5 >2.0E−5 >2.0E−5 229 >2.0E−5 >2.0E−5 >2.0E−5 230 >2.0E−5 >2.0E−5 >2.0E−5 231 >2.0E−05 >2.0E−05 >2.0E−05 233 >2.0E−5 >2.0E−5 >2.0E−5 234 >2.0E−5 >2.0E−5 >2.0E−5 235 >2.0E−05 >2.0E−05 1.2E−05 236 >2.0E−5 >2.0E−5 >2.0E−05 236 1.4E−05 237 >2.0E−5 >2.0E−5 >2.0E−5 238 >2.0E−5 >2.0E−5 1.0E−05 239 >2.0E−5 >2.0E−5 >2.0E−5 240 >2.0E−5 >2.0E−5 >2.0E−5 241 >2.0E−5 >2.0E−5 >2.0E−5 242 >2.0E−5 >2.0E−5 >2.0E−5 243 >2.0E−5 >2.0E−5 >2.0E−5 244 >2.0E−5 >2.0E−5 >2.0E−5 245 >2.0E−5 1.2E−05 >2.0E−05 245 1.9E−05 246 >2.0E−5 >2.0E−5 >2.0E−5 247 >2.0E−5 >2.0E−5 >2.0E−5 248 >2.0E−5 >2.0E−5 >2.0E−5 249 1.2E−06 >2.0E−5 >2.0E−5 250 >2.0E−5 >2.0E−5 >2.0E−5 251 6.0E−07 >2.0E−5 >2.0E−5 252 >2.0E−5 >2.0E−5 >2.0E−5 253 3.2E−07 >2.0E−5 >2.0E−5 254 3.2E−06 >2.0E−5 >2.0E−5 255 >2.0E−5 >2.0E−5 >2.0E−5 256 >2.0E−5 >2.0E−5 >2.0E−5 257 >2.0E−5 >2.0E−5 >2.0E−5 258 >2.0E−5 >2.0E−5 >2.0E−5 259 >2.0E−5 >2.0E−5 >2.0E−5 260 >2.0E−5 >2.0E−5 >2.0E−5 261 >2.0E−05 >2.0E−05 >2.0E−05 262 >2.0E−5 >2.0E−5 >2.0E−5 263 >2.0E−5 >2.0E−5 >2.0E−5 264 >2.0E−5 >2.0E−5 >2.0E−5 265 >2.0E−5 >2.0E−5 >2.0E−5 266 >2.0E−5 >2.0E−5 >2.0E−5 267 >2.0E−5 >2.0E−5 >2.0E−5 268 1.9E−05 >2.0E−5 >2.0E−5 269 >2.0E−5 >2.0E−5 >2.0E−5 270 >2.0E−5 >2.0E−5 >2.0E−5 271 >2.0E−5 >2.0E−5 >2.0E−5 272 >2.0E−5 >2.0E−5 >2.0E−5 273 >2.0E−05 >2.0E−05 >2.0E−05 274 >2.0E−5 5.4E−06 >2.0E−5 275 >2.0E−5 8.4E−06 >2.0E−5 276 >2.0E−5 >2.0E−5 >2.0E−5 277 >2.0E−05 >2.0E−5 >2.0E−5 277 1.8E−05 278 >2.0E−5 >2.0E−5 >2.0E−5 279 >2.0E−05 >2.0E−5 >2.0E−5 279 1.9E−05 280 >2.0E−5 1.1E−05 >2.0E−05 280 1.1E−05 281 >2.0E−5 >2.0E−5 >2.0E−5 282 >2.0E−5 >2.0E−5 >2.0E−5 283 >2.0E−5 >2.0E−5 284 >2.0E−5 >2.0E−5 >2.0E−5 285 >2.0E−5 >2.0E−5 >2.0E−5 286 >2.0E−5 1.4E−05 287 >2.0E−5 >2.0E−5 >2.0E−5 288 >2.0E−5 >2.0E−5 >2.0E−5 289 >2.0E−5 >2.0E−5 290 >2.0E−5 1.9E−05 >2.0E−5 291 >2.0E−5 1.4E−05 >2.0E−5 292 >2.0E−5 >2.0E−5 >2.0E−5 293 >2.0E−5 >2.0E−5 >2.0E−5 294 >2.0E−5 >2.0E−5 >2.0E−5 295 >2.0E−5 >2.0E−5 >2.0E−5 296 >2.0E−5 >2.0E−5 >2.0E−5 297 >2.0E−5 >2.0E−5 1.2E−05 298 >2.0E−5 >2.0E−5 >2.0E−5 299 >2.0E−5 >2.0E−5 >2.0E−5 300 >2.0E−5 >2.0E−5 >2.0E−5 301 >2.0E−5 >2.0E−5 >2.0E−5 302 >2.0E−5 >2.0E−5 >2.0E−5 303 2.0E−05 2.0E−05 2.0E−05 304 >2.0E−5 >2.0E−5 >2.0E−5 305 1.9E−05 2.0E−05 2.0E−05 306 2.0E−05 2.0E−05 2.0E−05 307 2.0E−05 2.0E−05 2.0E−05 308 2.0E−05 2.0E−05 2.0E−05 309 2.0E−05 2.0E−05 2.0E−05 310 2.0E−05 2.0E−05 311 >2.0E−5 >2.0E−5 >2.0E−5 312 2.0E−05 2.0E−05 2.0E−05 313 2.0E−05 2.0E−05 2.0E−05 314 2.0E−05 2.0E−05 2.0E−05 315 2.0E−05 2.0E−05 2.0E−05 316 2.0E−05 2.0E−05 2.0E−05 317 >2.0E−5 >2.0E−5 >2.0E−5 318 >2.0E−5 >2.0E−5 >2.0E−5 318 >2.0E−5 >2.0E−5 >2.0E−5 320 2.0E−05 2.0E−05 2.0E−05 321 1.4E−05 2.0E−05 2.0E−05 322 2.0E−05 2.0E−05 2.0E−05 323 1.8E−05 2.0E−05 2.0E−05 324 1.9E−05 2.0E−05 2.0E−05 325 2.0E−05 2.0E−05 2.0E−05 326 2.0E−05 2.0E−05 2.0E−05 327 2.0E−05 2.0E−05 2.0E−05 328 2.0E−05 2.0E−05 2.0E−05 329 2.0E−05 2.0E−05 2.0E−05 330 2.0E−05 2.0E−05 2.0E−05 331 2.0E−05 2.0E−05 332 2.0E−05 2.0E−05 2.0E−05 333 2.0E−05 2.0E−05 2.0E−05 334 2.0E−05 2.0E−05 2.0E−05 335 2.0E−05 2.0E−05 2.0E−05 336 2.0E−05 2.0E−05 2.0E−05 337 2.0E−05 2.0E−05 2.0E−05 338 2.0E−05 2.0E−05 2.0E−05 339 >2.0E−5 >2.0E−05 340 >2.0E−5 >2.0E−05 341 >2.0E−5 >2.0E−05 342 >2.0E−5 >2.0E−05 343 2.0E−05 2.0E−05 2.0E−05 344 2.0E−05 2.0E−05 >2.0E−05 345 2.0E−05 2.0E−05 >2.0E−05 346 2.0E−05 2.0E−05 >2.0E−05 347 2.0E−05 2.0E−05 >2.0E−05 348 2.0E−05 2.0E−05 349 2.0E−05 2.0E−05 350 2.0E−05 2.0E−05 351 2.0E−05 2.0E−05 >2.0E−05 352 1.9E−05 2.0E−05 >2.0E−05 353 2.0E−05 1.9E−05 354 2.0E−05 2.0E−05 355 2.0E−05 2.0E−05 356 >2.0E−5 >2.0E−5 >2.0E−05 357 >2.0E−5 >2.0E−5 >2.0E−05 358 >2.0E−5 >2.0E−5 >2.0E−05 359 >2.0E−5 >2.0E−5 >2.0E−05 360 >2.0E−5 >2.0E−5 >2.0E−05 361 >2.0E−5 >2.0E−5 >2.0E−05 362 1.4E−05 >2.0E−5 >2.0E−05 363 >2.0E−5 >2.0E−5 >2.0E−05 364 >2.0E−5 >2.0E−5 >2.0E−05 365 1.6E−05 >2.0E−5 >2.0E−05 366 >2.0E−5 >2.0E−05 367 >2.0E−5 >2.0E−5 >2.0E−05 368 >2.0E−5 >2.0E−5 >2.0E−05 369 >2.0E−5 >2.0E−5 >2.0E−05 370 >2.0E−5 >2.0E−5 371 >2.0E−5 >2.0E−5 372 >2.0E−5 >2.0E−5 >2.0E−05 373 >2.0E−5 >2.0E−5 >2.0E−05 374 >2.0E−5 >2.0E−5 >2.0E−05 375 >2.0E−5 >2.0E−5 >2.0E−05 376 >2.0E−5 >2.0E−5 >2.0E−05 377 >2.0E−05 >2.0E−5 378 2.0E−05 >2.0E−05 379 2.0E−05 >2.0E−05 380 >2.0E−05 >2.0E−5 381 >2.0E−05 >2.0E−5 382 >2.0E−5 >2.0E−5 >2.0E−5 383 2.0E−05 >2.0E−05 384 2.0E−05 >2.0E−05 385 >2.0E−05 386 >2.0E−05 >2.0E−05 387 >2.0E−5 >2.0E−05 2.0E−05 388 >2.0E−05 389 >2.0E−05 390 >2.0E−05 392 >2.0E−5 >2.0E−5 393 >2.0E−5 >2.0E−5 394 >2.0E−5 >2.0E−5 395 >2.0E−5 >2.0E−5 396 >2.0E−5 >2.0E−5 397 >2.0E−5 >2.0E−5 398 >2.0E−5 >2.0E−5 399 >2.0E−5 >2.0E−5 400 >2.0E−5 >2.0E−5 401 >2.0E−5 >2.0E−5 402 >2.0E−5 >2.0E−5 403 >2.0E−5 >2.0E−5 404 >2.0E−5 >2.0E−5 >2.0E−5 405 >2.0E−5 >2.0E−5 406 >2.0E−5 >2.0E−5 >2.0E−5 407 >2.0E−05 >2.0E−05 >2.0E−05 408 >2.0E−05 >2.0E−05 409 >2.0E−05 >2.0E−05 410 >2.0E−05 >2.0E−05 411 >2.0E−05 >2.0E−05 412 >2.0E−05 >2.0E−05 413 >2.0E−05 >2.0E−05 414 >2.0E−05 >2.0E−05 415 >2.0E−05 >2.0E−05 416 >2.0E−05 >2.0E−05 417 1.8E−06 >2.0E−05 418 >2.0E−05 >2.0E−05 419 >2.0E−05 >2.0E−05 420 2.0E−05 >2.0E−05 421 2.0E−05 422 2.0E−05 423 2.0E−05 424 >2.0E−05 >2.0E−05 424 2.0E−05 425 2.0E−05 2.0E−05 2.0E−05 426 2.0E−05 2.0E−05 2.0E−05 427 2.0E−05 2.0E−05 2.0E−05 428 >2.0E−05 >2.0E−05 >2.0E−05 429 >2.0E−05 >2.0E−05 >2.0E−05 430 >2.0E−05 >2.0E−05 >2.0E−05 431 >2.0E−05 >2.0E−05 >2.0E−05 432 >2.0E−05 >2.0E−05 >2.0E−05 433 >2.0E−05 >2.0E−05 434 >2.0E−05 >2.0E−05 >2.0E−05 434 1.9E−05 435 >2.0E−05 >2.0E−05 >2.0E−05

[2355] Proliferation Assay:

[2356] Cultivated tumor cells (cells were ordered from ATCC, except HeLa-MaTu and HeLa-MaTu-ADR, which were ordered from EPO-GmbH, Berlin) were plated at a density of 1000 to 5000 cells/well, depending on the growth rate of the respective cell line, in a 96-well multititer plate in 200 μL of their respective growth medium supplemented 10% fetal calf serum. After 24 hours, the cells of one plate (zero-point plate) were stained with crystal violet (see below), while the medium of the other plates was replaced by fresh culture medium (200 μl), to which the test substances were added in various concentrations (0 μM, as well as in the range of 0.001-10 μM; the final concentration of the solvent dimethyl sulfoxide was 0.5%). The cells were incubated for 4 days in the presence of test substances. Cell proliferation was determined by staining the cells with crystal violet: the cells were fixed by adding 20 μl/measuring point of an 11% glutaric aldehyde solution for 15 minutes at room temperature. After three washing cycles of the fixed cells with water, the plates were dried at room temperature. The cells were stained by adding 100 μl/measuring point of a 0.1% crystal violet solution (pH 3.0). After three washing cycles of the stained cells with water, the plates were dried at room temperature. The dye was dissolved by adding 100 μl/measuring point of a 10% acetic acid solution. Absorbtion was determined by photometry at a wavelength of 595 nm. The change of cell number, in percent, was calculated by normalization of the measured values to the aborbtion values of the zero-point plate (=0%) and the absorbtion of the untreated (0 μm) cells (=100%). The IC.sub.50 values were determined by means of a 4 parameter fit.

TABLE-US-00011 TABLE 7 Compounds had been evaluated in the following cell lines, which examplify the sub-indications listed Tumor indication Cell line Cervical cancer HeLa HeLa-MaTu-ADR Non-small cell lung cancer (NSCLC) NCI-H460 Prostate cancer DU145 Colon cancer Caco2 Melanoma B16F10

TABLE-US-00012 TABLE 8 Inhibition of proliferation of HeLa, HeLa-MaTu-ADR, NCI-H460, DU145, Caco-2 and B16F10 cells by compounds according to the present invention. All IC.sub.50 (inhibitory concentration at 50% of maximal effect) values are indicated in [mol/L]. HeLa- Example MaTu- NCI- No. HeLa ADR H460 DU145 Caco2 B16F10 1 5.7E−7  3.7E−7 2.4E−7 4.4E−7 2.6E−7 4.1E−7 2 4.9E−6  3 9.1E−7  4 1.8E−6  5 5.6E−7  3.7E−7 2.5E−7 5.2E−7 3.5E−7 3.5E−7 6 1.0E−5  7 5.8E−7  5.2E−7 8.1E−7 1.4E−6 9.2E−7 1.5E−6 8 2.8E−7  1.1E−7 1.0E−7 2.5E−7 1.5E−7 2.1E−7 9 2.2E−7  1.3E−7 9.8E−8 3.0E−7 1.6E−7 1.9E−7 10 3.3E−7  5.7E−8 1.7E−7 1.4E−7 1.8E−7 3.0E−7 11 1.8E−6  12 9.1E−7  6.4E−7 2.7E−7 1.1E−6 4.7E−7 4.0E−7 13 1.0E−5  14 1.5E−6  15 6.0E−7  3.2E−7 1.4E−7 1.5E−6 3.8E−7 3.9E−7 16 6.9E−7  2.9E−7 1.5E−7 7.2E−7 2.4E−7 2.9E−7 17 2.4E−6  18 1.2E−6  3.8E−7 6.4E−7 9.1E−7 2.7E−7 5.5E−7 19 3.5E−6  20 1.5E−6  21 8.7E−7  8.8E−7 7.5E−7 1.9E−6 1.4E−6 1.4E−6 22 7.6E−6  23 2.6E−6  24 1.0E−5  25 2.1E−6  26 1.0E−5  27 6.3E−7  2.5E−7 2.8E−7 6.8E−7 4.1E−7 6.1E−7 28 3.7E−6  29 1.0E−5  30 3.4E−7  2.3E−7 3.1E−7 6.4E−7 3.5E−7 3.9E−7 31 1.2E−6  8.8E−7 7.3E−7 3.0E−6 1.1E−6 9.5E−7 32 8.0E−6  33 2.4E−6  34 3.1E−6  35 1.0E−5  36 1.1E−6  3.3E−7 4.0E−7 8.6E−7 3.3E−7 5.5E−7 37 1.0E−5  38 8.1E−6  39 1.1E−6  8.1E−7 9.9E−7 2.0E−6 1.5E−6 2.2E−6 40 5.4E−7  3.2E−7 3.6E−7 6.6E−7 5.0E−7 7.8E−7 41 1.0E−5  42 2.3E−6  43 1.0E−5  44 1.0E−5  45 1.0E−5  46 1.0E−5  47 1.0E−5  48 1.0E−5  49 8.9E−7  5.9E−7 4.6E−7 1.1E−6 6.5E−7 9.1E−7 50 1.9E−6  51 1.0E−5  52 1.0E−5  53 2.7E−6  54 1.0E−5  55 1.0E−5  56 9.8E−6  57 1.0E−5  58 1.0E−5  59 1.0E−5  60 1.0E−5  61 1.0E−5  62 1.0E−5  63 3.6E−6  64 2.7E−6  65 8.2E−6  66 1.0E−5  67 1.0E−5  68 1.0E−5  69 4.0E−6  70 1.0E−5  71 1.0E−5  72 1.0E−5  73 9.4E−6  74 1.0E−5  75 1.0E−5  76 1.0E−5  77 1.0E−5  78 7.0E−6  79 1.0E−5  80 8.3E−6  81 1.0E−5  82 1.0E−5  83 1.0E−5  84 1.0E−5  85 8.9E−6  86 1.0E−5  87 4.5E−6  88 1.0E−5  89 1.0E−5  90 1.0E−5  91 1.0E−5  92 1.0E−5  93 9.9E−6  94 1.0E−5  95 1.0E−5  96 1.1E−6  4.1E−7 7.4E−7 8.0E−7 3.3E−7 1.1E−6 97 1.0E−5  98 6.9E−7  1.5E−7 1.7E−7 4.6E−7 1.1E−7 4.6E−7 99 1.0E−5  100 1.0E−5  101 1.0E−5  102 1.0E−5  103 1.0E−5  104 6.4E−6  105 1.0E−5  106 1.7E−6  107 3.0E−6  108 9.1E−7  3.3E−7 2.9E−7 5.7E−7 3.0E−7 7.0E−7 109 2.0E−7  1.7E−7 2.3E−7 6.6E−7 2.8E−7 3.5E−7 110 8.5E−7  9.5E−7 3.6E−7 2.0E−6 1.5E−6 8.0E−7 111 4.4E−6  112 8.8E−6  113 1.0E−5  114 1.0E−5  115 4.4E−6  116 3.0E−6  117 8.8E−7  6.6E−7 3.0E−7 3.1E−7 1.0E−7 7.3E−7 118 6.0E−7  3.2E−7 4.8E−7 7.5E−7 3.4E−7 3.8E−7 119 5.3E−6  120 121 8.2E−07 122 2.8E−07 123 1.3E−07 124 3.6E−07 125 126 127 4.6E−07 128 2.3E−07 129 2.5E−07 130 131 132 4.5E−07 133 4.2E−07 134 4.5E−07 135 136 137 1.8E−07 138 1.4E−07 139 2.6E−07 140 2.2E−07 141 3.4E−07 142 143 144 1.6E−07 145 1.6E−07 146 2.4E−07 147 3.2E−07 148 3.7E−07 149 >1.0E−5  150 2.8E−06 151 8.9E−06 152 >1.0E−5  153 2.8E−06 154 2.5E−06 155 9.9E−06 156 >1.0E−5  157 >1.0E−5  158 3.2E−06 159 2.3E−06 160 3.3E−06 162 3.3E−07 163 1.6E−07 164 1.6E−07 165 3.2E−06 166 8.3E−07 167 4.3E−06 168 9.1E−07 169 >1.0E−5  170 >1.0E−5  171 6.2E−06 172 >1.0E−5  173 >1.0E−5  174 >1.0E−5  175 >1.0E−5  176 5.0E−06 177 >1.0E−5  178 3.3E−06 179 3.8E−06 180 >1.0E−5  181 9.8E−07 182 6.6E−07 183 5.0E−06 184 3.8E−06 185 >1.0E−5  186 6.5E−06 187 >1.0E−5  188 >1.0E−5  189 9.4E−07 190 4.2E−07 191 1.6E−06 192 1.2E−06 193 2.7E−06 194 2.5E−06 195 3.1E−06 196 >1.0E−5  197 7.5E−06 198 6.7E−06 199 8.7E−06 200 >1.0E−5  201 >1.0E−5  202 >1.0E−5  203 >1.0E−5  204 >1.0E−5  205 >1.0E−5  206 5.1E−06 207 >1.0E−5  208 6.0E−06 209 >1.0E−5  210 1.9E−06 211 9.9E−06 212 >1.0E−5  213 2.5E−06 214 4.6E−06 215 1.4E−07 216 5.2E−07 217 1.7E−07 218 9.9E−06 219 >1.0E−5  220 6.2E−06 221 2.5E−06 222 6.2E−06 223 7.6E−07 224 3.2E−07 225 8.3E−06 226 9.1E−07 227 2.0E−06 228 2.7E−07 229 1.9E−07 230 5.8E−07 231 1.8E−06 233 >1.0E−5  234 9.6E−06 235 2.1E−06 236 4.1E−06 237 >1.0E−5  238 8.1E−06 239 1.1E−06 240 7.5E−07 241 9.3E−06 242 >1.0E−5  243 >1.0E−5  244 4.2E−06 245 9.9E−06 246 7.3E−06 247 >1.0E−5  248 3.1E−06 249 6.2E−06 250 >1.0E−5  251 4.5E−06 252 >1.0E−5  253 3.1E−06 254 >1.0E−5  255 6.1E−06 256 >1.0E−5  257 7.7E−06 258 7.0E−06 259 >1.0E−5  260 1.5E−06 261 4.8E−06 262 9.4E−06 263 3.2E−06 264 1.3E−07 265 3.2E−07 266 3.1E−07 267 5.8E−07 268 3.1E−07 269 8.4E−07 270 >1.0E−5  271 9.4E−06 272 5.8E−06 273 7.6E−06 274 >1.0E−5  275 >1.0E−5  276 4.9E−06 277 3.2E−06 278 2.6E−06 279 2.2E−06 280 >1.0E−5  281 8.0E−06 282 6.2E−06 283 8.4E−06 284 5.4E−07 285 >1.0E−5  286 1.0E−05 287 9.9E−06 288 9.9E−06 289 7.8E−06 290 8.8E−06 291 8.9E−06 292 1.8E−06 293 5.3E−06 294 1.3E−06 295 3.8E−07 296 6.0E−07 297 3.5E−07 298 3.3E−07 299 2.6E−07 300 5.5E−07 301 3.6E−07 302 3.4E−07 303 4.0E−07 304 3.6E−07 305 1.1E−06 306 5.7E−07 307 6.9E−07 308 3.4E−07 309 6.3E−07 310 2.3E−07 311 3.3E−07 312 4.2E−07 313 6.2E−07 314 4.1E−07 315 7.8E−07 316 4.3E−07 317 4.5E−07 318 2.2E−07 318 4.1E−07 320 6.8E−07 321 3.4E−06 322 6.9E−07 323 9.5E−07 324 8.7E−07 325 6.2E−07 326 3.0E−07 327 3.7E−07 328 3.6E−07 329 1.3E−06 330 1.2E−06 331 2.6E−07 332 3.5E−07 333 1.2E−06 334 3.7E−07 335 8.4E−07 336 3.9E−07 337 3.7E−07 338 4.5E−07 339 3.8E−07 340 4.3E−07 341 4.4E−07 342 4.7E−07 343 1.4E−06 344 9.9E−07 345 2.7E−07 346 2.7E−07 347 3.9E−07 348 1.0E−06 349 3.5E−07 350 2.8E−07 351 3.5E−07 352 1.1E−06 353 3.3E−07 354 3.3E−07 355 3.3E−07 356 7.7E−07 357 4.3E−07 358 3.2E−07 359 6.4E−07 360 3.5E−07 361 3.8E−07 362 3.4E−07 363 3.4E−07 364 2.9E−07 365 4.1E−07 366 3.0E−07 367 3.0E−07 368 3.5E−07 369 3.9E−07 370 3.0E−07 371 3.2E−07 372 1.5E−06 373 8.1E−07 374 9.2E−07 375 3.0E−07 376 3.1E−07 377 3.7E−07 378 2.9E−07 379 6.2E−07 380 5.5E−07 381 4.1E−07 382 1.8E−07 383 2.8E−07 384 3.4E−07 385 3.5E−07 386 2.9E−07 387 4.0E−07 388 3.7E−07 389 3.1E−07 390 3.2E−07 392 4.9E−07 393 4.3E−07 394 3.8E−07 395 4.8E−07 396 4.6E−07 397 8.3E−07 398 4.9E−07 399 6.5E−07 400 7.7E−07 401 4.3E−07 402 3.4E−07 403 4.5E−07 404 2.5E−07 405 4.4E−07 406 1.6E−07 407 3.3E−07 408 2.6E−07 409 1.9E−07 410 1.7E−07 411 1.7E−07 412 2.6E−07 413 2.7E−07 414 2.9E−07 415 3.5E−07 416 2.5E−07 417 4.1E−07 418 1.2E−06 419 7.6E−07 420 6.3E−07 421 5.5E−7  422 3.7E−7  423 4.1E−7  424 5.3E−07 425 1.3E−06 426 4.2E−07 427 8.6E−07 428 1.3E−06 429 2.6E−07 430 9.2E−07 431 >1.0E−05  432 >1.0E−05  433 5.4E−06 434 8.0E−06 435 >1.0E−05  450 >1.0E−05 

[2357] Thus the compounds of the present invention effectively inhibit the spindle assembly checkpoint and tumor cell proliferation and are therefore suitable for the treatment or prophylaxis of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly in which the diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses are haemotological tumours, solid tumours and/or metastases thereof, e.g. leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof